



(51) International Patent Classification:

C07D 471/04 (2006.01) **A61P 37/02** (2006.01)
A61K 31/4745 (2006.01)

(21) International Application Number:

PCT/JP2010/071773

(22) International Filing Date:

30 November 2010 (30.11.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/282,017 3 December 2009 (03.12.2009) US

(71) **Applicants** (for all designated States except US): **Dainippon Sumitomo Pharma Co., Ltd.** [JP/JP]; 6-8, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka, 5418524 (JP). **ASTRAZENECA AKTIEBOLAG** [SE/SE]; Soedertaelje, SE15185 (SE).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **ISOBE, Yoshiaki** [JP/JP]; c/o Dainippon Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, 5540022 (JP). **KASAI, Mai** [JP/JP]; c/o Dainippon Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, 5540022 (JP). **NAKAMURA, Tomoaki** [JP/JP]; c/o Dainippon Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, 5540022 (JP). **TOJO, Shingo** [JP/JP]; c/o Dainippon Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, 5540022 (JP). **KUREBAYASHI, Hirotaka** [JP/JP]; c/o

Dainippon Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, 5540022 (JP).

(74) **Agents:** **TANAKA, Mitsuo** et al.; AOYAMA & PARTNERS, IMP Building, 3-7, Shiromi 1-chome, Chuo-ku, Osaka-shi, Osaka, 5400001 (JP).


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR)



(I)

(57) **Abstract:** The present invention provides compounds of formula (I): wherein R^a , R^b , R^c , R^1 , R^2 , R^3 , X^1 , Y^1 , Z^1 , A , n and m are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

DESCRIPTION

IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR)

5 TECHNICAL FIELD

The present invention relates to imidazoquinoline derivatives, pharmaceutical compositions containing them and their use in therapy.

BACKGROUND ART

10 The immune system is comprised of innate and acquired immunity, both of which work cooperatively to protect the host from microbial infections. It has been shown that innate immunity can recognize conserved pathogen-associated molecular patterns through toll-like receptors (TLRs) expressed on the cell surface of immune cells. Recognition of invading pathogens then triggers
15 cytokine production (including interferon alpha (IFN α)) and upregulation of co-stimulatory molecules on phagocytes, leading to modulation of T cell function. Thus, innate immunity is closely linked to acquired immunity and can influence the development and regulation of an acquired response.


20 TLRs are a family of type I transmembrane receptors characterized by an NH₂-terminal extracellular leucine-rich repeat domain (LRR) and a COOH-terminal intracellular tail containing a conserved region called the Toll/IL1 receptor (TIR) homology domain. The extracellular domain contains a varying number of LRR, which are thought to be involved in ligand binding.
25 Eleven TLRs have been described to date in humans and mice. They differ from each other in ligand specificities, expression patterns, and in the target genes they can induce.

Ligands which act via TLRs (also known as immune response modifiers (IRMS))
30 have been developed, for example, the imidazoquinoline derivatives described in US Patent No. 4689338 which include the product Imiquimod for treating genital warts, and the adenine derivatives described in WO 98/01448 and WO 99/28321.

35 DISCLOSURE OF INVENTION

This patent application describes a class of imidazoquinoline compounds having immuno-modulating properties which act via TLR7 that are useful in the treatment of viral or allergic diseases and cancers.

- 5 In accordance with the present invention, there is therefore provided a compound of formula (I):



, wherein

- 10 R^1 represents C_1 - C_8 alkyl group, C_{3-8} cycloalkyl group, or a 3- to 8-membered saturated heterocyclic ring group comprising a O atom, wherein each of said groups is optionally substituted by one or more substituents independently selected from halogen, cyano, hydroxyl and C_1 - C_3 alkoxy;

- 15 Z^1 represents a C_2 - C_6 alkylene, wherein a carbon atom in Z^1 which is not adjacent to a nitrogen atom may be replaced with an oxygen atom;

X^1 represents NR^5 , $>N-COR^5$, $>N-CONR^5R^{5a}$, $CONR^5$, NR^5CO , NR^5CONR^6 or NR^6CONR^5 ;

Y^1 represents a single bond or C_1 - C_6 alkylene;

- 20 each R^2 is independently selected from halogen, cyano, hydroxy, thiol, C_1 - C_3 alkyl, C_1 - C_3 hydroxyalkyl, C_1 - C_3 haloalkyl, C_1 - C_3 alkoxy, C_1 - C_3 haloalkoxy, C_{1-3} alkylthio, C_{1-3} alkylsulfonyl and C_{1-3} alkylsulfinyl;

R^3 represents C_{1-6} alkyl optionally substituted by C_{1-6} alkoxy;

- 25 each R^a is independently selected from halogen, cyano, hydroxy, thiol, C_1 - C_3 alkyl, C_1 - C_3 hydroxyalkyl, C_1 - C_3 haloalkyl, C_1 - C_3 alkoxy, C_1 - C_3 haloalkoxy, C_{1-3} alkylthio, C_{1-3} alkylsulfonyl and C_{1-3} alkylsulfinyl;

R^5 and R^{5a} each independently represents hydrogen, a 3- to 8-membered saturated heterocyclic ring comprising a ring group O, $S(O)_p$ or NR^{10} , a C_1 - C_6 alkyl group or C_3 - C_6 cycloalkyl group, the latter two groups being optionally substituted by one or more substituents independently selected from NR^7R^8 or R^9 ;

R⁷ and R⁸ each independently represent hydrogen, a 3- to 8-membered saturated heterocyclic ring comprising a ring group O, S(O)_p or NR^{10a}, C₁-C₆ alkyl or C₃-C₆ cycloalkyl, the latter two groups being optionally substituted by one or more groups independently selected from halogen, cyano, S(O)_qR¹¹, OR¹², CO₂R¹², OC(O)R¹², SO₂NR¹²R¹³, CONR¹²R¹³, NR¹²R¹³, NR¹²SO₂R¹⁴, NR¹²COR¹³, or a 3- to 8-membered saturated heterocyclic ring comprising a ring group O, S(O)_p or NR^{10b},

or R⁷ and R⁸ together with the nitrogen atom to which they are attached form a 3- to 8-membered saturated heterocyclic ring comprising a ring nitrogen atom and optionally one or more further heteroatoms independently selected from nitrogen, oxygen, sulphur and sulphonyl, the heterocyclic ring being optionally substituted by one or more substituents independently selected from halogen, cyano, S(O)_qR¹⁵, OR¹⁵, CO₂R¹⁵, COR¹⁵, OC(O)R¹⁵, SO₂NR¹⁵R¹⁶, CONR¹⁵R¹⁶, NR¹⁵R¹⁶, NR¹⁵SO₂R¹⁷, NR¹⁵COR¹⁶, NR¹⁵CO₂R¹⁶, heteroaryl, C₁-C₆ haloalkyl, C₃-C₈ cycloalkyl and C₁-C₆ alkyl, the latter two groups being optionally substituted by one or more groups independently selected from cyano, S(O)_qR¹⁸, OR¹⁸, CO₂R¹⁸, SO₂NR¹⁸R¹⁹, CONR¹⁸R¹⁹ or NR¹⁸R¹⁹;

R⁹ represents halogen, cyano, CO₂R²⁰, S(O)_qR²⁰, OR²⁰, SO₂NR²⁰R²², CONR²⁰R²², NR²⁰SO₂R²¹, NR²⁰CO₂R²¹, NR²⁰COR²² or a 3- to 8-membered saturated heterocyclic ring comprising a ring group NR^{10c};

R¹⁰, R^{10a}, R^{10b} and R^{10c} independently represent hydrogen, CO₂R²³, S(O)_qR²³, COR²⁴, or a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₃-C₈ cycloalkyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen, cyano, OR²⁵ or NR²⁵R²⁶;

R⁶, R¹¹, R¹², R¹³, R¹⁵, R¹⁶, R¹⁸, R¹⁹, R²⁰, R²², R²⁴, R²⁵ and R²⁶ each independently represent hydrogen, C₁-C₆ alkyl or C₃-C₆ cycloalkyl;

R¹⁴, R¹⁷, R²¹ and R²³ each independently represent C₁-C₆ alkyl or C₃-C₆ cycloalkyl;

m, n, p and q each independently represent an integer 0, 1 or 2; and

A represents a monocyclic or bicyclic C₆-C₁₀ aryl or a monocyclic or bicyclic C₅-C₁₂ heteroaryl group containing 1-3 heteroatoms;

R^b and R^c each independently represent hydrogen or C₁-C₆ alkyl, or R^b

and R^c combine together to form C₃-C₈ cycloalkyl;

or a pharmaceutically acceptable salt thereof.

In the context of the present specification, unless otherwise stated, an alkyl substituent group or an alkyl moiety in a substituent group may be linear or branched. They may for example contain from 1 to 8 carbon atoms. Examples of C₁-C₈ alkyl groups/moieties include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, *tert*-butyl, n-pentyl, n-hexyl, n-heptyl or n-octyl. Similarly, an alkylene group/moiety may be linear or branched. Examples of C₁-C₆ alkylene groups/moieties include methylene, ethylene, n-propylene, n-butylene, n-pentylene, n-hexylene, 1-methylethylene, 2-methylethylene, 1,2-dimethylethylene, 1-ethylethylene, 2-ethylethylene, 1-, 2- or 3-methylpropylene and 1-, 2- or 3-ethylpropylene. An alkenyl or alkynyl group is an unsaturated linear or branched group, containing for example from 2 to 6 carbon atoms. It should be appreciated that, in formula (I), if more than one substituent contains a group or moiety S(O)_p or S(O)_q or if a substituent contains two or more S(O)_p or S(O)_q, then each "p" or each "q" independently represents an integer 0, 1 or 2. For example, if R⁷ represents a C₃-C₆ cycloalkyl group substituted by two groups S(O)_qR¹¹, then each "q" may be the same or different. In the same way, each group "R¹¹", where there is more than one such group, may be the same or different.

Cycloalkyl or carbocycle groups are rings containing, for example, from 3 to 8 carbon atoms and are saturated.

Heterocyclic groups are rings which may be saturated, partially unsaturated or unsaturated, and contain from 3 to 20 atoms, at least one and suitably from 1 to 4 atoms are heteroatoms selected from oxygen, sulphur and nitrogen. Rings may be monocyclic, fused, bridged, or spiro bicyclic heterocyclic ring system(s). Monocyclic heterocyclic rings contain from about 3 to 12 ring atoms, with from 1 to 5 heteroatoms selected from N, O and S, and suitably from 3 to 7 member atoms, in the ring. Bicyclic heterocycles contain from 7 to 17 member atoms, suitably 7 to 12 member atoms, in the ring. Bicyclic heterocyclic(s) rings may be fused, spiro, or bridged ring systems.

Examples of heterocyclic groups which are saturated or partially saturated include cyclic ethers (oxiranes) such as ethyleneoxide, tetrahydrofuran, dioxane, and substituted cyclic ethers. Heterocycles containing nitrogen include, for

example, azetidine, pyrrolidine, piperidine, piperazine, tetrahydrotriazine, tetrahydropyrazole, and the like. Typical sulfur containing heterocycles include tetrahydrothiophene, dihydro-1,3-dithiol-2-yl, and hexahydrothiepin-4-yl. Other heterocycles include dihydro-oxathiol-4-yl, tetrahydro-oxazolyl, tetrahydro-oxadiazolyl, tetrahydrodioxazolyl, tetrahydro-oxathiazolyl, hexahydrotriazinyl, tetrahydro-oxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl. For heterocycles containing sulfur, the oxidized sulfur heterocycles containing SO or SO₂ groups are also included. Examples include the sulfoxide and sulfone forms of tetrahydrothiophene. A suitable value for a heterocyclyl group which bears 1 or 2 oxo or thioxo substituents is, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl.

Heterocyclic groups which are aromatic in nature are referred to as "heteroaryl" groups. These groups are aromatic mono-, bi-, or polycyclic heterocyclic ring incorporating one or more (for example 1-4) heteroatoms selected from N, O, and S. The term heteroaryl includes both monovalent species and divalent species. Examples of heteroaryl groups include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl, pteridinyl, naphthyridinyl, carbazolyl, phenazinyl, benzisoquinolinyl, pyridopyrazinyl, thieno[2,3-*b*]furanyl, 2H-furo[3,2-*b*]-pyranyl, 5H-pyrido[2,3-*d*]-o-oxazinyl, 1H-pyrazolo[4,3-*d*]-oxazolyl, 4H-imidazo[4,5-*d*]thiazolyl, pyrazino[2,3-*d*]pyridazinyl, imidazo[2,1-*b*]thiazolyl, imidazo[1,2-*b*][1,2,4]triazinyl. "Heteroaryl" also covers ring systems wherein at least one ring is an aromatic ring containing 1 or more heteroatoms selected from O, S and N and one or more of the other rings is a non-aromatic, saturated or partially unsaturated ring optionally containing one or more heteroatoms selected from O, S and N, for example 1,2,3,4-tetrahydro-1,8-naphthyridinyl, 1,2,3,4-tetrahydropyrido[2,3-*b*]pyrazinyl and

3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]oxazinyl.

A preferred heteroaryl group is a 5-7 member aromatic ring or 6,6- or 6,5-fused bicyclic ring containing one or more ring heteroatoms selected from N, S, O.

5 Examples include pyridine, pyrimidine, thiazole, oxazole, pyrazole, imidazole, furan, isoxazole, pyrrole, isothiazole and azulene, naphthyl, indene, quinoline, isoquinoline, indole, indolizine, benzo[*b*]furan, benzo[*b*]thiophene, 1*H*-indazole, benzimidazole, benzthiazole, benzoxazole, purine, 4*H*-quinolizine, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, pteridine and
10 quinolone.

In one embodiment R^1 represents a straight or branched chain C_{1-8} alkyl group optionally substituted by C_{1-3} alkoxy or hydroxy, for example, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, *sec*-butyl, isobutyl, *t*-butyl, methoxymethyl,
15 methoxyethyl or hydroxyethyl. In another embodiment R^1 represents a straight or branched chain C_{1-4} alkyl group. In a particular embodiment R^1 is methyl, ethyl, propyl, or isopropyl.

In one embodiment R^b and R^c independently represent hydrogen or C_1 - C_3 alkyl, or
20 R^b and R^c combine together to form C_3 - C_6 cycloalkyl. In another embodiment R^b and R^c each independently represent hydrogen or methyl, or R^b and R^c combine together to form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

In one embodiment R^1 represents a straight chain C_{1-4} alkyl group, and at least
25 one of R^b and R^c independently represent C_1 - C_4 alkyl or R^b and R^c combine together to form C_3 - C_6 cycloalkyl. In another embodiment R^1 represents methyl or ethyl, and R^b represents methyl and R^c represents hydrogen or methyl, or R^b and R^c combine together to form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In another embodiment R^1 , R^b and R^c represent methyl. In
30 another embodiment R^1 represents ethyl, R^b represents methyl and R^c represents hydrogen.

In another embodiment when R^1 represents branched chain C_{3-6} alkyl group, C_{3-6} cycloalkyl or a tetrahydropyranyl, R^b and R^c represent hydrogen. For example,
35 R^1 represents isopropyl, and R^b and R^c represent hydrogen.

In a particular embodiment, Z^1 is a C_{2-6} alkylene, in particular a straight chain C_{2-6} alkylene group, for example a straight chain C_{2-4} alkylene group. A particular example of Z^1 is n-propylene. Another particular example of Z^1 is n-butylene.

In a particular embodiment, X^1 represents NR^5 , $>N-COR^5$, $>NCONR^5R^{5a}$, NR^5CO , $CONR^5$, NR^5CONR^6 , or NR^6CONR^5 . (For the avoidance of doubt, within the definition of X^1 , the first atom appearing is linked to the Z^1 group. Thus, when X^1 is $CONR^5$, the carbon atom is linked to the Z^1 group and the nitrogen atom is linked to the Y^1 group.) As will be understood, when X^1 represents $>N-COR^5$, the nitrogen is attached to Z^1 and Y^1 . The same applies when X^1 is $>NCONR^5R^{5a}$.

In another embodiment, X^1 represents NR^5 , $>N-COR^5$, or $>N-CONR^5R^{5a}$.

Where R^6 is present in any group X^1 , it is suitably selected from hydrogen or C_{1-6} alkyl such as methyl.

A particular example of X^1 is a group NR^5 .

Another particular example of an X^1 group is $>N-COR^5$.

Another particular example of an X^1 group is $>N-CONR^5R^{5a}$.

Particular examples of R^5 groups include hydrogen or a C_{1-6} alkyl optionally substituted by one or more substituents independently selected from NR^7R^8 or R^9 , where R^7 , R^8 and R^9 are as defined above.

For instance, R^5 represents a C_1-C_6 alkyl or C_1-C_4 alkyl optionally substituted by one or more substituents independently selected from NR^7R^8 or R^9 , where R^7 , R^8 and R^9 are as defined above.

In particular, R^5 is a C_1-C_6 alkyl, particularly C_1-C_3 alkyl such as methyl, ethyl or n-propyl, optionally substituted by one or more substituents independently selected from NR^7R^8 where R^7 and R^8 are as defined above.

In yet a further embodiment, R^5 is a C_1-C_6 alkylene which may be linked to a carbon atom within a C_2-C_6 alkylene group Z^1 so as to form a saturated 4-7 membered nitrogen containing ring. In particular, R^5 is linked to a carbon atom in the Z^1 chain so as to form for example, where X^1 is a group NR^5 , a piperidine ring.

In a particular embodiment, Y^1 represents C_1-C_6 alkylene, such as a CH_2 group.

In a further embodiment, where A is a heteroaryl group, it is suitably a monocyclic ring containing six atoms, one or two of which are nitrogen. Thus particular

examples of heteroaryl groups A include pyridyl and pyrimidinyl, suitably pyridyl. A particular example of ring A is phenyl.

In one embodiment A is phenyl and the groups Y¹ and O are in the meta- or para-position on A. In one embodiment A is 1,3-phenylene. In another one
5 embodiment A is 1,4-phenylene.

Where present, R² is suitably halogen such as fluoro or chloro, cyano, hydroxy, thiol, C₁-C₃ alkyl such as methyl, C₁-C₃ hydroxyalkyl such as hydroxymethyl, C₁-C₃ haloalkyl such as trifluoromethyl, C₁-C₃ alkoxy such as methoxy or ethoxy, C₁-C₃ haloalkoxy such as trifluoromethoxy, C₁₋₃alkylthio such as methylthio,
10 C₁₋₃alkylsulfonyl such as methylsulfonyl or C₁₋₃ alkylsulfinyl such as methylsulfinyl.

Preferably however, n is 0.

In a particular embodiment, R³ represents a C₁₋₆ alkyl group optionally substituted by a C₁₋₄ alkoxy group. Examples of alkyl groups include methyl,
15 ethyl, iso-propyl, n-propyl, and n-butyl. A particular example of R³ is n-propyl or n-butyl. Particular examples of an alkoxy substituted alkyl group R³ include a C₁₋₆ alkyl group substituted by a C₁₋₄ alkoxy group such as methoxy, ethoxy or propoxy, for example R³ is ethoxymethyl or 2-methoxyethyl. In one embodiment R³ is 2-methoxyethyl. In another embodiment R³ is ethoxymethyl. In another
20 embodiment R³ is a C₁₋₆ alkyl group substituted by a C₁₋₄ alkoxy group, provided R³ is not 2-methoxyethyl.

Where present, each R^a suitably independently represents halogen such as chloro or fluoro, cyano, hydroxy, thiol, C₁-C₃ alkyl such as methyl, C₁-C₃ hydroxyalkyl
25 such as hydroxymethyl, C₁-C₃ haloalkyl such as trifluoromethyl, C₁-C₃ alkoxy such as methoxy or ethoxy, C₁-C₃ haloalkoxy such as trifluoromethoxy, C₁₋₃alkylthio such as methylthio, C₁₋₃ alkylsulfonyl such as methylsulfonyl or C₁₋₃ alkylsulfinyl such as methylsulfinyl.

Suitably however, m is 0.
30

R⁷ and R⁸ each independently represent hydrogen, a 3- to 8- or 5- to 6-membered saturated heterocyclic ring comprising a ring group O, S(O)_p or NR^{10a}, C₁-C₆, or C₁-C₄, or C₁-C₂ alkyl or C₃-C₆ or C₅-C₆ cycloalkyl, the latter two groups being
35 optionally substituted by one or more (e.g. one, two, three or four) groups

independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), cyano, $S(O)_qR^{11}$, OR^{12} , CO_2R^{12} , $OC(O)R^{12}$, $SO_2NR^{12}R^{13}$, $CONR^{12}R^{13}$, $NR^{12}R^{13}$, $NR^{12}SO_2R^{14}$, $NR^{12}COR^{13}$, or a 3- to 8- or 5- to 6-membered saturated heterocyclic ring comprising a ring group O, $S(O)_p$ or NR^{10b} ,

5 or R^7 and R^8 together with the nitrogen atom to which they are attached form a 3- to 8-membered saturated heterocyclic ring comprising a ring nitrogen atom and optionally one or more (e.g. one, two or three) further heteroatoms independently selected from nitrogen, oxygen, sulphur and sulphonyl (such as piperidinyl, piperazinyl, morpholinyl or pyrrolidinyl), the heterocyclic ring being optionally
10 substituted by one or more (e.g. one, two, three or four) substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), cyano, $S(O)_qR^{15}$, OR^{15} , CO_2R^{15} , COR^{15} , $OC(O)R^{15}$, $SO_2NR^{15}R^{16}$, $CONR^{15}R^{16}$, $NR^{15}R^{16}$, $NR^{15}SO_2R^{17}$, $NR^{15}COR^{16}$, $NR^{15}CO_2R^{16}$, heteroaryl (particularly pyrimidinyl), C_1 - C_6 , or C_1 - C_4 , or C_1 - C_2 haloalkyl (e.g. trifluoromethyl,
15 trifluoromethoxy or pentafluoroethyl), C_3 - C_8 or C_5 - C_6 cycloalkyl and C_1 - C_6 , or C_1 - C_4 , or C_1 - C_2 alkyl, the latter two groups being optionally substituted by one or more (e.g. one, two, three or four) groups independently selected from cyano, $S(O)_qR^{18}$, OR^{18} , CO_2R^{18} , $SO_2NR^{18}R^{19}$, $CONR^{18}R^{19}$ or $NR^{18}R^{19}$.

20 In one embodiment, R^7 and R^8 each independently represent hydrogen, a 5- to 6-membered saturated heterocyclic ring comprising a ring group O or NR^{10a} , or a C_1 - C_6 , or C_1 - C_4 , or C_1 - C_2 alkyl group optionally substituted by one or more (e.g. one, two, three or four) groups independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), cyano, $S(O)_qR^{11}$, OR^{12} , CO_2R^{12} , $OC(O)R^{12}$,
25 $SO_2NR^{12}R^{13}$, $CONR^{12}R^{13}$, $NR^{12}R^{13}$, $NR^{12}SO_2R^{14}$, $NR^{12}COR^{13}$, or a 3- to 8- or 5- to 6-membered saturated heterocyclic ring comprising a ring group O, $S(O)_p$ or NR^{10b} .

In one embodiment, R^7 and R^8 represent methyl or ethyl.

In one embodiment, R^7 and R^8 represent ethyl.

30 In another embodiment, R^7 and R^8 each independently represent hydrogen, a 5- to 6-membered saturated heterocyclic ring comprising a ring group O or NR^{10a} , or a C_1 - C_4 alkyl group optionally substituted by one or two groups independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), cyano, $S(O)_qR^{11}$,
35 OR^{12} , CO_2R^{12} , $OC(O)R^{12}$, $SO_2NR^{12}R^{13}$, $CONR^{12}R^{13}$, $NR^{12}R^{13}$, $NR^{12}SO_2R^{14}$,

NR¹²COR¹³, or a 3- to 8- or 5- to 6-membered saturated heterocyclic ring comprising a ring group O, S(O)_p or NR^{10b}.

In a further embodiment, R⁷ and R⁸ each independently represent a 5- to 6-membered saturated heterocyclic ring comprising a ring group O or NR^{10a} (such as tetrahydropyranyl or N-acetylpiperidinyl) or a C₁-C₄ alkyl group optionally substituted by OR¹².

In an alternative embodiment, R⁷ and R⁸ together with the nitrogen atom to which they are attached form a 3- to 8-membered, particularly 4- to 7- or 5- to 6-membered, saturated heterocyclic ring comprising a ring nitrogen atom and optionally one or more further heteroatoms independently selected from nitrogen, oxygen, sulphur and sulphonyl, the heterocyclic ring being optionally substituted by one or more (e.g. one, two, three or four) substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), cyano, S(O)_qR¹⁵, OR¹⁵, CO₂R¹⁵, COR¹⁵, CONR¹⁵R¹⁶, NR¹⁵CO₂R¹⁶, heteroaryl and C₁-C₆, or C₁-C₄, or C₁-C₂ alkyl, the alkyl group being optionally substituted by one or more (e.g. one, two, three or four) groups independently selected from cyano, S(O)_qR¹⁸, OR¹⁸, CO₂R¹⁸, SO₂NR¹⁸R¹⁹, CONR¹⁸R¹⁹ or NR¹⁸R¹⁹.


According to a further embodiment, R⁷ and R⁸ together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring comprising a ring nitrogen atom and optionally one further heteroatom selected from nitrogen and oxygen, the heterocyclic ring being optionally substituted by one or two substituents independently selected from S(O)_qR¹⁵, OR¹⁵, CO₂R¹⁵, COR¹⁵, CONR¹⁵R¹⁶, NR¹⁵CO₂R¹⁶, pyrimidinyl and C₁-C₂ alkyl, the alkyl group being optionally substituted by one or two groups independently selected from OR¹⁸ and CO₂R¹⁸. In another embodiment of the invention X¹ represents >NCOR⁵ wherein R⁵ represents methyl substituted with NR⁷R⁸; and R⁷ and R⁸ represent independently methyl or ethyl. For example in one embodiment R⁷ and R⁸ are both methyl. In another embodiment R⁷ and R⁸ are both ethyl.

In another embodiment of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt thereof wherein:


Z¹ is n-propylene or n-butylene;

Y¹ is methylene;

A is



or



and;

5 R¹, R², R³, R^a, R^b, R^c, X¹, m and n have any of the values described hereinbefore.

In another embodiment of the invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof wherein:

Z¹ is n-propylene;

10 Y¹ is methylene;

X¹ represents >NCOR⁵ wherein R⁵ represents methyl substituted with NR⁷R⁸;

R⁷ and R⁸ represent, independently, methyl or ethyl;

A represents formula (I-1) above;

15 R¹ represents ⁱPr, and R^b and R^c represent hydrogen atom, or R¹, R^b and R^c represent methyl;

R³ represents n-butyl, methoxyethyl or ethoxymethyl; and

m and n represents 0.

20 In another embodiment of the invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof wherein:

Z¹ is n-propylene;

Y¹ is methylene;

X¹ represent >NCOR⁵ wherein R⁵ represents methyl substituted with NR⁷R⁸;

R⁷ and R⁸ represent, independently, methyl or ethyl;

25 A represents formula (I-1) above;

R¹ represents ⁱPr, and R^b and R^c represent hydrogen atom;

R³ represents ethoxyethyl; and

m and n represents 0.

30 In another embodiment of the invention, there is provided a compound of formula

(I), or a pharmaceutically acceptable salt thereof wherein:

Z¹ is n-propylene;

Y¹ is methylene;

X¹ represents >NCOR⁵ wherein R⁵ represents methyl substituted with NR⁷R⁸;

5 R⁷ and R⁸ represent, independently, methyl or ethyl;

A represents formula (I-1) above;

R¹, R^b and R^c represent methyl;

R³ represents methoxyethyl; and

m and n represents 0.

10

Examples of compounds of the invention include a compound selected from List A:

List A:

Methyl

15 2-(3-{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylamino}methyl}phenoxy)acetate

Methyl

(3-{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(chloroacetyl)amino}methyl}phenoxy)acetate

20 Methyl (4-{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}amino}methyl}phenoxy)acetate

Methyl

(4-{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(chloroacetyl)amino}methyl}phenoxy)acetate

25 Methyl (4-{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(*N,N*-dimethylglycyl)amino}methyl}phenoxy)acetate

Methyl

30 (4-{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(piperidin-1-ylacetyl)amino}methyl}phenoxy)acetate

Methyl

[4-{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}[(4-methylpiperazin-1-yl)acetyl]amino}methyl}phenoxy]acetate

Methyl

35 {4-[[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]{{4-(2-methoxyeth

yl)piperazin-1-yl]acetyl}amino)methyl]phenoxy)acetate

Methyl

(3-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(N,N-dimethylglycyl)amino)methyl}phenoxy)acetate

5 Methyl

(3-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(piperidin-1-ylacetyl)amino)methyl}phenoxy)acetate

Methyl

[3-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}[(4-methylpiperazin-1-yl)acetyl]amino)methyl}phenoxy]acetate

10

Methyl

{3-[[{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}{4-(2-methoxyethyl)piperazin-1-yl]acetyl}amino)methyl]phenoxy)acetate

Methyl

(3-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(pyrrolidin-1-ylacetyl)amino)methyl}phenoxy)acetate

15

Methyl

(3-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(N,N-diethylglycyl)amino)methyl}phenoxy)acetate

Methyl

(3-{{{3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}amino)methyl}phenoxy)acetate

20

Methyl

(3-{{{3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(chloroacetyl)amino)methyl}phenoxy)acetate

25

Methyl

(3-{{{3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(N,N-dimethylglycyl)amino)methyl}phenoxy)acetate

Methyl

(3-{{{3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}[(4-methylpiperazin-1-yl)acetyl]amino)methyl}phenoxy)acetate

30

Methyl

(3-{{{3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(piperidin-1-ylacetyl)amino)methyl}phenoxy)acetate

Methyl

(3-{{{3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(N,N-d

35

iethylglycyl)amino)methyl]phenoxy)acetate

Methyl

(3-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(3-morpholinopropyl)amino)methyl]phenoxy)acetate

5 Methyl

[4-{{{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}amino)carbonyl][3-(dimethylamino)propyl]amino)methyl]phenoxy]acetate

Ethyl

10 2-[3-{{{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}amino)methyl]phenoxy]acetate

Ethyl

2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]phenoxy]acetate

Ethyl

15 2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy]acetate

Propyl

2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy]acetate

20 Isopropyl

2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy]acetate

Isobutyl

25 2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy]acetate

2-Methoxyethyl

2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy]acetate

2-Hydroxyethyl

30 2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy]acetate

Ethyl

2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(pyrrolidin-1-yl)acetamido)methyl]phenoxy]acetate

35 Ethyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(piperidin-1-yl)acetamido)methyl]phenoxy}acetate

Ethyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(dimethylamino)acetamido)methyl]phenoxy}acetate

Methyl

2-[4-((3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl)phenoxy]acetate

Methyl

2-{4-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-chloroacetamido)methyl]phenoxy}acetate

Methyl

2-{4-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]phenoxy}acetate

Ethyl

2-{4-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]phenoxy}acetate

Methyl

2-[2-((3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl)phenoxy]acetate

Methyl

2-{2-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-chloroacetamido)methyl]phenoxy}acetate

Methyl

2-{2-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]phenoxy}acetate

Ethyl

2-{2-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]phenoxy}acetate

Ethyl

2-[3-((4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butylamino)methyl)phenoxy]acetate

Ethyl

2-{3-[(*N*-(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl)-2-chloroacetamido)methyl]phenoxy}acetate

Ethyl

2-{3-[(*N*-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate

Isopropyl

5 2-{3-[(*N*-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate

tert-Butyl

2-[3-({4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butylamino)methyl]phenoxy}acetate

10 *tert*-Butyl

2-{3-[(*N*-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-2-chloroacetamido)methyl]phenoxy}acetate

tert-Butyl

15 2-{3-[(*N*-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate

Methyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]phenoxy}propanoate

Methyl

20 2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]phenoxy}propanoate

Methyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}propanoate

25 Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}propanoate

Ethyl

30 2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]phenoxy}-2-methylpropanoate

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]phenoxy}-2-methylpropanoate

Ethyl

35 2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-

-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate

Methyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2

-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate

5 Ethyl

1-[3-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]phenoxy]cyclobutanecarboxylate

Ethyl

1-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2

10 -chloroacetamido)methyl]phenoxy}cyclobutanecarboxylate

Ethyl

1-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}cyclobutanecarboxylate

Ethyl

15 2-[5-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]-2-methoxyphenoxy]acetate

Ethyl

2-{5-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-2-methoxyphenoxy}acetate

20 Ethyl

2-{5-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-methoxyphenoxy}acetate

Methyl

25 2-{5-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-methoxyphenoxy}acetate

Ethyl

2-[5-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]-2-methylphenoxy]acetate

Ethyl

30 2-{5-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-2-methylphenoxy}acetate

Ethyl

2-{5-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-methylphenoxy}acetate

35 Isopropyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]-2-methylphenoxy}acetate

Methyl

2-[3-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylamino)methyl]phenoxy]butanoate

Methyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-chloroacetamido)methyl]phenoxy}butanoate

Methyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]phenoxy}butanoate

Ethyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]phenoxy}butanoate

Isopropyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]-2-methoxyphenoxy}acetate

Isopropyl

2-[5-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylamino)methyl]-2-methoxyphenoxy]acetate

Isopropyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-chloroacetamido)methyl]-2-methoxyphenoxy}acetate

Isopropyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(dimethylamino)acetamido)methyl]-2-methoxyphenoxy}acetate

Isopropyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(ethyl(methyl)amino)acetamido)methyl]-2-methoxyphenoxy}acetate

Methyl

1-[3-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylamino)methyl]phenoxy]cyclopropanecarboxylate

Methyl

1-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-chloroacetamido)methyl]phenoxy}cyclopropanecarboxylate

Methyl

1-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}cyclopropanecarboxylate

Cyclopentyl

5 2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}acetate

Cyclobutyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}acetate

10 Tetrahydro-2*H*-pyran-4-yl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}acetate

Butyl

15 2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}acetate

tert-Butyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]phenoxy]acetate

tert-Butyl

20 2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]phenoxy}acetate

tert-Butyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}acetate

25 Ethyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl}-2-methoxyphenoxy]acetate

Ethyl

30 2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-2-methoxyphenoxy}acetate

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-methoxyphenoxy}acetate

Isopropyl

35 2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2

-{diethylamino}acetamido)methyl]-2-methoxyphenoxy}acetate

Ethyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)-2-fluorophenoxy]acetate

5 Ethyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-chloroacetamido)methyl]-2-fluorophenoxy}acetate

Ethyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-{diethylamino}acetamido)methyl]-2-fluorophenoxy}acetate

10

Isopropyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-{diethylamino}acetamido)methyl]-2-fluorophenoxy}acetate

Ethyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-{dimethylamino}acetamido)methyl]-2-fluorophenoxy}acetate

15

Isopropyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-{dimethylamino}acetamido)methyl]-2-fluorophenoxy}acetate

Ethyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-{ethyl(methyl)amino}acetamido)methyl]-2-fluorophenoxy}acetate

20

Isopropyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-{ethyl(methyl)amino}acetamido)methyl]-2-fluorophenoxy}acetate

25

Ethyl

2-[3-({2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethylamino}methyl)phenoxy]acetate

Ethyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethyl)-2-chloroacetamido)methyl]phenoxy}acetate

30

Ethyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethyl)-2-{diethylamino}acetamido)methyl]phenoxy}acetate

35

Methyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-{diethylamino}acetamido)methyl]phenoxy}acetate

Isopropyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-{diethylamino}acetamido)methyl]phenoxy}acetate

Ethyl

2-{3-[(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethylamino)methyl]phenoxy}-2-methylpropanoate

Ethyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-chloroacetamido)methyl]phenoxy}-2-methylpropanoate

Ethyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate

Methyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate

Cyclopentyl

2-{3-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]phenoxy}acetate

Cyclopentyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-chloroacetamido)methyl]phenoxy}acetate

Cyclopentyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-{dimethylamino}acetamido)methyl]phenoxy}acetate

Cyclopentyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-{ethyl(methyl)amino}acetamido)methyl]phenoxy}acetate

Isopropyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-morpholinoacetamido)methyl]phenoxy}acetate

Isopropyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-{dimethylamino}acetamido)methyl]phenoxy}acetate

Isopropyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-ethyl(methyl)amino}acetamido)methyl]phenoxy}acetate

Isopropyl

5 2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-((2-methoxyethyl)(methyl)amino}acetamido)methyl]phenoxy}acetate

Isopropyl

2-[5-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]-2-fluorophenoxy}acetate

10 Isopropyl

2-{5-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-2-fluorophenoxy}acetate

Isopropyl

15 2-{5-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]-2-fluorophenoxy}acetate

Ethyl

2-{5-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]-2-fluorophenoxy}acetate

Methyl

20 2-{5-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]-2-fluorophenoxy}acetate

Isopropyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]-5-fluorophenoxy}acetate

25 Isopropyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-5-fluorophenoxy}acetate

Isopropyl

30 2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]-5-fluorophenoxy}acetate

Ethyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]-5-fluorophenoxy}acetate

Ethyl

35 2-{4-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{

2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy}acetate

Ethyl

2-{3-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{

2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy}acetate

5

Ethyl

2-{3-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{

2-(dimethylamino)ethyl}ureido)methyl]phenoxy}acetate

Ethyl

2-{3-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{

10

3-(piperidin-1-yl)propyl}ureido)methyl]phenoxy}acetate

Ethyl

2-{3-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{

3-(dimethylamino)propyl}ureido)methyl]phenoxy}acetate

Ethyl

15

2-{3-[(3-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-{

2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy}acetate

Ethyl

2-{4-[(3-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-{

2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy}acetate

20

Isopropyl

2-{3-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl){2-[di
methylamino]ethyl}amino)methyl]phenoxy}acetate

Isopropyl

2-{3-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl){3-mo

25

rpholinopropyl}amino)methyl]phenoxy}acetate

Ethyl

2-{3-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl){2-(di
methylamino)ethyl}amino)methyl]phenoxy}-2-methylpropanoate

Methyl

30

2-{3-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl){2-(di
methylamino)ethyl}amino)methyl]phenoxy}-2-methylpropanoate

Ethyl

2-{3-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl){3-mo
rpholinopropyl}amino)methyl]phenoxy}-2-methylpropanoate

35

Methyl

2-{3-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl){3-morpholinopropyl}amino)methyl]phenoxy}-2-methylpropanoate

Isopropyl

2-[5-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butylamino)methyl]-2-fluorophenoxy]acetate

Isopropyl

2-{5-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetate

Ethyl

2-{5-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetate

Methyl

2-{5-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetate

Isopropyl

2-{5-[(3-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetate

Ethyl

2-{5-[(3-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetate

Methyl

2-{5-[(3-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetate

Isopropyl

2-[3-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]-2-methylphenoxy]acetate

Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-2-methylphenoxy}acetate

Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-methylphenoxy}acetate

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate

Methyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate

Ethyl

5 2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{ethyl(methyl)amino}acetamido)methyl]phenoxy}-2-methylpropanoate

Methyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{ethyl(methyl)amino}acetamido)methyl]phenoxy}-2-methylpropanoate

10 Isopropyl

2-{3-[(1-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy}acetate

Ethyl

15 2-{3-[(*N*-{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}-2-(diethylamino)acetamido)methyl]phenoxy}-2-methylpropanoate

Methyl

2-{3-[(*N*-{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}-2-(diethylamino)acetamido)methyl]phenoxy}-2-methylpropanoate

Ethyl

20 2-{3-[(*N*-{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}-2-(dimethylamino)acetamido)methyl]phenoxy}-2-methylpropanoate

Methyl

2-{3-[(*N*-{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}-2-(dimethylamino)acetamido)methyl]phenoxy}-2-methylpropanoate

25 Isopropyl

2-{3-[(*N*-{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate

Isopropyl

30 2-{3-[(*N*-{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}-2-[ethyl(methyl)amino]acetamido)methyl]phenoxy}acetate

Isopropyl

2-{3-[(*N*-{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}-2-(dimethylamino)acetamido)methyl]phenoxy}acetate

Isopropyl

35 2-{3-[(*N*-{3-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate

mino)acetamido)methyl]phenoxy]acetate

Isopropyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}acetate

5 Ethyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate

Methyl

10 2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate

Isopropyl

2-[3-((N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl)-2-fluorophenoxy]acetate

Isopropyl

15 2-[3-((N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(dimethylamino)acetamido)methyl)-2-fluorophenoxy]acetate

Isopropyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-fluorophenoxy}acetate

20 Isopropyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]-2-fluorophenoxy}acetate

Ethyl

25 2-[3-((N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(pyrrolidin-1-yl)acetamido)methyl]phenoxy)-2-methylpropanoate

Methyl

2-[3-((N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(pyrrolidin-1-yl)acetamido)methyl]phenoxy)-2-methylpropanoate

Ethyl

30 2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{pyrrolidin-1-yl}acetamido)methyl]phenoxy}-2-methylpropanoate

Methyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{pyrrolidin-1-yl}acetamido)methyl]phenoxy}-2-methylpropanoate

35 Isopropyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{pyrrolidin-1-yl}acetamido)methyl]phenoxy}acetate,

Ethyl

2-{3-[(N-{3-[4-amino-2-(propoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate and

Methyl


2-{3-[(N-{3-[4-amino-2-(propoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate,

or a pharmaceutically acceptable salt thereof.

According to another embodiment of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt thereof as hereinbefore defined, other than any one of the compounds described in List A.


The present invention further provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above which comprises either:

(a) where X¹ is a group NR⁵, reacting a compound of formula (II):



(II)


wherein Z¹, R³, R^a and m are as defined in formula (I) and L¹ is a leaving group, with a compound of formula (III):



(III)


where Y¹, R¹, R², R⁵, A and n are as defined in formula (I); or

(b) where X¹ is a group NR⁵ and Y¹ is C₁-C₆ alkylene, reacting a compound of formula (IV):



(IV)


where R^a , R^3 , R^5 , Z^1 and m are as defined in formula (I), with a compound of formula (V):



(V)


5 where R^1 , R^2 , A and n are as defined in formula (I) and Y^2 is a bond or a C_{1-5} alkylene group in the presence of a suitable reducing agent (e.g. sodium triacetoxyborohydride); or

(c) where X^1 is a group NR^5 , reacting a compound of formula (VI):



(VI)


10 wherein X^3 is a group NR^5 , and Z^1 , R^3 , R^5 , R^a and m are as defined in formula (I), with a compound of formula (VII):



(VII)


where Y^1 , R^1 , R^2 , A and n are as defined in formula (I) and L^2 is a leaving group; or

15 (d) where X^1 is a group NR^5CO , NR^5CONR^6 or NR^6CONR^5 , reacting a compound of formula (IVA):



(IVA)


where R^a , R^3 , Z^1 and m are as defined in relation to formula (I) and R^{5b} is a group R^5 or R^6 as defined in relation to formula (I),
with a compound of formula (VIII):



(VIII)

where L^3 is a leaving group such as halo, phenoxy or 4-nitrophenoxy, X^2 is a CO, CONR⁶ or CONR⁵ group respectively, and Y^1 , R^1 , R^2 , A and n are as defined in relation to formula (I); or

(e) where X^1 is CONR⁵, reacting a compound of formula (IX):



(IX)

where X^4 is an activated acid such as an acid chloride, R^a , R^3 , Z^1 and m are as defined in formula (I), with a compound of formula (III) as defined above; or

(f) where X^1 is $>N-COR^5$, or $>N-CONR^5$ R^{5a} , reacting a compound of formula (I) where X^1 is NR⁵ where R^5 is hydrogen with a compound of formula (X) or (XI) respectively



(X)



(XI)

where L⁴ is a leaving group such as halo for instance chloro, and R⁵ is defined in relation to formula (I);

and thereafter, if desired or necessary, carrying out one or more of the following steps:


- 5
- converting the compound obtained to a further compound of formula (I)
 - removal of any protecting groups
 - forming a pharmaceutically acceptable salt of the compound.

10 In reactions (a) and (c) above, suitable leaving groups L¹ and L² are halogen atoms such as bromine, or chlorine, as well as an activated alcohol such as mesylate or tosylate. The reactions may conveniently be carried out in an organic solvent such as acetonitrile, 1-methyl-2-pyrrolidinone or *N,N*-dimethylformamide at a temperature, for example, in the range from 0 to 150°C. The reaction may be
15 suitably effected by the presence of a base (e.g. sodium carbonate or potassium carbonate).

In process (b), the reaction may conveniently be carried out in an organic solvent such as 1-methyl-2-pyrrolidinone, 1,2-dichloroethane or tetrahydrofuran at a temperature, for example, in the range from 0 to 100°C.

20

Compounds of formula (II) may be prepared as illustrated in the reaction scheme A:



Scheme A

where R^a , m , R^3 and Z^1 are as defined in relation to formula (I) and P is a protecting group.

- 5 The compound of formula (B) is prepared by nitration of a compound of formula (A). Suitable nitrating agents include nitric acid. The reaction is suitably effected in an organic solvent such as an organic acid such as propionic acid. The reaction may be carried out at elevated temperature, for example from room

temperature to 150°C.

Compounds of formula (C) may be prepared by reacting the compound of formula (B) with a mixture of thionyl chloride and DMF to give the aryl chloride which can then be displaced with an aminoalkanol. The chlorination is suitably carried out in a solvent such as dichloromethane, preferably at elevated temperature. The displacement of the chloride with an aminoalkanol, is suitably carried out in the presence of a base for example triethylamine or Hunigs base and in an organic solvent such as dichloromethane, at a temperature in the range from 0 to 40°C.

Compounds of formula (D) are prepared by adding a suitable protecting group to the hydroxy terminal group. This can be effected using conventional chemistry as outlined for example in 'Protective Groups in Organic Synthesis' by Theodora Green (publisher: John Wiley & Sons). A suitable protecting group P for the hydroxy group is, for example, an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl, or a silyl group for example *tert*-butyl(dimethyl)silyl.

Compounds of formula (D) may also be prepared by adding a protected aminoalkanol to a compound of formula (B), using the same conditions as above.

The compound of formula (D) is then reduced to form a compound of formula (E). Suitable reducing agents include iron powder in a suitable solvent such as acetic acid or sodium borohydride in the presence of a suitable catalyst such as a 15% of nickel chloride in a suitable solvent such as methanol or hydrogenation. Suitable hydrogenation conditions include the use of hydrogen gas at elevated pressure, for example at 2-5Bar in the presence of a suitable catalyst such as a 1% platinum on carbon catalyst. The reaction is suitably effected at room temperature.

Compounds of formula (E) are then cyclised to form the compound of formula (F). Suitable cyclisation conditions include reaction with an acid chloride in the presence of a base such as triethylamine in a suitable solvent such as N-methyl pyrrolidinone or an acid in the presence of a coupling reagent such as O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluroniumhexafluorophosphate (HATU) in the presence of a base such as triethylamine in a suitable

solvent such as N-methyl pyrrolidine. Alternatively the compound of formula (F) may be prepared by cyclisation reaction with an orthoester in a suitable solvent such as N-methyl pyrrolidinone in the presence of a suitable catalyst such as 10mol% of toluensulphuric acid. The reaction is suitably effected at elevated temperatures, for example from 30-150°C.

Compounds of formula (F) may be oxidised to compounds of formula (G) by reaction with an oxidising agent such as *meta*-chloroperoxybenzoic acid or hydrogen peroxide. The reaction is suitably effected in an organic solvent such as dichloromethane or ethanol at reduced temperatures for example in the range of -10°C to room temperature.


Subsequently, the compound of formula (G) is reacted with p-toluenesulphonyl chloride and aqueous ammonia to convert it to the compound of formula (H). The reaction is suitably effected in an organic solvent such as dichloromethane. Temperatures in the range from 0-40°C and conveniently at room temperature are suitably employed.

Deprotection of the resultant compound of formula (H) yields a compound of formula (J). The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The product of formula (J) is then converted to a compound of formula (II) by formation of a suitable leaving group such as halo, for instance chloro or bromo, or an activated alcohol such as a mesylate or tosylate. For example, the chloride may be formed by reacting the compound of formula (J) with thionyl chloride, preferably in a solvent such as dichloromethane at a temperature between 20-40°C.

Compounds of formulae (IV) and (IVA) may be prepared by an analogous route as

illustrated in Scheme B.



Scheme B

where R^a , m , R^3 and Z^1 are as defined in relation to formula (I), R^{5b} is as defined in relation to formula (IVA) and P^1 is an amino protecting group.

Compounds of formula (K) or (L) may be prepared by reacting the compound of

formula (B) with a mixture of thionyl chloride and DMF to give the aryl chloride which can then be displaced with a di-amino alkane, or a protected form thereof. The chlorination is suitably carried out in a solvent such as dichloromethane, preferably at elevated temperature. The displacement of the chloride with a di-amino alkane, or a protected form thereof, is suitably carried out in the presence of a base for example triethylamine or Hunigs base and in an organic solvent such as dichloromethane, at a temperature in the range from 0 to 40°C.

Where a diaminoalkane is used, a compound of formula (K) is prepared which may be subsequently protected to form a compound of formula (L) using conventional methods.

A suitable protecting group P¹ is for example, a group such as an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl. A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group.


Reduction of the product of formula (L) using for example analogous conditions to those described above for the reduction of the compound of formula (D), will yield a compound of formula (M). This in turn may be cyclised to a compound of formula (N) using conditions analogous to those described above for the cyclisation of the compound of formula (E), oxidised to a compound of formula (Q) using conditions analogous to those described above for the oxidation of the compound of formula (F), and the product reacted with *p*-toluenesulphonyl chloride and aqueous ammonia to form the compound of formula (S) using for example conditions analogous to those described above for the preparation of the compound of formula (H).

Deprotection of the resultant compound of formula (S) yields a compound of formula (IV). The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an alkoxycarbonyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an alkoxycarbonyl group such as a *t*-butoxycarbonyl group may be

removed, for example, by treatment with a suitable acid as hydrochloric, sulfuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A phthaloyl protecting group which be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.


Suitably in Scheme B, R^5 is hydrogen, which may be converted to a different R^5 group later, for example once the compound of formula (IV) has been converted to a compound of formula (I).

Compounds of formula (VI) where X^3 is NR^5 may be prepared by reacting compounds of formula (II) with compounds of formula (XI):



Coupling conditions will be similar to those described above for the reactions (a) and (c).

Compounds of formula (I) may be converted to other compounds of formula (I) using conventional methods. For example, in process (h) above, compounds where R^5 is hydrogen may be reacted with compounds of formula (X):




where L^4 is a leaving group such as halo for instance chloro, and R^5 is defined in relation to formula (I). The reaction is suitably carried out in an organic solvent such as acetonitrile, dimethylformamide and/or dichloromethane optionally in the presence of a base such as triethylamine. Temperatures in the range from 0 to 150°C are suitably employed.

Similarly, oxidation of compounds of formula (I) during process (d) above can be carried out under conventional conditions, for example by reaction with an oxidising agent such as *meta*-chloroperoxybenzoic acid or hydrogen peroxide.

The reaction is suitably effected in an organic solvent such as dichloromethane or

ethanol at temperatures for example in the range of 0-40°C.

Compounds of formula (IX) above where X^4 is an activated acid such as an acid chloride are suitably prepared by a reaction as set out in Scheme C.



Scheme C

where R^a , m , R^3 and Z^1 are as defined in relation to formula (I), R^x is an alkyl such as methyl or ethyl, or ester protecting group.


Conditions used for the reactions shown in Scheme C are generally similar to those used in analogous steps in Scheme B. A compound of formula Y may be converted to a compound of formula Z with a base such as lithium or sodium hydroxide, in a suitable solvent such as tetrahydrofuran or methanol and water.

Alternatively the ester may be hydrolysed under acidic conditions such as aqueous HCl, preferably at elevated temperature. A compound of formula (IX) may be prepared from a compound of formula (Z) by activation of the acid to an acyl halide, such as chloride with a reagent such as thionyl chloride then treated with a compound of formula (III). The formation of the acid chloride may conveniently be carried out neat or in an organic solvent such as dichloromethane at a temperature, for example, in the range from 0 to 80°C. The activated acid is then treated with a compound of formula (III), the reaction may conveniently be carried out in an organic solvent such as tetrahydrofuran or dimethylformamide, with a base such as triethylamine at a temperature, for example, in the range from 0 to 80°C. Alternatively the acid may be activated with a coupling agent such as 1,3-dicyclohexylcarbodiimide or benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate.

A compound of formula (I) in which X^1 is NR^5 and R^5 is hydrogen may be converted to a corresponding compound of formula (I) in which R^5 is $-COCH_2NR^7R^8$ by reaction with chloroacetyl chloride followed by an amine of formula R^7R^8NH where R^7 and R^8 are as defined above. The first stage is suitably carried out in an organic solvent such as chloroform, dichloromethane or acetonitrile, with one equivalent of chloroacetyl chloride. Temperatures in the range from 0 to 50°C are suitably employed. In the second stage the reaction is suitably carried out in an organic solvent such as dichloromethane or acetonitrile, with excess of an amine R^7R^8NH . Temperatures in the range from 0°C to 100°C are suitably employed.

A compound of formula (I) in which X^1 is NR^5 and R^5 is hydrogen may also be converted to a corresponding compound of formula (I) in which R^5 is a C_1 - C_6 alkyl (e.g. propyl) group substituted by NR^7R^8 by reaction with a compound of formula (XX), $L^{10}-R^5$, where L^{10} is a leaving group such as halo for instance chloro and R^5 is as defined above. The reaction is suitably carried out in an organic solvent such as dimethylformaldehyde or acetonitrile, with preferably one equivalent of formula (XX) compound optionally in the presence of a base such as triethylamine and a salt such as sodium iodide or potassium iodide. Temperatures in the range from 0°C to 100°C are suitably employed.


A compound of formula (I) in which X^1 is NR^5 and R^5 is a C_1 - C_6 alkyl (e.g. propyl) group substituted by NR^7R^8 may also be prepared by reacting a compound of formula (XII):



where L^5 is a leaving group for example chloro or mesylate and m R^a , R^1 , n , R^2 , R^3 , A , Z^1 and Y^1 are as defined above, with an amine of formula (XXI), R^7R^8NH , where R^7 and R^8 are as defined above. The reaction may be carried out using an excess of the amine R^7R^8NH in an organic solvent such as DMF or dioxane at a temperature in the range of, for example, 40°C - 150°C . Sodium iodide may be used as an additive in the reaction.

10

A compound of formula (XII) may be prepared from a corresponding compound of formula (XIII):



The alcohol may be converted into a leaving group using conventional methods, for example, by reaction with thionyl chloride in an appropriate solvent such as DCM at a temperature from 20 - 100°C .

20

A compound of formula (XIII) may be formed using the route in scheme A and the chemistry above.

Compounds of formulae (III), (V), (VII), (VIII), A, (X), (XI), (XX) and (XXI) are known compounds or can be prepared from known compounds by conventional


25

methods.

It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the reagents may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups.

The protection and deprotection of functional groups is described in 'Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Synthesis', 3rd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience (1999).

In another embodiment of the invention there is provided an intermediate compound of the formula (I'):



wherein Z¹, Y¹, R^a, R^b, R^c, R², R³, m and n are as defined in Claim 1; and R^{1'} represents hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, or a 3- to 8-membered saturated heterocyclic ring group comprising a O atom, wherein R^{1'} is optionally substituted by one or more substituents independently selected from halogen, cyano, hydroxyl and C₁-C₃ alkoxy; or a salt thereof, for synthesis of a compound of formula (I) or its pharmaceutically acceptable salt.

The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, trifluoroacetate, sulphate, phosphate, acetate, fumarate, maleate, tartrate, lactate, citrate, pyruvate, succinate, oxalate, methanesulphonate or *p*-toluenesulphonate. Preferred salts include dimethane sulphonic acid,

monosaccharin, disaccharin, di-1-hydroxy-2-naphthoic acid (di-xinafoate), dibenzenesulphonic acid (di-besylate), mandelic and fumaric acid salts.

Compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses the use of all geometric and optical isomers (including atropisomers) of the compounds of formula (I) and mixtures thereof including racemates. The use of tautomers and mixtures thereof also form an aspect of the present invention. Enantiomerically pure forms are particularly desired.

The compounds of formula (I) and their pharmaceutically acceptable salts have activity as pharmaceuticals, in particular as modulators of toll-like receptor (especially TLR7) activity, and is expected to provide an immuno-modulator effect and thus be useful as a therapeutic and prophylactic agent for diseases associated with an abnormal immune response (e.g. autoimmune diseases and allergic diseases) and various infections and cancers which are required for activation of an immune response. Compound (I), or a pharmaceutically acceptable salt thereof may also be useful as a vaccine adjuvant. For example, Compound (I), or a pharmaceutically acceptable salt thereof, may be administered to a mammal, including man, for the treatment of the following conditions or diseases:

1. respiratory tract: obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin and NSAID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, and iatrogenic cough; acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and

seasonal allergic rhinitis including rhinitis nervosa (hay fever); nasal polyposis; acute viral infection including the common cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus;

2. skin: psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, actinic keratosis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis; hemangioma; pre-cancerous skin lesions; basal cell carcinoma, for example superficial basal cell carcinoma, nodular basal cell carcinoma and bowen's disease; cutaneous lymphomas, non-melanoma skin cancer and other dysplastic lesions; drug-induced disorders including fixed drug eruptions, skin scarring, including keloids; cutaneous infections, including viral cutaneous infections; and cosmetic effects including photo-damaged skin;

3. eyes: blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; iritis; anterior and posterior uveitis; choroiditis; autoimmune, degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; infections including viral, fungal, and bacterial;

4. genitourinary: nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer; acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvo-vaginitis; Peyronie's disease; erectile dysfunction (both male and female);

5. allograft rejection: acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; or chronic graft versus host disease;

6. other auto-immune and allergic disorders including rheumatoid arthritis, irritable bowel syndrome, systemic lupus erythematosus, multiple sclerosis, Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic thrombocytopaenic purpura, eosinophilic fasciitis, hyper-IgE

syndrome, antiphospholipid syndrome and Sazary syndrome;

7. oncology: treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes; and,

8. infectious diseases: virus diseases such as genital warts, common warts, plantar warts, hepatitis B, hepatitis C, herpes simplex virus, molluscum contagiosum, variola, human immunodeficiency virus (HIV), human papilloma virus (HPV), cytomegalovirus (CMV), varicella zoster virus (VZV), rhinovirus, adenovirus, coronavirus, influenza, para-influenza; bacterial diseases such as tuberculosis and mycobacterium avium, leprosy; other infectious diseases, such as fungal diseases, chlamydia, candida, aspergillus, cryptococcal meningitis, pneumocystis carinii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection and leishmaniasis.

The compounds of formula (I) and their pharmaceutically acceptable salts have antedrug properties. An antedrug is defined as an active synthetic derivative that is designed to undergo biotransformations to a readily excretable less active form upon entry into the systemic circulation, therefore minimizing systemic side-effects. Thus, on administration, a compound of the invention is rapidly degraded enzymatically to yield a degradation product having a substantially reduced medical effect. A medical effect as defined herein means a pharmacological activity of the compound of the invention, including specifically interferon inducing activity and/or suppression of IL4/IL5 production activity.

The medical effect of the degradation product is preferably 10 times, more preferably 100 times less than that of the compound of the invention (i.e. parent compound).

The pharmacological activity can be measured using methods known in the art, preferably using in vitro evaluation methods such as commercially available ELISA kits or the biological assay described in Example 7 of the present specification.

Furthermore a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R¹ represents branched chain alkyl, ⁱPr, or R^b and R^c represent methyl show good chemical stability.

5

Thus, the present invention provides a compound of formula (I) or a pharmaceutically- acceptable salt thereof as hereinbefore defined for use in therapy.

10 In a further aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for use in therapy.

In the context of the present specification, the term "therapy" also includes
15 "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at
20 increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.

25

In particular, the compounds of the invention may be used in the treatment of asthma, COPD, allergic rhinitis, allergic conjunctivitis, cancer, hepatitis B, hepatitis C, HIV, HPV, bacterial infections or a skin condition as listed
hereinbefore (for example, atopic dermatitis, actinic keratosis, pre-cancerous skin
30 lesions or cutaneous viral infections). Compound (I), or a pharmaceutically acceptable salt thereof, may also be useful as a vaccine adjuvant.

The anti-cancer treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one
35 or more of the following categories of anti-tumour agents:

(i) other antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea or paclitaxel); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere and polokinese inhibitors); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);

(ii) cytostatic agents such as antioestrogens (for example tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and idoxifene), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 α -reductase such as finasteride;

(iii) anti-invasion agents (for example c-Src kinase family inhibitors like 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (AZD0530; International Patent Application WO 01/94341) and *N*-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino}thiazole-5-carboxamide (dasatinib, BMS-354825; J. Med. Chem., 2004, 47, 6658-6661), and metalloproteinase inhibitors like marimastat, inhibitors of urokinase plasminogen activator receptor function or antibodies to Heparanase);

(iv) inhibitors of growth factor function: for example such inhibitors include growth factor antibodies and growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [HerceptinTM], the anti-EGFR antibody panitumumab, the anti-erbB1 antibody cetuximab [Erbix, C225] and any growth factor or growth factor receptor antibodies disclosed by Stern *et al.* Critical reviews in oncology/haematology, 2005, Vol. 54, pp11-29); such inhibitors also

include tyrosine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as *N*-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, ZD1839),
5 *N*-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-*N*-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)-quinazolin-4-amine (CI 1033), erbB2 tyrosine kinase inhibitors such as lapatinib, inhibitors of the hepatocyte growth factor family, inhibitors of the platelet-derived growth
10 factor family such as imatinib, inhibitors of serine/threonine kinases (for example Ras/Raf signalling inhibitors such as farnesyl transferase inhibitors, for example sorafenib (BAY 43-9006)), inhibitors of cell signalling through MEK and/or AKT kinases, inhibitors of the hepatocyte growth factor family, c-kit inhibitors, abl kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors;
15 aurora kinase inhibitors (for example AZD1152, PH739358, VX-680, MLN8054, R763, MP235, MP529, VX-528 AND AX39459) and cyclin dependent kinase inhibitors such as CDK2 and/or CDK4 inhibitors;

(v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, [for example the anti-vascular endothelial cell growth
20 factor antibody bevacizumab (Avastin™) and VEGF receptor tyrosine kinase inhibitors such as 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline (ZD6474; Example 2 within WO 01/32651), 4-(4-fluoro-2-methylindol-5-ylloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quina
25 zoline (AZD2171; Example 240 within WO 00/47212), vatalanib (PTK787; WO 98/35985) and SU11248 (sunitinib; WO 01/60814), compounds such as those disclosed in International Patent Applications WO97/22596, WO 97/30035, WO 97/32856 and WO 98/13354 and compounds that work by other mechanisms (for example linomide, inhibitors of integrin $\alpha\beta 3$ function and angiostatin)];

30 (vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213;

(vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;

35 (viii) gene therapy approaches, including for example approaches to replace

aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and

(ix) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

The invention still further provides a method of treating, or reducing the risk of, an obstructive airways disease or condition (e.g. asthma or COPD) which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.

Accordingly, as a further aspect of the invention there is provided Compound (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of asthma, COPD or allergic rhinitis.

As a further aspect of the invention, there is provided Compound (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of asthma.

As a further aspect of the invention, there is provided Compound (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of COPD.

As a further aspect of the invention, there is provided Compound (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of allergic rhinitis.

As a further aspect of the invention, there is provided Compound (I), or a pharmaceutically acceptable salt thereof, for use as a vaccine adjuvant.

As a further aspect of the invention, there is provided Compound (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of a skin condition as hereinbefore described (for example atopic dermatitis, actinic keratosis, pre-cancerous lesions or cutaneous viral infections).

As a further aspect of the invention, there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of asthma, COPD or allergic rhinitis.

As a further aspect of the invention, there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of asthma.

As a further aspect of the invention, there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of COPD.

As a further aspect of the invention, there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of allergic rhinitis.

As a further aspect of the invention, there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a skin condition as hereinbefore described (for example atopic dermatitis, actinic keratosis, pre-cancerous lesions or cutaneous viral infections).

As a further aspect of the invention, there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, as a vaccine adjuvant, in the manufacture of a vaccine for the treatment of a disease or condition.

The invention therefore provides a method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of Compound (I), or a pharmaceutically acceptable salt thereof.

The invention also provides a method of treating an airways disease, e.g. a reversible obstructive airways disease such as asthma, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of Compound (I), or a pharmaceutically acceptable salt thereof.

The invention still further provides a method of treating, or reducing the risk of, a disease or condition comprising or arising from abnormal cell growth (e.g. a cancer), which method comprises administering to a patient in need thereof a therapeutically effective amount of Compound (I), or a pharmaceutically acceptable salt thereof.

The invention still further provides a method of treating, or reducing the risk of, a skin disease or condition as hereinbefore described (for example atopic dermatitis,

actinic keratosis, pre-cancerous lesions or cutaneous viral infections), which method comprises administering to a patient in need thereof a therapeutically effective amount of Compound (I), or a pharmaceutically acceptable salt thereof. The invention still further provides a method of treating, or reducing the risk of, a disease or condition, which method comprises administering to a patient in need thereof a therapeutically effective amount of a vaccine and a salt of Compound (I) defined herein or a solvate of the salt.

The invention still further provides a method of increasing the response to a vaccine in a patient, which method comprises administering to a patient in need thereof a therapeutically effective amount of a vaccine and Compound (I), or a pharmaceutically acceptable salt thereof.

For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. For example, the daily dosage of the compound of the invention, if inhaled, may be in the range from 0.05 micrograms per kilogram body weight ($\mu\text{g/kg}$) to 100 micrograms per kilogram body weight ($\mu\text{g/kg}$). For example, a dose of about 0.1 to 100 $\mu\text{g/kg}$ such as a dose of about 0.1, 0.5, 1, 2, 5, 10, 20, 50 or 100 $\mu\text{g/kg}$. Alternatively, if the compound is administered orally, then the daily dosage of the compound of the invention may be in the range from 0.01 micrograms per kilogram body weight ($\mu\text{g/kg}$) to 100 milligrams per kilogram body weight (mg/kg).

The dosages mentioned herein refer to the dose of Compound (I) as the free base. Accordingly, the equivalent dose of a particular salt will be higher because of the increased molecular weight of the salt compared to the free base.

The compounds of formula (I) and pharmaceutically acceptable salts thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals-The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.

Depending on the mode of administration, the pharmaceutical composition will

preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

5

The present invention also provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

10

The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined with a pharmaceutically acceptable adjuvant, diluent or carrier.

15

The pharmaceutical compositions may be administered topically (including to the skin, eye, buccal cavity, respiratory tract or nasally) in the form, e.g., of creams, solutions, suspensions, heptafluoroalkane (HFA) aerosols and dry powder formulations, for example, formulations administered from a suitable device such as a pressurised metered dose inhaler (pMDI), a dry powder inhaler (DPI) or nebuliser, such as the inhaler device known as the Turbuhaler™; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules; or by parenteral administration in the form of a sterile solution, suspension or emulsion for injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion); or by rectal administration in the form of suppositories.

20

25

Dry powder formulations and pressurized HFA aerosols of the compounds of the invention (including pharmaceutically acceptable salts) may be administered by oral or nasal inhalation. For inhalation, the compound is desirably finely divided. The finely divided compound preferably has a mass median diameter of less than 10 micrometres (μm), and may be suspended in a propellant mixture with the assistance of a dispersant, such as a C₈-C₂₀ fatty acid or salt thereof, (for example, oleic acid), a bile salt, a phospholipid, an alkyl saccharide, a perfluorinated or polyethoxylated surfactant, or other pharmaceutically acceptable dispersant.

30

35

For nasal administration the compound is suitably dissolved in an aqueous medium, which is suitably buffered to maintain the pH at a desired level.

The compounds of the invention may also be administered by means of a dry powder inhaler. The inhaler may be a single or a multi dose inhaler, and may be a breath actuated dry powder inhaler.

One possibility is to mix the finely divided compound of the invention with a carrier substance, for example, a mono-, di- or polysaccharide, a sugar alcohol, or another polyol. Suitable carriers are sugars, for example, lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol; and starch. Alternatively the finely divided compound may be coated by another substance. The powder mixture may also be dispensed into hard gelatine capsules, each containing the desired dose of the active compound.

Another possibility is to process the finely divided powder into spheres which break up during the inhalation procedure. This spheronized powder may be filled into the drug reservoir of a multidose inhaler, for example, that known as the Turbuhaler™ in which a dosing unit meters the desired dose which is then inhaled by the patient. With this system the active ingredient, with or without a carrier substance, is delivered to the patient.

For oral administration the compound of the invention may be admixed with an adjuvant or a carrier, for example, lactose, saccharose, sorbitol, mannitol; a starch, for example, potato starch, corn starch or amylopectin; a cellulose derivative; a binder, for example, gelatine or polyvinylpyrrolidone; and/or a lubricant, for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and the like, and then compressed into tablets. If coated tablets are required, the cores, prepared as described above, may be coated with a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum and titanium dioxide. Alternatively, the tablet may be coated with a suitable polymer dissolved in a readily volatile organic solvent.

For the preparation of soft gelatine capsules, the compound of the invention may be admixed with, for example, a vegetable oil or polyethylene glycol. Hard gelatine capsules may contain granules of the compound using either the

above-mentioned excipients for tablets. Also liquid or semisolid formulations of the compound of the invention may be filled into hard gelatine capsules.

Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing the compound of the invention, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid preparations may contain colouring agents, flavouring agents, saccharine and/or carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art.

The compounds of the invention may also be administered in conjunction with other compounds used for the treatment of the above conditions.

The invention therefore further relates to combination therapies wherein a compound of the invention or a pharmaceutical composition or formulation comprising a compound of the invention is administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed.

In particular, for the treatment of the inflammatory diseases COPD, asthma and allergic rhinitis the compounds of the invention may be combined with agents such as tumour necrosis factor alpha (TNF-alpha) inhibitors such as anti-TNF monoclonal antibodies (for example Remicade, CDP-870 and adalimumab) and TNF receptor immunoglobulin molecules (such as Enbrel); non-selective cyclo-oxygenase COX-1/COX-2 inhibitors whether applied topically or systemically (such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, azapropazone, pyrazolones such as phenylbutazone, salicylates such as aspirin), COX-2 inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib, lumarocoxib, parecoxib and etoricoxib); glucocorticosteroids (whether administered by topical, oral, intramuscular, intravenous, or intra-articular routes); methotrexate, lefunomide; hydroxychloroquine, d-penicillamine, auranofin or other parenteral or oral gold preparations.

The present invention still further relates to the combination of a compound of the

invention and a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist such as; zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; a N-(5-substituted)-thiophene-2-alkylsulfonamide;

5 2,6-di-*tert*-butylphenolhydrazones; a methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; a pyridinyl-substituted 2-cyanonaphthalene compound such as L-739,010; a 2-cyanoquinoline compound such as L-746,530; or an indole or quinoline compound such as MK-591, MK-886, and BAY x 1005.

10 The present invention further relates to the combination of a compound of the invention and a receptor antagonist for leukotrienes (LT B₄, LTC₄, LTD₄, and LTE₄) selected from the group consisting of the phenothiazin-3-*ls* such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as
15 ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195.

20 The present invention still further relates to the combination of a compound of the invention and a phosphodiesterase (PDE) inhibitor such as a methylxanthanine including theophylline and aminophylline; a selective PDE isoenzyme inhibitor including a PDE4 inhibitor an inhibitor of the isoform PDE4D, or an inhibitor of PDE5.

25 The present invention further relates to the combination of a compound of the invention and a histamine type 1 receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, or mizolastine; applied orally, topically or parenterally.

30 The present invention still further relates to the combination of a compound of the invention and a gastroprotective histamine type 2 receptor antagonist.

35 The present invention further relates to the combination of a compound of the invention and an antagonist of the histamine type 4 receptor.

The present invention still further relates to the combination of a compound of the invention and an alpha-1/alpha-2 adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, tramazoline hydrochloride or ethylnorepinephrine hydrochloride.

The present invention further relates to the combination of a compound of the invention and an anticholinergic agent including muscarinic receptor (M1, M2, and M3) antagonists such as atropine, hyoscine, glycopyrrrolate, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirzepine or telenzepine.

The present invention still further relates to the combination of a compound of the invention together with a beta-adrenoceptor agonist (including beta receptor subtypes 1-4) such as isoprenaline, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol.

The present invention further relates to the combination of a compound of the invention and a chromone, such as sodium cromoglycate or nedocromil sodium.

The present invention still further relates to the combination of a compound of the invention together with an insulin-like growth factor type I (IGF-1) mimetic.

The present invention still further relates to the combination of a compound of the invention and a glucocorticoid, such as flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, ciclesonide or mometasone furoate.

The present invention still further relates to the combination of a compound of the invention together with an inhibitor of matrix metallo proteases (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11) and MMP-9 and MMP-12.

The present invention still further relates to the combination of a compound of the invention together with modulators of chemokine receptor function such as antagonists of CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, 5 CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX3CR1 for the C-X3-C family.

The present invention still further relates to the combination of a compound of the invention together with a cytokine or modulator of cytokine function, including 10 alpha-, beta-, and gamma-interferon; interleukins (IL) including IL1 to 15, and interleukin antagonists or inhibitors, including agents which act on cytokine signalling pathways.

The present invention still further relates to the combination of a compound of the invention together with an immunoglobulin (Ig) or Ig preparation or an antagonist 15 or antibody modulating Ig function such as anti-IgE (omalizumab).

The present invention further relates to the combination of a compound of the invention and another systemic or topically-applied anti-inflammatory agent, 20 such as thalidomide or a derivative thereof, a retinoid, dithranol or calcipotriol.

The present invention further relates to the combination of a compound of the invention together with an antibacterial agent such as a penicillin derivative, a tetracycline, a macrolide, a beta-lactam, a fluoroquinolone, metronidazole, an 25 inhaled aminoglycoside; an antiviral agent including acyclovir, famciclovir, valaciclovir, ganciclovir, cidofovir, amantadine, rimantadine, ribavirin, zanamavir and oseltamavir; a protease inhibitor such as indinavir, nelfinavir, ritonavir, and saquinavir; a nucleoside reverse transcriptase inhibitor such as didanosine, lamivudine, stavudine, zalcitabine or zidovudine; or a non-nucleoside reverse 30 transcriptase inhibitor such as nevirapine or efavirenz.

The present invention will be further explained by reference to the following illustrative examples.

Experimental

Unless otherwise stated organic solutions were dried over magnesium sulphate. RPHPLC means reversed phase preparative HPLC using Waters Symmetry C8, Xterra, Xbridge or Phenomenex Gemini columns using acetonitrile and either aqueous ammonium acetate, ammonia, formic acid or trifluoroacetic acid as buffer where appropriate. Column chromatography was carried out on silica gel. Treating with SCX means the mixture was absorbed on SCX and eluted with an appropriate solvent such as methanol or acetonitrile then the free base product eluted with aqueous ammonia/methanol.

The following abbreviations are used;

EtOAc	ethyl acetate
DCM	dichloromethane
NMP	<i>N</i> -methylpyrrolidinone
NBS	<i>N</i> -bromosuccinimide
DMF	<i>N,N</i> -dimethylformamide
DMSO	dimethylsulfoxide
THF	tetrahydrofuran
MeOH	methanol
TFA	trifluoroacetic acid
HCl	hydrogen chloride
K ₂ CO ₃	potassium carbonate
NaHCO ₃	sodium hydrogen carbonate
TEA	triethylamine
MeCN	acetonitrile
HATU	O-(7-azabenzotriazol-1-yl)- <i>N,N,N',N'</i> -tetramethyluronium

hexafluorophosphate

EDCI	<i>N</i> -(3-dimethylaminopropyl)- <i>N'</i> -ethylcarbodiimide
------	---

hydrochloride

HOBt	1-hydroxybenzotriazole
rt	room temperature
h	hours
min	minutes
M	molar

MS	mass spectrometry
----	-------------------

PyBop Benzotriazol-1-yloxytripyrrolidinophosphonium
hexafluorophosphate

APCI atmospheric chemical ionisation method


ESI electron spray ionisation method

5 NMR nuclear magnetic resonance

Example 1

Methyl

10 2-(3-([3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylamino)methyl]phenoxy)acetate



(i) 3-Nitroquinolin-4-ol

4-Hydroxyquinoline (79.3 g) and propionic acid (790 mL) were combined and heated to 125°C. Nitric acid (79 mL) was added dropwise over 40 minutes. The reaction mixture was stirred at reflux temperature for a further 3h and cooled to rt. The mixture was diluted with ethanol and the solid was collected by vacuum filtration. The solid was washed with ethanol, water then ethanol. The residue was refluxed in ethanol and the hot mixture was filtered and dried to give the subtitle compound (80.9 g). Yield: 76%

20 ¹H NMR δ (DMSO-*d*₆) 13.00 (1H, s), 9.19 (1H, s), 8.26-8.23 (1H, m), 7.81-7.77 (1H, m), 7.75-7.71 (1H, m), 7.53-7.49 (1H, m)

(ii) *tert*-Butyl {3-[(3-nitroquinolin-4-yl)amino]propyl}carbamate

To a stirred solution of 3-nitroquinolin-4-ol (30 g) in DCM (250 mL) was added DMF (6 mL) and thionyl chloride (13.9 mL) and the reaction mixture was refluxed for 2.5 h when all solids dissolved. The solution was cooled to 0 °C and a solution of (3-aminopropyl)-carbamic acid *tert*-butyl ester (45.6 g) and Et₃N (67 mL) in DCM (250 mL) was added dropwise. The reaction mixture was stirred overnight and then evaporated. Potassium carbonate solution and MTBE were added to the residue and stirred for 1h. The product was filtered and washed

with water and MTBE and dried to give the subtitle compound (50.7 g). Yield: 94%
 ^1H NMR δ (CDCl_3) 9.66 (1H, s), 9.36 (1H, s), 8.31-8.29 (1H, m), 7.98-7.95 (1H, m),
7.77-7.72 (1H, m), 7.48-7.44 (1H, m), 4.67 (1H, s), 4.00-3.96 (2H, m), 3.34-3.29
(2H, m), 2.03-1.96 (2H, m), 1.41 (9H, s)

5 MS: ESI 347 (M+1)

(iii) *tert*-Butyl {3-[(3-aminoquinolin-4-yl)amino]propyl}carbamate

10 $\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$ (15.4 g) was dissolved in MeOH (220 ml) and cooled to 5-10°C. After
the addition of sodium borohydride (2.4 g), the product from step (ii) (22.4 g) was
added. More sodium borohydride (9.8 g) was added slowly under 23°C and the
reaction mixture was stirred for 1h. The reaction mixture was filtered using
celite and the filtrate was poured into sodium bicarbonate solution (300 ml). After
removal of the 250 ml of solvent, extracted with chloroform, dried, filtered and
evaporated to give the subtitle compound (21.7 g). Yield 85%.

15 ^1H NMR δ ($\text{DMSO}-d_6$) 8.36 (1H, s), 8.00-7.97 (1H, m), 7.72-7.70 (1H, m), 7.36 -
7.29 (2H, m), 6.87-6.84 (1H, m), 5.00 (2H, s), 4.76 (1H, t, $J = 6.4$ Hz), 3.13-3.09
(2H, m), 3.01-2.97 (2H, m), 1.62-1.58 (2H, m), 1.39 (9H, s)

(iv) *tert*-Butyl [3-(2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]carbamate

20 The product from step (iii) (49.7 g) was dissolved in NMP (150 mL) and
ortho-valeric acid triethyl ester (54.6 mL) and para-toluene sulufonic acid mono
hydrate (2.7 g) were added. The reaction mixture was stirred at 80°C for 1h.
Sodium bicarbonate solution (300 ml), water (500 ml) and diethyl ether (200 ml)
were added to the reaction mixture and stirred for 1h. The solid precipitate was
25 filtered and washed with water and diethyl ether to give subtitle compound (44.8
g).

^1H NMR δ ($\text{DMSO}-d_6$) 9.12 (1H, s), 8.37-8.35 (1H, m), 8.15-8.12 (1H, m), 7.69-7.66
(2H, m), 7.15-7.10 (1H, brs), 4.59 (2H, t, $J = 7.6$ Hz), 3.11-3.07 (2H, m), 2.95 (2H,
t, $J = 7.2$ Hz), 1.97-1.92 (2H, m), 1.86-1.81 (2H, m), 1.48-1.37 (11H, m), 0.95 (3H,
30 t, $J = 7.6$ Hz),

MS: ESI 383 (M+1)

(v) *tert*-Butyl

[3-(2-butyl-5-oxido-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]carbamate

35 The product from step (iv) (42 g) was dissolved in DCM (2000 mL) and cooled to

5°C. 3-Chloroperoxybenzoic acid (38 g) was added and the reaction was allowed to warm to room temperature. The reaction mixture was stirred for 12h. The reaction mixture was washed with saturated sodium thiosulfate solution and sodium bicarbonate solution, dried, filtered and evaporated to give the subtitle compound (48 g).

MS: ESI 399 (M+1)

(vi) *tert*-Butyl

[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]carbamate

p-Toluenesulphonyl chloride (25 g) was added portionwise to a vigorously stirred mixture of the product from step (v) (48 g) in DCM (420 mL) and ammonium hydroxide solution (35%, 2.5 mL) at 0°C. The mixture was allowed to warm to rt over night then partitioned between water/DCM, washed with saturated sodium bicarbonate solution, dried, filtered and the solvent evaporated. The solid product was recrystallized from the mixture of MeOH and acetonitrile to give the subtitle compound (25 g) (yield 57% by 2 steps).

¹H NMR δ (DMSO-*d*₆) 8.04-8.02 (1H, m), 7.60-7.57 (1H, m), 7.42-7.38 (1H, m), 7.24-7.20 (1H, m), 7.14-7.11 (1H, m), 6.45 (2H, s), 4.48 (2H, t, *J* = 7.6 Hz), 3.11-3.06 (2H, m), 2.91-2.87 (2H, m), 1.93-1.89 (2H, m), 1.82-1.75 (2H, m), 1.47-1.37 (11H, m), 0.97 (3H, t, *J* = 7.6 Hz),

MS: ESI 398 (M+1)

(vii) 1-(3-Aminopropyl)-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine

The product from step (vi) (124 g) was suspended in EtOH (270 mL) and 6N HCl (270 mL) was added. The reaction mixture was stirred at 50°C for 1h. After the removal of the 300 ml of the solvent, the residue was washed with chloroform and then poured into 7% NH₃ solution, extracted with EtOH/CHCl₃ (1/5), dried and evaporated to give the subtitle compound (63 g). Yield 94%.

¹H NMR δ (CDCl₃) 8.12 (1H, d, *J* = 7.2 Hz), 7.60-7.58 (1H, m), 7.41-7.37 (1H, m), 7.25-7.21 (1H, m), 6.43 (2H, s), 4.55 (2H, t, *J* = 7.6 Hz), 2.93 (2H, t, *J* = 7.6 Hz), 2.67 (2H, t, *J* = 7.6 Hz), 1.87-1.75 (4H, m), 1.55-1.41 (4H, m), 0.95 (3H, t, *J* = 7.6 Hz).

MS: ESI 298 (M+1)

(viii) Methyl

2-(3-([3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylamino)methyl]phenoxy)acetate


To a solution of the product from step (vii) (5.01 g, 16.8 mmol) in MeOH (75 ml) were added methyl (3-formylphenoxy)acetate (3.26 g, 16.8 mmol), AcOH (1.94 ml, 33.6 mmol) and NaBH₃CN (2.21 g, 33.7 mmol) at room temperature. After stirring for 26 h at the same temperature, the reaction mixture was concentrated. The residue was washed with 1% NH₃ aq. (100 ml), and extracted with CHCl₃ (100 ml x 3). The combined extracts were dried over MgSO₄ and concentrated. The residue was purified by flash column chromatography to afford the subtitle compound (5.38 g, 67%) as colorless amorphous.

¹H NMR δ (CDCl₃) 8.13 (1H, d, J = 8.2), 7.60 (1H, d, J = 8.2), 7.40 (1H, dd, J = 7.2, 7.9), 7.26-7.18 (2H, m), 6.97-6.95 (2H, m), 6.81-6.77 (1H, m), 6.46 (2H, brs), 4.78 (2H, s), 4.58 (2H, brt, J = 7.1), 3.68 (3H, s), 3.68 (2H, s), 2.94 (2H, t, J = 7.7), 2.62-2.58 (2H, m), 2.38 (1H, brs), 2.00-1.91 (2H, m), 1.79 (2H, tt, J = 7.5, 7.7), 1.44 (2H, qt, J = 7.3, 7.5), 0.95 (3H, t, J = 7.3).

Example 2

Methyl

(3-([3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl](chloroacetyl)amino)methyl]phenoxy)acetate hydrochloride




To a solution of the product from example 1 (5.38 g, 11.3 mmol) in CHCl₃ (160 ml) was added chloroacetyl chloride (0.9 ml, 11.3 mmol) at 0°C. After stirring for 2 h at the same temperature, the reaction mixture was quenched by 0.2N HCl (220 ml). The aq. layer was extracted with CHCl₃ (220 ml x 3), dried over MgSO₄, and concentrated. The residue was purified by flash column chromatography to give the title compound (6.46 g, 97%) as a white solid.

¹H NMR δ (DMSO-*d*₆) 13.69 (1H, brs), 8.58 (1H, brs), 8.17 (1/2H, d, J = 8.4), 8.13 (1/2H, d, J = 8.2), 7.83-7.81 (1H, m), 7.71 (1/2H, d, J = 7.5), 7.69 (1/2H, d, J = 8.0), 7.56-7.50 (1H, m), 7.22 (1/2H, dd, J = 7.7, 7.9), 7.17 (1/2H, dd, J = 7.8, 7.9),

6.82-6.73 (3H, m), 4.75 (1H, s), 4.72 (1H, s), 4.64-4.57 (1H, m), 4.58 (1H, s), 4.56-4.47 (1H, m), 4.51 (1H, s), 4.49 (1H, s), 4.42 (1H, s), 3.69 (3/2H, s), 3.68 (3/2H, s), 3.53 (1H, brt, $J = 7.6$), 3.45 (1H, brt, $J = 7.6$), 2.95 (1H, dd, $J = 7.7, 7.8$), 2.92 (1H, dd, $J = 7.6, 7.8$), 2.11-1.92 (2H, m), 1.83-1.77 (2H, m), 1.50-1.39 (2H, m), 0.96 (3/2H, t, $J = 7.4$), 0.95 (3/2H, t, $J = 7.3$).

Example 3

Methyl (4-{[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]amino}methoxy)phenylacetate




The title compound was prepared by the method of example 1 step (viii) using methyl (4-formylphenoxy)acetate (5.01 g) to afford the title compound, 2.70 g (34%) as colorless amorphous.

^1H NMR δ (CDCl_3) 8.12 (1H, d, $J = 8.1$), 7.16 (1H, d, $J = 8.2$), 7.40 (1H, dd, $J = 7.2, 8.2$), 7.27-7.24 (2H, m), 7.20 (1H, dd, $J = 7.2, 8.1$), 6.88-6.86 (2H, m), 6.45 (2H, brs), 4.78 (2H, s), 4.58 (2H, brt, $J = 7.2$), 3.70 (3H, s), 3.63 (2H, s), 2.93 (2H, dd, $J = 7.6, 7.9$), 2.60-2.55 (2H, m), 2.26 (1H, brs), 2.00-1.91 (2H, m), 1.79 (2H, tt, $J = 7.5, 7.7$), 1.43 (2H, qt, $J = 7.3, 7.5$), 0.95 (3H, t, $J = 7.3$).

Example 4

Methyl (4-{[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl](chloroacetyl)amino}methoxy)phenylacetate hydrochloride



By the method of example 2 using the product of example 3 (2.70 g), there was


obtained the title compound, 3.13 g (94%) as a white solid.

¹H NMR δ (DMSO-d₆) 13.82 (1H, brs), 8.60 (1H, brs), 8.21 (1/2H, d, J = 8.2), 8.13 (1/2H, d, J = 8.2), 7.82 (1H, dd, J = 3.1, 8.3), 7.73-7.68 (1H, m), 7.57-7.52 (1H, m), 7.15 (1H, d, J = 8.6), 7.08 (1H, d, J = 8.6), 6.87 (1H, d, J = 8.6), 6.81 (1H, d, J = 8.6), 4.77 (1H, s), 4.75 (1H, s), 4.65-4.59 (1H, m), 4.55 (1H, s), 4.55-4.49 (1H, m), 4.48 (1H, s), 4.45 (1H, s), 4.43 (1H, s), 3.70 (3H, s), 3.54-3.39 (2H, m), 2.97-2.89 (2H, m), 2.12-1.92 (2H, m), 1.86-1.74 (2H, m), 1.50-1.39 (2H, m), 0.96 (3/2H, t, J = 7.3), 0.95 (3/2H, t, J = 7.3).

Example 5

Methyl

(4-[[[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl](*N,N*-dimethylglycyl)amino]methyl}phenoxy)acetate



The product from example 4 (206 mg) was dissolved in MeCN (6 ml) and Me₂NH (2.0 M THF solution, 0.93 ml) was added. After stirring for 15 h, the reaction mixture was diluted with EtOAc, washed with water (twice), brine, dried and filtered, and the solvent was evaporated. The residue was purified by silica gel chromatography which afforded 189 mg of the desired product as a colorless gum.

Yield 90%.


¹H NMR δ (DMSO-d₆) 8.02 (0.5H, d, J = 8.1 Hz), 7.96 (0.5H, d, J = 8.3 Hz), 7.63-7.60 (1H, m), 7.47-7.41 (1H, m), 7.27-7.23 (1H, m), 7.13 (1H, d, J = 8.6 Hz), 7.09 (1H, d, J = 8.6 Hz), 6.88 (1H, d, J = 8.6 Hz), 6.83 (1H, d, J = 8.6 Hz), 6.47 (2H, brs), 4.76 (1H, s), 4.75 (1H, s), 4.61 (1H, s), 4.52 (1H, t, J = 7.4 Hz), 4.44-4.40 (2H, m), 3.70 (3H, s), 3.44-3.36 (2H, m), 3.12 (1H, s), 2.97 (1H, s), 2.88-2.83 (2H, m), 2.20 (2H, s), 2.14-2.06 (1H, m), 2.00 (3H, s), 1.97-1.91 (1H, m), 1.80-1.74 (2H, m), 1.46-1.41 (2H, m), 0.95 (3H, t, J = 7.3 Hz).

MS: ESI 561 (M+1)

Example 6

Methyl

(4-([3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl](piperidin-1-ylacetyl)amino)methyl)phenoxy)acetate




5 The title compound was prepared by the method of example 5 using the product from example 4 (260 mg) and piperidine, to give a colorless gum (229 mg). Yield 82%.

¹H NMR δ (CDCl₃) 8.01 (1/2H, d, J = 8.2), 7.95 (1/2H, d, J = 8.2), 7.63-7.60 (1H, m), 7.46-7.40 (1H, m), 7.25 (1H, dd, J = 7.1, 15.0), 7.15 (1H, d, J = 8.6), 7.05 (1H, d J = 8.6), 6.88 (1H, d, J = 8.6), 6.82 (1H, d, J = 8.6), 6.48 (2H, brs), 4.76 (1H, s), 4.75 (1H, s), 4.62 (1H, s), 4.54 (1H, brt, J = 7.0), 4.42-4.38 (1H, m), 4.40 (1H, s), 3.70 (3/2H, s), 3.69 (3/2H, s), 3.47-3.30 (2H, m), 3.14 (1H, s), 2.95 (1H, s), 2.85 (2H, dd, J = 7.6, 15.3), 2.40-2.31 (2H, m), 2.23-2.17 (2H, m), 2.17-2.03 (1H, m), 1.99-1.89 (1H, m), 1.82-1.72 (2H, m), 1.48-1.22 (8H, m), 0.94 (3H, t, J = 7.4).

Example 7

Methyl

[4-([3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl][(4-methylpiperazin-1-yl)acetyl]amino)methyl)phenoxy]acetate



20 By the method of example 5 using the product from example 4 (300 mg) and 1-methylpiperazine, there was obtained the title compound as a colorless gum (228 mg). Yield 68%.

¹H NMR δ (DMSO-*d*₆) 8.01 (0.5H, d, J = 8.0 Hz), 7.94 (0.5H, d, J = 8.0 Hz), 7.62 (0.5 H, d, J = 7.8 Hz), 7.61 (0.5 H, d, J = 7.8 Hz), 7.45-7.40 (1H, m), 7.27-7.21 (1H,


m), 7.15 (1H, d, J = 8.5 Hz), 7.05 (1H, d, J = 8.5 Hz), 6.88 (1H, d, J = 8.6 Hz), 6.82 (1H, d, J = 8.6 Hz), 6.46 (2H, brs), 4.76 (1H, s), 4.75 (1H, s), 4.60 (1H, s), 4.53 (1H, t, J = 7.1 Hz), 4.42-4.35 (2H, m), 3.69 (3H, s), 3.43 (1H, t, J = 7.0 Hz), 3.37 (1H, t, J = 7.0 Hz), 3.16 (1H, s), 2.98 (1H, s), 2.89-2.81 (2H, m), 2.44-2.37 (2H, m), 2.30-2.17 (4H, m), 2.14-2.05 (3H, m), 2.09 (1.5H, s), 2.03 (1.5H, s), 1.97-1.88 (1H, m), 1.83-1.71 (2H, m), 1.45-1.39 (2H, m), 0.94 (3H, t, J = 7.3 Hz).

MS: ESI 616 (M + 1)

Example 8

Methyl

{4-[[[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl][4-(2-methoxyethyl)piperazin-1-yl]acetyl]amino)methyl]phenoxy}acetate



By the method of example 5 using the product from example 4 (300 mg) and 1-(2-methoxyethyl)piperazine, there was obtained the title compound as a white solid (277 mg). Yield 77%.


¹H NMR δ (CDCl₃) 7.83 (2H, m), 7.52 (1H, m), 7.33 (1H, m), 7.02 (2H, d, J = 8.6 Hz), 6.79 (2H, d, J = 8.6 Hz), 5.57 (2H, brs), 4.61 (2H, s), 4.58 (2H, s), 4.41 (2H, t, J = 7.6 Hz), 3.81 (3H, s), 3.49-3.44 (4H, m), 3.33 (3H, s), 3.25 (2H, s), 2.86-2.02 (14H, m), 1.85-1.80 (2H, m), 1.51-1.44 (2H, m), 0.99 (3H, t, J = 7.4 Hz).

MS:ESI 660 (M+1)

Example 9

Methyl

(3-[[[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl](*N,N*-dimethylglycyl)amino]methyl]phenoxy)acetate



By the method of example 5 using the product from example 2 (304 mg), there was obtained the title compound as a colorless gum (265 mg). Yield 86%.


¹H NMR δ (DMSO- d_6) 8.00 (0.5H, d), 7.96 (0.5H, d), 7.60 (1H, d), 7.42 (1H, dd), 7.27-7.18 (2H, m), 6.83-6.75 (3H, m), 6.46 (2H, brs), 4.76 (1H, s), 4.73 (1H, t), 4.68 (1H, s), 4.51 (1H, t), 4.46 (1H, s), 4.41 (1H, t), 3.68 (1.5H, s), 3.67 (1.5H, s), 3.46 (1H, t), 3.41 (1H, t), 3.09 (1H, s), 2.98 (1H, s), 2.88-2.82 (2H, m), 2.19 (3H, s), 2.15-2.06 (1H, m), 2.00 (3H, s), 2.00-1.92 (1H, m), 1.81-1.72 (2H, m), 1.46-1.38 (2H, m), 0.94 (3H, t).

MS:ESI 561(M+1)

Example 10

Methyl

(3-[[[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl](piperidin-1-yl)acetate



By the method of example 5 using the product from example 2 (261 mg) and piperidine, there was obtained the title compound as a colorless gum (254 mg). Yield 90%.


¹H NMR δ (DMSO- d_6) 8.01 (1/2H, d, J = 8.0), 7.96 (1/2H, d, J = 7.9), 7.63-7.60 (1H, m), 7.43 (1H, dd, J = 8.0, 7.9), 7.27-7.17 (2H, m), 6.84-6.74 (3H, m), 6.47 (2H, brs), 4.77 (1H, s), 4.73 (1H, s), 4.54 (1H, brt, J = 7.1), 4.47 (1H, s), 4.42 (1H, brt, J = 7.8), 3.69 (3/2H, s), 3.68 (3/2H, s), 3.50 (1H, brt, J = 7.6), 3.42 (1H, brt, J = 6.9), 3.10 (1H, s), 2.95 (1H, s), 2.88-2.83 (2H, m), 2.39-2.32 (2H, m), 2.22-2.16 (2H, m), 2.16-2.07 (1H, m), 2.01-1.91 (1H, m), 1.82-1.73 (2H, m), 1.47-1.22 (8H, m), 0.95

(3/2H, t, J = 7.3), 0.94 (3/2H, t, J = 7.4).

Example 11

Methyl

5 [3-({[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl][(4-methylpiperazin-1-yl)acetyl]amino)methyl]phenoxy]acetate




By the method of example 5 using the product from example 2 (396 mg) and 1-methylpiperazine, there was obtained the title compound as a colorless gum (303 mg). Yield 93%.

¹H NMR δ (CDCl₃) 8.01 (1/2H, d, J = 8.1), 7.95 (1/2H, d, J = 7.9), 7.63-7.59 (1H, m), 7.42 (1H, dd, J = 8.1, 7.2), 7.28-7.17 (2H, m), 6.84-6.73 (3H, m), 6.46 (2H, brs), 4.77 (1H, s), 4.73 (1H, s), 4.68 (1H, s), 4.54 (1H, brt, J = 6.9), 4.47 (1H, s), 4.39 (1H, brt, J = 8.0), 3.69 (3/2H, s), 3.68 (3/2H, s), 3.50 (1H, brt, J = 7.1), 3.45 (1H, brt, J = 7.0), 3.18 (1H, s), 2.98 (1H, s), 2.86 (2H, dd, J = 6.9, 14.9), 2.43-2.08 (5H, m), 2.08 (3/2H, s), 2.04 (3/2H, s), 2.01-1.90 (1H, m), 1.83-1.73 (2H, m), 1.48-1.38 (2H, m), 0.95 (3/2H, t, J = 7.3), 0.94 (3/2H, t, J = 7.4).

Example 12

Methyl

20 {3-[[[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl][(4-(2-methoxyethyl)piperazin-1-yl)acetyl]amino)methyl]phenoxy}acetate



By the method of example 5 using the product from example 2 (300 mg) and 1-(2-methoxyethyl)piperazine, there was obtained the title compound as a pale


yellow gum (300 mg). Yield 83%.

¹H NMR δ (DMSO-d₆) 7.99 (0.5H, d), 7.94 (0.5H, d), 7.61-7.58 (1H, m), 7.42-7.39 (1H, m), 7.25-7.16 (2H, m), 6.81-6.45 (3H, m), 6.44 (2H, brs), 4.75 (1H, s), 4.71 (1H, s), 4.67 (1H, s), 4.57-4.50 (1H, m), 4.45 (1H, s), 4.43-4.36 (1H, m), 3.67 (1.5H, s), 3.66 (1.5H, s), 3.52-3.39 (2H, m), 3.37-3.29 (2H, s), 3.18 (1.5H, s), 3.17 (1.5H, s), 3.11 (1H, s), 2.96 (1H, s), 2.88-2.80 (2H, m), 2.48-2.08 (11H, m), 2.00-1.92 (1H, m), 1.82-1.73 (2H, m), 1.49-1.37 (2H, m), 0.95-0.90 (3H, m).

MS:ESI 660(M+1)

Example 13

Methyl (3-([3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl](pyrrolidin-1-ylacetyl)amino)methylphenoxy)acetate



By the method of example 5 using the product from example 2 (441 mg) and pyrrolidine, there was obtained the title compound as a colorless gum (315 mg). Yield 67%.


¹H NMR δ (CDCl₃) 7.87 (1H, d, *J* = 8.2 Hz), 7.83 (1H, dd, *J* = 8.32, 0.84 Hz), 7.51 (1H, ddd, *J* = 8.12, 8.12, 1.12 Hz), 7.33 (1H, m), 7.19 (1H, m), 6.79-6.77 (0.6H, m), 6.74-6.71 (2.4H, m), 5.61 (1.1H, brs), 5.51 (0.3H, brs), 4.68 (1.6H, s), 4.58 (2H, s), 4.55 (0.4H, s), 4.43 (2H, m), 3.79 (3H, s), 3.54-3.46 (2H, m), 3.67 (1.6H, s), 3.20 (0.4H, s), 2.85 (1.6H, t, *J* = 7.68 Hz), 2.79 (0.4H, t, *J* = 7.6 Hz), 2.60 (3H, brm), 2.45 (1H, brm), 2.19-2.16 (0.4H, m), 2.09-2.02 (1.6H, m), 1.89-1.78 (4H, m), 1.76(3H, brm), 1.67 (1H, brm), 1.53-1.44 (2H, m), 0.99 (3H, t, *J* = 7.32 Hz).

MS:ESI 587 (M+1)

Example 14

Methyl

(3-([3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl](*N,N*-diethylglycyl)amino)methylphenoxy)acetate



By the method of example 5 using the product from example 2 (441 mg) and Et_2NH , there was obtained the title compound as a colorless gum (348 mg). Yield 73%.


- 5 ^1H NMR δ (CDCl_3) 7.88-7.83 (2H, m), 7.53 (1H, ddd, $J = 7.12, 7.12, 1.2$ Hz), 7.34 (1H, m), 7.19 (1H, m), 6.79-6.71 (3H, m), 5.69 (1H, brs), 5.59 (0.3H, brs), 4.74 (1.6H, s), 4.59 (2H, s), 4.56 (0.4H, s), 4.45-4.39 (2H, m), 3.80 (3H, s), 3.58-3.50 (2H, m), 3.31 (1.6H, s), 3.25 (0.4H, s), 2.88-2.80 (2H, m), 2.61 (3.1H, q, $J = 7.16$ Hz), 2.52 (0.9H, q, $J = 7.24$ Hz), 2.22 (0.7H, m), 2.10-2.03 (1.3H, m), 1.94 (2H, brs),
10 1.88-1.81 (2H, m), 1.49 (2H, m), 0.99 (9H, m).

MS:ESI 589 ($\text{M}+1$)

Example 15

Methyl

- 15 (3-[[[3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]amino]methyl]phenoxy)acetate



i) *tert*-Butyl

3-[2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylcarbamate

- 20 To the product of example 1 step (iii) (1.9 g) in NMP (25 mL), 3-methoxypropanoic acid (0.678 mL, 7.21 mmol) was added followed by HATU (2.74 g) and TEA (0.837 mL) under nitrogen. The resulting solution was stirred at 60°C for 15h. The reaction mixture was diluted with diethyl ether (300 mL) and EtOAc (300 mL), and washed with water (300 mL), sat. NaHCO_3 (200 mL), and saturated brine
25 (200 mL). The organic layer was dried, filtered and evaporated to afford the

subtitle product (3.5 g).

MS APCI +ve 385

ii) 1-[3-(*tert*-Butoxycarbonylamino)propyl]-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinoline 5-oxide

The subtitle compound was prepared by the method of example 1 step (v) using the product from step (i).

MS APCI +ve: 401

iii) *tert*-Butyl

3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylcarbamate

The subtitle compound was prepared by the method of example 1 step (vi) using the product from step (ii).

MS APCI +ve: 400

iv) 1-(3-Aminopropyl)-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine

The subtitle compound was prepared by the method of example 1 step (vii) using the product of step (iii).

MS APCI +ve: 300

v) Methyl

(3-[[[3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]amino]methyl]phenoxy)acetate

By the method of example 1 step (viii) using the product from step (iv) (197 mg) there was obtained the title compound, 234 mg (74%) as a white solid.

¹H NMR δ (CDCl₃) 8.06 (2H, dd, *J* = 8.28, 1.00 Hz), 7.81 (1H, dd, *J* = 8.36, 1.00 Hz), 7.49 (1H, m), 7.30-7.24 (2H, m), 6.97 (1H, d, *J* = 7.6 Hz), 6.94 (1H, m), 6.79 (1H, dd, *J* = 8.24, 2.12 Hz), 5.53 (1.6H, brs), 4.67-4.63 (4H, m), 3.88 (2H, t, *J* = 6.6 Hz), 3.78 (3H, s), 3.36 (3H, s), 3.23 (2H, t, *J* = 6.48 Hz), 2.73 (2H, t, *J* = 6.28 Hz), 2.07 (2H, m).


MS:ESI 478 (M+1)

Example 16

Methyl

(3-[[[3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl](chlor

oacetyl]amino]methyl]phenoxy)acetate hydrochloride



By the method of example 2 using the product of example 15 (100 mg), there was obtained the title compound, 166 mg (quant.) as a colorless gum.


¹H NMR δ (CDCl₃) 7.94 (2H, dd, J = 8.0, 8.0 Hz), 7.61 (1H, dd, J = 8.0, 8.0 Hz), 7.52 (1H, dd, J = 8.0, 8.0 Hz), 7.24 (1H, m), 6.78-6.73 (3H, m), 4.62-4.59 (4H, m), 4.55 (2H, m), 4.12 (2H, s), 3.85 (2H, t, J = 8.0 Hz), 3.79 (3H, s), 3.58 (2H, t, J = 8.0 Hz), 3.35 (3H, s), 3.14 (2H, t, J = 8.0 Hz), 2.13 (2H, m).

MS:ESI 554 (M+1)

Example 17

Methyl

(3-([3-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)propyl](N,N-dimethylglycyl)amino]methyl]phenoxy)acetate



The title compound was prepared by the method of example 5 using the product from example 16 (166 mg), to give a colorless gum (72 mg). Yield 61%.


¹H NMR δ (CDCl₃) 7.89 (1H, d, J = 8.4 Hz), 7.85 (1H, d, J = 8.08 Hz), 7.53 (1H, t, J = 7.36 Hz), 7.36 (1H, t, J = 7.68 Hz), 7.21 - 7.17 (1H, m), 6.81-6.77 (1H, m), 6.74-6.71 (2H, m), 4.69 (1.5H, s), 4.58 (2H, s), 4.56 (0.5H, s), 4.49 (2H, m), 3.85 (2H, t, J = 6.32 Hz), 3.79 (3H, s), 3.53-3.47 (2H, m), 3.35 (3H, s), 3.15-3.11 (3H, m), 3.08-3.05 (1H, m), 2.30 (4H, s), 2.12 (2H, s), 2.07 (2H, m).

MS:ESI 563 (M+1)

Example 18

Methyl

(3-{[[[3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]
 [(4-methylpiperazin-1-yl)acetyl]amino]methyl}phenoxy)acetate



5 The title compound was prepared by the method of example 5 using the product from example 16 (137 mg) and 1-methylpiperazine, to give a colorless gum (99.6 mg). Yield 65%.

¹H NMR δ (CDCl₃) 7.87 (1H, d, *J* = 8.24 Hz), 7.84 (1H, d, *J* = 8.36 Hz), 7.52 (1H, dd, *J* = 7.64, 7.64 Hz), 7.35 (1H, m), 7.19 (1H, m), 6.78-6.70 (3H, m), 5.63 (1H, brs),
 10 4.65 (1.5H, s), 4.59 (2H, s), 4.55 (0.5H, s), 4.52-4.46 (2H, m), 3.86 (2H, s), 3.80 (3H, s), 3.52 (2H, m), 3.35 (3H, s), 3.22 (1.5H, s), 3.12 (2H, t, *J* = 6.36 Hz), 3.06 (0.5H, s), 2.56-2.42 (6H, m), 2.25 (2H, s), 2.20 (1H, s), 2.11-2.04 (2H, m), 1.85 (2H, m).


MS:ESI 618 (M+1)

15

Example 19

Methyl

(3-{[[[3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]
 (piperidin-1-ylacetyl)amino]methyl}phenoxy)acetate



20

The title compound was prepared by the method of example 5 using the product from example 16 (137 mg) and piperidine, to give a colorless gum (110 mg). Yield 74%.

¹H NMR δ (CDCl₃) 7.88 (1H, d, *J* = 8.2 Hz), 7.85 (1H, d, *J* = 8.36 Hz), 7.53 (1H, dd, *J* = 7.12, 7.12 Hz), 7.38-7.33 (1H, m), 7.21-7.17 (1H, m), 6.77-6.71 (3H, m), 4.71

25


(1.5H, s), 4.58-4.56 (2.5H, m), 4.53-4.45 (2H, m), 3.85 (2H, m), 3.80 (3H, s), 3.51 (2H, m), 3.34 (3H, s), 3.17 (1.5H, s), 3.14-3.06 (2.5H, m), 2.44 (3H, brm), 2.33 (1H, brm), 2.20 (0.6H, m), 2.06 (1.4H, m), 1.89 (2H, brs), 1.56-1.50 (4H, m), 1.39 (2H, m).

5 MS:ESI 603 (M+1)

Example 20

Methyl

10 (3-{[[3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl](*N,N*-diethylglycyl)amino]methyl}phenoxy)acetate




The title compound was prepared by the method of example 5 using the product from example 16 (331 mg) and Et₂NH, to give a white solid (231 mg). Yield 66%. ¹H NMR δ (CDCl₃) 7.88 (1H, d, *J* = 7.48 Hz), 7.82 (1H, d, *J* = 8.4 Hz), 7.51 (1H, m), 7.33 (1H, m), 7.19 (1H, m), 6.78-6.71 (3H, m), 5.46-5.43 (1.7H, brm), 4.75 (1.5H, s), 4.58 (2H, s), 4.56 (0.5H, s), 4.48 (2H, m), 3.86 (2H, t, *J* = 6.36 Hz), 3.80 (3H, s), 3.59-3.49 (2H, m), 3.35 (2H, s), 3.33 (1H, s), 3.29 (1.5H, s), 3.26 (0.5H, s), 3.13 (1.5H, t, *J* = 6.36 Hz), 3.08 (0.5H, t, *J* = 6.28 Hz), 2.59 (3H, q, *J* = 7.16 Hz), 2.52 (1H, q, *J* = 7.08 Hz), 2.21 (0.5H, m), 2.08 (1.5H, m), 0.99 (6H, t, *J* = 7.08 Hz).

20 MS:ESI 591 (M+1)

Example 21


Methyl

25 (3-{[[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl](3-morpholinopropyl)amino]methyl}phenoxy)acetate



(i)

N-[3-(4-Amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-propyl]-2-nitro-benzenesulfonamide



5

To a solution of the product from example 1 step (vii) (250 mg, 0.841 mmol) in CHCl_3 (8.4 mL), 2-nitrobenzenesulfonylchloride (186.4 mg, 0.841 mmol) was added at rt, and stirring rt for 3.5h. Then sat. NaHCO_3 aq. was added and extracted with CHCl_3 . The organic layer was dried over MgSO_4 then concentrated under reduced pressure. The crude product was purified by silica gel column chromatography to afford the subtitle compound (353 mg, yield 87%) as a pale yellow solid.

10

^1H NMR δ (CDCl_3) 8.07 (1H, dd, $J = 7.4, 1.64$ Hz), 7.94 (1H, d, $J = 7.44$ Hz), 7.85 (1H, dd, $J = 7.8, 1.68$ Hz), 7.81 (1H, dd, $J = 8.36, 0.92$ Hz), 7.70 (2H, m), 7.45 (1H, m), 7.36 (1H, m), 4.61 (2H, t, $J = 7.76$ Hz), 3.27 (2H, t, $J = 6.32$ Hz), 2.91 (2H, t, $J = 7.72$ Hz), 2.18 (2H, m), 1.88 (2H, m), 1.52 (2H, m), 1.02 (3H, t, $J = 7.32$ Hz).


15

MS:ESI 483 ($\text{M}+1$)

(ii)

N-[3-(4-Amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)-propyl]-*N*-(3-morpholin-4-yl-propyl)-2-nitro-benzenesulfonamide

20



To a solution of the product from step (i) (164 mg, 0.340 mmol) in DMF (3.4 mL), 4-(3-bromopropyl)morpholine (141 mg, 0.680 mmol) was added at rt. After stirring at 60°C for 3.5 h, sat. NaHCO₃ aq. was added and extracted with CHCl₃.


5 The organic layer was dried over MgSO₄ then concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography to afford the title compound (200 mg, yield 97%) as a pale yellow solid

¹H NMR δ (CDCl₃) 8.03 (1H, dd, *J* = 7.56, 1.24 Hz), 7.98 (1H, d, *J* = 8.16 Hz), 7.94 (1H, d, *J* = 8.44 Hz), 7.72-7.58 (4H, m), 7.46 (1H, t, *J* = 8.12 Hz), 4.57 (2H, m),
 10 3.62-3.57 (6H, m), 3.39 (2H, t, *J* = 7.44 Hz), 2.92 (2H, t, *J* = 7.6 Hz), 2.28 (4H, m), 2.24-2.14 (4H, m), 1.89 (2H, m), 1.65 (2H, m), 1.53 (2H, m), 0.99 (3H, t, *J* = 7.32 Hz).

MS:ESI 610 (M+1)

15 (iii)

2-Butyl-1-[3-(3-morpholin-4-yl-propylamino)-propyl]-1*H*-imidazo[4,5-*c*]quinolin-4-ylamine




The sulfonamide from step (ii) (200 mg, 0.329 mmol) was dissolved into THF (5
 20 mL), and to this solution, CsCO₃ (355 mg, 1.09 mmol) was added followed by PS-thiophenol (485 mg of a resin with 1.49 mmol/g loading, 0.724 mmol). The reaction mixture was stirred at rt for 8h. Additional PS-thiophenol was added (243 mg, 0.362 mmol) and the mixture was stirred for 16h. Then the content of the flask was filtered, and the solid was washed several times with THF and
 25 CH₂Cl₂. The solvent was evaporated and the residue was isolated to give the subtitle compound, 130mg (93% yield) as a white solid.

^1H NMR δ (CDCl_3) 8.06 (1H, d, $J = 8.16$ Hz), 7.84 (1H, d, $J = 8.32$ Hz), 7.52 (1H, m), 7.33 (1H, m), 5.63 (1.5H, brs), 4.59 (2H, dd, $J = 7.52, 7.12$ Hz), 3.70 (4H, m), 2.96 (2H, dd, $J = 7.96, 7.76$ Hz), 2.71 (4H, m), 2.44-2.41 (6H, m), 2.08 (2H, m), 1.87 (2H, m), 1.73 (4H, m), 1.51 (2H, m), 1.01 (3H, t, $J = 7.32$ Hz).

MS:ESI 425 (M+1)

(iv) Methyl

(3-[[[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl](3-morpholinopropyl)amino]methyl]phenoxy)acetate



The product from step (iii) (134 mg, 0.316 mmol) was dissolved in MeOH, and to this solution, methyl 2-(4-formylphenoxy)acetate (56.3 mg, 0.316 mmol) was added followed by NaBH_3CN (39.7 mg, 0.632 mmol) and acetic acid (36.7 μL , 0.632 mmol) and stirred at 0°C for 3h. The reaction was quenched with sat. NaHCO_3 aq. and extracted with CHCl_3 . The organic layer was dried over MgSO_4 then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to afford the title compound (86.4 mg, Yield 45%) as colorless oil.


^1H NMR δ (CDCl_3) 7.95 (1H, dd, $J = 8.24, 0.92$ Hz), 7.84 (1H, dd, $J = 8.36, 0.92$ Hz), 7.49 (1H, m), 7.25-7.20 (2H, m), 6.99 (1H, d, $J = 7.96$ Hz), 6.96 (1H, m), 6.79 (1H, dd, $J = 7.72, 2.08$ Hz), 5.75 (1.5H, brs), 4.62 (2H, s), 4.41 (2H, m), 3.76 (3H, s), 3.68 (4H, m), 3.61 (2H, s), 2.87 (2H, t, $J = 7.64$ Hz), 2.61 (2H, t, $J = 6.32$ Hz), 2.54 (2H, t, $J = 7.32$ Hz), 2.40 (4H, brm), 2.34 (2H, t, $J = 7.28$ Hz), 2.01 (2H, m), 1.88-1.72 (6H, m), 1.48 (2H, m), 0.99 (3H, t, $J = 7.32$ Hz).

MS:ESI 603 (M+1)


Example 22

Methyl

[4-(((3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)amino)carbonyl)[3-(dimethylamino)propyl]amino}methyl]phenoxy]acetate



(i) Methyl [4-({[3-(dimethylamino)propyl]amino}methyl)phenoxy]acetate




The suspension of copper sulfate (1.6 g 10 mmol), methyl (4-formylphenoxy)acetate (1.5 g 7.7 mmol) and 3-dimethylaminopropylamine (4.3 ml 35 mmol) in toluene (10 ml) was stirred at ambient temperature for 14h. The reaction mixture was filtered and filtrate was concentrated *in vacuo*. Methanol (10 ml) was added to the residue, and then sodium borohydride (380 mg, 10 mmol) was added at 0°C. The resulting solution was stirred at 0-10°C for 10 min, then sodium bicarbonate aq.(100 mL) was added and extracted with CHCl₃ (100 mL, twice). Organic layer was dried over sodium sulfate then concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the 690 mg of subtitled compound as colourless oil. Yield 42%.

¹H NMR δ (DMSO-d₆) 7.19 (2H, d, J = 6.8 Hz), 6.83 (2H, d, J = 6.8 Hz), 4.75 (2H, s), 3.68 (3H, s), 3.57 (2H, s), 2.44 (1H, t, J = 7.2 Hz), 2.18 (1H, t, J = 7.2 Hz), 2.07 (6H, s), 1.97 (1H, brs), 1.54-1.46 (2H, m).

(ii) Methyl

[4-({[3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl]amino}carbonyl)[3-(dimethylamino)propyl]amino}methyl)phenoxy]acetate




4-Nitrophenyl chloroformate (197 mg, 0.98 mmol) was added to the mixture of triethylamine (0.177 ml, 1.3 mmol) and the product from step (i) (276 mg, 0.98 mmol) in tetrahydrofuran (5 ml) at 0°C and stirred for 0.5h. Then the product from example 15 step (iv) (409 mg, 1.1 mmol), triethylamine (0.409 ml, 3 mmol) and DMSO (7 ml) were added to the reaction mixture and stirred at ambient temperature for 14h. The reaction mixture was poured into ethyl acetate (50 ml) and the mixture was washed with potassium carbonate aq. Organic layer was dried over sodium sulfate then concentrated *in vacuo*. The residue was purified by silica gel chromatography to give the titled compound, 130 mg as a colourless gum. Yield 22%.

¹H NMR δ (DMSO-d₆) 8.04 (1H, d, *J* = 7.6 Hz), 7.59 (1H, dd, *J* = 0.8, 7.6 Hz), 7.43-7.35 (1H, m), 7.18-7.12 (3H, m), 7.03 (1H, brs), 6.84 (2H, d, *J* = 7.6 Hz), 6.47 (2H, s), 4.74 (2H, s), 4.54 (1H, t, *J* = 7.6 Hz), 4.36 (2H, s), 3.80 (1H, t, *J* = 6.8 Hz), 3.67 (3H, s), 3.29-3.20 (5H, m), 3.19-3.15 (2H, m), 3.09 (2H, t, *J* = 6.8 Hz), 2.11 (2H, t, *J* = 6.8 Hz), 2.02-1.92 (8H, m), 1.57-1.50 (2H, m).

Example 23

Ethyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)phenoxy]acetate



(i) Ethyl 2-(3-formylphenoxy)acetate

To a solution of 3-hydroxybenzaldehyde (3.00 g, 24.6 mmol) in DMF (30 ml) ethyl bromoacetate (4.53 g, 27.1 mmol) and K₂CO₃ (3.75 g, 27.1 mmol) was added at rt. After stirring for 3 h at 80°C, diluted with AcOEt, and H₂O was added. The aq. layer was extracted with AcOEt, dried over Na₂SO₄, and concentrated. The residue was purified by flash column chromatography to give the title compound (5.22 g, 100%) as colorless oil.

¹H NMR δ (CDCl₃) 9.96 (1H, s), 7.50 (1H, ddd, *J*=7.48, 1.36, 1.32 Hz), 7.46 (1H, dd, *J*=7.56, 7.56 Hz), 7.35 (1H, m), 7.25 (1H, m), 4.68 (2H, s), 4.27 (2H, q, *J*=7.16 Hz), 1.29 (3H, t, *J*=7.12 Hz).

MS:ESI 209 (M+1)

(ii) Ethyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)phenoxy]acetate

5 By the method of example 1 step (viii) using the product from example 15 step (iv) (1.50 g) and ethyl 2-(3-formylphenoxy)acetate (1.04 g) to afford the title compound, 2.02 g (82%) as a white solid.


¹H NMR δ (CDCl₃) 8.10 (1H, dd, *J*=8.10, 0.84Hz), 7.84 (1H, dd, *J*=8.36, 1.00Hz), 7.51(1H, m), 7.32-7.25 (2H, m), 6.98 (1H, d, *J*=7.48Hz), 6.95 (1H, m), 6.81 (1H, dd, *J*=8.16, 2.04Hz), 5.69 (2H, brs), 4.67 (2H, t, *J*=7.52Hz), 4.64 (2H, s), 4.26 (2H, q, *J*=7.16Hz), 3.90 (2H, t, *J*=6.56Hz), 3.80 (2H, s), 3.38 (3H, s), 3.25 (2H, t, *J*=6.52Hz), 2.75 (2H, t, *J*=6.2Hz), 2.08 (2H, m), 1.29 (3H, m).

MS:ESI 492 (M+1)

15 Example 24

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl)phenoxy]acetate hydrochloride



20 By the method of example 2 using the product of example 23 (2.01 g), there was obtained the title compound, 2.61 g (quant.) as a colorless gum.

¹H NMR δ (CDCl₃) 8.01 (1H, d, *J*=8.28Hz), 7.96 (1H, d, *J*=7.96Hz), 7.66 (1H, m), 7.54 (1H, m), 7.25 (1H, m), 6.80-6.73 (3H, m), 4.63 (2H, s), 4.61 (2H, s), 4.59-4.53 (2H, m), 4.27 (2H, q, *J*=7.16Hz), 4.12 (2H, s), 3.87 (2H, t, *J*=6.00Hz), 3.59 (2H, t, *J*=6.84Hz), 3.36 (3H, s), 3.15 (2H, t, *J*=6.00Hz), 2.13 (2H, m), 1.31 (3H, t, *J*=7.12Hz).


MS:ESI 568 (M+1)

Example 25

30 Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2

-(diethylamino)acetamido)methyl]phenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 24 (2.60 g) and diethylamine, to give a colorless gum (2.27 g). Yield 92%.


¹H NMR δ (CDCl₃) 7.92-7.85 (2H, m), 7.58-7.52 (1H, m), 7.42-7.32 (1H, m), 7.22-7.18 (2H, m), 6.79-6.73 (3H, m), 4.76 (1.5H, s), 4.58 (2.5H, s), 4.49 (2H, m), 4.27 (2H, q, $J=7.12$ Hz), 3.86 (2H, t, $J=6.28$ Hz), 3.59-3.51 (2H, m), 3.36 (2.3H, s), 3.34 (0.7H, s), 3.32 (1.5H, s), 3.28 (0.5H, s), 3.15-3.07 (2H, m), 2.63-2.52 (4H, m), 2.22-2.04 (2H, m), 1.30 (3H, t, $J=7.12$ Hz), 1.00 (6H, t, $J=7.08$ Hz).

MS:ESI 605 (M+1)

Example 26

Propyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetic acid



(i)

(3-[[[3-(4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)propyl] (N,N-diethylglycyl)amino]methyl]phenoxy)acetic acid

To a solution of example 25 (556.3 mg, 0.920 mmol) in THF/MeOH (1:1, 8 ml), 2N NaOH (1.6mL) was added at rt. After stirring for 3 h at rt, the reaction mixture was neutralized with 1N HCl. The aq. layer was extracted with CHCl₃/EtOH (5/1), dried over Na₂SO₄, and concentrated to give the title compound (551.1 mg, quant.) as a white solid.

¹H NMR δ (CD₃OD) 7.92 (1H, d, $J=8.24$ Hz), 7.64(1H, t, $J=7.92$ Hz), 7.49 (1H,m), 7.35(1H, $J=7.24$ Hz), 7.15 (0.7H, t, $J=8.04$ Hz), 7.08 (0.3H, t, $J=7.88$ Hz), 6.80-6.62 (3H, m), 4.55- 4.44(4H, m), 4.36 (1.4H, s), 4.35 (0.6H, s), 3.88-3.82 (3.3H, m), 3.63 (0.7H, s), 3.52(1.4H, t, $J=7.4$ Hz), 3.40-3.34 (3.6H, m), 3.15-3.10 (2H, m),

2.94 (2.7H, m), 2.81 (1.3H, m), 2.13-1.99 (2H, m), 1.15-1.05 (6H, m).

MS:ESI 577 (M+1)

(ii) Propyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate

To a solution of the product from step (i) (161.2 mg) in nPrOH (3mL), 4N HCl/dioxane solution (0.5mL) was added. The reaction mixture was stirred at 50°C for 3h. After the removal of the solvent, the residue was diluted with CHCl₃ and then poured into 7% NH₃ solution, and extracted with CHCl₃. The combined extracts were dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography to afford the title compound (99.6 mg, 65%) as a colorless gum.


¹H NMR δ (CDCl₃) 7.92-7.85 (2H, m), 7.58-7.52 (1H, m), 7.41-7.37 (1H, m), 7.2 (1H, dd, J=7.6, 7.6 Hz), 6.80-6.73 (3H, m), 4.76 (1.5H, s), 4.59 (2H, s), 4.58 (0.5H, s), 4.51-4.47 (2H, m), 4.16 (2H, t, J=6.72 Hz), 3.86 (2H, t, J=6.32 Hz), 3.59-3.51 (2H, m), 3.36 (2.3H, s), 3.34 (0.7H, s), 3.31 (1.5H, s), 3.28 (0.5H, s), 3.14 (1.5H, t, J=6.24 Hz), 3.08 (0.5H, t, J=6.24 Hz), 2.63-2.52 (4H, m), 2.22-2.01 (2H, m), 1.69 (2H, m), 1.00 (6H, t, J=7.08 Hz), 0.93 (3H, t, J=7.4 Hz).

MS:ESI 619 (M+1)

Example 27

Isopropyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate



The title compound was prepared by the method of example 26 step (ii) using the product from example 26 step (i) (100.3 mg) and 2-propanol, to give a colorless gum (58.4 mg). Yield 54%.

¹H NMR δ (CDCl₃) 7.91-7.82 (2H, m), 7.52 (1H, m), 7.33 (1H, m), 7.20 (1H, m), 6.80-6.72 (3H, m), 5.43 (2H, m), 5.13 (1H, m), 4.76 (1.5H, s), 4.58 (0.5H, s), 4.54 (2H, s), 4.49 (2H, m), 3.87 (2H, m), 3.60-3.49 (2H, m), 3.36 (2.3H, s), 3.34 (0.7H, s),

3.30 (1.5H, s), 3.26 (0.5H, s), 3.14 (1.5H, t, $J=6.36$ Hz), 3.09 (0.5H, t, $J=6.2$ Hz), 2.63-2.50 (4H, m), 2.22- 2.05 (2H, m), 1.28 (6H, d, $J=6.28$ Hz), 1.00 (6H, t, $J=7.08$ Hz).


MS:ESI 619 (M+1)

5

Example 28

Isobutyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate



10

The title compound was prepared by the method of example 26 step (ii) using the product from example 26 step (i) (76.4mg) and 2-methyl-1-propanol, to give a colorless gum (55.7 mg). Yield 67%.

15

^1H NMR δ (CDCl_3) 7.89-7.81 (2H, m), 7.51 (1H, m), 7.32 (1H, m), 7.18 (1H, m), 6.78-6.71 (3H, m), 5.44 (2H, brs), 4.74 (1.5H, s), 4.58 (2H, s), 4.56 (0.5H, s), 4.48 (2H, m), 3.97 (2H, d, $J=6.68$ Hz), 3.85 (2H, m), 3.51 (2H, m), 3.34 (2.3H, s), 3.33 (0.7H, s), 3.29 (1.5H, s), 3.25 (0.5H, s), 3.13 (1.5H, t, $J=6.36$ Hz), 3.07 (0.5H, t, $J=6.24$ Hz), 2.59 (3H, q, $J=7.16$ Hz), 2.52 (1H, q, $J=7.08$ Hz), 2.09-2.05 (2H, m), 1.94 (1H, m), 0.98 (6H, t, $J=7.08$ Hz), 0.90 (6H, d, $J=6.72$ Hz).

20


MS:ESI 633 (M+1)

Example 29

2-Methoxyethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate

25



The title compound was prepared by the method of example 26 step (ii) using the product from example 26 step (i) (101.6 mg) and 2-methoxyethanol, to give a colorless gum (76.3 mg). Yield 68%.


¹H NMR δ (CDCl₃) 7.90-7.82 (2H, m), 7.52 (1H, m), 7.34 (1H, m), 7.20 (1H, dd, *J*=8.92, 7.16Hz), 6.80-6.72 (3H, m), 5.45 (2H, brs), 4.76 (1.5H, s), 4.63 (2H, s), 4.57 (0.5H, s), 4.49 (2H, m), 4.36 (2H, m), 3.86 (2H, m), 3.75 (2H, m), 3.62 (2H, m), 3.41 (3H, s), 3.39 (3H, s), 3.30 (1.5H, s), 3.26 (0.5H, s), 3.14 (1.5H, t, *J*=6.36Hz), 3.10 (0.5H, t, *J*=6.2Hz), 2.63-2.52 (4H, m), 2.10-2.05 (2H, m), 1.00 (6H, t, *J*=7.12Hz).

MS:ESI 635 (M+1)

Example 30

2-Hydroxyethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate



The title compound was prepared by the method of example 26 step (ii) using the product from example 26 step (i) (101.6 mg) and ethyleneglycol, to give a colorless gum (58.5 mg). Yield 54%.


¹H NMR δ (CDCl₃) 7.82-7.75 (2H, m), 7.50 (1H, m), 7.31-7.28 (1H, m), 7.11 (1H, m), 6.75 (1.25H, d, *J*=7.96Hz), 6.60 (0.75H, dd, *J*=8.24, 2.08Hz), 6.45 (0.25H, s), 6.38 (0.75H, s), 5.56 (2H, brs), 4.60 (1.5H, s), 4.50-4.41 (2.5H, m), 4.37-4.34 (2H, m), 4.31 (0.5H, s), 4.25 (1.5H, s), 3.93-3.88 (2H, m), 3.82 (2H, t, *J*=6.44Hz), 3.50 (0.5H, m), 3.39-3.28 (6H, m), 3.26 (0.5H, s), 3.09 (1.5H, t, *J*=6.36Hz), 3.04 (0.5H, t, *J*=6.16Hz), 2.61-2.53 (4H, m), 2.00 (2H, m), 0.99 (6H, t, *J*=7.16Hz).

MS:ESI 621 (M+1)

Example 31

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(pyrrolidin-1-yl)acetamido)methyl]phenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 24 (195.7 mg) and pyrrolidine, to give a pale yellow gum (142.1 mg). Yield 68%.


¹H NMR δ (CDCl₃) 7.89-7.82 (2H, m), 7.52 (1H, m), 7.34 (1H, m), 7.21 (1H, m), 6.82-6.74 (3H, m), 5.41 (2H, brs), 4.70 (1.5H, s), 4.58 (2.5H, s), 4.50 (2H, m), 4.27 (2H, q, *J*=7.12 Hz), 3.86 (2H, m), 3.56-3.49 (2H, m), 3.37 (0.7H, s), 3.36 (2.3H, s), 3.35 (1.5H, s), 3.24 (0.5H, s), 3.15 (1.5H, t, *J*=6.44 Hz), 3.07 (0.5H, t, *J*=6.16 Hz), 2.61 (3H, brm), 2.48 (1H, brm), 2.19-2.05 (2H, m), 1.77-1.68 (4H, m), 1.30 (3H, t, *J*=7.12 Hz).

MS:ESI 603 (M+1)

Example 32

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(piperidin-1-yl)acetamido)methyl]phenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 24 (186.9 mg) and piperidine, to give a colorless gum (179.4 mg). Yield 88%.


¹H NMR δ (CDCl₃) 7.90-7.81 (2H, m), 7.52 (1H, m), 7.34 (1H, m), 7.20 (1H, m), 6.80-6.73 (3H, m), 5.38 (2H, brs), 4.73 (1.5H, s), 4.58 (2H, s), 4.57 (0.5H, s), 4.54-4.47 (2H, m), 4.27 (2H, q, *J*=7.16 Hz), 3.87 (2H, t, *J*=6.4 Hz), 3.53 (2H, m), 3.36 (2.3H, s), 3.34 (0.7H, s), 3.18 (1.5H, s), 3.14 (1.5H, t, *J*=6.36 Hz), 3.09 (0.5H, t, *J*=6.16 Hz), 3.06 (0.5H, s), 2.45 (3H, brm), 2.34 (1H, brm), 2.10-2.06 (2H, m), 1.56-1.50 (4H, m), 1.40 (2H, brm), 1.31 (3H, t, *J*=7.12 Hz).

MS:ESI 617 (M+1)

Example 33

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(dimethylamino)acetamido)methyl]phenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 24 (201.0 mg) and dimethylamine, to give a colorless gum (188.0 mg). Yield 92%.


5 ^1H NMR δ (CDCl_3) 7.90-7.80 (2H, m), 7.51 (1H, m), 7.32 (1H, m), 7.19 (1H, m), 6.80-6.72 (3H, m), 5.41 (2H, brs), 4.69 (1.5H, s), 4.56 (2.5H, s), 4.48 (2H, m), 4.25 (2H, q, $J=7.16$ Hz), 3.85 (2H, t, $J=6.4$ Hz), 3.54-3.46 (2H, m), 3.34 (2.3H, s), 3.33 (0.7H, s), 3.15-3.04 (4H, m), 2.30 (4.5H, s), 2.22-2.03 (2H, m), 2.11 (1.5H, s), 1.29 (3H, t, $J=7.12$ Hz).

10 MS:ESI 577 ($\text{M}+1$)

Example 34

Methyl

2-[4-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)phenoxy]acetate



(i) Methyl 2-(4-formylphenoxy)acetate

By the method of example 23 step (i) using the 4-hydroxybenzaldehyde (1.50 g) and the methyl bromoacetate (1.28 mL) to afford the title compound, 2.42 g (100%) as a white solid.

^1H NMR δ (CDCl_3) 9.91 (1H, s), 7.81 (2H, ddd, $J=8.84, 2.68, 2.64$ Hz), 7.02 (2H, ddd, $J=8.76, 2.68, 2.64$ Hz), 4.72 (2H, s), 3.83 (3H, s).

MS:ESI 195 ($\text{M}+1$)

25 (ii) Methyl

2-[4-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)phenoxy]acetate

By the method of example 1 step (viii) using the product from example 15 step (iv) (500 mg) and methyl 2-(4-formylphenoxy)acetate (324.3 mg) to afford the title

compound, 651.0 mg (81%) as a white solid.


¹H NMR δ (CDCl₃) 8.10 (1H, dd, *J*=8.24, 0.88Hz), 7.84 (1H, dd, *J*=8.32, 0.92Hz), 7.51(1H, m), 7.31-7.25 (3H, m), 6.92-6.88 (2H, m), 5.68 (2H, brs), 4.67-4.62 (4H, m), 3.89 (2H, t, *J*=6.52Hz), 3.82 (3H, s), 3.76 (2H, s), 3.38 (3H, s), 3.24 (2H, t, *J*=6.48Hz), 2.74 (2H, t, *J*=6.28Hz), 2.12-2.02 (2H, m).

MS:ESI 478 (M+1)

Example 35

Methyl

2-{4-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-chloroacetamido)methyl]phenoxy}acetate hydrochloride



By the method of example 2 using the product of example 34 (328.1 mg), there was obtained the title compound, 340.0 mg (91%) as a colorless gum.


¹H NMR δ (CDCl₃) 8.00 (1H, d, *J*=8.2Hz), 7.95 (1H, d, *J*=8.16Hz), 7.64 (1H, m), 7.52-7.49 (1H, m), 7.10-7.04 (2H, m), 6.88-6.81 (2H, m), 4.64-4.52 (6H, m), 4.14 (2H, s), 3.87 (2H, t, *J*=6.04Hz), 3.82 (3H, s), 3.57 (2H, t, *J*=7.24Hz), 3.36 (3H, s), 3.14 (2H, t, *J*=6.04Hz), 2.18-2.10 (2H, m).

MS:ESI 554 (M+1)

Example 36

Methyl

2-{4-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]phenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 35 (348.0 mg) and diethylamine, to give a colorless gum (305.2 mg). Yield 82%.

¹H NMR δ (CDCl₃) 7.90 (1H, d, *J*=8.36 Hz), 7.87 (1H, d, *J*=8.32Hz), 7.55 (1H, m),


7.35 (1H, m), 7.09-7.04 (2H, m), 6.83-6.79 (2H, m), 5.95 (1.5H, brs), 5.72 (0.5H, brs), 4.69 (1.5H, s), 4.62 (0.5H, s), 4.61 (2H, s), 4.49 (2H, m), 3.86 (2H, t, $J=6.32\text{Hz}$), 3.82 (3H, s), 3.57-3.47 (2H, m), 3.36 (2.3H, s), 3.35 (1.5H, s), 3.33 (0.7H, s), 3.27 (0.5H, s), 3.12 (1.5H, t, $J=6.32\text{Hz}$), 3.08 (0.5H, t, $J=6.12\text{Hz}$), 2.61 (3.0H, q, $J=7.12\text{Hz}$), 2.54 (1H, q, $J=7.12\text{Hz}$), 2.23-2.02 (2H, m), 0.99 (6H, t, $J=7.12\text{Hz}$).

MS:ESI 591 (M+1)

Example 37

Ethyl

2-{4-[(N-{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate



(i)

2-{4-[(N-{3-[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 36 (163.7 mg), to give a white solid (162.8 mg). Yield quant.

^1H NMR δ (DMSO- d_6) 7.99 (0.5H, d, $J=7.96\text{ Hz}$), 7.95 (0.5H, d, $J=8.12\text{ Hz}$), 7.59 (1H, dd, $J=8.4, 1.48\text{Hz}$), 7.41 (1H, t, $J=7.0\text{ Hz}$), 7.24 (1H, q, $J=7.08\text{ Hz}$), 7.04 (1H, d, $J=8.56\text{ Hz}$), 7.00 (1H, d, $J=8.6\text{ Hz}$), 6.73 (1H, d, $J=8.6\text{ Hz}$), 6.68 (1H, d, $J=8.64\text{ Hz}$), 6.50 (2H, brs), 4.61 (1H, s), 4.52 (1H, m), 4.42 (1H, m), 4.36 (1H, s), 4.00 (1H, s), 3.99 (1H, s), 3.78 (2H, q, $J=6.84\text{Hz}$), 3.43 (1H, m), 3.37 (1H, m), 3.26 (3H, s), 3.22 (1H, s), 3.16-3.09 (3H, m), 2.53-2.47 (2H, m), 2.36 (2H, m), 2.10 (1H, m), 1.94 (1H, m), 0.88 (3H, t, $J=7.08\text{Hz}$), 0.81 (3H, t, $J=7.04\text{Hz}$).

MS:ESI 577 (M+1)

(ii) Ethyl

2-{4-[(N-{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (65.6 mg) and EtOH, to give a colorless gum (44.8 mg). Yield

65%.


¹H NMR δ (CDCl₃) 7.90-7.82 (2H, m), 7.53 (1H, m), 7.32 (1H, m), 7.09-7.03 (2H, m), 6.83-6.80 (2H, m), 5.48 (2H, brs), 4.69 (1.5H, s), 4.60 (0.5H, s), 4.59 (2H, s), 4.49 (2H, m), 4.28 (2H, q, *J*=7.12Hz), 3.86 (2H, t, *J*=6.4Hz), 3.56-3.47 (2H, m), 3.36 (2.3H, s), 3.35 (0.7H, s), 3.22 (1.5H, s), 3.26 (0.5H, s), 3.13 (1.5H, t, *J*=6.4Hz), 3.09 (0.5H, t, *J*=6.28Hz), 2.61 (3H, q, *J*=7.16Hz), 2.53 (1H, q, *J*=7.12Hz), 2.22 (0.5H, m), 2.10-2.03 (1.5H, m), 1.31 (3H, t, *J*=7.16Hz), 1.01 (6H, t, *J*=7.12Hz).

MS:ESI 605 (M+1)

10 Example 38

Methyl

2-[2-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)phenoxy]acetate



15 (i) Methyl 2-(2-formylphenoxy)acetate

By the method of example 23 step (i) using the 2-hydroxybenzaldehyde (501.8 mg) and the methyl bromoacetate (408.9 uL) to afford the title compound, 734.0 mg (92%) as a white solid.

¹H NMR δ (CDCl₃) 10.58 (1H, s), 7.88 (1H, dd, *J*=7.68, 1.8Hz), 7.55 (1H, m), 7.11 (1H, dd, *J*=7.52, 7.52Hz), 6.87 (1H, d, *J*=8.36Hz), 4.79 (2H, s), 3.83 (3H, s).

(ii) Methyl

2-[2-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)phenoxy]acetate

25 By the method of example 1 step (viii) using the product from example 15 step (iv) (166.7 mg) and methyl 2-(2-formylphenoxy)acetate 108.2 mg) to afford the title compound, 222.8 mg (84%) as a colorless gum.

¹H NMR δ (CDCl₃) 8.08 (1H, dd, *J*=8.24, 0.96Hz), 7.80 (1H, dd, *J*=8.36, 1.00Hz), 7.48 (1H, m), 7.29-7.21 (3H, m), 6.97 (1H, m), 6.75 (1H, d, *J*=8.12Hz), 5.39 (2H, brs), 4.68 (2H, s), 4.65 (2H, t, *J*=7.48Hz), 3.90-3.87 (4H, m), 3.73 (3H, s), 3.37 (3H,


s), 3.24 (2H, t, $J=6.6\text{Hz}$), 2.70 (2H, t, $J=6.36\text{Hz}$), 2.10 (2H, m).

MS:ESI 478 (M+1)

Example 39

5 Methyl

2-{2-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}-2-chloroacetamido)methyl]phenoxy}acetate hydrochloride



By the method of example 2 using the product of example 38 (213.9 mg), there was obtained the title compound, 286.6 mg (quant.) as a colorless gum.


^1H NMR δ (CDCl_3) 7.90-7.82 (2H, m), 7.53 (1H, m), 7.33 (1H, m), 7.16 (1H, m), 7.00 (1H, dd, $J=7.8, 1.76\text{Hz}$), 6.86 (1H, m), 6.65 (1H, d, $J=8.12\text{Hz}$), 5.49 (2H, brs), 4.75 (0.3H, s), 4.66 (1.7H, s), 4.60 (1.7H, s), 4.58 (0.3H, s), 4.50 (2H, m), 4.40 (1.7H, s), 4.06 (0.3H, s), 3.87 (2H, t, $J=6.44\text{Hz}$), 3.78 (2.5H, s), 3.77 (0.5H, s), 3.54 (2H, t, $J=6.96\text{Hz}$), 3.38 (3H, s), 3.13 (2H, t, $J=6.44\text{Hz}$), 2.06 (2H, m).

MS:ESI 554 (M+1)

Example 40

Methyl

2-{2-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 39 (249.2 mg) and diethylamine, to give a colorless gum (198.3 mg).

Yield 75%.

^1H NMR δ (CDCl_3) 7.88 (1H, m), 7.80 (1H, d, $J=8.36\text{Hz}$), 7.49 (1H, m), 7.34-7.24


(1H, m), 7.12 (1H, m), 7.05 (1H, dd, $J=7.52$, 1.36Hz), 6.92-6.85 (1H, m), 6.66 (0.2H, d, $J=7.88\text{Hz}$), 6.60 (0.8H, d, $J=7.96\text{Hz}$), 5.56 (2H, brs), 4.79 (1.6H, s), 4.73 (0.4H, s), 4.55 (2H, s), 4.47 (2H, m), 3.84 (2H, m), 3.71 (3H, s), 3.66 (0.4H, m), 3.52 (1.6H, t, $J=7.00\text{Hz}$), 3.35 (1.6H, s), 3.34 (2.4H, s), 3.33 (0.6H, s), 3.19 (0.4H, s), 3.11 (2H, t, $J=6.48\text{Hz}$), 2.59 (3.0H, q, $J=7.16\text{Hz}$), 2.46 (1H, q, $J=7.16\text{Hz}$), 2.05 (2H, m), 0.99 (4.8H, t, $J=7.12\text{Hz}$), 0.92 (1.2H, t, $J=7.12\text{Hz}$).

MS:ESI 591 (M+1)

Example 41

Ethyl

2-{2-[(N-{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate



(i)

2-{2-[(N-{3-[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 40 (145.2 mg), to give a white solid (140.5 mg). Yield 99%.

^1H NMR δ (DMSO- d_6) 8.02 (0.5H, d, $J=8.52\text{ Hz}$), 7.94 (0.5H, d, $J=8.2\text{ Hz}$), 7.55 (1H, m), 7.34 (1H, m), 7.25-7.07 (5H, m), 6.88-6.82 (2H, m), 4.75 (1H, s), 4.58-4.41 (5H, m), 3.78 (2H, m), 3.63 (2H, m), 3.47-3.42 (2H, m), 3.99 (1H, s), 3.27 (1.5H, s), 3.25 (1.5H, s), 3.21-3.09 (2H, m), 2.56 (2H, q, $J=7.16\text{Hz}$), 2.39 (2H, q, $J=7.12\text{Hz}$), 2.18 (1H, m), 1.96 (1H, m), 0.91 (3H, t, $J=7.08\text{Hz}$), 0.83 (3H, t, $J=7.16\text{Hz}$).

MS:ESI 577 (M+1)

(ii) Ethyl

2-{2-[(N-{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (62.9 mg) and EtOH, to give a colorless gum (58.1 mg). Yield 83%.


¹H NMR δ (CDCl₃) 7.94-7.90 (1H, m), 7.82 (1H, d, *J*=8.4Hz), 7.50 (1H, m), 7.35-7.31 (1H, m), 7.21-7.12 (1H, m), 7.06 (1H, d, *J*=7.52Hz), 6.95-6.87 (1H, m), 6.69 (0.3H, d, *J*=8.24Hz), 6.63 (0.7H, d, *J*=7.88Hz), 5.51 (2H, brs), 4.82 (1.5H, s), 4.75 (0.5H, s), 4.56 (2H, s), 4.49 (2H, m), 4.19 (2H, q, *J*=7.12Hz), 3.86 (2H, t, *J*=6.52Hz), 3.68 (0.5H, m), 3.55 (1.5H, t, *J*=7.00Hz), 3.37 (1.5H, s), 3.36 (2.3H, s), 3.35 (0.7H, s), 3.20 (0.5H, s), 3.13 (2H, t, *J*=6.48Hz), 2.61 (3H, q, *J*=7.12Hz), 2.47 (1H, q, *J*=7.16Hz), 2.28-2.05 (2H, m), 1.25 (3H, m), 1.01 (4.5H, t, *J*=7.12Hz), 0.93 (1.5H, t, *J*=7.12Hz).

MS:ESI 605 (M+1)

Example 42

Ethyl

2-[3-({4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butylamino}methyl)phenoxy]acetate



(i) *tert*-Butyl 4-(3-nitroquinolin-4-ylamino)butylcarbamate

The subtitle compound (27.4 g) was prepared by the same procedure of example 1 step (ii) using 3-nitroquinolin-4-ol (15 g) and (4-aminobutyl)-carbamic acid *tert*-butyl ester (22.6 ml). Yield: 96%

¹H NMR δ (CDCl₃) 9.70 (1H, brs), 9.37 (1H, s), 8.30 (1H, dd, *J* = 0.9, 8.6), 7.99 (1H, dd, *J* = 1.1, 8.3), 7.77 (1H, ddd, *J* = 1.3, 7.6, 7.7), 7.49 (1H, ddd, *J* = 1.3, 7.7, 7.8), 4.63 (1H, brs), 4.00 (2H, m), 3.21 (2H, m), 1.88 (2H, m), 1.68 (2H, m), 1.44 (9H, s). MS: ESI 361 (M+1)

(ii) *tert*-Butyl 4-(3-aminoquinolin-4-ylamino)butylcarbamate

The subtitle compound (960 mg) was prepared by the same procedure of example 1 step (iii) using product from step (i) (1.06 g). Yield: 99%

¹H NMR δ (CDCl₃) 8.48 (1H, s), 7.98 (1H, dd, *J* = 1.9, 8.5), 7.84 (1H, dd, *J* = 1.8, 8.1), 7.50-7.43 (2H, m), 4.61 (1H, brs), 3.81 (2H, brs), 3.30 (2H, m), 3.17 (2H, m), 1.76-1.60 (4H, m), 1.44 (9H, s).

MS: ESI 331 (M+1)

(iii) *tert*-Butyl4-[2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butylcarbamate

The subtitile compound (1.69 g) was prepared by the same procedure of example 15 step (i) using product from step (ii) (1.49 g). Yield: 94%

¹H NMR δ (CDCl₃) 9.28 (1H, s), 8.35 (1H, d, J = 8.2), 8.15 (1H, dd, J = 1.5, 7.9), 7.68 (2H, m), 4.61 (3H, m), 3.97 (2H, t, J = 6.5), 3.39 (3H, s), 3.27-3.21 (4H, m), 2.00 (2H, m), 1.71 (2H, m), 1.42 (9H, s).

MS: ESI 399 (M+1)

(iv)

1-[4-(*tert*-Butoxycarbonylamino)butyl]-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinoline 5-oxide

The subtitile compound (1.32 g) was prepared by the same procedure of example 1 step (v) using product from step (iii) (1.29 g). Yield: 98%

¹H NMR δ (CDCl₃) 9.13 (1H, s), 9.03 (1H, m), 8.17 (1H, m), 7.80 (2H, m), 4.68 (1H, brs), 4.61 (2H, brs), 3.93 (2H, t, J = 6.12), 3.38 (3H, s), 3.25-3.22 (4H, m), 2.00 (2H, m), 1.72 (2H, m), 1.42 (9H, s).

MS: ESI 415 (M+1)

(v) *tert*-Butyl4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butylcarbamate

The subtitile compound (1.18 g) was prepared by the same procedure of example 1 step (vi) using product from step (iv) (1.32 g). Yield: 91%

¹H NMR δ (CDCl₃) 7.86 (1H, d, J = 8.2), 7.78 (1H, d, J = 8.4), 7.46 (1H, t, J = 7.2), 7.28 (1H, t, J = 7.2), 5.45 (1H, brs), 4.65 (1H, brs), 4.48 (2H, m), 3.85 (2H, t, J = 6.4), 3.34 (3H, s), 3.14 (2H, m), 1.91 (2H, m), 1.62 (2H, m), 1.38 (9H, s).

MS: ESI 414 (M+1)

(vi) 1-(4-Aminobutyl)-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine

The subtitile compound (766 mg) was prepared by the same procedure of example 1 step (vii) using product from step (v) (1.06 g). Yield: 95%


¹H NMR δ (CDCl₃) 7.96 (1H, d, J = 8.1), 7.82 (1H, d, J = 8.3), 7.51 (1H, dd, J = 7.2, 8.1), 7.33 (1H, t, J = 7.2, 8.1), 5.47 (2H, brs), 4.53 (2H, t, J = 7.8), 3.90 (2H, t, J = 6.5), 3.38 (3H, s), 3.19 (2H, t, J = 6.5), 2.28 (2H, t, J = 7.0), 2.03-1.93 (2H, m), 1.70-1.56 (4H, m).

MS: ESI 314 (M+1)

Example 44

Ethyl

2-{3-[(*N*-(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl)-2-(diethylamino)acetamido)methyl]phenoxy}acetate



5

The title compound was prepared by the method of example 5 using the product from example 43 (480.2 mg) and diethylamine, to give a pale yellow gum (450.2 mg). Yield 96%.


¹H NMR δ (CDCl₃) 7.86-7.79 (2H, m), 7.49 (1H, m), 7.30 (1H, m), 7.23-7.19 (1H, m), 6.82-6.71 (3H, m), 5.39 (2H, brs), 4.67 (1.5H, s), 4.57 (2H, s), 4.54 (0.5H, s), 4.67-4.45 (2H, m), 4.24 (2H, q, *J*=7.12Hz), 3.86 (2H, t, *J*=6.48Hz), 3.39-3.34 (2H, m), 3.35 (3H, s), 3.23 (0.5H, s), 3.19 (1.5H, s), 3.15 (1.5H, t, *J*=6.44Hz), 3.11 (0.5H, t, *J*=6.44Hz), 2.50 (4H, m), 1.85 (2H, m), 1.71-1.63 (2H, m), 1.28 (3H, t, *J*=7.12Hz), 0.95-0.89 (6H, m).

MS:ESI 619 (M+1)

Example 45

Isopropyl

2-{3-[(*N*-(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl)-2-(diethylamino)acetamido)methyl]phenoxy}acetic acid



(i)

2-{3-[(*N*-(4-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl)-2-(diethylamino)acetamido)methyl]phenoxy}acetic acid

The title compound was prepared by the method of example 26 step (i) using the

product from example 44 (391.4 mg), to give a pale yellow solid (371.0 mg). Yield 99%

¹H NMR δ (DMSO-d₆) 7.87 (1H, m), 7.59 (0.5H, d, $J=3.16\text{Hz}$), 7.57 (0.5H, d, $J=3.8\text{Hz}$), 7.42 (1H, m), 7.28-7.20 (2H, m), 6.85-6.78 (3H, m), 4.65 (1H, s), 4.58 (1H, s), 4.56 (1H, s), 4.49 (1H, s), 4.44 (2H, m), 3.80 (2H, m), 3.40-3.32 (2H, m), 3.30 (1.5H, s), 3.29 (1.5H, s), 3.26 (2H, m), 3.14 (2H, m), 2.56-2.50 (4H, m), 1.70 (3H, m), 1.59 (1H, m), 0.92-0.87 (6H, m).

MS:ESI 591 (M+1)

(ii) Isopropyl

2-{3-[(*N*-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-2-{diethylamino}acetamido)methyl]phenoxy}acetate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (80.6 mg) and iPrOH, to give a colorless gum (58.9 mg). Yield 68%.


¹H NMR δ (CDCl₃) 7.91-7.82 (2H, m), 7.52 (1H, m), 7.33 (1H, m), 7.20 (1H, m), 6.80-6.72 (3H, m), 5.43 (2H, m), 5.13 (1H, m), 4.76 (1.5H, s), 4.58 (0.5H, s), 4.54 (2H, s), 4.49 (2H, m), 3.87 (2H, m), 3.60-3.49 (2H, m), 3.36 (2.3H, s), 3.34 (0.7H, s), 3.30 (1.5H, s), 3.26 (0.5H, s), 3.14 (1.5H, t, $J=6.36\text{ Hz}$), 3.09 (0.5H, t, $J=6.2\text{Hz}$), 2.63-2.50 (4H, m), 2.22- 2.05 (2H, m), 1.71-1.63 (2H, m), 1.28 (6H, d, $J=6.28\text{ Hz}$), 1.00 (6H, t, $J=7.08\text{ Hz}$).

MS:ESI 633 (M+1)

Example 46

tert-Butyl

2-[3-({4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butylamino}methyl)phenoxy]acetate



(i) *tert*-Butyl 2-(3-formylphenoxy)acetate

By the method of example 23 step (i) using the 3-hydroxybenzaldehyde (500 mg) and the *t*-butyl bromoacetate (633.4 μL) to afford the title compound, 969.3 mg (100%) as colorless oil.

^1H NMR δ (CDCl_3) 9.96 (1H, s), 7.50 (1H, ddd, $J=7.48, 1.4, 1.36$ Hz), 7.46 (1H, dd, $J=7.72, 7.48$ Hz), 7.34 (1H, m), 7.22 (1H, ddd, $J=7.8, 2.72, 1.48$ Hz), 4.58 (2H, s), 1.49 (9H, s).

(ii) *tert*-Butyl

2-[3-({4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butylamino}methyl)phenoxy]acetate

By the method of example 1 step (viii) using the product from example 42 step (vi) (183.0 mg) and *tert*-butyl 2-(3-formylphenoxy)acetate (138.9 mg) to afford the title compound, 217.0 mg (70%) as a pale yellow gum.


^1H NMR δ (CDCl_3) 7.99 (1H, dd, $J=8.24, 1.00$ Hz), 7.83 (1H, dd, $J=8.32, 1.00$ Hz), 7.52 (1H, m), 7.32 (1H, m), 7.23 (1H, dd, $J=7.92, 7.84$ Hz), 6.92 (1H, d, $J=7.64$ Hz), 6.88 (1H, d, $J=2.24$ Hz), 6.78 (1H, dd, $J=8.12, 2.08$ Hz), 5.42 (2H, brs), 4.54 (2H, m), 4.51 (2H, s), 3.90 (2H, t, $J=6.56$ Hz), 3.77 (2H, s), 3.39 (3H, s), 3.20 (2H, t, $J=6.52$ Hz), 2.70 (2H, t, $J=6.96$ Hz), 2.01 (2H, m), 1.72-1.63 (2H, m), 1.43 (9H, s).

MS:ESI 534 ($M+1$)

Example 47

tert-Butyl

2-{3-[(*N*-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-2-chloroacetamido)methyl]phenoxy}acetate hydrochloride



By the method of example 2 using the product of example 46 (209.0 mg), there was obtained the title compound, 301.2 mg (quant.) as a colorless gum.


^1H NMR δ (CDCl_3) 7.89-7.80 (2H, m), 7.53-7.48 (1H, m), 7.32 (1H, m), 7.24-7.19 (1H, m), 6.82-6.70 (3H, m), 5.46 (2H, brs), 4.57-4.47 (6H, m), 4.09 (0.5H, s), 4.00 (1.5H, s), 3.87 (2H, m), 3.43 (1.5H, t, $J=7.2$ Hz), 3.36 (2.3H, s), 3.35 (0.7H, s), 3.28 (0.5H, t, $J=7.64$ Hz), 3.17 (1.5H, t, $J=6.4$ Hz), 3.11 (0.5H, t, $J=6.32$ Hz), 1.94-1.86 (2H, m), 1.73-1.63 (2H, m), 1.43 (9H, s).

MS:ESI 610 ($M+1$)

Example 48

tert-Butyl

2-{3-[(*N*-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-2-{diethylamino}acetamido)methyl]phenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 47 (226.0 mg) and diethylamine, to give a colorless gum (221.5 mg). Yield 92%.


¹H NMR δ (CDCl₃) 7.89-7.80 (2H, m), 7.49 (1H, m), 7.33-7.18 (2H, m), 6.82-6.71 (3H, m), 5.40 (2H, brs), 4.68 (1.4H, s), 4.55 (0.6H, s), 4.51-4.46 (4H, m), 3.87 (2H, t, *J*=6.48Hz), 3.41-3.35 (5H, m), 3.24 (0.6H, s), 3.20 (1.4H, s), 3.16 (1.4H, t, *J*=6.48Hz), 3.11 (0.6H, t, *J*=6.4Hz), 2.51 (4H, m), 1.85 (2H, m), 1.70-1.62 (2H, m), 1.47 (9H, s), 0.95-0.90 (6H, m).

MS:ESI 647 (M+1)

Example 49

Methyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)phenoxy]propanoate



(i) Methyl 2-(3-formylphenoxy)propanoate

By the method of example 23 step (i) using the 3-hydroxybenzaldehyde (500 mg) and the methyl 2-bromopropanoate (501 μL) to afford the title compound, 827.1 mg (97%) as colorless oil.

¹H NMR δ (CDCl₃) 9.96 (1H, s), 7.50 (2H, ddd, *J*=7.48, 1.32, 1.32Hz), 7.46 (1H, dd, *J*=7.84, 7.52Hz), 7.33 (1H, m), 7.18 (1H, m), 4.86 (1H, q, *J*=6.8Hz), 3.78 (3H, s), 1.66 (3H, d, *J*=6.8Hz).

MS:ESI 209 (M+1)

(ii) Methyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)phenoxy]propanoate

By the method of example 1 step (viii) using the product from example 15 step (iv) (200.0 mg) and methyl 2-(3-formylphenoxy)propanoate (139.1 mg) to afford the title compound, 289.4 mg (88%) as a white solid.


¹H NMR δ (CDCl₃) 8.08 (2H, dd, *J*=8.2, 0.88Hz), 7.80 (1H, dd, *J*=8.36, 1.00Hz), 7.48 (1H, m), 7.29-7.22(2H, m), 6.95 (1H, d, *J*=7.6Hz), 6.91 (1H, d, *J*=2.12Hz), 6.75 (1H, dd, *J*=8.04, 2.16Hz), 5.37 (2H, brs), 4.78 (2H, q, *J*=6.76Hz), 4.65 (2H, t, *J*=7.4Hz), 3.88 (2H, t, *J*=6.56Hz), 3.77 (2H, s), 3.73 (3H, s), 3.37 (3H, s), 3.243 (2H, t, *J*=6.56Hz), 2.73 (2H, t, *J*=6.28Hz), 2.07 (2H, m), 1.61 (3H, d, *J*=6.8Hz).

MS:ESI 492 (M+1)

Example 50

Methyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]phenoxy}propanoate hydrochloride



By the method of example 2 using the product of example 49 (285.4 mg), there was obtained the title compound, 341.8 mg (quant.) as a colorless gum.


¹H NMR δ (CDCl₃) 7.93-7.83 (2H, m), 7.53 (1H, m), 7.35 (1H, m), 7.23 (1H, m), 6.75-6.71 (3H, m), 5.33-5.47 (2H, m), 4.73 (1H, q, *J*=6.8Hz), 4.60 (1.5H, s), 4.56-4.49 (2.5H, m), 4.10 (2H, s), 3.87 (2H, t, *J*=6.36Hz), 3.75 (3H, s), 3.63-3.42 (2H, m), 3.37 (3H, s), 3.17-3.10 (2H, m), 2.28-2.13 (2H, m), 1.62 (3H, d, *J*=6.8Hz).

MS:ESI 568 (M+1)

Example 51

Methyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}propanoate



The title compound was prepared by the method of example 5 using the product from example 50 (185.0 mg) and diethylamine, to give a colorless gum (121.9 mg). Yield 62%.


¹H NMR δ (CDCl₃) 7.88-7.80 (2H, m), 7.50 (1H, m), 7.32 (1H, m), 7.18 (1H, m), 6.77-6.67 (3H, m), 5.40 (2H, brs), 4.74 (1.5H, s), 4.70 (1H, q, $J=6.76$ Hz), 4.56 (0.5H, s), 4.48 (2H, m), 3.85 (2H, m), 3.73 (3H, s), 3.56-3.51 (2H, m), 3.35 (2.3H, s), 3.33 (0.7H, s), 3.28 (1.5H, s), 3.25 (0.5H, s), 3.13 (1.5H, t, $J=6.36$ Hz), 3.08 (0.5H, t, $J=6.24$ Hz), 2.59 (3H, t, $J=7.12$ Hz), 2.51 (1H, t, $J=7.12$ Hz), 2.10-2.06 (2H, m), 1.60 (2H, d, $J=6.8$ Hz), 0.98 (6H, t, $J=7.08$ Hz).

MS:ESI 605 (M+1)

Example 52

Ethyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}propanoate



(i)

2-{3-[(N-{3-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}propanoic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 51 (79.9 mg), to give a white solid (78.0 mg). Yield quant.

¹H NMR δ (DMSO-*d*₆) 7.94 (0.5H, d, $J=8.16$ Hz), 7.90 (0.5H, d, $J=8.48$ Hz), 7.59 (1H, d, $J=7.28$ Hz), 7.44 (1H, m), 7.27-7.16 (2H, m), 7.12 (2H, brs), 6.78-6.72 (3H, m), 4.75- 4.68 (2H, m), 4.51-4.48 (2H, m), 4.40 (1H, m), 3.79 (2H, m), 3.38 (2H, m), 3.28 (3H, s), 3.13 (2H, m), 2.68-2.58 (2H, m), 2.51-2.50 (2H, m), 2.09 (1H, m), 1.49 (1.5H, d, $J=6.68$ Hz), 1.48 (1.5H, d, $J=6.72$ Hz), 0.95-0.85 (6H, m).

MS:ESI 591 (M+1)

(ii) Ethyl

2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy]propanoate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (57.8 mg) and EtOH, to give a colorless gum (42.5 mg). Yield 70%.


¹H NMR δ (CDCl₃) 7.92-7.84 (2H, m), 7.53 (1H, m), 7.38-7.31 (1H, m), 7.20 (1H, m), 6.79-6.71 (3H, m), 5.63 (2H, brs), 4.77-4.68 (2.5H, m), 4.58 (0.5H, m), 4.50 (2H, m), 4.20 (2H, m), 3.87 (2H, m), 3.59-3.53 (2H, m), 3.37 (2.3H, s), 3.35 (0.7H, s), 3.30 (1.5H, s), 3.27 (0.5H, s), 3.15 (1.5H, t, *J*=6.32Hz), 3.10 (0.5H, t, *J*=6.24Hz), 2.61 (3H, q, *J*=7.12Hz), 2.54 (1H, q, *J*=7.08Hz), 2.11-2.05 (2H, m), 1.61 (3H, d, *J*=6.80Hz), 1.25 (3H, t, *J*=7.12Hz), 1.00 (6H, t, *J*=7.12Hz).

MS:ESI 619 (M+1)

Example 53

Ethyl

2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl]phenoxy]-2-methylpropanoate



(i) Ethyl 2-(3-formylphenoxy)-2-methylpropanoate

By the method of example 23 step (i) using the 3-hydroxybenzaldehyde (300 mg) and the ethyl 2-bromo-2-methylpropionate (582.6 mg) to afford the title compound, 244.2 mg (42%) as colorless oil.

¹H NMR δ (CDCl₃) 9.94 (1H, s), 7.51 (1H, ddd, *J*=7.52, 1.2, 1.2Hz), 7.42 (1H, dd, *J*=7.96, 7.68Hz), 7.32 (1H, m), 7.13 (1H, ddd, *J*=8.12, 2.64, 1.04Hz), 4.25 (2H, q, *J*=7.12Hz), 1.64 (6H, s), 1.26 (3H, t, *J*=7.12Hz).

(ii) Ethyl

2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl]phenoxy]-2-methylpropanoate

By the method of example 1 step (viii) using the product from example 15 step (iv) (127.2 mg) and ethyl 2-(3-formylphenoxy)-2-methylpropanoate (100.4 mg) to

afford the title compound, 189.1 mg (86%) as a white solid.


^1H NMR δ (CDCl_3) 8.09 (1H, dd, $J=8.28$, 1.00Hz), 7.82 (1H, dd, $J=8.36$, 1.04Hz), 7.50 (1H, m), 7.32-7.28 (1H, m), 7.21 (1H, dd, $J=7.92$, 7.8Hz), 6.98 (1H, d, $J=7.68\text{Hz}$), 6.89 (1H, m), 6.73 (1H, dd, $J=8.2$, 1.88Hz), 5.40 (2H, brs), 4.66 (2H, t, $J=7.4\text{Hz}$), 4.23 (2H, q, $J=7.12\text{Hz}$), 3.90 (2H, t, $J=6.56\text{Hz}$), 3.38 (3H, s), 3.25 (2H, t, $J=6.48\text{Hz}$), 2.74 (2H, t, $J=6.24\text{Hz}$), 2.08 (2H, m), 1.61 (6H, s), 1.24 (2H, t, $J=7.12\text{Hz}$).

MS:ESI 520 ($\text{M}+1$)

10 Example 54

Ethyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-chloroacetamido)methyl]phenoxy}-2-methylpropanoate hydrochloride



15 By the method of example 2 using the product of example 53 (186.3 mg), there was obtained the title compound, 222.4 mg (quant.) as a colorless gum.


^1H NMR δ (CDCl_3) 7.91 (1H, d, $J=7.52\text{Hz}$), 7.82 (1H, d, $J=8.36\text{Hz}$), 7.51 (1H, m), 7.34 (1H, m), 7.21-7.13 (1H, m), 6.74-6.67 (3H, m), 5.55 (1.5H, brs), 5.47 (0.5H, brs), 4.58 (1.5H, s), 4.54-4.46 (2.5H, m), 4.19 (2H, q, $J=7.12\text{Hz}$), 4.07 (2H, s), 3.85 (2H, t, $J=6.36\text{Hz}$), 3.58 (1.5H, t, $J=6.72\text{Hz}$), 3.42-3.37 (0.5H, m), 3.34 (2.3H, s), 3.32 (0.7H, s), 3.14 (1.5H, t, $J=6.32\text{Hz}$), 3.10 (0.5H, t, $J=6.2\text{Hz}$), 2.23-2.09 (2H, m), 1.56 (4.5H, s), 1.55 (1.5H, s), 1.22 (3H, t, $J=7.12\text{Hz}$).

MS:ESI 596 ($\text{M}+1$)

25 Example 55

Ethyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]phenoxy}-2-methylpropanoate



The title compound was prepared by the method of example 5 using the product from example 54 (217.8 mg) and diethylamine, to give a colorless gum (170.4 mg). Yield 74%.


¹H NMR δ (CDCl₃) 7.92-7.83 (2H, m), 7.53 (1H, m), 7.35 (1H, m), 7.19-7.16 (1H, m), 6.81-6.70 (3H, m), 5.43 (2H, brs), 4.77 (1.5H, s), 4.58 (0.5H, s), 4.51 (2H, m), 4.22 (2H, q, *J*=7.16Hz), 3.88 (2H, m), 3.57 (2H, m), 3.37 (2.3H, s), 3.35 (0.7H, s), 3.30 (1.5H, s), 3.27 (0.5H, s), 3.17 (1.5H, t, *J*=6.36Hz), 3.11 (0.5H, t, *J*=6.32Hz), 2.61 (3H, q, *J*=7.2Hz), 2.53 (1H, q, *J*=7.04Hz), 2.19-2.09 (2H, m), 1.58 (6H, s), 1.24 (3H, q, *J*=7.16Hz), 1.00 (6H, t, *J*=7.08Hz).

MS:ESI 633 (M+1)

Example 56

Methyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate



(i)

2-{3-[(*N*-{3-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 55 (147.2 mg), to give a white solid (135.9 mg). Yield 97%.

¹H NMR δ (DMSO-*d*₆) 7.88 (0.5H, d, *J*=8.24Hz), 7.85 (0.5H, d, *J*=8.32Hz), 7.59 (1H, d, *J*=8.24Hz), 7.43 (1H, m), 7.23-7.12 (2H, m), 6.76-6.67 (3H, m), 4.68 (1H, s), 4.43 (2H, m), 4.33 (1H, m), 3.80-3.74 (4H, m), 3.50 (1H, m), 3.41 (1H, m), 3.22 (1H, s), 3.21 (1H, s), 3.10 (2H, m), 2.47-2.39 (2H, m), 2.04 (1H, m), 1.86 (1H, m), 1.48 (3H, s), 1.47 (3H, s), 0.88-0.82 (6H, m).

MS:ESI 605 (M+1)

(ii) Methyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate

The title compound was prepared by the method of example 26 step (ii) using the

product from step (i) (84.3 mg) and MeOH, to give a colorless gum (66.4 mg). Yield 74%.


¹H NMR δ (CDCl₃) 7.92-7.83 (2H, m), 7.53 (1H, m), 7.35 (1H, m), 7.22-7.17 (1H, m), 6.82-6.69 (3H, m), 5.41 (2H, brs), 4.77 (1.5H, s), 4.57 (0.5H, s), 4.51 (2H, m), 3.88 (2H, m), 3.76 (3H, s), 3.56 (2H, t, *J*=7.00Hz), 3.37 (2.3H, s), 3.35 (0.7H, s), 3.30 (1.5H, s), 3.27 (0.5H, s), 3.17 (1.5H, t, *J*=6.36Hz), 3.11 (0.5H, t, *J*=6.24Hz), 2.61 (3H, q, *J*=7.16Hz), 2.53 (1H, q, *J*=7.12Hz), 2.15-2.07 (2H, m), 1.58 (6H, s), 1.00 (6H, t, *J*=7.08Hz).

MS:ESI 619 (M+1)

Example 57

Ethyl

1-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)phenoxy]cyclobutanecarboxylate



(i) Ethyl 1-(3-formylphenoxy)cyclobutanecarboxylate

By the method of example 23 step (i) using the 3-hydroxybenzaldehyde (500 mg) and the ethyl 1-bromocyclobutanecarboxylate (694.6 uL) to afford the title compound, 76.2 mg (8%) as colorless oil.

¹H NMR δ (CDCl₃) 9.93 (1H, s), 7.46 (1H, m), 7.41 (1H, dd, *J*=7.88, 7.6Hz), 7.13 (1H, m), 6.98 (1H, ddd, *J*=8.00, 2.64, 1.16Hz), 4.21 (2H, q, *J*=7.08Hz), 2.82-2.76 (2H, m), 2.51-2.43 (2H, m), 2.10-1.99 (2H, m), 1.18 (3H, t, *J*=7.12Hz).

(ii) Ethyl

1-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)phenoxy]cyclobutanecarboxylate

By the method of example 1 step (viii) using the product from example 15 step (iv) (87.4 mg) and ethyl 2-(3-formylphenoxy)-2-methylpropanoate (100.4 mg) to afford the title compound, 109.4 mg (71%) as a white solid.

¹H NMR δ (CDCl₃) 8.09 (1H, m), 7.82 (1H, dd, *J*=8.32, 0.88Hz), 7.51 (1H, m), 7.29 (1H, m), 7.21 (1H, dd, *J*=7.92, 7.84Hz), 6.93 (1H, d, *J*=7.52Hz), 6.93 (1H, m), 6.78 (1H, m), 6.54 (1H, dd, *J*=7.96, 2.24Hz), 5.41 (2H, brs), 4.67 (2H, m), 4.19 (2H, q,

$J=7.12\text{Hz}$), 3.91 (2H, t, $J=6.52\text{Hz}$), 3.78 (2H, s), 3.39 (3H, s), 3.26 (2H, t, $J=6.52\text{Hz}$), 2.80-2.73 (4H, m), 2.51-2.43 (2H, m), 2.11-1.97 (4H, m), 1.17 (3H, t, $J=7.08\text{Hz}$).


MS:ESI 532 (M+1)

5

Example 58

Ethyl

1-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]phenoxy}cyclobutanecarboxylate hydrochloride



10

By the method of example 2 using the product of example 57 (107.1 mg), there was obtained the title compound, 116.1 mg (quant.) as a colorless gum.

^1H NMR δ (CDCl_3) 7.92 (1H, d, $J=7.44\text{Hz}$), 7.84 (1H, d, $J=8.28\text{Hz}$), 7.53 (1H, m), 7.36 (1H, m), 7.19 (1H, dd, $J=7.88, 7.88\text{Hz}$), 6.71 (1H, d, $J=7.52\text{Hz}$), 6.57 (1H, d, $J=6.48\text{Hz}$), 6.53 (1H, dd, $J=8.04, 2.24\text{Hz}$), 5.59 (2H, brs), 4.59 (2H, s), 4.56-4.51 (2H, m), 4.17 (2H, q, $J=7.12\text{Hz}$), 4.07 (2H, s), 3.87 (2H, t, $J=6.36\text{Hz}$), 3.60 (2H, t, $J=6.68\text{Hz}$), 3.36 (2.3H, s), 3.34 (0.7H, s), 3.16 (1.5H, t, $J=6.36\text{Hz}$), 3.12 (0.5H, m), 2.72 (2H, m), 2.42 (2H, m), 2.15 (2H, m), 2.03-1.97 (2H, m), 1.17 (3H, t, $J=7.08\text{Hz}$).

15

20


MS:ESI 608 (M+1)

Example 59

Ethyl

1-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-diethylamino)acetamido)methyl]phenoxy}cyclobutanecarboxylate

25



The title compound was prepared by the method of example 5 using the product from example 58 (116.1 mg) and diethylamine, to give a colorless gum (80.5 mg). Yield 77%.


¹H NMR δ (CDCl₃) 7.91-7.83 (2H, m), 7.53 (1H, m), 7.34 (1H, m), 7.17 (1H, dd, *J*=8.04, 7.92Hz), 6.74-6.70 (1H, m), 6.63 (0.25H, s), 6.57 (0.75H, s), 6.49 (1H, dd, *J*=8.4, 2.4Hz), 4.76 (1.5H, s), 4.56 (0.5H, s), 4.50 (2H, m), 4.17 (2H, q, *J*=7.12Hz), 3.87 (2H, m), 3.55 (2H, m), 3.36 (2.3H, s), 3.34 (0.7H, s), 3.28 (2H, s), 3.15 (1.5H, t, *J*=6.36Hz), 3.10 (0.5H, m), 2.72 (2H, m), 2.59 (3H, q, *J*=7.16Hz), 2.52 (1H, q, *J*=7.08Hz), 2.41 (2H, m), 2.09 (2H, m), 2.02-1.96 (2H, m), 1.16 (3H, q, *J*=7.08Hz), 0.99 (6H, t, *J*=7.08Hz).

MS:ESI 645 (M+1)

10 Example 60

Ethyl

2-[5-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl}-2-methoxyphenoxy]acetate



15 By the method of example 1 step (viii) using the product from example 15 step (iv) (200.0 mg) ethyl 2-(5-formyl-2-methoxyphenoxy)acetate (159.1 mg) there was obtained the title compound, 261.5 mg (75%) as a white solid.


¹H NMR δ (CDCl₃) 8.08 (1H, dd, *J*=8.20, 0.88Hz), 7.81 (1H, dd, *J*=8.36, 1.00Hz), 7.49 (1H, m), 7.28 (1H, m), 6.93 (1H, dd, *J*=8.12, 1.88Hz), 6.93 (2H, m), 6.87-6.85 (2H, m), 5.40 (2H, brs), 4.69 (2H, s), 4.64 (2H, t, *J*=7.36Hz), 4.22 (2H, q, *J*=7.12Hz), 3.89 (2H, t, *J*=6.64Hz), 3.88 (3H, s), 3.72 (2H, s), 3.37 (3H, s), 3.24 (2H, t, *J*=6.60Hz), 2.72 (2H, t, *J*=6.32Hz), 2.07 (2H, m), 1.25 (3H, t, *J*=7.12Hz).

MS:ESI 522 (M+1)

25 Example 61

Ethyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-chloroacetamido)methyl]-2-methoxyphenoxy}acetate hydrochloride



By the method of example 2 using the product of example 60 (261.5 mg), there was obtained the title compound, 310.9 mg (quant.) as a colorless gum.


¹H NMR δ (CDCl₃) 7.91-7.81 (2H, m), 7.53 (1H, d, *J*=7.96Hz), 7.38-7.31 (1H, m), 6.80-6.65 (3H, m), 5.79 (1.5H, brs), 5.63 (0.5H, brs), 4.63 (1.5H, s), 4.62 (0.5H, s), 4.54-4.48 (4H, m), 4.22 (2H, q, *J*=7.16Hz), 4.11 (1.5H, s), 4.05 (0.5H, s), 3.88-3.85 (5H, m), 3.54 (2H, t, *J*=7.00Hz), 3.36 (3H, s), 3.15-3.09 (2H, m), 2.24-2.07 (2H, m), 1.28 (3H, t, *J*=7.12Hz).

MS:ESI 598 (M+1)

Example 62

Ethyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]-2-methoxyphenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 61 (306.0 mg) and diethylamine, to give a colorless gum (224.9 mg). Yield 71%.


¹H NMR δ (CDCl₃) 7.91-7.83 (2H, m), 7.53 (1H, m), 7.34 (1H, m), 7.35 (1H, m), 6.80-6.66 (3H, m), 5.48-5.453 (2H, brm), 4.65 (1.5H, s), 4.67 (1.5H, s), 4.63 (1.5H, s), 4.62 (0.5H, s), 4.51-4.47 (2.5H, m), 4.26-4.20 (2H, m), 3.89-3.85 (5H, m), 3.56-3.48 (2H, m), 3.37 (2.3H, s), 3.35 (0.7H, s), 3.32 (1.5H, s), 3.25 (0.5H, s), 3.14 (1.5H, t, *J*=6.4Hz), 3.09 (0.5H, t, *J*=6.24Hz), 2.62 (3H, q, *J*=7.16Hz), 2.53 (1H, q, *J*=7.12Hz), 2.21-2.06 (2H, m), 1.30-1.25 (3H, m), 1.03-0.97 (6H, m).

MS:ESI 635 (M+1)

Example 63

Methyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]-2-methoxyphenoxy}acetate



(i)

2-{5-[(*N*-(3-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-{diethylamino}acetamido)methyl]-2-methoxyphenoxy}acetic acid

5 The title compound was prepared by the method of example 26 step (i) using the product from example 62 (124.7 mg), to give a white solid (121.0 mg). Yield quant. ¹H NMR δ (DMSO-*d*₆) 7.95 (0.5H, d, *J*=8.68Hz), 7.92 (0.5H, d, *J*=8.56Hz), 7.57 (1H, d, *J*=8.12Hz), 7.42 (1H, m), 7.27 (0.5H, d, *J*=7.24Hz), 7.24 (0.5H, d, *J*=6.56Hz), 6.89 (1H, d, *J*=8.24Hz), 6.83 (1H, d, *J*=8.16Hz), 6.75-6.64 (2H, m), 4.61 (1H, s), 4.50 (1H, m), 4.40-4.39 (4H, m), 3.79 (2H, m), 3.74 (2H, m), 3.28 (3H, s), 3.26 (1H, s), 3.18 (1H, s), 3.11 (2H, m), 2.58-2.50 (2H, m), 2.42 (2H, m), 2.08 (1H, m), 1.92 (1H, m), 0.91 (3H, t, *J*=7.10Hz), 0.85 (3H, d, *J*=7.14Hz).

MS:ESI 607 (M+1)

15 (ii) Methyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-{diethylamino}acetamido)methyl]-2-methoxyphenoxy}acetate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (59.8 mg) and MeOH, to give a colorless gum (37.2 mg). Yield 61%.


20 ¹H NMR δ (CDCl₃) 7.91-7.83 (2H, m), 7.53 (1H, m), 7.34 (1H, m), 7.35 (1H, m), 6.80-6.66 (3H, m), 5.48-5.453 (2H, brm), 4.65 (1.5H, s), 4.67 (1.5H, s), 4.63 (1.5H, s), 4.62 (0.5H, s), 4.51-4.47 (2.5H, m), 3.89-3.85 (5H, m), 3.75 (3H, s), 3.56-3.48 (2H, m), 3.37 (2.3H, s), 3.35 (0.7H, s), 3.32 (1.5H, s), 3.25 (0.5H, s), 3.14 (1.5H, t, *J*=6.4Hz), 3.09 (0.5H, t, *J*=6.24Hz), 2.62 (3H, q, *J*=7.16Hz), 2.53 (1H, q, *J*=7.12Hz), 2.21-2.06 (2H, m), 1.03-0.97 (6H, m).

MS:ESI 621 (M+1)

Example 64

30 Ethyl

2-[5-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]-2-methylphenoxy]acetate



(i) 5-(Hydroxymethyl)-2-methylphenol

To a solution of $\text{BH}_3 \cdot \text{THF}$ (1.06M in THF solution, 4.66mL, 4.94mmol) 3-hydroxy-4-methylbenzoic acid (500 mg, 3.29 mmol) and $\text{B}(\text{OMe})_3$ (683.7 mg, 6.58mmol) in THF (3.3 ml) was added at rt. After stirring for 6 h at rt, cooled to 0°C , and H_2O was added. The aq. layer was extracted with AcOEt, dried over Na_2SO_4 , and concentrated. The mixture was stirred at rt for 30min, and concentrated. The residue was diluted with AcOEt, H_2O was added. The aq. layer was extracted with AcOEt, dried over Na_2SO_4 , and concentrated. The residue was purified by flash column chromatography to give the title compound (446.2 mg, 98%) as a white solid.

^1H NMR δ (CDCl_3) 7.10 (1H, d, $J=7.4\text{Hz}$), 6.83(1H, d, $J=8.16\text{Hz}$), 6.81 (1H, s), 4.90 (1H, m), 4.62 (2H, d, $J=5.08\text{Hz}$), 2.24 (3H, s), 1.64 (1H, t, $J=7.12\text{Hz}$ brs).

(ii) 3-Hydroxy-4-methylbenzaldehyde

To a solution of the product step (i) (440.0 mg, 3.18mmol) in THF (4.4mL) MnO_2 (552.9 mg, 6.36 mmol) was added at rt. After stirring for 6 h at 50°C , the mixture was filtered through the celite pad. The filtrate was concentrated, and the residue was purified by flash column chromatography to give the title compound (46.1 mg, 11%) as a pale yellow solid.

^1H NMR δ (CDCl_3) 9.90 (1H, s), 7.36 (1H, dd, $J=7.76, 1.44\text{Hz}$), 7.30 (1H, s), 7.29 (1H, d, $J=5.52\text{Hz}$), 5.33 (1H, s), 2.33 (3H, s).

(iii) Ethyl 2-(5-formyl-2-methylphenoxy)acetate

To a solution of the product step (ii) (43.6 mg, 0.32 mmol) in DMF (0.5 ml) ethylbromoacetate (37.3 ul, 0.336 mmol) and K_2CO_3 (46.4 mg, 0.336mmol) was added at rt. After stirring for 3 h at 60°C , deluted with AcOEt and H_2O was added. The aq. layer was extracted with AcOEt, dried over Na_2SO_4 , and concentrated. The residue was purified by flash column chromatography to give the title compound (68.9 mg, 97%) as colorless oil.

^1H NMR δ (CDCl_3) 9.91 (1H, s), 7.41 (1H, dd, $J=7.52, 1.32\text{Hz}$), 7.34 (1H, d, $J=7.56\text{Hz}$), 7.22 (1H, m), 4.72 (2H, s), 4.28 (2H, q, $J=7.16\text{Hz}$), 2.38 (3H, s), 1.31

(3H, t, $J=7.12\text{Hz}$),.

(iv) Ethyl

2-[5-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamin
o}methyl)-2-methylphenoxy]acetate

By the method of example 1 step (viii) using the product from example 15 step (iv) (91.0 mg) and ethyl 2-(5-formyl-2-methylphenoxy)acetate (67.5 mg) there was obtained the title compound, 123.7 mg (81%) as a white solid.


^1H NMR δ (CDCl_3) 8.08 (1H, dd, $J=8.24, 0.92\text{Hz}$), 7.82 (1H, dd, $J=8.36, 1.04\text{Hz}$), 7.50 (1H, m), 7.30-7.26 (1H, m), 7.12 (1H, d, $J=7.56\text{Hz}$), 6.88 (1H, dd, $J=7.44, 1.00\text{Hz}$), 6.73 (1H, s), 5.42 (2H, brs), 4.65 (4H, m), 4.23 (2H, q, $J=7.126\text{Hz}$), 3.89 (2H, t, $J=6.64\text{Hz}$), 3.75 (2H, s), 3.38 (3H, s), 3.25 (2H, t, $J=6.52\text{Hz}$), 2.73 (2H, t, $J=6.32\text{Hz}$), 2.29 (3H, s), 2.08 (2H, m), 1.26 (3H, t, $J=7.16\text{Hz}$).

MS:ESI 506 ($\text{M}+1$)

Example 65

Ethyl

2-{5-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-2-methylphenoxy}acetate hydrochloride



By the method of example 2 using the product of example 64 (122.5 mg), there was obtained the title compound, 146.9 mg (quant.) as a colorless gum.


^1H NMR δ (CDCl_3) 7.91-7.81 (2H, m), 7.53 (1H, m), 7.34 (1H, m), 7.10 (0.75H, d, $J=7.48\text{Hz}$), 7.04 (0.25H, d, $J=7.16\text{Hz}$), 6.66-6.61 (1H, m), 6.54 (0.25H, s), 6.46 (0.75H, s), 5.61-5.52 (2H, brm), 4.57-4.48 (6H, m), 4.27-4.21 (2H, m), 4.11 (1.5H, s), 4.06 (0.5H, s), 3.87 (2H, t, $J=6.40\text{Hz}$), 3.57 (2H, t, $J=6.88\text{Hz}$), 3.36 (2.3H, s), 3.34 (0.7H, s), 3.14 (1.5H, t, $J=6.32\text{Hz}$), 3.10 (0.5H, t, $J=6.04\text{Hz}$), 2.31-2.23 (3.5H, m), 2.13 (1.5H, m), 1.25 (3H, t, $J=7.08\text{Hz}$).

MS:ESI 582 ($\text{M}+1$)

Example 66

Ethyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]-2-methylphenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 65 (128.2 mg) and diethylamine, to give a colorless gum (132.4 mg). Yield 97%.


¹H NMR δ (CDCl₃) 7.91-7.82 (2H, m), 7.52 (1H, m), 7.33 (1H, m), 7.09 (0.75H, d, *J*=7.76Hz), 7.05 (0.25H, d, *J*=7.44Hz), 6.66 (1H, d, *J*=7.52Hz), 5.46-5.45 (2H, brm), 4.72(1.5H, s), 4.56 (2H, s), 4.53 (0.5H, s), 4.49 (2H, m), 4.24 (2H, q, *J*=7.12Hz), 3.87 (2H, m), 3.56-3.50 (2H, m), 3.36 (2.3H, s), 3.35 (0.7H, s), 3.31 (1.5H, s), 3.26 (0.5H, s), 3.14 (1.5H, t, *J*=6.36Hz), 3.14 (0.5H, t, *J*=6.16Hz), 2.61 (3H, q, *J*=7.12Hz), 2.54 (1H, q, *J*=7.16Hz), 2.26 (3H, s), 2.20-2.06 (2H, m), 1.29 (3H, t, *J*=7.16Hz), 1.02-0.98 (6H, m).

MS:ESI 619 (M+1)

Example 67

Isopropyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]-2-methylphenoxy}acetic acid



(i)

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]-2-methylphenoxy}acetic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 66 (93.2 mg), to give a white solid (91.7 mg). Yield quant.

¹H NMR δ (DMSO-*d*₆) 7.97 (0.5H, d, *J*=8.72Hz), 7.95 (0.5H, d, *J*=8.44Hz), 7.59 (1H, d, *J*=8.32Hz), 7.42 (0.5H, d, *J*=7.24Hz), 7.40 (0.5H, d, *J*=7.16Hz), 7.26 (0.5H, d, *J*=8.12Hz), 7.21 (0.5H, d, *J*=7.84Hz), 7.03 (0.5H, d, *J*=7.64Hz), 6.98 (0.5H, d, *J*=7.68Hz), 6.63 (2H, brs), 6.58 (1H, d, *J*=7.76Hz), 6.55 (1H, d, *J*=7.32Hz), 4.65

(1H, s), 4.51 (2H, m), 4.44-4.40 (2H, m), 4.24 (2H, m), 3.78 (2H, m), 3.26 (3H, s), 3.21 (2H, s), 3.15 (2H, s), 3.12 (2H, t, $J=6.68\text{Hz}$), 2.53-2.49 (2H, m), 2.37 (2H, m), 2.12 (3H, s), 2.08 (1H, m), 1.95 (1H, m), 0.90-0.80 (6H, m).

MS:ESI 591 (M+1)

5

(ii) Isopropyl

2-{5-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-diethylamino)acetamido)methyl]-2-methylphenoxy}acetate

10 The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (48.8 mg) and iPrOH, to give a colorless gum (45.5 mg). Yield 87%.

^1H NMR δ (CDCl_3) 7.91-7.82 (2H, m), 7.52 (1H, m), 7.33 (1H, m), 7.08 (0.75H, d, $J=7.68\text{Hz}$), 7.05 (0.25H, d, $J=7.36\text{Hz}$), 6.66 (1H, d, $J=7.32\text{Hz}$), 6.60 (0.25H, s), 6.47 (0.75H, s), 5.49 (2H, brm), 5.10 (1H, m), 4.72 (1.5H, s), 4.53-4.46 (4.5H, m), 3.86 (2H, m), 3.57-3.50 (2H, m), 3.36 (2.3H, s), 3.34 (0.7H, s), 3.31 (1.5H, s), 3.25 (0.5H, s), 3.13 (1.5H, t, $J=6.4\text{Hz}$), 3.06 (0.5H, t, $J=6.2\text{Hz}$), 2.61 (3H, q, $J=7.12\text{Hz}$), 2.53 (1H, q, $J=7.2\text{Hz}$), 2.27 (3H, s), 2.20-2.06 (2H, m), 1.26 (6H, d, $J=6.28\text{Hz}$), 1.00 (6H, m).


MS:ESI 633 (M+1)

20

Example 68

Methyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]phenoxy]butanoate



25

(i) Methyl 2-(3-formylphenoxy) butanoate

By the method of example 23 step (i) using the 3-hydroxybenzaldehyde (500 mg) and the methyl 2-bromobutanoate (535.6 μL) to afford the title compound, 743.9 mg (82%) as colorless oil.

30

^1H NMR δ (CDCl_3) 9.96 (1H, s), 7.50 (2H, ddd, $J=7.48, 1.32, 1.32\text{Hz}$), 7.46 (1H, dd, $J=7.84, 7.52\text{Hz}$), 7.33 (1H, m), 7.18 (1H, m), 4.86 (1H, q, $J=6.8\text{Hz}$), 3.78 (3H, s), 1.66 (3H, d, $J=6.8\text{Hz}$).

MS:ESI 223 (M+1)

(ii) Methyl

2-[3-((3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl)phenoxy]butanoate

By the method of example 1 step (viii) using the product from example 15 step (iv) (201.2 mg) and methyl 2-(3-formylphenoxy)butanoate (149.3 mg) to afford the title compound, 252.7 mg (74%) as a white solid.


¹H NMR δ (CDCl₃) 8.10 (1H, d, *J*=7.36Hz), 7.82 (1H, dd, *J*=8.36, 0.92Hz), 7.50 (1H, m), 7.31-7.23 (2H, m), 6.96 (1H, d, *J*=7.56Hz), 6.94 (1H, m), 6.77 (1H, dd, *J*=7.96, 2.2 Hz), 5.45 (2H, brs), 4.67 (2H, m), 4.61 (2H, t, *J*=6.12Hz), 3.90 (2H, t, *J*=6.56Hz), 3.79 (2H, s), 3.74 (3H, s), 3.38 (3H, s), 3.26 (2H, t, *J*=6.52Hz), 2.75 (2H, t, *J*=6.28Hz), 2.12-2.05 (2H, m), 2.03-1.96 (2H, m), 1.08 (3H, d, *J*=7.48Hz).

MS:ESI 506 (M+1)

Example 69

Methyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-chloroacetamido)methyl]phenoxy}butanoate hydrochloride



By the method of example 2 using the product of example 68 (239.6 mg), there was obtained the title compound, 280.9 mg (quant.) as a colorless gum.

¹H NMR δ (CDCl₃) 7.943-7.83 (2H, m), 7.55 (1H, m), 7.38 (1H, m), 7.24 (1H, m), 6.77-6.73 (3H, m), 5.75-5.69 (2H, m), 4.62 (1.5H, s), 4.57-4.53 (3.5H, m), 4.10 (2H, s), 3.88 (2H, t, *J*=6.28Hz), 3.75 (3H, s), 3.61 (2H, m), 3.37 (3H, s), 3.18-3.11 (2H, m), 2.27-2.14 (2H, m), 2.05-1.96 (2H, m), 1.08 (3H, t, *J*=7.44Hz).


MS:ESI 582 (M+1)

Example 70

Methyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2

-{diethylamino}acetamido)methyl]phenoxy}butanoate



The title compound was prepared by the method of example 5 using the product from example 69 (277.9 mg) and diethylamine, to give a colorless gum (264.5 mg).

Yield 90%.


¹H NMR δ (CDCl₃) 7.92-7.82 (2H, m), 7.52 (1H, m), 7.33 (1H, m), 7.20 (1H, m), 6.80-6.71 (3H, m), 5.49 (2H, brs), 4.76 (1.5H, s), 4.58-4.48 (3.5H, m), 3.85 (2H, m), 3.87 (2H, t, $J=6.36$ Hz), 3.74 (3H, s), 3.59-3.53 (2H, m), 3.36 (2.3H, s), 3.34 (0.7H, s), 3.30 (1.5H, s), 3.27 (0.5H, s), 3.15 (1.5H, t, $J=6.36$ Hz), 3.10 (0.5H, t, $J=6.24$ Hz), 2.60 (3H, t, $J=7.12$ Hz), 2.53 (1H, t, $J=7.08$ Hz), 2.23 (0.5H, m), 2.10 (1.5H, m), 1.98 (2H, m), 1.07 (3H, t, $J=7.44$ Hz), 1.00 (6H, t, $J=7.12$ Hz).

MS:ESI 619 (M+1)

Example 71

Ethyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}butanoate



(i)

2-{3-[(N-{3-[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}butanoic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 70 (182.4 mg), to give a white solid (144.1 mg). Yield 81%.

¹H NMR δ (DMSO-d₆) 7.94 (0.5H, d, $J=8.12$ Hz), 7.90 (0.5H, d, $J=7.96$ Hz), 7.58 (1H, d, $J=8.32$ Hz), 7.42 (1H, m), 7.25-7.16 (2H, m), 7.08 (1H, brs), 7.00 (1H, brs), 6.77-6.72 (3H, m), 4.69 (1H, s), 4.55- 4.46 (3H, m), 4.40 (1H, m), 3.78 (2H, m), 3.56-3.42 (4H, m), 3.27 (3H, s), 3.11 (2H, m), 2.56-2.45 (4H, m), 2.09 (1H, m), 1.94 (3H, m), 0.98 (3H, t, $J=7.36$ Hz), 0.92-0.84 (6H, m).

MS:ESI 605 (M+1)

(ii) Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}butanoate


5 The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (71.7 mg) and EtOH, to give a colorless gum (61.6 mg). Yield 82%.

¹H NMR δ (CDCl₃) 7.93-7.84 (2H, m), 7.53 (1H, m), 7.38-7.32 (1H, m), 7.21 (1H, m), 6.81-6.72 (3H, m), 5.61 (2H, brs), 4.77 (1.5H, d, *J*=4.16Hz), 4.59-4.48 (3.5H, m), 4.20 (2H, m), 3.87 (2H, t, *J*=6.4Hz), 3.55 (2H, m), 3.37 (2.3H, s), 3.35 (0.7H, s), 3.31 (1.5H, s), 3.27 (0.5H, s), 3.16 (1.5H, t, *J*=6.32Hz), 3.11 (0.5H, t, *J*=6.16Hz), 2.60 (3H, q, *J*=7.12Hz), 2.54 (1H, q, *J*=7.00Hz), 2.24 (0.5H, m), 2.10 (1.5H, m), 1.99 (2H, m), 1.25 (3H, t, *J*=7.12Hz), 1.08 (3H, t, *J*=7.4Hz), 1.00 (6H, t, *J*=7.08Hz). MS:ESI 633 (M+1)

Example 72

Isopropyl

2-{5-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-methoxyphenoxy}acetate



20 The title compound was prepared by the method of example 26 step (ii) using the product from example 63 step (i) (37.2 mg) and iPrOH, to give a colorless gum (31.4 mg). Yield 79%.


¹H NMR δ (CDCl₃) 7.91-7.83 (2H, m), 7.53 (1H, m), 7.34 (1H, m), 7.35 (1H, m), 6.80-6.66 (3H, m), 5.48-5.45 (2H, brm), 5.08 (1H, m), 4.65 (1.5H, s), 4.67 (1.5H, s), 4.63 (1.5H, s), 4.62 (0.5H, s), 4.51-4.47 (2.5H, m), 3.89-3.85 (5H, m), 3.56-3.48 (2H, m), 3.37 (2.3H, s), 3.35 (0.7H, s), 3.32 (1.5H, s), 3.25 (0.5H, s), 3.14 (1.5H, t, *J*=6.4Hz), 3.09 (0.5H, t, *J*=6.24Hz), 2.62 (3H, q, *J*=7.16Hz), 2.53 (1H, q, *J*=7.12Hz), 2.21-2.06 (2H, m), 1.26-1.23 (6H, m), 1.03-0.97 (6H, m).

30 MS:ESI 649 (M+1)

Example 73

Isopropyl

2-[5-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)-2-methoxyphenoxy]acetate



5

(i) Isopropyl 2-(5-formyl-2-methoxyphenoxy)acetate

By the method of example 23 step (i) using the 4-methoxy-3-hydroxybenzaldehyde (1.00g) and the isopropyl 2-bromoacetate (898.6 μ L) to afford the title compound, 1.62 g (98 %) as a white solid.

10 ^1H NMR δ (CDCl_3) 9.82 (1H, s), 7.50 (1H, dd, $J=8.24$, 1.84Hz), 7.31 (1H, d, $J=1.84$ Hz), 7.00 (1H, d, $J=8.24$ Hz), 5.12 (1H, m), 4.70 (2H, s), 3.97 (3H, s), 1.26 (6H, d, $J=6.28$ Hz).

MS:ESI 253 ($\text{M}+1$)

15 (ii) Isopropyl

2-[5-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)-2-methoxyphenoxy]acetate

By the method of example 1 step (viii) using the product from example 15 step (iv) (604.7 mg) and isopropyl 2-(5-formyl-2-methoxyphenoxy)acetate (509.2 mg) to

20 afford the title compound, 729.6 mg (67%) as a white solid.

^1H NMR δ (CDCl_3) 8.08 (1H, dd, $J=7.4$, 0.84Hz), 7.82 (1H, dd, $J=0.96$, 8.36Hz), 7.50 (1H, m), 7.29 (1H, m), 6.93 (1H, dd, $J=1.84$, 8.2Hz), 6.87-6.85 (2H, m), 5.52 (2H, brs), 5.10 (1H, m), 4.66-4.61 (4H, m), 3.92-3.88 (5H, m), 3.72 (2H, s), 3.38 (3H, s), 3.25 (2H, t, $J=6.52$ Hz), 2.73 (2H, t, $J=6.36$ Hz), 2.08 (2H, m), 1.23 (6H, d, $J=6.28$ Hz).


25

MS:ESI 536 ($\text{M}+1$)

Example 74

Isopropyl

30 2-{5-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-2-methoxyphenoxy}acetate hydrochloride



By the method of example 2 using the product of example 73 (714.6 mg), there was obtained the title compound, 821.1mg (quant.) as a colorless gum.


¹H NMR δ (CDCl₃) 7.93-7.82 (2H, m), 7.55 (1H, m), 7.38 (1H, m), 6.80 (0.8H, d, *J*=8.24Hz), 6.75-6.69 (2.2H, m), 6.18 (2H, brs), 5.08 (1H, m), 4.61 (2H, s), 4.54-4.49 (4H, m), 4.12 (1.6H, s), 4.06 (0.4H, s), 3.88-3.85 (3H, s), 3.55 (2H, t, *J*=6.96Hz), 3.36 (3H, s), 3.18-3.09 (2H, m), 2.22-2.08 (2H, m), 1.25 (6H, d, *J*=6.24Hz).

MS:ESI 612 (M+1)

Example 75

Isopropyl

2-{5-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]-2-methoxyphenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 74 (374.7 mg) and dimethylamine (2.0M THF solution, 1.53mL), to give a colorless gum (242.7 mg). Yield 64%.

¹H NMR δ (CDCl₃) 7.92-7.85 (2H, m), 7.54 (1H, m), 7.38-7.32 (1H, m), 6.80-6.73 (1.5H, m), 6.69-6.68 (1.5H, m), 5.78 (1.5H, brs), 5.65 (0.5H, brs), 5.08 (1H, m), 4.61-4.60 (3.5H, s), 4.51-4.47 (2.5H, m), 3.88-3.85 (5H, m), 3.53-3.44 (2H, m), 3.36 (3H, s), 3.17 (1.5H, s), 3.13 (1.5H, t, *J*=6.36Hz), 3.09 (0.5H, t, *J*=6.2Hz), 2.32 (4.5H, s), 2.22-2.18 (0.5H, m), 2.12 (1.5H, s), 2.10-2.03 (1.5H, m), 1.26-1.23 (6H, m).


MS:ESI 621 (M+1)

Example 76

Isopropyl

2-{5-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2

-{ethyl(methyl)amino}acetamido)methyl]-2-methoxyphenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 74 (285.6 mg) and N-ethylmethylamine, to give a colorless gum (240.1 mg). Yield 81%.


¹H NMR δ (CDCl₃) 7.91-7.83 (2H, m), 7.52 (1H, m), 7.37-7.31 (1H, m), 6.79-6.67 (3H, m), 5.58 (1.5H, brs), 5.50 (0.5H, brs), 5.07 (1H, m), 4.64 (1.5H, s), 4.60 (1.5H, s), 4.59 (0.5H, s), 4.51-4.47 (2.5H, m), 3.88-3.85 (5H, m), 3.50 (2H, t, $J=7.16$ Hz), 3.36 (2.3H, s), 3.35 (0.7H, s), 3.23 (1.5H, s), 3.15-3.07 (2.5H, m), 2.50 (1.5H, q, $J=7.16$ Hz), 2.36 (0.5H, q, $J=7.2$ Hz), 2.30 (2.3H, s), 2.21-2.17 (0.5H, m), 2.30 (0.7H, s), 2.10-2.03 (1.5H, s), 1.26-1.23 (6H, m), 1.05 (2.3H, t, $J=7.08$ Hz), 0.99 (0.7H, t, $J=7.12$ Hz).

MS:ESI 635 (M+1)

Example 77

Methyl

1-[3-({3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propylamino}methyl)phenoxy]cyclopropanecarboxylate



(i) 3-(2-Oxotetrahydrofuran-3-yloxy)benzaldehyde

To a solution of 3-hydroxybenzaldehyde (500 mg, 4.09 mmol) in acetone (10 ml) 2-bromo- γ -butyrolactone (755.7 μ L, 8.18 mmol) and K₂CO₃ (1.70 g, 12.3 mmol) was added at rt. After refluxed for 12 h, cooled to rt, then the mixture was concentrated. The residue was purified by flash column chromatography to give the title compound (206.7 mg, 24%) as colorless oil.

¹H NMR δ (CDCl₃) 9.98 (1H, s), 7.56-7.47 (3H, m), 7.33 (1H, m), 5.04 (1H, t, $J=7.96$ Hz), 4.55 (1H, m), 4.38 (1H, m), 2.78 (1H, m), 2.48 (1H, m).

(ii) Methyl 2-(3-formylphenoxy)-4-hydroxybutanoate

To a solution of the product of step (i) (201.1 mg, 0.975 mmol) in MeOH (5 ml) HCl (0.5mL) was added at rt. After refluxed for 6 h, diluted with AcOEt, and H₂O was added. The aq. layer was extracted with AcOEt, dried over Na₂SO₄, and concentrated. The residue was purified by flash column chromatography to give the title compound (71.3 mg, 31%) as colorless oil.

¹H NMR δ (CDCl₃) 9.95 (1H, s), 7.50 (1H, m), 7.45 (1H, t, *J*=7.84Hz), 7.36 (1H, m), 7.19 (1H, m), 4.97 (1H, t, *J*=6.08Hz), 3.89 (2H, brm), 3.77 (3H, s), 2.22 (2H, m).

(iii) Methyl 1-(3-formylphenoxy)cyclopropanecarboxylate

To a solution of the product of step (ii) (68.8 mg, 0.289 mmol) and Et₃N (50.3uL, 0.361mmol) in CH₂Cl₂ (2 ml), *p*-toluenesulfonylchloride (55.7mg, 0.292mmol) was added at 0°C and the mixture was stirred overnight at room temperature. Water was added and the mixture extracted with AcOEt, dried over Na₂SO₄, and concentrated. This crude material was dissolved in THF (2mL), Cs₂CO₃ (282.5 mg, 0.867 mmol) was added to the solution, and stirred overnight at room temperature. Water was added and the mixture extracted with AcOEt, dried over Na₂SO₄, and concentrated. The residue was purified by flash column chromatography to give the title compound (45.1mg, 71%) as colorless oil.

¹H NMR δ (CDCl₃) 9.95 (1H, s), 7.51- 7.43 (2H, m), 7.35 (1H, m), 7.18 (1H, m), 3.74 (3H, s), 2.54-2.43 (4H, m).

(iv) Methyl

1-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)phenoxy]cyclopropanecarboxylate

By the method of example 1 step (viii) using the product from example 15 step (iv) (664.6 mg) and methyl 1-(3-formylphenoxy)cyclopropanecarboxylate (488.4 mg) to afford the title compound, 1.03 g (92%) as a pale yellow solid.


¹H NMR δ (CDCl₃) 8.09 (1H, m), 7.82 (1H, dd, *J*=8.32, 0.88Hz), 7.51 (1H, m), 7.32-7.28 (1H, m), 7.21 (1H, dd, *J*=7.92, 7.84Hz), 6.93 (1H, d, *J*=7.52Hz), 6.93 (1H, m), 6.78 (1H, m), 6.54 (1H, dd, *J*=7.96, 2.24Hz), 5.41 (2H, brs), 4.67 (2H, m), 3.91 (2H, t, *J*=6.52Hz), 3.78 (2H, s), 3.74 (3H, s), 3.39 (3H, s), 3.26 (2H, t, *J*=6.52Hz), 2.80-2.73 (4H, m), 2.51-2.43 (2H, m), 2.11-2.02 (2H, m).

MS:ESI 504 (M+1)

Example 78

Methyl

1-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-chloroacetamido)methyl]phenoxy}cyclopropanecarboxylate hydrochloride



5 By the method of example 2 using the product of example 77 (252.6 mg), there was obtained the title compound, 243.2 mg (83%) as a colorless gum.


¹H NMR δ (CDCl₃) 7.92 (1H, d, *J*=7.44Hz), 7.82 (1H, d, *J*=8.28Hz), 7.53 (1H, m), 7.36 (1H, m), 7.19 (1H, dd, *J*=7.88, 7.88Hz), 6.71 (1H, d, *J*=7.52Hz), 6.57 (1H, d, *J*=6.48Hz), 6.53 (1H, dd, *J*=8.04, 2.24Hz), 5.59 (2H, brs), 4.59 (2H, s), 4.56-4.51 (2H, m), 4.07 (2H, s), 3.87 (2H, t, *J*=6.36Hz), 3.73 (3H, s), 3.60 (2H, t, *J*=6.68Hz), 3.36 (2.3H, s), 3.34 (0.7H, s), 3.16 (1.5H, t, *J*=6.36Hz), 3.12 (0.5H, m), 2.72 (2H, m), 2.42 (2H, m), 2.15 (2H, m).

MS:ESI 581 (M+1)

15 Example 79

Methyl

1-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-{diethylamino}acetamido)methyl]phenoxy}cyclopropanecarboxylate



20 The title compound was prepared by the method of example 5 using the product from example 78 (88.7 mg) and diethylamine, to give a colorless gum (63.2 mg). Yield 67%.

¹H NMR δ (CDCl₃) 7.91-7.83 (2H, m), 7.53 (1H, m), 7.34 (1H, m), 7.17 (1H, dd, *J*=8.04, 7.92Hz), 6.74-6.70 (1H, m), 6.63 (0.25H, s), 6.57 (0.75H, s), 6.49 (1H, dd, *J*=8.4, 2.4Hz), 4.76 (1.5H, s), 4.56 (0.5H, s), 4.50 (2H, m), 3.87 (2H, m), 3.74 (3H, s), 3.55 (2H, m), 3.36 (2.3H, s), 3.34 (0.7H, s), 3.28 (2H, s), 3.15 (1.5H, t, *J*=6.36Hz), 3.10 (0.5H, m), 2.72 (2H, m), 2.59 (3H, q, *J*=7.16Hz), 2.52 (1H, q, *J*=7.08Hz), 2.41(2H, m), 2.09 (2H, m), 0.99 (6H, t, *J*=7.08Hz).


MS:ESI 617 (M+1)

Example 80

Cyclopentyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2

5 -{(diethylamino)acetamido)methyl]phenoxy}acetate



By the method of example 26 step (ii) using the product from example 26 step (i) (0.21 g, 0.36 mmol) and cyclopentanol (6.0 mL) and CH₃CN (1.0 mL) to afford the title compound (0.19 g, 83 %) as a colorless gum.

¹H NMR δ (CDCl₃) 7.90-7.83 (2H, m), 7.53 (1H, t, *J* = 7.3 Hz), 7.35 (1H, t, *J* = 7.0 Hz), 7.21 (1H, t, *J* = 8.4 Hz), 6.80-6.73 (3H, m), 5.52-5.16 (2H, m), 5.31-5.28 (1H, m), 4.77 (1.5H, s), 4.58-4.48 (4.5H, m), 3.87 (2H, t, *J* = 6.4 Hz), 3.59-3.52 (2H, m), 3.37-3.27 (5H, m), 3.17-3.08 (2H, m), 2.64-2.52 (4H, m), 2.28-2.18 (0.5H, m), 2.13-2.00 (1.5H, m), 1.93-1.84 (2H, m), 1.72-1.27 (6H, m), 1.01 (6H, t, *J* = 7.1 Hz)


ESI-MS [*M*+2*H*]²⁺ : 323

Example 81

Cyclobutyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2

20 -{(diethylamino)acetamido)methyl]phenoxy}acetate



By the method of example 26 step (ii) using the product from example 26 step (i) (0.11 g, 0.18 mmol) and cyclobutanol (1.0 mL) to afford the title compound (0.096 g, 83 %) as a colorless gum.


^1H NMR δ (CDCl_3) 7.90-7.85 (2H, m), 7.54 (1H, t, $J = 8.0$ Hz), 7.40-7.31 (1H, m), 7.21 (1H, t, $J = 8.4$ Hz), 6.80-6.73 (3H, m), 5.75-5.62 (2H, m), 5.15-5.07 (0.75H, m), 4.76 (1.5H, s), 4.58-4.50 (4.5H, m), 4.31-4.21 (0.25H, m), 3.87 (2H, t, $J = 6.4$ Hz), 3.63-3.52 (2H, m), 3.37-3.28 (5H, m), 3.16-3.09 (2H, m), 2.64-2.53 (4H, m), 2.40-2.29 (4H, m), 2.14-2.07 (4H, m), 1.01 (6H, t, $J = 7.1$ Hz)

ESI-MS $[\text{M}+2\text{H}]^{2+} : 331$

Example 82

Tetrahydro-2H-pyran-4-yl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate



By the method of example 26 step (ii) using the product from example 26 step (i) (0.10 g, 0.17 mmol) and toluene (2.0 mL), CH_3CN (1.0 mL) and Tetrahydro-4H-pyran-4-ol (0.20 mL) to afford the title compound (7.4 mg, 6 %) as a pale yellow gum.


^1H NMR δ (CDCl_3) 7.83-7.76 (2H, m), 7.47 (1H, t, $J = 8.0$ Hz), 7.29-7.27 (1H, m), 7.13 (1H, t, $J = 8.0$ Hz), 6.73-6.64 (3H, m), 5.53-5.48 (2H, m), 5.05-4.99 (1H, m), 4.69 (1.5H, s), 4.51-4.50 (2.5H, m), 4.42 (2H, t, $J = 6.7$ Hz), 3.82-3.70 (4H, m), 3.60-3.43 (4H, m), 3.29-3.19 (5H, m), 3.19-3.01 (2H, m), 2.56-2.45 (4H, m), 2.18-2.12 (0.5H, m), 2.03-2.00 (1.5H, m), 1.89-1.84 (2H, m), 1.67-1.61 (2H, m), 0.93 (6H, t, $J = 7.1$ Hz)

ESI-MS $[\text{M}+2\text{H}]^{2+} : 318$

Example 83

Butyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate




By the method of example 26 step (ii) using the product from example 26 step (i) (0.11 g, 0.19 mmol) in *n*-butanol (2.0 mL) and CH₃CN (1.0 mL) to afford the title compound (0.095 g, 81 %) as a colorless gum.

- 5 ¹H NMR δ (CDCl₃) 7.91-7.85 (2H, m), 7.85-7.83 (1H, m), 7.55-7.51 (1H, m), 7.36-7.32 (1H, m), 7.21 (1H, t, *J* = 7.8 Hz), 6.80-6.73 (3H, m), 5.49-5.46 (2H, m), 4.76 (2H, s), 4.59 (2H, s), 4.50 (2H, t, *J* = 7.8 Hz), 4.21 (2H, t, *J* = 6.7 Hz), 3.89-3.86 (2H, t, *J* = 6.4 Hz), 3.54 (2H, t, *J* = 7.1 Hz), 3.37-3.27 (5H, m), 3.15 (1.5H, t, *J* = 6.4 Hz), 3.10 (0.5H, t, *J* = 6.4 Hz), 2.61 (3H, q, *J* = 7.1 Hz), 2.61 (1H, q, *J* = 7.1 Hz), 2.28-2.22 (0.5H, m), 2.11-2.07 (1.5H, m), 1.65 (2H, quint, *J* = 7.4 Hz), 1.36 (2H, sext, *J* = 7.4 Hz), 1.01 (6H, t, *J* = 7.1 Hz), 0.93 (3H, t, *J* = 7.4 Hz)
- 10 ESI-MS [M+2H]²⁺ : 317

Example 84

15 *tert*-Butyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)phenoxy]acetate



- 20 By the method of example 1 step (viii) using the product of example 15 step (iv) (0.20 g, 0.67 mmol) and the product of example 46 step (i) (0.60 g, 0.67 mmol) to afford the title compound (0.27 g, 78%) as a pale yellow solid.

¹H NMR δ (CDCl₃) 8.10 (1H, dd, *J* = 8.4, 1.0 Hz), 7.84 (1H, dd, *J* = 8.4 Hz, 1.0 Hz), 7.53-7.49 (1H, m), 7.32-7.25 (2H, m), 6.99-6.94 (2H, m), 6.81 (1H, dd, *J* = 7.7 Hz,

2.1 Hz), 5.55 (2H, brs), 4.67 (2H, t, $J = 7.3$ Hz), 4.54 (2H, s), 3.91 (2H, t, $J = 6.5$ Hz), 3.80 (2H, s), 3.39 (3H, m), 3.26 (2H, t, $J = 6.5$ Hz), 2.75 (2H, t, $J = 6.3$ Hz), 2.09 (2H, quint, $J = 6.5$ Hz), 1.73 (1H, brs), 1.49 (9H, s)


ESI-MS $[M+H]^+$: 520

5

Example 85

tert-Butyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-chloroacetamido)methyl]phenoxy}acetate Hydrochloride



10

By the method of example 2 using the product of example 84 (0.27 g, 0.51 mmol), there was obtained the title compound (0.26 g, 82%) as a colorless gum.

^1H NMR δ (CDCl_3) 7.93 (1H, d, $J = 8.4$ Hz), 7.88 (1H, d, $J = 7.6$ Hz), 7.58-7.54 (1H, m), 7.40 (1H, t, $J = 7.1$ Hz), 7.26-7.22 (1H, m), 6.78-6.74 (3H, m), 4.62 (2H, s), 4.57-4.54 (2H, m), 4.52-4.50 (2H, m), 4.11-4.09 (2H, m), 3.88 (2H, t, $J = 6.3$ Hz), 3.60 (2H, t, $J = 6.8$ Hz), 3.37-3.35 (3H, m), 3.16 (2H, t, $J = 6.3$ Hz), 2.17-2.13 (2H, m), 1.50 (9H, 1.50)

15


ESI-MS $[M+H]^+$: 596

20

Example 86

tert-Butyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-(diethylamino)acetamido)methyl]phenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 85 (0.26 g, 0.44 mmol) and diethylamine, to give the title compound as a pale yellow gum (0.22 g, 84%).


- 5 ^1H NMR δ (CDCl_3) 7.92-7.84 (2H, m), 7.53 (1H, t, $J = 8.1$ Hz), 7.35 (1H, t, $J = 7.0$ Hz), 7.23-7.21 (1H, m), 6.80-6.73 (3H, m), 5.52-5.48 (2H, m), 4.77 (1.5H, s), 4.59 (0.5H, s), 4.51-4.48 (4H, m), 3.89-3.86 (2H, m), 3.60-3.53 (2H, m), 3.37-3.27 (5H, m), 3.15 (1.5H, t, $J = 6.4$ Hz), 3.09 (0.5H, t, $J = 6.4$ Hz), 2.61 (3H, q, $J = 7.1$ Hz), 2.54 (1H, t, $J = 7.1$ Hz), 2.26-2.23 (0.5H, m), 2.24- 2.21 (1.5H, m), 1.55 (9H, s),
10 1.01 (6H, t, $J = 7.1$ Hz)

ESI-MS $[\text{M}+\text{H}]^+ : 633$

Example 87

Ethyl

- 15 2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl}-2-methoxyphenoxy]acetate



(i) 3-Hydroxy-2-methoxybenzaldehyde

- 20 A solution of 2,3-dihydroxybenzaldehyde (1.0 g, 7.24 mmol) in DMF (10 mL) was treated with K_2CO_3 (1.0 g, 7.24 mmol) and the mixture was stirred at rt for 30 min. Iodomethane (0.50 ml, 7.96 mmol) was added and the reaction was further stirred for 20h. The reaction was quenched with H_2O and extracted with Et_2O . The organic layer was dried over Na_2SO_4 and concentrated. The residue was purified

flash column chromatography to afford the title compound (0.63 g, 57 %) as a colorless needle.

^1H NMR δ (CDCl_3) 10.28 (1H, s), 7.39 (1H, dd, $J = 7.8$ Hz, 1.8 Hz), 7.25 (1H, dd, $J = 7.8$ Hz, 1.8 Hz), 7.17 (1H, t, $J = 7.8$ Hz), 5.81 (1H, s), 3.99 (1H, s)

5 ESI-MS $[\text{M}+\text{H}]^+$: 153

(ii) Ethyl 2-(3-formyl-2-methoxyphenoxy)acetate

The title compound was prepared by the method of example 23 step (i) using the product from step (i) (0.63 g, 0.41 mmol) and Ethyl bromoacetate (0.48 mL, 4.35 mmol), to give the title compound as colorless oil (0.90 g, 91%).

10 ^1H NMR δ (CDCl_3) 10.43 (1H, d, $J = 1.0$ Hz), 7.48 (1H, dd, $J = 7.4$ Hz, 2.0 Hz), 7.13-7.06 (2H, m), 4.72 (2H, s), 4.27 (2H, q, $J = 7.1$ Hz), 4.07 (3H, s), 1.30 (3H, t, $J = 7.1$ Hz)

ESI-MS $[\text{M}+\text{H}]^+$: 239

15

(iii) Ethyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)-2-methoxyphenoxy]acetate

By the method of example 1 step (viii) using the product of example 15 step (iv) (0.64 g, 2.12 mmol) and the product from step (ii) (0.51 g, 2.12 mmol) to afford the title compound (0.80 g, 72%) as a pale yellow solid.


20 ^1H NMR δ (CDCl_3) 8.07 (1H, dd, $J = 8.2$ Hz, 1.0 Hz), 7.81 (1H, dd, $J = 8.4$ Hz, 1.0 Hz), 7.49 (1H, td, $J = 7.7$ Hz, 1.2 Hz), 7.30-7.27 (1H, m), 7.01-6.92 (2H, m), 6.76 (1H, dd, $J = 8.0$ Hz, 1.6 Hz), 5.41 (2H, brs), 4.68 (2H, s), 4.64 (2H, t, $J = 6.4$ Hz), 4.27 (2H, q, $J = 7.1$ Hz), 3.93 (3H, s), 3.89 (2H, t, $J = 6.6$ Hz), 3.83 (2H, s), 3.36 (3H, s), 3.24 (2H, t, $J = 6.6$ Hz), 2.70 (2H, t, $J = 6.4$ Hz), 2.07 (2H, quint, $J = 6.4$ Hz), 1.74 (1H, brs), 1.30 (3H, t, $J = 7.1$ Hz)

ESI-MS $[\text{M}+\text{H}]^+$: 522

30 Example 88

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-2-methoxyphenoxy}acetate hydrochloride



By the method of example 2 using the product of example 87 (0.39 g, 0.74 mmol), there was obtained the title compound (0.46 g, 98%) as pale yellow amorphousness.


¹H NMR δ (CDCl₃) 7.92-7.88 (2H, m), 7.57 (1H, t, *J* = 7.1 Hz), 7.41 (1H, t, *J* = 7.1 Hz), 6.86 (1H, t, *J* = 8.0 Hz), 6.68 (1H, dd, *J* = 8.3 Hz, 1.2 Hz), 6.62 (1H, d, *J* = 7.6 Hz), 6.42 (1H, brs), 4.68-4.59 (4H, m), 4.52 (2H, t, *J* = 7.9 Hz), 4.28-4.23 (3.5H, m), 4.06 (0.5H, s), 3.88-3.83 (5H, m), 3.55-3.43 (2H, m), 3.36-3.34 (3H, m), 3.14 (2H, t, *J* = 6.2 Hz), 2.14-2.05 (2H, m), 1.30 (3H, t, *J* = 7.2 Hz)

ESI-MS [M+H]⁺ : 598

Example 89

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-methoxyphenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 88 (0.45 g, 0.75 mmol) and diethylamine (0.78 mL, 7.50 mmol) to give the title compound as a pale yellow gum (0.33 g, 72%).

¹H NMR δ (CDCl₃) 7.92-7.89 (1H, m), 7.82 (1H, *J* = 8.4 Hz), 7.51 (1H, t, *J* = 7.1 Hz), 7.33 (1H, t, *J* = 7.6 Hz), 6.94-6.84 (1H, m), 6.73-6.64 (2H, m), 5.49 (2H, brs), 4.76 (1.5H, s), 4.70 (0.5H, s), 4.66 (0.5H, s), 4.61 (1.5H, s), 4.51-4.46 (2H, m), 4.30-4.23 (2H, m), 3.88-3.84 (5H, m), 3.59-3.48 (2H, m), 3.37-3.34 (4.5H, m),

3.23 (0.5H, s), 3.14 (2H, t, $J=6.4$ Hz), 2.61 (3H, q, $J=7.1$ Hz), 2.51 (1H, q, $J=7.1$ Hz), 2.28-2.22 (0.5H, m), 2.09-2.04 (1.5H, m), 1.32-1.25 (3H, m), 1.02-0.94 (6H, m)


ESI-MS $[M+2H]^{2+}$: 318

5

Example 90

Isopropyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-{diethylamino}acetamido)methyl]-2-methoxyphenoxy}acetate



10

(i)

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-{diethylamino}acetamido)methyl]-2-methoxyphenoxy}acetic acid

15

The title compound was prepared by the method of example 26 step (i) using the product from example 89 (0.24 g, 0.37 mmol) to give the title compound as a white solid (0.22 g, 97%).

20

^1H NMR δ (CDCl_3) 8.04 (0.25H, d, $J=8.2$ Hz), 7.95 (0.75H, d, $J=8.2$ Hz), 7.71-7.68 (1H, m), 7.55 (1H, t, $J=8.2$ Hz), 7.42-7.37 (1H, m), 6.79-6.74 (2H, m), 6.60-6.56 (1H, m), 4.63 (0.5H, t, $J=6.5$ Hz), 4.52-4.47 (2H, m), 4.45 (1.5H, s), 4.41 (0.5H, s), 4.38 (1.5H, s), 4.09 (1.5H, s), 3.93-3.88 (2.5H, m), 3.85 (2.25H, s), 3.77 (0.5H, s), 3.68 (0.75H, s), 3.45 (1.5H, t, $J=7.5$ Hz), 3.37-3.36 (3H, m), 3.20 (0.5H, t, $J=6.1$ Hz), 3.15 (1.5H, t, $J=6.1$ Hz), 3.09 (3H, q, $J=7.2$ Hz), 2.92 (1H, q, $J=7.2$ Hz), 2.20-2.14 (0.5H, m), 2.15-1.96 (1.5H, m), 1.24 (4.5H, t, $J=7.2$ Hz), 1.45 (1.5H, t, $J=7.2$ Hz)

25

ESI-MS $[M+2H]^{2+}$: 304

(ii) Isopropyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-{diethylamino}acetamido)methyl]-2-methoxyphenoxy}acetic acid

-{diethylamino}acetamido)methyl]-2-methoxyphenoxy} acetate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.22 g, 0.36 mmol) and isopropylalcohol to give the title compound as a pale yellow gum (0.18 g, 77%).


5 ¹H NMR δ (CDCl₃) 7.93-7.90 (1H, m), 7.83 (1H, *J* = 8.4 Hz), 7.51 (1H, t, *J* = 7.5 Hz), 7.34 (1H, t, *J* = 7.3 Hz), 6.94-6.84 (1H, m), 6.72-6.63 (2H, m), 5.48 (2H, brs), 5.15-5.09 (1H, m), 4.76 (1.5H, s), 4.71 (0.5H, s), 4.63 (0.5H, s), 4.58 (1.5H, s), 4.49 (2H, t, *J* = 7.6 Hz), 3.88-3.85 (4H, m), 3.71 (1H, s), 3.55 (0.5H, t, *J* = 7.0 Hz), 3.50 (1.5H, t, *J* = 7.0 Hz), 3.37-3.34 (4.5H, m), 3.23 (0.5H, s), 3.15 (2H, t, *J* = 6.4 Hz), 2.61 (3H, q, *J* = 7.1 Hz), 2.51 (1H, q, *J* = 7.1 Hz), 2.30-2.26 (0.5H, m), 2.10-2.05 (1.5H, m), 1.28-1.26 (6H, m), 1.02-0.94 (6H, m)

ESI-MS [M+2H]²⁺ : 325

Example 91

15 Ethyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)-2-fluorophenoxy]acetate



(i) Ethyl 2-(2-fluoro-3-formylphenoxy)acetate

20 The title compound was prepared by the method of example 23 step (i) using 2-fluoro-3-hydroxybenzaldehyde (obtained from *J. Med. Chem.* 1996, 29, 1982) (0.79 g, 5.65 mmol) and Ethyl bromoacetate (0.69 mL, 6.21 mmol), to give the title compound as a colorless needle (1.0 g, 81%).

25 ¹H NMR δ (CDCl₃) 10.39 (1H, s), 7.52-7.48 (1H, m), 7.19-7.16 (2H, m), 4.74 (2H, s), 4.28 (2H, q, *J* = 7.1 Hz), 1.30 (3H, t, *J* = 7.1 Hz)

ESI-MS [M+H]⁺ : 227

(ii) Ethyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)-2-fluorophenoxy]acetate

o)methyl]-2-fluorophenoxy]acetate

By the method of example 1 step (viii) using the product of example 15 step (iv) (0.75 g, 2.51 mmol) and the product from step (i) (0.57 g, 2.51 mmol) to afford the title compound (0.84 g, 65%) as a colorless solid.


¹H NMR δ (CDCl₃) 8.07 (1H, d, J = 8.4 Hz), 7.81 (1H, d, J = 8.4 Hz), 7.51-7.47 (1H, m), 7.31-7.28 (1H, m), 7.04-6.94 (2H, m), 6.84 (1H, td, J = 7.9 Hz, 1.8 Hz), 5.45 (2H, brs), 4.69 (2H, s), 4.65 (2H, t, J = 7.3 Hz), 4.27 (2H, q, J = 7.2 Hz), 3.91-3.88 (4H, m), 3.37 (3H, s), 3.24 (2H, t, J = 6.4 Hz), 2.72 (2H, t, J = 6.4 Hz), 2.08 (2H, quint, J = 7.3 Hz), 1.66 (1H, brs), 1.30 (3H, t, J = 7.2 Hz)

ESI-MS [M+H]⁺ : 511

Example 92

Ethyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-2-fluorophenoxy}acetate hydrochloride



By the method of example 2 using the product of example 91 (0.54 g, 1.06 mmol), there was obtained the title compound (0.60 g, 90%) as colorless amorphousness.

¹H NMR δ (CDCl₃) 7.89 (2H, t, J = 8.7 Hz), 7.55 (1H, t, J = 7.7 Hz), 7.40-7.36 (1H, m), 6.98-6.88 (1H, m), 6.82-6.73 (1H, m), 6.62 (1H, d, J = 7.1 Hz), 4.68 (1H, s), 4.64-4.63 (3H, m), 4.52 (2H, t, J = 7.7 Hz), 4.26 (2H, q, J = 7.1 Hz), 4.19 (1.5H, s), 4.04 (0.5H, s), 3.87 (2H, t, J = 6.2 Hz), 3.55-3.47 (2H, m), 3.37-3.35 (3H, m), 3.15 (2H, t, J = 6.2 Hz), 2.33-2.30 (0.5H, m), 2.14-2.07 (1.5H, m), 1.32-1.28 (3H, m)


ESI-MS [M+H]⁺ : 586

Example 93

Ethyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-

-{diethylamino}acetamido)methyl]-2-fluorophenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 92 (0.59 g, 1.01 mmol) and diethylamine (1.1 mL, 10.1 mmol) to give the title compound as a pale yellow gum (0.33 g, 55%).


¹H NMR δ (CDCl₃) 7.93-7.88 (1H, m), 7.83 (1H, d, J = 8.4 Hz), 7.52 (1H, t, J = 7.8 Hz), 7.35 (1H, t, J = 7.8 Hz), 7.00-6.66 (3H, m), 5.53 (2H, brs), 4.85 (1.5H, s), 4.69-4.68 (1H, m), 4.63 (1.5H, s), 4.56-4.47 (2H, m), 4.30-4.23 (2H, m), 3.87 (2H, t, J = 6.4 Hz), 3.61 (0.5H, t, J = 7.0), 3.51 (1.5H, t, J = 7.0 Hz), 3.36-3.34 (4.5H, m), 3.22 (0.5H, s), 3.15 (2H, t, J = 6.4 Hz), 2.59 (3H, q, J = 7.1 Hz), 2.48 (1H, q, J = 7.1 Hz), 2.31-2.28 (0.5H, m), 2.10-2.05 (1.5H, m), 1.32-1.28 (3H, m), 1.00 (4.5H, t, J = 7.1 Hz), 0.95 (1.5H, t, J = 7.1 Hz)

ESI-MS $[M+2H]^{2+}$: 312

Example 94

Isopropyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-fluorophenoxy}acetic acid



(i)

2-{3-[(N-{3-[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-fluorophenoxy}acetic acid

The title compound was prepared by the method of example 26 step (i) using the

product from example 93 (0.32 g, 0.51 mmol) to give the title compound as a pale yellow solid 0.32 g (quant).

¹H NMR δ (CDCl₃) 8.11 (0.25H, d, *J* = 8.2 Hz), 8.03 (0.75H, d, *J* = 8.2 Hz), 7.74-7.71 (1H, m), 7.58 (1H, t, *J* = 7.2 Hz), 7.47-7.41 (1H, m), 6.84-6.80 (2H, m), 6.62-6.58 (1H, m), 4.65 (0.5H, t, *J* = 6.5 Hz), 4.56-4.51 (3.5H, m), 4.44 (0.5 Hz, s), 4.40 (1.5H, s), 4.02 (1.5H, s), 3.93-3.87 (2H, m), 3.49 (0.5H, s), 3.47 (1.5H, t, *J* = 6.6 Hz), 3.37-3.31 (3.5H, m), 3.23-3.15 (2H, m), 3.06 (3H, q, *J* = 7.1 Hz), 2.85 (1H, q, *J* = 7.1 Hz), 2.22-2.19 (0.5H, m), 2.07-1.99 (1.5H, m), 1.21 (4.5H, t, *J* = 7.1 Hz), 1.11 (1.5H, t, *J* = 7.1 Hz)

ESI-MS [M+2H]²⁺ : 298

(ii) Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-fluorophenoxy}acetate

The title compound was prepared by the method of example 5 using the product from step (i) (0.18 g, 0.30 mmol) and isopropylalcohol to give the title compound as a pale yellow gum (0.14 g, 74%).


¹H NMR δ (CDCl₃) 7.92-7.88 (1H, m), 7.82 (1H, d, *J* = 8.3 Hz), 7.51 (1H, t, *J* = 7.2 Hz), 7.33 (1H, t, *J* = 7.1 Hz), 6.97-6.65 (3H, m), 5.46 (2H, brs), 5.12 (1H, sept, *J* = 6.3 Hz), 4.85 (1.5H, s), 4.69 (0.5H, s), 4.64 (0.5H, s), 4.60 (1.5H, s), 4.55-4.46 (2H, m), 3.86 (2H, t, *J* = 6.4 Hz), 3.61 (0.5H, t, *J* = 7.1 Hz), 3.51 (1.5H, t, *J* = 7.1 Hz), 3.36-3.33 (4.5H, m), 3.21 (0.5H, s), 3.16-3.12 (2H, m), 2.59 (3H, q, *J* = 7.1 Hz), 2.48 (1H, q, *J* = 7.1 Hz), 2.31-2.28 (0.5H, m), 2.10-2.04 (1.5H, m), 1.27-1.26 (6H, m), 0.99 (4.5H, t, *J* = 7.1 Hz), 0.93 (1.5H, t, *J* = 7.1 Hz)

ESI-MS [M+2H]²⁺ : 319

Example 95

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]-2-fluorophenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 92 (0.46 g, 0.741 mmol) and dimethylamine in THF (2M, 3.7 mL) to give the title compound as a pale yellow gum (0.41 g, 93%).


5 ^1H NMR δ (CDCl_3) 7.94-7.89 (1H, m), 7.84 (1H, d, $J = 8.4$ Hz), 7.55-7.51 (1H, m), 7.38-7.34 (1H, m), 7.00-6.88 (1.3H, m), 6.83-6.79 (0.3H, m), 6.76-6.72 (0.7H, m), 6.69-6.65 (0.7H, m), 5.64-5.55 (2H, m), 4.78 (1.4H, s), 4.69-4.68 (1.2H, m), 4.64 (1.4H, s), 4.56-4.49 (2H, m), 4.30-4.23 (2H, m), 3.89-3.85 (2H, m), 3.52 (2H, t, $J =$
10 (4.2H, s), 2.28-2.22 (0.6H, m), 2.08 (1.8H, s), 2.10-2.05 (1.4H, m), 1.32-1.28 (3H, m)

ESI-MS $[\text{M}+2\text{H}]^{2+} : 298$

Example 96

15 Isopropyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-{dimethylamino}acetamido)methyl]-2-fluorophenoxy}acetate



(i)

20 2-{3-[(*N*-(3-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-{dimethylamino}acetamido)methyl]-2-fluorophenoxy}acetic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 95 (0.22 g, 0.372 mmol) to give the title compound as

colorless solid (0.19, g 88%).

^1H NMR δ (MeOD- d_4) 8.16 (0.4H, d, J = 8.3 Hz), 8.08 (0.6H, d, J = 8.3 Hz), 7.76 (1H, d, J = 7.1 Hz), 7.66 (1H, t, J = 7.1 Hz), 7.53-7.49 (1H, m), 6.86-6.78 (2H, m), 6.65 (0.6H, t, J = 6.5 Hz), 6.65 (0.4H, t, J = 6.5 Hz), 4.72 (1.6H, t, J = 6.8 Hz), 4.59-4.49 (2.4H, m), 4.41-4.39 (2H, m), 4.04 (1.2H, s), 3.95-3.90 (2.8H, m), 3.48-3.40 (2H, m), 3.37 (3H, s), 3.21 (1.6H, t, J = 6.2 Hz), 3.13 (0.4H, t, J = 6.2 Hz), 2.75 (3.6H, s), 2.68 (2.4H, s), 2.24-2.18 (0.8H, m), 2.11-2.01 (1.2H, m)

ESI-MS $[\text{M}+2\text{H}]^{2+}$: 284

(ii) Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]-2-fluorophenoxy}acetate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.13 g, 0.246 mmol) and isopropylalcohol(3.5 mL) to give the title compound as pale yellow gum (0.13 g, 88%).


^1H NMR δ (CDCl_3) 7.94-7.87 (1H, m), 7.86 (1H, d, J = 8.2 Hz), 7.52 (1H, t, J = 7.9 Hz), 7.38 (1H, t, J = 7.5 Hz), 6.98-6.89 (1.4H, m), 6.79-6.63 (1.6H, m), 5.82-5.71 (2H, m), 5.12 (1H, quint, J = 6.3 Hz), 4.69 (1.4H, s), 4.65 (0.6H, s), 4.61 (0.6H, s), 4.55 (1.4H, s), 4.54-4.48 (2H, m), 3.89-3.85 (2H, m), 3.53 (2H, t, J = 7.2 Hz), 3.36-3.35 (3H, m), 3.20 (1.4H, s), 3.16-3.12 (2H, m), 3.02 (0.6H, s), 2.31-2.22 (4.8H, m), 2.13-2.05 (3.2H, m), 1.29-1.26 (6H, m)

ESI-MS $[\text{M}+2\text{H}]^{2+}$: 305

Example 97

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{ethyl(methyl)amino}acetamido)methyl]-2-fluorophenoxy}acetate



The title compound was prepared by the method of example 5 using the product

from example 92 (0.50 g, 0.797 mmol) and *N*-Ethylmethylamine (0.34 mL, 3.99 mmol) to give the title compound as a pale yellow gum (0.39 g, 81%).


¹H NMR δ (CDCl₃) 7.93-7.89 (1H, m), 7.85-7.83 (1H, m), 7.53 (1H, t, *J* = 8.2 Hz), 7.38-7.31 (1H, m), 7.00-6.88 (1.3H, m), 6.83-6.79 (0.3H, m), 6.76-6.66 (1.4H, m), 5.64-5.55 (2H, m), 4.82 (1.4H, s), 4.69-4.68 (1.2H, m), 4.64 (1.4H, s), 4.56-4.48 (2H, m), 4.30-4.24 (2H, m), 3.89-3.85 (2H, m), 3.59-3.50 (2H, m), 3.36-3.35 (3H, m), 3.25 (1.4H, s), 3.16-3.12 (2H, m), 3.09 (0.6H, s), 2.49 (1.4H, q, *J* = 7.2 Hz), 2.36-2.29 (3.1H, m), 2.14-2.05 (2.5H, m), 1.32-1.28 (3H, m), 1.04 (2.1H, t, *J* = 7.2 Hz), 0.95 (0.9H, t, *J* = 7.2 Hz)

ESI-MS [M+2H]²⁺ : 305

Example 98

Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-ethyl(methyl)amino}acetamido)methyl]-2-fluorophenoxy}acetate



(i)

2-{3-[(*N*-{3-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-ethyl(methyl)amino}acetamido)methyl]-2-fluorophenoxy}acetic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 97 (0.30 g, 0.493 mmol) to give the title compound as a colorless solid (0.19 g, 66%).

¹H NMR δ (MeOD-*d*₄) 8.01 (0.3H, d, *J* = 8.1 Hz), 7.91 (0.7H, d, *J* = 8.1 Hz), 7.68-7.63 (1H, m), 7.55 (1H, t, *J* = 7.6 Hz), 7.46-7.39 (1H, m), 6.90-6.78 (2H, m), 6.69-6.66 (0.7H, m), 6.60-6.58 (0.3H, m), 4.61 (0.7H, t, *J* = 6.8 Hz), 4.52-4.44 (5.3H, m), 4.08 (1.4H, s), 3.94-3.88 (2.6H, m), 3.46 (1.4H, t, *J* = 7.6 Hz), 3.37-3.35 (3H, m), 3.20 (0.6H, t, *J* = 6.0 Hz), 3.13 (1.4H, t, *J* = 6.0 Hz), 3.06 (1.4H, q, *J* = 7.2 Hz), 2.93 (0.6H, q, *J* = 7.2 Hz), 2.75 (2.1H, s), 2.63 (0.9H, s), 2.17-2.14 (0.6H, m), 2.02-1.96 (1.4H, m), 1.28-1.16 (3H, m)

ESI-MS $[M+2H]^{2+}$: 291

(ii)

2-{3-[(*N*-(3-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-{ethyl(methyl)amino}acetamido)methyl]-2-fluorophenoxy}acetate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.13 g, 0.231 mmol) and isopropylalcohol (3.5 mL) to give the title compound as a pale yellow gum (0.14 g, 100%).


^1H NMR δ (CDCl_3) 7.94-7.90 (1H, m), 7.84 (1H, d, $J = 8.4$ Hz), 7.53 (1H, t, $J = 7.2$ Hz), 7.37 (1H, t, $J = 7.7$ Hz), 6.96-6.89 (1.3H, m), 6.84-6.78 (0.3H, m), 6.75-6.68 (1.4H, m), 5.65-5.56 (2H, m), 5.12 (1H, quint, $J = 6.3$ Hz), 4.82 (1.4H, s), 4.70 (0.6H, s), 4.65 (0.6H, s), 4.61 (1.4H, s), 4.54-4.48 (2H, m), 3.88-3.85 (2H, m), 3.57-3.51 (2H, m), 3.36-3.35 (3H, m), 3.25 (1.4H, s), 3.16-3.13 (2H, m), 3.09 (0.6H, s), 2.49 (1.4H, q, $J = 7.2$ Hz), 2.33-2.29 (3.3H, m), 2.12-2.07 (2.3H, m), 1.29-1.26 (6H, m), 1.04 (2.1H, t, $J = 7.2$ Hz), 0.95 (0.9H, t, $J = 7.2$ Hz)

ESI-MS $[M+2H]^{2+}$: 312

Example 99

Ethyl

2-[3-[(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethylamino)methyl]phenoxy]acetate



(i) *tert*-Butyl 2-(3-nitroquinolin-4-ylamino)ethylcarbamate

By the method of example 1 step (ii) using the product of example step (i) (2.0 g, 10.5 mmol) and , *tert*-butyl 2-aminoethylcarbamate (1.8g, 0.11 mmol) there was obtained the title compound (2.7g, 77%) as a yellow solid.

^1H NMR δ ($\text{DMSO}-d_6$) 9.05 (1H, s), 8.89 (1H, brs), 8.43 (1H, d, $J = 8.3$ Hz), 7.90 (1H, dd, $J = 1.2$ Hz, 8.3 Hz), 7.85-7.81(1H, m), 7.61-7.56 (1H, m), 7.04 (1H, t, $J = 5.5$ Hz), 3.60-3.52 (2H, m), 3.34 (2H, m), 1.29 (9H, s)

ESI-MS $[M+H]^+$: 333

(ii) *tert*-Butyl 2-(3-aminoquinolin-4-ylamino)ethylcarbamate

By the method of example 1 step (iii) using the product of step (i) (2.7g, 8.12 mmol) there was obtained the title compound (1.6 g, 67%) as dark amorphousness.

^1H NMR δ (DMSO- d_6) 8.36 (1H, s), 8.06-7.98 (1H, m), 7.78-7.70 (1H, m), 7.42-7.34 (2H, m), 6.96 (1H, t, J = 5.5 Hz), 5.05 (2H, brs), 3.32-3.20 (2H, m), 3.16-3.06 (2H, m), 1.35 (9H, s)

ESI-MS $[M+H]^+$: 303

(iii) *tert*-Butyl

2-[2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethylcarbamate

By the method of example 1 step (iv) using the product of step (ii) (1.6g, 8.12 mmol) there was obtained the title compound (1.7 g, 85%) as a pale yellow solid.

^1H NMR δ (DMSO- d_6) 9.10 (1H, s), 8.49-8.43 (1H, m), 8.18-8.12 (1H, m), 7.73-7.65 (2H, m), 7.10 (1H, t, J = 5.9 Hz), 4.67 (2H, t, J = 6.0 Hz), 3.87 (2H, t, J = 6.9 Hz), 3.52-3.45 (2H, m), 3.32 (3H, s), 3.21 (2H, t, J = 6.9 Hz), 1.30 (9H, s)

ESI-MS $[M+H]^+$: 371

(iv)

1-[2-(*tert*-Butoxycarbonylamino)ethyl]-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinoline 5-oxide

By the method of example 1 step (v) using the product of step (iii) (1.7g, 4.62 mmol), there was obtained the title compound (1.7 g, 96%) as pale yellow solid.

^1H NMR δ (CDCl_3) 9.02-8.98 (2H, m), 8.38 (1H, d, J = 8.0 Hz), 7.81-7.74 (2H, m), 5.13 (1H, brs), 4.76 (2H, t, J = 6.3 Hz), 3.92 (2H, t, J = 6.2 Hz), 3.69-3.65 (2H, m), 3.37 (3H, s), 3.23 (2H, t, J = 6.1 Hz), 1.43 (9H, s)

ESI-MS $[M+H]^+$: 387

(v) *tert*-Butyl

2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethylcarbamate

By the method of example 1 step (vi) using the product of step (iv) (1.7g, 4.43 mmol) to afford the title compound as a pale yellow solid (1.7 g).

ESI-MS $[M+H]^+$: 386

(vi) 1-(2-Aminoethyl)-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine

By the method of example 1 step (vii) using the product of step (v) (1.7 g), there was obtained the title compound (1.1 g, 96% from step (iv)) as a yellow solid.

¹H NMR δ (MeOD-*d*₄) 8.13 (1H, d, *J* = 7.4 Hz), 7.69 (1H, dd, *J* = 8.4 Hz, 1.0 Hz), 7.49 (1H, td, *J* = 7.0 Hz, 1.2 Hz), 7.37-7.33 (1H, m), 4.64 (2H, t, *J* = 7.4 Hz), 3.90 (2H, t, *J* = 6.2 Hz), 3.38 (3H, s), 3.30 (2H, t, *J* = 6.2 Hz), 3.12 (2H, t, *J* = 7.4 Hz)

ESI-MS [M+H]⁺ : 286

(vii) Ethyl

2-[3-({2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethylamino}methyl)phenoxy]acetate

By the method of example 1 step (viii) using the product of step (vi) (0.79 g, 2.75 mmol) and the product of example 23 step (i) (0.57 g, 2.75 mmol) to afford the title compound (0.73 g, 56%) as pale yellow amorphousness.


¹H NMR δ (CDCl₃) 7.95 (1H, dd, *J* = 8.2 Hz, 0.80 Hz), 7.82 (1H, dd, *J* = 8.4 Hz, 1.2 Hz), 7.53-7.49 (1H, m), 7.31 (1H, td, *J* = 7.2 Hz, 1.2 Hz), 7.19 (1H, t, *J* = 7.8 Hz), 6.88-6.84 (2H, m), 6.76 (1H, dd, *J* = 8.0 Hz, 2.3 Hz), 5.63 (2H, brs), 4.62 (2H, t, *J* = 6.6 Hz), 4.58 (2H, s), 4.26 (2H, q, *J* = 7.2 Hz), 3.88 (2H, t, *J* = 6.4 Hz), 3.76 (2H, s), 3.34 (3H, s), 3.24 (2H, t, *J* = 6.4 Hz), 3.16 (2H, t, *J* = 6.6 Hz), 1.84 (1H, brs), 1.29 (3H, t, *J* = 7.2 Hz)

ESI-MS [M+H]⁺ : 478

Example 100

Ethyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-chloroacetamido)methyl]phenoxy}acetate hydrochloride



By the method of example 2 using the product of example 99 (0.73 g, 1.53 mmol), there was obtained the title compound (0.83 g, 91%) as pale yellow

amorphousness.


^1H NMR δ (CDCl_3) 8.20 (1H, d, $J = 8.0$ Hz), 7.93 (1H, d, $J = 8.3$ Hz), 7.60 (1H, t, $J = 7.4$ Hz), 7.49 (1H, t, $J = 7.4$ Hz), 7.26-7.22 (1H, m), 6.83 (1H, td, $J = 8.2$ Hz, 2.1 Hz), 6.77-6.76 (2H, m), 4.70 (2H, t, $J = 7.2$ Hz), 4.60 (2H, s), 4.49 (2H, s), 4.25 (2H, q, $J = 7.1$ Hz), 4.18 (2H, s), 3.81-3.76 (4H, m), 3.26 (3H, s), 2.96 (2H, t, $J = 5.8$ Hz), 1.29 (3H, t, $J = 7.1$ Hz)

ESI-MS $[\text{M}+\text{H}]^+ : 554$

Example 101

Ethyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-{diethylamino}acetamido)methyl]phenoxy}acetate



By the method of example 5 using the product of example 100 (0.83 g, 1.40 mmol) and diethylamine (1.5 mL, 14.0 mmol) to give the title compound as a pale yellow solid (0.66 g, 80%).


^1H NMR δ (CDCl_3) 8.05 (0.9H, d, $J = 8.0$ Hz), 7.82 (0.1H, d, $J = 8.0$ Hz), 7.79 (1H, d, $J = 8.3$ Hz), 7.50-7.47 (1H, m), 7.33-7.21 (2H, m), 6.81-6.72 (3H, m), 5.53-5.46 (2H, m), 4.78 (0.2H, t, $J = 7.6$ Hz), 4.66 (1.8H, t, $J = 7.6$ Hz), 4.58-4.20 (4H, m), 4.23 (2H, q, $J = 7.1$ Hz), 4.03-3.99 (0.2, m), 3.84-3.81 (1.8H, m), 3.71 (2H, t, $J = 7.6$ Hz), 3.33 (2H, s), 3.29 (3H, s), 3.07 (2H, t, $J = 6.1$ Hz), 2.65-2.60 (3.6H, m), 2.00-1.97 (0.4H, m), 1.25 (3H, t, $J = 7.1$ Hz), 1.03 (5.4H, t, $J = 7.1$ Hz), 0.79 (0.6H, t, $J = 7.1$ Hz)

ESI-MS $[\text{M}+2\text{H}]^{2+} : 296$

Example 102

Methyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-{diethylamino}acetamido)methyl]phenoxy}acetate



(i)

2-{3-[(*N*-(2-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethyl)-2-{diethylamino}acetamido)methyl]phenoxy}acetic acid

5 The title compound was prepared by the method of example 26 step (i) using the product from example 101 (0.56 g, 0.945 mmol) to give the title compound as a pale yellow solid (0.53 g, quant).

¹H NMR δ (MeOD-*d*₄) 8.29 (1H, brs), 7.46-7.42 (2H, m), 7.37 (1H, t, *J* = 7.3 Hz), 7.28-7.24 (1H, m), 7.17-7.14 (1H, m), 7.01 (1H, d, *J* = 7.3 Hz), 6.95 (1H, s),
10 4.89-4.77 (4H, m), 4.28 (2H, brs), 4.28 (2H, brs), 3.67-3.63 (2H, m), 3.31 (3H, s), 3.25 (4H, brs), 2.53 (2H, brs), 1.39 (6H, t, *J* = 7.1 Hz)

ESI-MS [*M*+2*H*]²⁺ : 282

(ii) Methyl

15 2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethyl)-2-{diethylamino}acetamido)methyl]phenoxy}acetate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.10 g, 0.181 mol) and MeOH (3.5 mL) to give the title compound as a pale yellow solid (0.99 g, 94%).

20 ¹H NMR δ (CDCl₃) 8.05 (1H, d, *J* = 7.7 Hz), 7.80 (1H, d, *J* = 8.4 Hz), 7.51-7.47 (1H, m), 7.33-7.22 (2H, m), 6.81-6.71 (3H, m), 5.57-5.46 (2H, m), 4.66 (2H, t, *J* = 7.2 Hz), 4.58-4.53 (2H, m), 3.83 (2H, t, *J* = 6.1 Hz), 3.77 (2H, s), 3.72-3.69 (5H, m), 3.33 (2H, s), 3.29 (3H, s), 3.07 (2H, t, *J* = 7.2 Hz), 2.63 (3.6H, q, *J* = 7.1 Hz), 2.36 (0.4H, t, *J* = 7.1 Hz), 1.03 (5.4H, t, *J* = 7.1 Hz), 0.80 (0.6H, t, *J* = 7.1 Hz)


25 ESI-MS [*M*+2*H*]²⁺ : 289

Example 103

Isopropyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethyl)-2-{

diethylamino}acetamido)methyl]phenoxy}acetate



The title compound was prepared by the method of example 26 step (ii) using the product from example 102 step (i) (0.11 g, 0.194 mmol) and isopropylalcohol (3.0 mL) to give the title compound as a yellow solid (0.11 g, 94%).


^1H NMR δ (CDCl_3) 8.07 (1H, d, $J = 8.2$ Hz), 7.86-7.79 (1H, m), 7.52-7.41 (1H, m), 7.34-7.30 (1H, m), 7.26-7.22 (1H, m), 6.80-6.74 (3H, m), 5.62-5.48 (2H, m), 5.10 (1H, quint, $J = 6.3$ Hz), 4.66 (2H, t, $J = 7.6$ Hz), 4.59-4.57 (2H, m), 4.53 (2, s), 3.83 (2H, t, $J = 6.1$ Hz), 3.77 (2H, s), 3.72-3.69 (2H, m), 3.34 (2H, s), 3.29 (3H, s), 3.06 (2H, t, $J = 6.1$ Hz), 2.64 (3.6H, q, $J = 7.1$ Hz), 2.35 (0.4H, t, $J = 7.1$ Hz), 1.27-1.19 (6H, m), 1.03 (5.4H, t, $J = 7.1$ Hz), 0.79 (0.6H, t, $J = 7.1$ Hz)

ESI-MS $[\text{M}+2\text{H}]^{2+} : 303$

Example 104

Ethyl

2-[3-({2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethylamino}methyl)phenoxy]-2-methylpropanoate



By the method of example 1 step (viii) using the example 99 step (vi) (0.32 g, 1.11 mmol) and example 53 step (i) (0.26 g, 1.11 mmol) to afford the title compound (0.41 g, 72%) as pale yellow amorphousness

^1H NMR δ (CDCl_3) 7.95 (1H, dd, $J = 8.4$ Hz, 1.0 Hz), 7.83 (1H, dd, $J = 8.4$ Hz, 1.0 Hz), 7.56-7.50 (1H, m), 7.34-7.30 (1H, m), 7.16 (1H, t, $J = 7.8$ Hz), 6.88 (1H, d, $J =$


7.7 Hz), 6.82 (1H, s), 6.69 (1H, dd, $J = 7.2$ Hz, 2.0 Hz), 5.66 (2H, brs), 4.63 (2H, t, $J = 6.8$ Hz), 4.20 (2H, q, $J = 7.1$ Hz), 3.88 (2H, t, $J = 6.4$ Hz), 3.74 (2H, s), 3.34 (3H, s), 3.25 (2H, t, $J = 6.4$ Hz), 3.15 (2H, t, $J = 6.8$ Hz), 2.17 (1H, brs), 1.57 (6H, s), 1.20 (3H, t, $J = 7.1$ Hz)

5 ESI-MS $[M+H]^+$: 506

Example 105

Ethyl

10 2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-chloroacetamido)methyl]phenoxy}-2-methylpropanoate hydrochloride



By the method of example 2 using the product of example 104 (0.41 g, 0.80 mmol), there was obtained the title compound (0.42 g, 86%) as colorless amorphousness.


15 ^1H NMR δ (CDCl_3) 8.11 (1H, d, $J = 8.1$ Hz), 7.87 (1H, d, $J = 8.4$ Hz), 7.57-7.52 (1H, m), 7.40 (1H, t, $J = 8.2$ Hz), 7.20 (1H, t, $J = 7.9$ Hz), 6.74-6.66 (3H, m), 6.43 (1H, brs), 4.72 (2H, t, $J = 7.1$ Hz), 4.33 (2H, s), 4.17 (2H, q, $J = 7.2$ Hz), 4.10 (2H, s) 3.87-3.78 (4H, m), 3.26 (3H, s), 3.06 (2H, t, $J = 5.9$ Hz), 1.57 (6H, s), 1.19 (3H, t, $J = 7.2$ Hz)

20 ESI-MS $[M+H]^+$: 582

Example 106

Ethyl

25 2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-diethylamino)acetamido)methyl]phenoxy}-2-methylpropanoate




By the method of example 5 using the product of example 105 (0.42 g, 0.685 mmol) and diethylamine (0.72 mL, 6.85 mmol), to give the title compound as a pale yellow gum (0.38 g, 91%).

- 5 ^1H NMR δ (CDCl_3) 8.08 (1H, d, $J = 8.2$ Hz), 7.80 (1H, d, $J = 8.3$ Hz), 7.50 (1H, t, $J = 8.2$ Hz), 7.34 (1H, t, $J = 7.1$ Hz), 7.21-7.17 (1H, m), 6.75-6.69 (3H, m), 5.60-5.47 (2H, m), 4.77 (0.2H, t, $J = 7.6$ Hz), 4.67 (1.8H, t, $J = 7.6$ Hz), 4.59 (2H, s), 4.16 (2H, q, $J = 7.1$ Hz), 4.01 (0.2H, t, $J = 6.1$ Hz), 3.83 (2H, t, $J = 6.1$ Hz), 3.72 (1.8H, t, $J = 7.2$ Hz), 3.35 (0.3H, s), 3.31 (2H, s), 3.28 (2.7H, s), 3.11 (2H, t, $J = 6.1$ Hz), 2.61 (3.6H, q, $J = 7.1$ Hz), 2.36 (0.4H, q, $J = 7.1$ Hz), 1.56-1.54 (6H, m), 1.17 (3H, t, $J = 7.1$ Hz), 1.02 (5.4H, t, $J = 7.1$ Hz), 0.79 (0.6H, t, $J = 7.1$ Hz)
- 10

ESI-MS $[\text{M}+2\text{H}]^{2+}$: 310

Example 107

- 15 Methyl
2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate



(i)

- 20 2-{3-[(*N*-(2-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 106 (0.29 g, 0.464 mmol) to give the title compound as a

colorless solid (0.26 g, 96%).

¹H NMR δ (MeOD-d₄) 8.19 (0.8H, d, J = 7.9 Hz), 7.97 (0.2H, d, J = 7.9 Hz), 7.64-7.43 (1.2H, m), 7.36-7.31 (1.8H, m), 7.27-7.18 (1H, m), 6.99-6.95 (1.8H, m), 6.86-6.77 (0.2H, m), 4.88 (2H, brs), 4.56 (2H, brs), 3.90-3.88 (0.4H, m), 3.77-3.74 (3.6H, m), 3.69-3.57 (2H, m), 3.38 (0.3H, s), 3.32 (2.7H, s), 2.84-2.78 (5.6H, m), 2.49-2.43 (0.4H, m), 1.63 (5.4H, s), 1.52 (0.6H, s), 1.13 (5.4H, t, J = 7.1 Hz), 0.78 (0.6H, t, J = 7.1 Hz)

ESI-MS [M+2H]²⁺ : 296

(ii) Methyl

2-{3-[(N-{2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.12 g, 0.204 mmol) and MeOH (5m L), to give the title compound as a pale yellow solid (0.89 g, 72%).


¹H NMR δ (CDCl₃) 8.07 (1H, d, J = 7.6 Hz), 7.86-7.78 (1H, m), 7.49-7.47 (1H, m), 7.35 (1H, t, J = 7.6 Hz), 7.12-7.17 (1H, m), 6.74 (1H, d, J = 7.7 Hz), 6.69-6.68 (2H, m), 5.59-5.47 (2H, m), 4.78 (0.2H, t, J = 7.4 Hz), 4.67 (1.8H, t, J = 7.4 Hz), 4.58 (2H, s), 3.98 (0.2H, t, J = 6.1 Hz), 3.84 (1.8H, t, J = 6.1 Hz), 3.73-3.69 (5H, m), 3.35 (0.3H, s), 3.31 (1.8H, s), 3.28 (2.7H, s), 2.91 (0.2H, s), 2.61 (3.6H, q, J = 7.1 Hz), 2.36 (0.4H, q, J = 7.1 Hz), 1.56-1.54 (6H, m), 1.02 (5.4H, t, J = 7.1 Hz), 0.80 (0.6H, t, J = 7.1 Hz)

ESI-MS [M+2H]²⁺ : 303

Example 108

Cyclopentyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propylamino}methyl)phenoxy]acetate



To a solution of the product of example 15 (0.53 g, 1.12 mmol) in MeOH (17 mL), 2N NaOH aq (7.0 mL) were added. After being stirred at 50°C for 2h and neutralized with 6N HCl aq, the resulting mixture was extracted with CHCl₃/EtOH (3/1), dried over Na₂SO₄ and concentrated in vacuo. After the
5 obtained solid was suspended with cyclopentanol (10 mL) and CH₃CN (7.0 mL), 4N HCl/dioxane (1.5 mL) was added to the suspension. After being stirred at 50°C for 3h and at rt for 60h, the resulting mixture was quenched with 7% NH₃ aq. The solution was extracted with CHCl₃ and the organic layer was washed with brine, dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by
10 flash column chromatography to afford the title compound (0.49 g, 83 %) as a yellow solid.


¹H NMR δ (CDCl₃) 8.09 (1H, dd, *J* = 8.2 Hz, 0.8 Hz), 7.82 (1H, dd, *J* = 8.4 Hz, 1.0 Hz), 7.50 (1H, td, *J* = 7.2 Hz, 1.2 Hz), 7.30-7.24 (2H, m), 6.98-6.93 (2H, m), 6.80 (1H, dd, *J* = 8.0 Hz, 2.2 Hz), 5.50 (2H, brs), 5.28-5.27 (1H, m), 4.66 (2H, t, *J* = 7.4
15 Hz), 4.59 (2H, s), 3.89 (2H, t, *J* = 6.4 Hz), 3.79 (2H, s), 3.38 (3H, s), 3.25 (2H, t, *J* = 6.4 Hz), 2.74 (2H, t, *J* = 6.3 Hz), 2.10-2.06 (2H, m), 1.87-1.84 (3H, m), 1.71-1.57 (6H, m)

ESI-MS [M+H]⁺ : 532

20 Example 109

Cyclopentyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]phenoxy}acetate hydrochloride



By the method of example 2 using the product of example 108 (0.49 g, 0.927mmol), there was obtained the title compound (0.54 g, 90%) as colorless amorphousness.

¹H NMR δ (CDCl₃) 7.91 (1H, d, *J* = 7.5 Hz), 7.85-7.80 (1H, m), 7.53 (1H, td, *J* = 7.2 Hz, 1.2 Hz), 7.24-7.16 (2H, m), 6.78-6.73 (3H, m), 5.58-5.50 (2H, m), 5.30-5.26


(1H, m), 4.60 (1.5H, s), 4.55-4.48 (4.5H, m), 4.10-4.07 (2H, m), 3.87 (2H, t, $J = 6.4$ Hz), 3.58 (1.5H, t, $J = 6.8$ Hz), 3.42 (0.5H, t, $J = 6.8$ Hz), 3.34-3.32 (3H, m), 3.17-3.09 (2H, m), 2.24-2.20 (0.5H, m), 2.17-2.10 (1.5H, m), 1.92-1.85 (2H, m), 1.72-1.61 (6H, m)

5 ESI-MS $[M+H]^+ : 608$

Example 110

Cyclopentyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-
10 -{dimethylamino}acetamido)methyl]phenoxy}acetate



By the method of example 5 using the product of example 109 (0.29 g, 0.450 mmol) and dimethylamine in THF (2M, 2.3 mL), to give the title compound as a pale yellow gum (0.24 g, 87%).


15 ^1H NMR δ (CDCl_3) 7.91 (1H, d, $J = 7.7$ Hz), 7.85 (1H, d, $J = 8.3$ Hz), 7.54 (1H, td, $J = 7.1$ Hz, 1.2 Hz), 7.36 (1H, t, $J = 7.1$ Hz), 7.20 (1H, t, $J = 8.0$ Hz), 6.79-6.73 (3H, m), 5.80-5.62 (2H, m), 5.28-5.27 (1H, m), 4.70 (1.5H, s), 4.58 (0.5H, s), 4.54 (2H, s), 4.52-4.48 (2H, m), 3.86 (2H, t, $J = 6.4$ Hz), 3.55-3.47 (2H, m), 3.36-3.35 (3H, m), 3.16-3.06 (4H, m), 2.31 (4.5H, s), 2.25-2.18 (0.5H, m), 2.13 (1.5H, s), 2.13-2.08
20 (1.5H, m), 1.88-1.85 (5H, m), 1.71-1.57 (3H, m)

ESI-MS $[M+2H]^{2+} : 309$

Example 111

Cyclopentyl

25 2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-{ethyl(methyl)amino}acetamido)methyl]phenoxy}acetate




By the method of example 5 using the product of example 109 (0.25 g, 0.388 mmol) and ethylmethylaniline (0.33 mL, 3.88 mmol), to give the title compound as a pale yellow gum (0.18 g, 73%).

- 5 ^1H NMR δ (CDCl_3) 7.91 (1H, d, $J = 7.8$ Hz), 7.86 (1H, d, $J = 8.3$ Hz), 7.54 (1H, t, $J = 8.0$ Hz), 7.39-7.24 (1H, m), 7.20 (1H, t, $J = 7.8$ Hz), 6.80-6.72 (3H, m), 5.83-5.65 (2H, m), 5.29-5.26 (1H, m), 4.73 (1.5H, s), 4.58 (0.5H, s), 4.54 (2H, s), 4.58-4.48 (2H, m), 3.86 (2H, t, $J = 6.4$ Hz), 3.53 (2H, t, $J = 7.0$ Hz), 3.36-3.34 (3H, m), 3.22 (1.5H, s), 3.16-3.14 (2H, m), 3.12 (0.5H, t, $J = 6.4$ Hz), 2.49 (1.5H, q, $J = 7.2$ Hz),
 10 2.35 (0.5H, q, $J = 7.2$ Hz), 2.30 (2.25H, s), 2.25-2.20 (0.5H, m), 2.17 (0.75H, s), 2.18-2.10 (1.5H, m), 1.92-1.86 (5H, m), 1.73-1.57 (3H, m), 1.06-0.99 (3H, m)
 ESI-MS $[\text{M}+2\text{H}]^{2+}$: 316

Example 112

15 Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-morpholinoacetamido)methyl]phenoxy}acetate



20 (i) Isopropyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]phenoxy]acetate

By the method of example 1 step (viii) using the product from example 15 step (iv)

(0.40 g, 1.34 mmol) and isopropyl 2-(3-formylphenoxy)acetate (0.30 g, 1.34 mmol) there was obtained the title compound, 0.57 g (1.13 mmol, 85%) as a pale yellow gum.

5 (ii) Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]phenoxy}acetate hydrochloride

By the method of example 2 using the product of step (i) (0.57 g, 1.13 mmol), there was obtained the title compound, 0.59 g (0.95 mmol, 84%) as a colorless gum.

10

(iii) Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-morpholinoacetamido)methyl]phenoxy}acetate

15 The title compound was prepared by the method of example 5 using the product from step iii) (0.26 g, 0.45 mmol) and morpholine (0.50 mL, 4.8 mmol), to give the title compound as a colorless gum (0.27 g, 84%).

¹H NMR δ (CDCl₃) 7.91-7.83 (2H, m), 7.53 (1H, td, *J* = 8.1 Hz, 1.2 Hz), 7.35 (1H, td, *J* = 7.6 Hz, 1.2 Hz), 7.22 (1H, t, *J* = 8.0 Hz), 6.79-6.73 (3H, m), 5.50-5.45 (2H, m), 5.14 (1H, sept, *J* = 6.6 Hz), 4.66 (1.5H, s), 4.57-4.48 (4.5H, m), 3.87 (2H, t, *J* = 6.4 Hz), 3.70 (3H, t, *J* = 4.5 Hz), 3.63-3.61 (1H, m), 3.55 (1.5H, t, *J* = 7.1 Hz), 3.47 (0.5H, t, *J* = 7.1 Hz), 3.37-3.35 (3H, m), 3.24 (1.5H, s), 3.14 (1.5H, t, *J* = 6.4 Hz), 3.11 (0.5H, t, *J* = 6.4 Hz), 3.00 (0.5H, s), 2.55-2.53 (3H, m), 2.36-2.34 (1H, m), 2.26-2.18 (0.5H, m), 2.14-2.08 (1.5H, m), 1.29 (6H, d, *J* = 6.6 Hz)


ESI-MS [*M*+2*H*]²⁺: 317

25

Example 113

Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]phenoxy}acetate



30

The title compound was prepared by the method of example 5 using the product from example 112 step (ii) (0.15 g) and dimethylamine, to give a colorless gum

(0.14 g). Yield 97%.


¹H NMR δ (DMSO-d₆) 8.02-7.95 (1H, m), 7.61 (1H, d, J = 8.3 Hz), 7.44 (1H, dd, J = 7.7 Hz, 7.4 Hz), 7.27-7.17 (2H, m), 6.82-6.73 (3H, m), 6.48 (2H, brs), 5.08-4.91 (1H, m), 4.71-4.65 (3H, m), 4.57-4.40 (3H, m), 3.80 (2H, q, J = 6.7 Hz), 3.50-3.39 (2H, m), 3.27 (3H, s), 3.16-3.12 (2H, m), 3.08 (1H, s), 2.99 (1H, s), 2.19 (3H, s), 2.18-2.06 (1H, m), 2.00 (3H, s), 2.00-1.95 (1H, m), 1.19 (3H, d, J = 6.0 Hz), 1.17 (3H, d, J = 5.2 Hz).

MS:ESI 591 (M+1)

Example 114

Isopropyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-ethyl(methyl)amino}acetamido)methyl]phenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 112 step (ii) (0.22 g) and ethylmethylamine, to give a pale yellow gum (0.21 g). Yield 99%.


¹H NMR δ (DMSO-d₆) 8.02-7.95 (1H, m), 7.61 (1H, d, J = 8.2 Hz), 7.43 (1H, dd, J = 7.7 Hz, 7.3 Hz), 7.27-7.17 (2H, m), 6.82-6.74 (3H, m), 6.49 (2H, brs), 5.04-4.93 (1H, m), 4.72-4.65 (3H, m), 4.55-4.40 (3H, m), 3.80 (2H, q, J = 6.4 Hz), 3.52-3.38 (2H, m), 3.27 (3H, s), 3.16-3.12 (3H, m), 3.06 (1H, s), 2.40 (1H, q, J = 7.0 Hz), 2.24 (1H, q, J = 7.0 Hz), 2.17 (1.5H, s), 2.17-2.06 (1H, m), 2.01 (1.5H, s), 2.01-1.90 (1H, m), 1.18 (3H, d, J = 5.6 Hz), 1.17 (3H, d, J = 5.5 Hz), 0.92 (1.5H, t, J = 7.0 Hz), 0.83 (1.5 H, t, J = 7.0 Hz).

MS:ESI 605 (M+1)

Example 115

Isopropyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-((2-methoxyethyl)(methyl)amino}acetamido)methyl]phenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 112 step (ii) (0.22 g) and methoxyethylmethylamine, to give a colorless gum (0.17 g). Yield 77%.


¹H NMR δ (DMSO- d_6) 8.02-7.95 (1H, m), 7.61 (1H, d, J = 8.3 Hz), 7.43 (1H, dd, J = 8.1 Hz, 7.2 Hz), 7.28-7.17 (2H, m), 6.82-6.74 (3H, m), 6.48 (2H, brs), 5.03-4.93 (1H, m), 4.72 (1H, s), 4.70 (1H, s), 4.66 (1H, s), 4.55-4.50 (1H, m), 4.47-4.42 (2H, m), 3.80 (2H, q, J = 6.9 Hz), 3.55-3.38 (2H, m), 3.34-3.25 (2H, m), 3.28 (3H, s), 3.24-3.18 (2H, m), 3.14-3.10 (2H, m), 3.12 (1.5H, s), 3.10 (1.5H, s), 2.55 (1H, t, J = 5.5 Hz), 2.50 (1H, t, J = 6.5 Hz), 2.23 (1.5H, s), 2.13 (1.5H, s), 2.13-2.06 (1H, m), 2.03-1.95 (1H, m), 1.18 (3H, d, J = 6.0 Hz), 1.17 (3H, d, J = 6.0 Hz).

MS:ESI 635 (M+1)

Example 116

Isopropyl

2-[5-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)-2-fluorophenoxy]acetate



(i) 2-Fluoro-5-(hydroxymethyl)phenol

To a suspension of LiBH₄ (2.37 g, 109 mmol) in THF (50 ml) was added methyl 4-fluoro-3-hydroxybenzoate (5.0 g, 27.2 mmol) at room temperature. After stirring for 24 h under reflux, the reaction mixture was concentrated. The residue was partitioned between EtOAc (100 ml) and 1N HCl (100 ml). The aqueous layer was extracted with EtOAc (50ml, twice), the combined organic layers were washed with brine, dried over MgSO₄, and concentrated. The residue was purified by flash column chromatography to give the title compound (2.76 g, 19.4 mmol, 66%) as a white solid.

¹H NMR δ (CDCl₃) 7.09-7.00 (2H, m), 6.88-6.82 (1H, m), 5.24 (1H, d, J = 4.0 Hz), 4.60 (2H, s), 1.68 (1H, brs).

(ii) 4-Fluoro-3-hydroxybenzaldehyde

The title compound was prepared by the method of example 64 step (ii) using the product from step (i) (2.74 g, 19.3 mmol), to give a white solid (0.22 g, 1.57 mmol).

Yield 8%.

^1H NMR δ (CDCl_3) 9.91 (1H, s), 7.55 (1H, dd, $J = 8.4$ Hz, 2.0 Hz), 7.47-7.42 (1H, m), 7.27-7.22 (1H, m), 5.44 (1H, d, $J = 4.2$ Hz).

(iii) Isopropyl 2-(2-fluoro-5-formylphenoxy)acetate

The title compound was prepared by the method of example 64 step (iii) using the product from step (ii) (0.22 g, 1.57 mmol), to give the title compound (0.34 g, 1.40 mmol, 89%) as colorless oil.

^1H NMR δ (CDCl_3) 9.90 (1H, s), 7.53-7.48 (1H, m), 7.44 (1H, dd, $J = 8.0$ Hz, 1.7 Hz), 7.30-7.24 (1H, m), 5.15 (1H, hept, $J = 6.3$ Hz), 4.74 (2H, s), 1.28 (6H, d, $J = 6.3$ Hz).

(iv) Isopropyl

2-[5-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]-2-fluorophenoxy]acetate

By the method of example 1 step (viii) using the product from example 15 step (iv) (0.41 g, 1.37 mmol) and isopropyl 2-(2-fluoro-5-formylphenoxy)acetate (0.33 g, 1.37 mmol) there was obtained the title compound, 0.51 g (0.97 mmol, 71%) as a white solid


^1H NMR δ (CDCl_3) 8.07 (1H, d, $J = 7.3$ Hz), 7.82 (1H, dd, $J = 8.4$ Hz, 1.0 Hz), 7.53-7.49 (1H, m), 7.30-7.25 (1H, m), 7.09-7.03 (1H, m), 6.98-6.92 (2H, m), 5.47 (2H, brs), 5.11 (1H, hept, $J = 6.3$ Hz), 4.67 (2H, s), 4.67-4.62 (2H, m), 3.90 (2H, t, $J = 6.6$ Hz), 3.74 (2H, s), 3.38 (3H, s), 3.25 (2H, t, $J = 6.6$ Hz), 2.73 (2H, t, $J = 6.3$ Hz), 2.09 (2H, tt, $J = 7.1, 6.5$ Hz), 1.25 (6H, d, $J = 6.3$ Hz).

MS:ESI 524 ($\text{M}+1$)

Example 117

Isopropyl

2-[5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-chloroacetamido)methyl]-2-fluorophenoxy]acetate hydrochloride



By the method of example 2 using the product of example 116 (0.51 g, 0.97 mmol), there was obtained the title compound, 0.61 g (0.96 mmol, 99%) as a colorless gum.


¹H NMR δ (CDCl₃) 7.91-7.80 (2H, m), 7.56-7.51 (1H, m), 7.37-7.33 (1H, m), 7.07-6.95 (1H, m), 6.75-6.65 (2H, m), 5.75-5.51 (2H, brm), 5.08 (1H, hept, d = 6.4 Hz), 4.63-4.47 (6H, m), 4.09 (1.5H, s), 4.05 (0.5H, s), 3.87 (2H, t, J = 6.3 Hz), 3.54 (1.5H, t, J = 6.9 Hz), 3.40-3.32 (0.5H, m), 3.36 (2.3H, s), 3.34 (0.7H, s), 3.16-3.09 (2H, m), 2.26-2.09 (3H, m), 1.25 (6H, d, J = 6.4 Hz).

MS:ESI 601 (M+1)

Example 118

Isopropyl

2-{5-[(N-{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-diethylamino)acetamido)methyl]-2-fluorophenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 117 (0.61 g, 0.96 mmol) and diethylamine, to give a pale yellow gum (0.58 g). Yield 95%.


¹H NMR δ (DMSO-d₆) 8.00-7.93 (1H, m), 7.61 (1H, d, J = 8.3 Hz), 7.43 (1H, dd, J = 8.0 Hz, 7.2 Hz), 7.25-7.12 (2H, m), 6.95-6.90 (1H, m), 6.85-6.74 (1H, m), 6.49 (2H, brs), 4.96-4.90 (1H, m), 4.80 (1H, s), 4.73 (1H, s), 4.69 (1H, s), 4.55-4.48 (1H, m), 4.45-4.40 (1H, m), 4.43 (1H, s), 3.80 (2H, q, J = 6.7 Hz), 3.52-3.38 (2H, m), 3.27 (3H, s), 3.22 (1H, s), 3.17 (1H, s), 3.15-3.09 (2H, m), 2.50 (2H, q, J = 7.1 Hz), 2.38 (2H, q, J = 7.1 Hz), 2.17-2.06 (1H, m), 2.01-1.88 (1H, m), 1.18 (3H, d, J = 6.3 Hz), 1.15 (3H, d, J = 6.3 Hz), 0.88 (3H, t, J = 7.1 Hz), 0.83 (3H, t, J = 7.1 Hz).

MS:ESI 637 (M+1)

Example 119

Ethyl

2-{5-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-fluorophenoxy}acetate



5 (i)

2-{5-[(*N*-{3-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-fluorophenoxy}acetic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 118 (0.44 g), to give a white solid (0.35 g). Yield 86%.

10 ¹H NMR δ (DMSO-*d*₆) 7.89-7.82 (1H, m), 7.70 (2H, brs), 7.83-7.82 (1H, m), 7.43-7.37 (1H, m), 7.29-7.24 (1H, m), 7.19-7.11 (1H, m), 7.13-6.94 (1H, m), 6.83-6.65 (1H, m), 4.64 (1H, s), 4.59-4.50 (2H, m), 4.44-4.38 (2H, m), 4.34-4.30 (1H, m), 3.80-3.72 (2H, m), 3.50-3.42 (1H, m), 3.36-3.40 (1H, m), 3.28 (3H, s), 3.23 (1H, s), 3.13-3.06 (3H, m), 2.55-2.48 (2H, m), 2.45-2.40 (2H, m), 2.09-1.95 (1H, m), 1.93-1.85 (1H, m), 0.90 (3H, t, *J* = 7.0 Hz), 0.85 (3H, t, *J* = 7.1 Hz).

15 MS:ESI 595 (M+1)

(ii) Ethyl

20 2-{5-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-fluorophenoxy}acetate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.17 g) and ethanol, to give a pale yellow gum (0.16 g). Yield 93%.


25 ¹H NMR δ (DMSO-*d*₆) 8.00-7.93 (1H, m), 7.60 (1H, d, *J* = 8.2 Hz), 7.42 (1H, dd, *J* = 7.7 Hz, 7.4 Hz), 7.26-7.10 (2H, m), 6.93-6.87 (1H, m), 6.80-6.74 (1H, m), 6.50 (2H, brs), 4.83 (1H, s), 4.77 (1H, s), 4.68 (1H, s), 4.55-4.48 (1H, m), 4.45-4.40 (2H, m), 4.16-4.06 (2H, m), 3.80 (2H, q, *J* = 6.1 Hz), 3.52-3.35 (2H, m), 3.27 (3H, s), 3.23 (1H, s), 3.18 (1H, s), 3.15-3.09 (2H, m), 2.55-2.45 (2H, m), 2.42-2.36 (2H, m), 2.12-2.06 (1H, m), 1.96-1.88 (1H, m), 1.17 (3H, d, *J* = 6.9 Hz), 0.89 (3H, t, *J* = 6.7 Hz), 0.83 (3H, t, *J* = 6.8 Hz).

30 MS:ESI 623 (M+1)

Example 120

Methyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]-2-fluorophenoxy}acetate



The title compound was prepared by the method of example 26 step (ii) using the product from example 119 step (i) (0.15 g) and methanol, to give a pale yellow gum (0.15 g). Yield 96%.


¹H NMR δ (DMSO-*d*₆) 8.01-7.93 (1H, m), 7.61 (1H, d, *J* = 8.3 Hz), 7.43 (1H, dd, *J* = 7.5 Hz, 7.4 Hz), 7.24-7.10 (2H, m), 6.96-6.88 (1H, m), 6.80-6.74 (1H, m), 6.51 (2H, brs), 4.85 (1H, s), 4.80 (1H, s), 4.68 (1H, s), 4.53 (1H, t, *J* = 7.2 Hz), 4.47-4.44 (2H, m), 3.80 (2H, q, *J* = 6.6 Hz), 3.68 (1.5H, s), 3.66 (1.5H, s), 3.52-3.35 (2H, m), 3.24 (3H, s), 3.24 (1H, s), 3.19 (1H, s), 3.16-3.09 (2H, m), 2.54-2.45 (2H, m), 2.42-2.36 (2H, m), 2.12-2.06 (1H, m), 1.96-1.88 (1H, m), , 0.89 (3H, t, *J* = 7.1 Hz), 0.83 (3H, t, *J* = 7.1 Hz).

MS:ESI 609 (M+1)

Example 121

Isopropyl

2-[3-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylamino]methyl]-5-fluorophenoxy]acetate



(i) (3-Bromo-5-fluorophenoxy)(*tert*-butyl)dimethylsilane

To a solution of 3-bromo-5-fluorophenol (1.50 g, 7.88 mmol) in THF (15 ml) was added *tert*-butyldimethylsilyl chloride (1.54 g, 10.2 mmol) and imidazole (1.07 g, 15.8 mmol) at 0°C. After stirring for 3 h at room temperature, the reaction mixture was quenched with aqueous citric acid. The mixture was extracted with EtOAc (50ml, twice), the combined organic layers were washed with brine, dried over

MgSO₄, and concentrated. The residue was purified by flash column chromatography to give the title compound (2.21 g, 7.23 mmol, 92%) as a white solid.

¹H NMR δ (CDCl₃) 6.89-6.84 (1H, m), 6.81-6.79(1H, m), 6.52-6.46 (1H, m), 0.98 (9H, s), 0.22 (6H, s).

(ii) 3-Fluoro-5-hydroxybenzaldehyde

To a solution of the product from step (i) (2.20 g, 7.23 mmol) in THF (20 ml) was added *n*-butyllithium (1.6 M hexane solution, 4.97 ml, 7.95 mmol) at -78 °C. After stirring for 30 min at -78 °C, DMF (1.57 ml, 10.8 mmol) was added to the reaction mixture, and then stirred for 1.5 h at 0°C. Water was added to the mixture, and then the mixture was extracted with EtOAc (50ml, twice), the combined organic layers were washed with brine, dried over MgSO₄, and concentrated. The residue was purified by flash column chromatography to give 3-(tert-butyldimethylsilyloxy)-5-fluorobenzaldehyde. The compound was dissolved in THF 1.6 ml, thereto tetrabutylammonium fluoride (1.0 M THF solution, 3.38 ml, 3.38 mmol) was added and stirred for 4 h. The reaction was quenched with aqueous citric acid. The mixture was extracted with EtOAc (50ml, twice), the combined organic layers were washed with brine, dried over MgSO₄, and concentrated. The residue was purified by flash column chromatography to give the title compound (0.13 g, 0.92 mmol, 13%) as a white solid.

¹H NMR δ (CDCl₃) 9.90 (1H, s), 7.19-7.14 (2H, m), 6.89-6.84(1H, m), 5.56 (1H, brs).

(iii) Isopropyl 2-(3-fluoro-5-formylphenoxy)acetate

The title compound was prepared by the method of example 64 step (iii) using the product from step (ii) (0.13 g, 0.89 mmol), to give the title compound (0.18 g, 0.76 mmol, 85%) as colorless oil.

¹H NMR δ (CDCl₃) 9.91 (1H, s), 7.24-7.18 (2H, m), 6.95-6.90(1H, m), 5.15 (1H, hept, J = 6.3 Hz), 4.65 (2H, s), 1.28 (6H, d, J = 6.3 Hz).

(iv) Isopropyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)-5-fluorophenoxy]acetate

By the method of example 1 step (viii) using the product from example 15 step (iv)

(0.22 g, 0.73 mmol) and isopropyl 2-(3-fluoro-5-formylphenoxy)acetate (0.18 g, 0.73 mmol) there was obtained the title compound, 0.29 g (0.56 mmol, 77%) as a white solid.


¹H NMR δ (CDCl₃) 8.08 (1H, d, J = 8.1 Hz), 7.83 (1H, d, J = 8.3 Hz), 7.51 (1H, dd, J = 8.1 Hz, 7.2 Hz), 7.32-7.25 (1H, m), 6.76-6.72 (2H, m), 6.55-6.50 (1H, m), 5.57 (2H, brs), 5.14 (1H, hept, J = 6.3 Hz), 4.67 (2H, t, J = 7.4 Hz), 4.59 (2H, s), 3.90 (2H, t, J = 6.5 Hz), 3.77 (2H, s), 3.38 (3H, s), 3.25 (2H, t, J = 6.5 Hz), 2.74 (2H, t, J = 6.2 Hz), 2.13-2.04 (2H, m), 1.26 (6H, d, J = 6.3 Hz).

MS:ESI 524 (M+1)

Example 122

Isopropyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-5-fluorophenoxy}acetate hydrochloride



By the method of example 2 using the product of example 121 (0.29 g, 0.55 mmol), there was obtained the title compound, 0.33 g (0.52 mmol, 94%) as a colorless gum.


¹H NMR δ (CDCl₃) 7.93-7.80 (2H, m), 7.57-7.51 (1H, m), 7.40-7.34 (1H, m), 6.53-6.48 (3H, m), 5.90-5.51 (2H, brm), 5.13 (1H, hept, d = 6.3 Hz), 4.60-4.50 (6H, m), 4.08 (2H, s), 3.87 (2H, t, J = 6.2 Hz), 3.59 (1.5H, t, J = 6.9 Hz), 3.50-3.40 (0.3H, m), 3.37 (2H, s), 3.34 (0.7H, s), 3.18-3.09 (2H, m), 2.26-2.04 (3H, m), 1.28 (6H, d, J = 6.4 Hz).

MS:ESI 601 (M+1)

Example 123

Isopropyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-5-fluorophenoxy}acetate



The title compound was prepared by the method of example 5 using the product from example 122 (0.32 g, 0.51 mmol) and diethylamine, to give a colorless gum (0.26 g). Yield 82%.


¹H NMR δ (CDCl₃) 7.95-7.88 (2H, m), 7.59 (1H, dd, J = 7.7 Hz, 7.4 Hz), 7.47-7.42 (1H, m), 6.57-6.50 (2H, m), 6.49-6.44 (1H, m), 5.85-5.55 (2H, brm), 5.13 (1H, hept, J = 6.3 Hz), 4.76 (1.5H, s), 4.55-4.47 (4.5H, m), 3.87 (2H, t, J = 6.2 Hz), 3.67-3.50 (2H, m), 3.36-3.28 (5H, m), 3.16-3.08 (2H, m), 2.62-2.53 (4H, m), 2.30-2.05 (2H, m), 1.28 (6H, d, J = 6.3 Hz), 1.01-0.98 (6H, m).

MS:ESI 637 (M+1)

Example 124

Ethyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]-5-fluorophenoxy}acetate



(i)

2-{3-[(N-{3-[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]-5-fluorophenoxy}acetic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 123 (0.16 g), to give a white solid (0.16 g). Yield 100%.

¹H NMR δ (DMSO-d₆) 7.99-7.91 (1H, m), 7.59 (1H, d, J = 8.3 Hz), 7.44 (1H, dd, J = 7.7 Hz, 7.5 Hz), 7.29-7.22 (1H, m), 7.13 (2H, brs), 6.66-6.52 (3H, m), 4.71 (1H, s), 4.55-4.40 (5H, m), 3.79 (2H, q, J = 6.8 Hz), 3.56-3.51 (1H, m), 3.44-3.28 (1H, m), 3.27 (3H, s), 3.25 (1H, s), 3.23 (1H, s), 3.16-3.10 (2H, m), 2.55-2.48 (2H, m), 2.45-2.40 (2H, m), 2.15-2.05 (1H, m), 2.00-1.92 (1H, m), 0.89 (3H, t, J = 7.0 Hz), 0.84 (3H, t, J = 7.1 Hz).

MS:ESI 595 (M+1)

(ii) Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]-5-fluorophenoxy}acetate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.093 g) and ethanol, to give a pale yellow gum (0.088 g). Yield 91%.


¹H NMR δ (CDCl₃) 7.91-7.83 (2H, m), 7.54 (1H, dd, *J* = 7.4 Hz, 7.4 Hz), 7.38-7.28 (1H, m), 6.66-6.44 (3H, m), 5.85-5.55 (2H, brm), 4.75 (1.5H, s), 4.56-4.46 (4.5H, m), 4.28 (2H, q, *J* = 7.1 Hz), 3.87 (2H, t, *J* = 6.3 Hz), 3.65-3.49 (2H, m), 3.36-3.34 (3H, m), 3.28-3.26 (2H, m), 3.17-3.09 (2H, m), 2.62-2.50 (4H, m), 2.30-1.90 (2H, m), 1.30 (3H, t, *J* = 7.1 Hz), 0.97 (6H, t, *J* = 7.1 Hz).

MS:ESI 623 (M+1)

Example 125

Ethyl

2-{4-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy}acetate



(i) Ethyl 2-(4-formylphenoxy)acetate

To a solution of 2-(4-formylphenoxy)acetic acid (4.00 g, 22.2 mmol) in EtOH (100 ml) was added conc. H₂SO₄ (1 ml). After stirring at reflux temperature for 4 h, the reaction mixture was concentrated, neutralized with satd. NaHCO₃ aq. (200 ml), and extracted with AcOEt (100 ml x2). The combined extracts were dried over MgSO₄ and concentrated to afford the subtitle compound (4.45 g, 96%) as a white solid.

(ii) Ethyl

2-{4-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy}acetate

To a solution of the product of example 42 step (vi) (277 mg, 0.883 mmol) and product from step (i) (184 mg, 0.882 mmol) in MeOH (10 ml) were added AcOH (101 μ l, 1.77 mmol) and NaBH₃CN (56.1 mg, 0.893 mmol) at 0°C. After stirring at between 0 °C and room temperature over night, the reaction mixture was concentrated, and poured with satd. NaHCO₃ aq. (50 ml). The aq. Layer was extracted with CHCl₃-MeOH (20:1, 50 ml x2), dried over Na₂SO₄, and concentrated. The residue was purified by flash column chromatography to give esubtitle compound (223 mg, 50%) as a colorless gum.

(iii) Ethyl

2-{4-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy}acetate

To a solution of the product from step (ii) (221 mg, 0.437 mmol) and *i*-Pr₂NEt (188 μ l, 1.09 mmol) in THF (5 ml). The mixture was added 4-nitrophenyl carbonochloridate (116 mg, 0.576 mmol) at 0°C. After stirring at the same temperature for 30 min, the mixture was added 2-(piperidin-1-yl)ethanamine (73.8 mg, 0.576 mmol) and DMSO (5ml). After further stirring at room temperature over night, the reaction mixture was diluted with satd. NaHCO₃ aq. (30 ml), and extracted with AcOEt (50 ml x2). The extracts were washed with H₂O (50 ml x2) and brine (50 ml x1), dried over Na₂SO₄, and concentrated. The residue was purified by flash column chromatography to afford the title compound (207 mg, 72%) as a colorless gum.

¹H NMR δ (DMSO-*d*₆) 7.97 (1H, d, *J* = 8.2), 7.61 (1H, dd, *J* = 1.0, 8.2), 7.42 (1H, dt, *J* = 1.0, 7.1), 7.25 (1H, dt, *J* = 1.0, 7.1), 7.15-7.10 (2H, m), 6.87 (2H, m), 6.47 (2H, brs), 6.19-6.12 (1H, m), 4.73 (2H, s), 4.48 (2H, t, *J* = 7.1), 4.33 (2H, s), 4.15 (2H, q, *J* = 7.1), 3.81 (2H, t, *J* = 6.8), 3.29 (3H, s), 3.19-3.08 (6H, m), 2.31-2.18 (6H, m), 1.79-1.68 (2H, m), 1.65-1.54 (2H, m), 1.44-1.29 (6H, m), 1.20 (3H, t, *J* = 7.1).


MS: ESI 660 (M+1)

Example 126

Ethyl

2-{3-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{

2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy}acetate



The title compound (149 mg) was obtained by the same procedure of example 125 step (iii) using the product of example 42 (151 mg, 0.299 mmol). Yield 76%


¹H NMR δ (DMSO- d_6) 7.98 (1H, d, J = 8.0), 7.61 (1H, d, J = 8.0), 7.42 (1H, t, J = 7.5), 7.25 (1H, t, J = 7.5), 7.19 (1H, d, J = 8.0), 6.83-6.72 (3H, m), 6.48 (2H, brs), 6.22-6.17 (1H, m), 4.72 (2H, s), 4.49 (2H, t, J = 7.2), 4.38 (2H, s), 4.15 (2H, q, J = 7.1), 3.81 (2H, t, J = 6.7), 3.29 (3H, s), 3.21-3.08 (6H, m), 2.32-2.19 (6H, m), 1.80-1.79 (2H, m), 1.65-1.55 (2H, m), 1.43-1.28 (6H, m), 1.20 (3H, t, J = 7.1).

MS: ESI 660 (M+1)

Example 127

Ethyl

2-{3-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{2-(dimethylamino)ethyl}ureido)methyl]phenoxy}acetate



The title compound (50.4 mg) was obtained by the same procedure of example 125 step (iii) using the product of example 42 (124 mg, 0.246 mmol). Yield 33%


¹H NMR δ (DMSO- d_6) 7.98 (1H, d, J = 8.2), 7.61 (1H, d, J = 8.2), 7.42 (1H, t, J = 7.6), 7.27-7.18 (2H, m), 6.81-6.74 (3H, m), 6.47 (2H, brs), 6.24 (1H, t, J = 5.4), 4.72 (2H, s), 4.49 (2H, t, J = 7.4), 4.38 (2H, s), 4.15 (2H, q, J = 7.1), 3.81 (2H, t, J = 6.7), 3.29 (3H, s), 3.20-3.06 (6H, m), 2.21 (2H, t, J = 6.9), 2.07 (6H, s), 1.79-1.70 (2H, m), 1.64-1.54 (2H, m), 1.20 (3H, t, J = 7.1).

MS: ESI 620 (M+1)

Example 128

Ethyl

2-{3-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{
 5 3-(piperidin-1-yl)propyl)ureido)methyl]phenoxy}acetate




The title compound (38.4 mg) was obtained by the same procedure of example 125 step (iii) using the product of example 42 (141 mg, 0.278 mmol). Yield 21%
¹H NMR δ (DMSO-*d*₆) 7.82 (1H, dd, *J* = 0.8, 8.2), 7.73 (1H, dd, *J* = 1.0, 8.4),
 10 7.44-7.39 (1H, m), 7.26-7.21 (1H, m), 7.16-7.12 (1H, m), 6.76-6.67 (3H, m), 5.93
 (1H, t, *J* = 4.6), 5.42 (2H, brs), 4.51 (2H, s), 4.43 (2H, t, *J* = 7.5), 4.28 (2H, s), 4.19
 (2H, q, *J* = 7.1), 3.80 (2H, t, *J* = 6.5), 3.30 (3H, s), 3.30-3.19 (2H, m), 3.09 (2H, t, *J*
 = 6.5), 2.25-2.11 (6H, m), 1.88-1.77 (2H, m), 1.65-1.51 (4H, m), 1.27-1.18 (9H,
 m).

15 MS: ESI 674 (*M*+1)

Example 129

Ethyl

2-{3-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{
 20 3-(dimethylamino)propyl)ureido)methyl]phenoxy}acetate



The title compound (30.5 mg) was obtained by the same procedure of example 125 step (iii) using the product of example 42 (133 mg, 0.262 mmol). Yield 18%
¹H NMR δ (DMSO-*d*₆) 7.82 (1H, dd, *J* = 0.8, 8.2), 7.74 (1H, dd, *J* = 1.0, 8.4),
 25 7.44-7.40 (1H, m), 7.26-7.21 (1H, m), 7.15 (1H, t, *J* = 8.0), 6.75-6.65 (3H, m), 6.50


(1H, t, J = 4.4), 5.48 (2H, brs), 4.51 (2H, s), 4.44 (2H, t, J = 7.6), 4.26 (2H, s), 4.18 (2H, q, J = 7.1), 3.81 (2H, t, J = 6.5), 3.30 (3H, s), 3.32-3.26 (2H, m), 3.26-3.20 (2H, m), 3.10 (2H, t, J = 6.5), 2.19 (2H, t, 5.8), 2.13-1.92 (4H, m), 1.88-1.78 (2H, m), 1.87 (6H, s), 1.69-1.58 (2H, m), 1.54-1.47 (2H, m), 1.23 (3H, t, J = 7.1).

MS: ESI 634 (M+1)

Example 130

Ethyl

2-{3-[(3-{4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl}-1-{2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy}acetate



To a solution of ethyl 2-(3-formylphenoxy)acetate (500 mg, 2.40 mmol) and 2-(piperidin-1-yl)ethanamine (308 mg, 2.40 mmol) in MeOH (20 ml) were added AcOH (275 μ l, 4.81 mmol) and NaBH₃CN (151 mg, 2.41 mmol) at 0 °C. After stirring at between 0°C and room temperature over night, the reaction mixture was concentrated, and poured with satd. NaHCO₃ aq. (50 ml). The aq. layer was extracted with CHCl₃-MeOH (20:1, 50 ml x2), dried over Na₂SO₄, and concentrated. The residue was purified by flash column chromatography to give ethyl 2-(3-((2-(piperidin-1-yl)ethylamino)methyl) phenoxy)acetate. (555 mg, 72%) as a colorless gum.

The title compound (178 mg) was obtained by the same procedure of example 22 step (i) using the product of example 42 step (vi) and ethyl 2-(3-((2-(piperidin-1-yl)ethylamino)methyl)phenoxy)acetate. Yield 60%


¹H NMR δ (DMSO-d₆) 8.00 (1H, d, J = 7.8), 7.61 (1H, dd, J = 1.1, 8.3), 7.41 (1H, dt, J = 1.1, 7.1), 7.24-7.14 (2H, m), 7.03 (1H, brs), 6.77-6.72 (3H, m), 6.48 (2H, brs), 4.71 (2H, s), 4.54 (2H, t, J = 7.3), 4.37 (2H, s), 4.14 (2H, q, J = 7.1), 3.82 (2H, t, J = 6.8), 3.29 (3H, s), 3.19 (2H, t, J = 6.8), 3.15-3.05 (4H, m), 2.28-2.12 (6H, m), 1.87-1.77 (2H, m), 1.63-1.52 (2H, m), 1.40-1.25 (6H, m), 1.19 (3H, t, J = 7.1).

MS: ESI 660 (M+1)

Example 131

Ethyl

2-{4-[(3-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-{2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy}acetate



5 The title compound (190 mg) was obtained by the same procedure of example 130 using the product of example 42 step (vi) (174 mg, 0.555 mmol). Yield 52%


¹H NMR δ (DMSO-*d*₆) 8.00 (1H, d, *J* = 8.2), 7.61 (1H, d, *J* = 8.2), 7.41 (1H, t, *J* = 7.2), 7.22 (1H, t, *J* = 7.2), 7.11-7.06 (2H, m), 7.03-6.97 (1H, m), 6.83-6.79 (2H, m), 6.48(2H, brs), 4.73 (2H, s), 4.54 (2H, t, *J* = 7.2), 4.32 (2H, s), 4.16 (2H, q, *J* = 7.1),
 10 3.82 (2H, t, *J* = 6.7), 3.29 (3H, s), 3.19 (2H, t, *J* = 6.7), 3.14-3.02 (4H, m), 2.28-2.10 (6H, m), 1.87-1.76 (2H, m), 1.63-1.52 (2H, m), 1.39-1.24 (6H, m), 1.21 (3H, t, *J* = 7.1).

MS: ESI 660 (*M*+1)

15 Example 132

Isopropyl

2-{3-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl){2-[di methylamino]ethyl}amino)methyl]phenoxy}acetate



20 (i) *N*-{4-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-2-nitrobenzenesulfonamide

To a solution of the product of example 42 step (vi) (1.51 g, 4.80 mmol) in CHCl₃ (150 ml) and THF (30 ml) was added *o*-nitrobenzenesulfonyl chloride (1.18 g, 5.31 mmol) at 0°C. After stirring at room temperature for 2 h, the reaction mixture
 25 was quenched by satd. NaHCO₃ aq. (100 ml), and extracted with CHCl₃ (200 ml x2). The combined extracts were dried over Na₂SO₄ and concentrated. The

residue was purified by flash column chromatography to afford the subtile compound (2.23 g, 93%) as a white solid.

(ii) *N*-{4-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-*N*-[2-(dimethylamino)ethyl]-2-nitrobenzenesulfonamide

To a solution of the product of step (i) (703 mg, 1.41 mmol) PPh₃ (1.11 g, 4.22 mmol) and 2-(dimethylamino)ethanol (262 ul, 2.20 mmol) in THF (30 ml) was added DIAD (2.21 ml, 4.20 mmol) at 50°C. After stirring at the same temperature for 30 min, the reaction mixture was concentrated and purified by flash column chromatography to give the subtile compound (589 mg, 73%) as colorless amorphous.

(iii) *N*1-{4-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-*N*2,*N*2-dimethylethane-1,2-diamine

To a solution of the product of step (ii) (589 mg, 1.03 mmol) in DMF (15 ml) were added 2-mercaptoacetic acid (485 ul, 7.00 mmol) and lithium hydroxide (334 mg, 13.9 mmol) at room temperature. After stirring at the same temperature over night, the reaction mixture was quenched by satd. NaHCO₃ aq. (50 ml) and extracted with CHCl₃ (50 ml x 3). The combined organic layers were dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography to afford the subtile compound (286 mg, 53%) as a white solid.

¹H NMR δ (DMSO-*d*₆) 8.07 (1H, dd, *J* = 1.1, 8.3), 7.60 (1H, dd, *J* = 1.2, 8.3), 7.42 (1H, ddd, *J* = 1.1, 7.0, 8.2), 7.25 (1H, ddd, *J* = 1.2, 7.0, 8.2), 6.47 (2H, s), 4.54 (2H, t, *J* = 7.4), 3.83 (2H, t, *J* = 6.9), 3.30 (3H, s), 3.19 (2H, t, *J* = 6.7), 2.58-2.51 (4H, m), 2.25 (2H, t, *J* = 6.4), 2.09 (6H, s), 1.88-1.79 (2H, m), 1.60-1.51 (2H, m).

MS: ESI 385 (M+1)

(iv) Isopropyl

2-{3-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl){2-[dimethylamino]ethyl}amino)methyl]phenoxy}acetate

To a solution of the product of step (iii) (187 mg, 0.424 mmol) in THF (5ml) were added isopropyl 2-(3-formylphenoxy)acetate (292.4 mg, 1.32 mmol), acetic acid (48 ul, 0.839 mmol) and NaBH(OAc)₃ (273 mg, 1.29 mmol) at room temperature. After stirring for 5 days at the same temperature, the reaction mixture was quenched by satd. NaHCO₃ aq. (50 ml) and extracted with CHCl₃ (50 ml x 2). The

combined organic layers were dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography to afford the title compound (57.6 mg, 28%) as a colorless gum.


¹H NMR δ (DMSO-d₆) 8.03 (1H, d, J = 7.8), 7.60 (1H, d, J = 7.8), 7.41 (1H, dd, J = 7.2, 7.6), 7.25 (1H, dd, J = 7.2, 8.0), 7.15 (1H, dd, J = 7.8, 7.9), 6.87-6.79 (2H, m), 6.74 (1H, dd, J = 2.2, 7.9), 6.47 (2H, s), 4.93 (1H, sep, J = 6.1), 4.62 (2H, s), 4.51 (2H, t, J = 7.9), 3.82 (2H, t, J = 6.7), 3.50 (2H, s), 3.28 (3H, s), 3.17 (2H, t, J = 6.7), 2.48-2.39 (4H, m), 2.27-2.21 (2H, m), 2.03 (6H, s), 1.88-1.77 (2H, m), 1.65-1.54 (2H, m), 1.15 (6H, d, J = 6.1).

MS: ESI 591 (M+1).

Example 133

Isopropyl

2-{3-[[{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}{3-morpholinopropyl}amino)methyl]phenoxy}acetate



(i) *N*-{4-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-*N*-(3-morpholinopropyl)-2-nitrobenzenesulfonamide

The subtitle compound (421 mg) was prepared by the same procedure of example 131 step (ii) using the product of example 131 step (i) (1.17 g). Yield: ~100%

(ii) 2-(2-Methoxyethyl)-1-[4-(3-morpholinopropylamino)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine

The subtitle compound (421 mg) was prepared by the same procedure of example 131 step (iii) using the product of step (i) (1.17 g). Yield: 68%

¹H NMR δ (DMSO-d₆) 8.07 (1H, d, J = 8.0), 7.60 (1H, d, J = 7.9), 7.45-7.39 (1H, m), 7.28-7.22 (1H, m), 6.48 (2H, brs), 4.54 (2H, t, J = 7.3), 3.83 (2H, t, J = 6.8), 3.55-3.48 (4H, m), 3.30 (3H, s), 3.19 (2H, t, J = 6.8), 2.32-2.20 (6H, m), 1.90-1.80 (2H, m), 1.60-1.58 (4H, m).

MS: ESI 441 (M+1).

(iii) Isopropyl

2-{3-[[[4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl]{3-morpholinopropyl}amino)methyl]phenoxy}acetate

5 The title compound (99.0 mg) was synthesized by the same procedure of example 131 step (iv) using the product from step (ii) (187 mg). Yield: 36%


¹H NMR δ (DMSO-*d*₆) 8.03 (1H, d, *J* = 8.0), 7.60 (1H, d, *J* = 8.0), 7.41 (1H, dd, *J* = 7.4, 8.0), 7.23 (1H, dd, *J* = 7.3, 7.4), 7.15 (1H, dd, 7.8, 8.0), 6.85-6.79 (2H, m), 6.75-6.71 (1H, m), 6.47 (2H, brs), 4.98-4.88 (1H, m), 4.62 (2H, s), 4.51 (2H, t, *J* = 7.3), 3.82 (2H, t, *J* = 6.7), 3.50-3.42 (6H, m), 3.35-3.22 (2H, m), 3.28 (3H, s), 3.17 (2H, t, *J* = 6.7), 2.44-2.37 (2H, m), 2.37-2.30 (2H, m), 2.23-2.10 (6H, m), 1.87-1.76 (2H, m), 1.63-1.55 (2H, m), 1.55-1.44 (2H, m), 1.15 (6H, d, *J* = 6.2).

MS: ESI 647 (M+1).

15 Example 134

Ethyl

2-{3-[[[4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl]{2-(dimethylamino)ethyl}amino)methyl]phenoxy}-2-methylpropanoate



20 The title compound (132 mg) was synthesized by the same procedure of example 132 step (iv) using the product of example 132 step (iii) (149 mg) and example 53 step (i). Yield: 56%


¹H NMR δ (DMSO-*d*₆) 8.02 (1H, d, *J* = 7.9), 7.60 (1H, dd, *J* = 1.0, 8.3), 7.41 (1H, dd, 7.1, 7.2), 7.23 (1H, ddd, *J* = 1.0, 7.1, 8.0), 7.13 (1H, dd, *J* = 7.8, 7.9), 6.84 (1H, d, *J* = 7.6), 6.72 (1H, m), 6.62 (1H, dd, *J* = 2.0, 8.0), 6.47 (2H, s), 4.51 (2H, t, *J* = 7.4), 4.08 (2H, q, *J* = 7.1), 3.82 (2H, t, *J* = 6.8), 3.48 (2H, s), 3.28 (3H, s), 3.17 (2H, t, 6.8), 2.47-2.38 (4H, m), 2.26-2.21 (2H, m), 2.03 (6H, s), 1.86-1.76 (2H, m), 1.65-1.56 (2H, m), 1.43 (6H, s), 1.10 (3H, t, *J* = 7.1).

MS: ESI 605 (M+1).

Example 135

Methyl

2-{3-[[{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}{2-(dimethylamino)ethyl}amino)methyl]phenoxy}-2-methylpropanoate



(i) 2-{3-[[{4-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}{2-(dimethylamino)ethyl}amino)methyl]phenoxy}-2-methylpropanoic acid

To a solution of the product of example 134 (118 mg, 0.195 mmol) in THF (3 ml) was added 1N NaOH (1 ml) at 0°C. After stirring at 60°C for 8 h, the reaction mixture was neutralized by 1N HCl (1 ml), diluted with brine (10 ml) and extracted with CHCl₃-EtOH (3:1, 15 ml x3). The combined extracts were dried over Na₂SO₄ and concentrated to give the subtitile compound (116 mg, ~100%) as a white solid.

(ii) Methyl

2-{3-[[{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}{2-(dimethylamino)ethyl}amino)methyl]phenoxy}-2-methylpropanoate

To a solution of the product of step (i) (115 mg, 0.200 mmol) in MeOH (5 ml) was added conc. sulfuric acid (5 drops) at 0°C. After stirring at 60°C for 8 h, the reaction mixture was quenched by satd. NaHCO₃ aq. (20 ml) and extracted with CHCl₃ (30 ml x2). The combined extracts were dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography to afford the title compound (34.9 mg, 30%) as a colorless gum.


¹H NMR δ (DMSO-*d*₆) 8.03 (1H, d, *J* = 7.7), 7.61 (1H, dd, *J* = 1.1, 8.3), 7.44-7.39 (1H, m), 7.25-7.21 (1H, m), 7.13 (1H, t, *J* = 7.8), 6.85 (1H, d, *J* = 7.6), 6.71 (1H, m), 6.60 (1H, dd, 2.0, 8.1), 6.48 (2H, brs), 4.51 (2H, t, *J* = 7.5), 3.82 (2H, t, *J* = 6.8), 3.63 (3H, s), 3.48 (2H, s), 3.48 (2H, s), 3.28 (3H, s), 3.17 (2H, t, *J* = 6.7), 2.47-2.38 (4H, m), 2.27-2.21 (2H, m), 2.03 (6H, s), 1.86-1.76 (2H, m), 1.64-1.54 (2H, m), 1.43 (6H, s).

MS: ESI 591 (M+1).

Example 136

Ethyl

- 5 2-{3-[[{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}{3-morpholinopropyl}amino)methyl]phenoxy}-2-methylpropanoate



The title compound (175 mg) was synthesized by the same procedure of example 131 step (iv) using the product of example 133 step (ii). Yield: 52%


- 10 ¹H NMR δ (DMSO-*d*₆) 8.02 (1H, d, *J* = 7.9), 7.61 (1H, dd, *J* = 0.1, 8.3), 7.43-7.39 (1H, m), 7.27-7.21 (1H, m), 7.12 (1H, dd, *J* = 7.8, 7.9), 6.82 (1H, d, *J* = 7.5), 6.73-6.69 (1H, m), 6.61 (1H, dd, 2.1, 7.9), 6.50 (2H, brs), 4.51 (2H, t, *J* = 7.5), 4.08 (2H, q, *J* = 7.1), 3.82 (2H, t, *J* = 6.8), 3.49-3.41 (6H, m), 3.28 (3H, s), 3.17 (2H, t, *J* = 6.8), 2.39 (2H, t, *J* = 6.5), 2.34 (2H, t, *J* = 6.8), 2.23-2.11 (6H, m), 1.86-1.75 (2H, m), 1.64-1.53 (2H, m), 1.53-1.45 (2H, m), 1.44 (6H, s), 1.10 (3H, t, *J* = 7.1).

MS: ESI 661 (M+1).

Example 137

Methyl

- 20 2-{3-[[{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}{3-morpholinopropyl}amino)methyl]phenoxy}-2-methylpropanoate



- (i) 2-{3-[[{4-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}{3-morpholinopropyl}amino)methyl]phenoxy}-2-methylpropanoic acid

- 25 The subtitle compound (149 mg) was prepared by the same procedure of example 26 step (i) using product of example 136 (159 mg). Yield: 98%

(ii) Methyl

2-{3-[[{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}{3-morpholinopropyl}amino)methyl]phenoxy}-2-methylpropanoate


5 The title compound (102 mg) was synthesized by the same procedure of example 26 step (ii) using the product from step (i) (138 mg). Yield: 72%

¹H NMR δ (DMSO-*d*₆) 8.02 (1H, d, *J* = 8.0), 7.60 (1H, dd, *J* = 1.0 8.3), 7.43-7.39 (1H, m), 7.25-7.21 (1H, m), 7.12 (1H, dd, *J* = 7.8, 7.9), 6.83 (1H, d, *J* = 7.8), 6.70 (1H, m), 6.60 (1H, dd, 2.0, 7.8), 6.48 (2H, brs), 4.51 (2H, t, *J* = 7.2), 3.82 (2H, t, *J* = 6.8), 3.62 (3H, s), 3.50-3.42 (6H, m), 3.28 (3H, s), 3.17 (2H, t, *J* = 6.7), 2.42-2.30 (4H, m), 2.23-2.12 (6H, m), 1.87-1.66 (2H, m), 1.65-1.55 (2H, m), 1.55-1.45 (2H, m), 1.44 (6H, s). MS: ESI 647 (*M*+1).

Example 138

15 Isopropyl

2-[5-({4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butylamino}methyl)-2-fluorophenoxy]acetate



20 By the method of example 1 step (viii) using the product from example 42 step (vi) (0.66 g, 2.10 mmol) and example 116 step (iii) (0.50 g, 2.10 mmol) there was obtained the title compound, 0.76 g (1.41 mmol, 67%) as yellow oil.


¹H NMR δ (CDCl₃) 7.97 (1H, d, *J* = 8.1 Hz), 7.82 (1H, d, *J* = 8.3 Hz), 7.53-7.49 (1H, m), 7.33-7.28 (1H, m), 7.06-6.98 (1H, m), 6.93-6.85 (2H, m), 5.45 (2H, brs), 5.13-5.05 (1H, m), 4.63 (2H, s), 4.53 (2H, t, *J* = 7.8 Hz), 3.90 (2H, d, *J* = 6.6 Hz), 3.70 (2H, s), 3.38 (3H, s), 3.17 (2H, t, *J* = 8.3 Hz), 2.67 (2H, t, *J* = 7.0 Hz), 2.04-1.95 (2H, m), 1.71-1.63 (2H, m), 1.24 (6H, d, *J* = 6.3 Hz).

MS:ESI 538 (*M*+1)

Example 139

Isopropyl

2-{5-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetate




- 5 The title compound was prepared by the method of example 125 step (iii) using the product from example 138 (0.39 g) to give a colorless gum (0.19 g). Yield 39%. ¹H NMR δ (CDCl₃) 7.91 (1H, d, J = 7.8 Hz), 7.82 (1H, d, J = 8.4 Hz), 7.53-7.49 (1H, m), 7.36-7.30 (1H, m), 7.06-6.99 (1H, m), 6.83-6.77 (2H, m), 5.52 (2H, brs), 5.09 (1H, hept, J = 6.3 Hz), 4.62 (2H, s), 4.54 (2H, t, J = 7.6 Hz), 4.36 (2H, s), 3.89 (2H, t, J = 6.4 Hz), 3.38-3.30 (7H, m), 3.17 (2H, t, J = 6.4 Hz), 2.55-2.42 (5H, m), 2.00-1.60 (11H, m), 1.60-1.30 (7H, m), 1.25 (6H, d, J = 6.3 Hz).
- 10 MS:ESI 692 (M+1)

Example 140

15 Ethyl

2-{5-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetate



(i)

- 20 2-{5-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 139 (0.13 g), to give a white solid (0.10 g). Yield 86%.

- ¹H NMR δ (DMSO-*d*₆) 7.92 (1H, d, J = 8.0 Hz), 7.59 (1H, d, J = 7.6 Hz), 7.42 (1H, dd, J = 7.4 Hz, 7.3 Hz), 7.27-7.22 (1H, m), 7.13-7.06 (1H, m), 7.07 (2H, brs),
- 25

6.85-6.82 (1H, m), 6.74-6.70 (1H, m), 6.54-6.48 (1H, brt), 4.47 (2H, t, J = 7.1 Hz), 4.37 (2H, s), 4.35 (2H, s), 3.80 (2H, t, J = 6.7 Hz), 3.30-3.25 (4H, m), 3.21 (2H, t, J = 7.0 Hz), 3.14 (2H, t, J = 6.7 Hz), 3.02-2.80 (7H, m), 1.75-1.63 (8H, m), 1.51-1.40 (2H, m).

5 MS:ESI 650 (M+1)

(ii) Ethyl

2-{5-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetate

10 The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.042 g) and ethanol, to give a pale yellow gum (0.036 g). Yield 85%.

¹H NMR δ (CDCl₃) 7.91 (1H, d, J = 8.2 Hz), 7.82 (1H, dd, J = 8.4 Hz, 1.0 Hz), 7.53-7.48 (1H, m), 7.35-7.31 (1H, m), 7.05-6.99 (1H, m), 6.83-6.78 (2H, m), 5.70-5.42 (3H, m), 4.65 (2H, s), 4.53 (2H, t, J = 7.6 Hz), 4.35 (2H, s), 4.24 (2H, q, J = 7.1 Hz), 3.88 (2H, t, J = 6.5 Hz), 3.38-3.30 (7H, m), 3.17 (2H, t, J = 6.5 Hz), 2.50-2.30 (6H, m), 2.00-1.88 (2H, m), 1.75-1.60 (2H, m), 1.70-1.35 (6H, m), 1.28 (3H, t, J = 7.1 Hz).


MS:ESI 678 (M+1)

20

Example 141

Methyl

2-{5-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetate



The title compound was prepared by the method of example 26 step (ii) using the product from example 140 step (i) (0.040 g) and methanol, to give a pale yellow gum (0.037 g). Yield 90%.

¹H NMR δ (CDCl₃) 7.91 (1H, dd, J = 8.2 Hz, 0.9 Hz), 7.82 (1H, dd, J = 8.4 Hz, 1.0 Hz), 7.51-7.47 (1H, m), 7.34-7.30 (1H, m), 7.03-6.99 (1H, m), 6.83-6.78 (2H, m),

30


5.44 (2H, brs), 4.67 (2H, s), 4.53 (2H, t, $J = 7.6$ Hz), 4.34 (2H, s), 3.88 (2H, t, $J = 6.5$ Hz), 3.78 (3H, s), 3.38-3.31 (5H, m), 3.30-3.27 (2H, m), 3.17 (2H, t, $J = 6.5$ Hz), 2.48-2.30 (6H, m), 1.98-1.87 (2H, m), 1.76-1.67 (2H, m), 1.72-1.25 (6H, m).

MS:ESI 664 ($M+1$)

Example 142

Isopropyl

2-{5-[(3-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetate



(i) Isopropyl 2-(2-fluoro-5-{[2-(piperidin-1-yl)ethylamino]methyl}phenoxy)acetate

By the method of example 22 step (i) using 2-(piperidin-1-yl)ethanamine (0.31 ml, 2.19 mmol) and the product from example 116 step (iii) (0.46 g, 1.91 mmol) there was obtained the title compound, 0.57 g (1.61 mmol, 84%) as yellow oil.

^1H NMR δ (CDCl_3) 7.06-7.00 (1H, m), 6.95-6.86 (2H, m), 7.30-7.24 (1H, m), 5.14 (1H, hept, $J = 6.3$ Hz), 4.67 (2H, s), 3.73 (2H, s), 2.67 (2H, t, $J = 6.2$ Hz), 2.45 (2H, t, $J = 6.2$ Hz), 2.40-2.31 (4H, m), 1.60-1.54 (4H, m), 1.50-1.38 (2H, m), 1.28 (6H, d, $J = 6.3$ Hz).

(ii) Isopropyl

2-{5-[(3-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetate

The title compound was prepared by the method of example 22 step (ii) using the product from step (i) (0.57 g) to give a pale yellow gum (0.69 g). Yield 78%.


^1H NMR δ (CDCl_3) 8.12 (1H, brs), 7.95 (1H, d, $J = 7.5$ Hz), 7.83 (1H, d, $J = 8.2$ Hz), 7.49 (1H, dd, $J = 7.2$ Hz, 7.1 Hz), 7.31-7.25 (1H, m), 7.03-6.96 (1H, m), 6.89-6.85 (1H, m), 6.85-6.77 (1H, m), 5.47 (2H, brs), 5.11 (1H, hept, $J = 6.3$ Hz), 4.63 (2H, s), 4.56 (2H, t, $J = 7.7$ Hz), 4.39 (2H, s), 3.89 (2H, t, $J = 6.5$ Hz), 3.38 (3H, s), 3.29-3.22 (2H, m), 3.21 (2H, t, $J = 6.5$ Hz), 3.05-3.00 (2H, m), 2.30-2.20 (6H, m),

2.05-1.94 (2H, m), 1.75-1.65 (2H, m), 1.40-1.30 (6H, m), 1.26 (6H, d, J = 6.3 Hz).
MS:ESI 692 (M+1)

Example 143

5 Ethyl

2-{5-[(3-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetate



(i)

10 2-{5-[(3-{4-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 142 (0.52 g), to give a white solid (0.42 g). Yield 87%.

15 ¹H NMR δ (DMSO-*d*₆) 7.94 (1H, d, J = 8.2 Hz), 7.60 (1H, d, J = 7.7 Hz), 7.50 (2H, brs), 7.41 (1H, dd, J = 7.5 Hz, 7.5 Hz), 7.22 (1H, dd, J = 7.3 Hz, 7.3 Hz), 7.09-7.02 (1H, m), 7.00 (1H, brt), 6.87 (1H, d, J = 8.3 Hz), 6.87-6.64 (1H, m), 4.50 (2H, t, J = 7.3 Hz), 4.48 (2H, s), 4.28 (2H, s), 3.81 (2H, t, J = 6.7 Hz), 3.28 (3H, s), 3.17 (2H, t, J = 6.7 Hz), 3.12-3.04 (4H, m), 2.35-2.25 (6H, m), 1.79-1.70 (2H, m), 1.62-1.51 (2H, m), 1.43-1.35 (4H, m), 1.33-1.26 (2H, m).

20 MS:ESI 650 (M+1)

(ii) Ethyl

25 2-{5-[(3-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.19 g) and ethanol, to give a pale yellow gum (0.19 g). Yield 97%.

30 ¹H NMR δ (CDCl₃) 8.10 (1H, brs), 7.95 (1H, d, J = 7.5 Hz), 7.83 (1H, d, J = 8.2 Hz), 7.49 (1H, dd, J = 7.1 Hz, 7.1 Hz), 7.32-7.25 (1H, m), 7.04-6.96 (1H, m), 6.90-6.85 (1H, m), 6.85-6.77 (1H, m), 5.56 (2H, brs), 4.66 (2H, s), 4.56 (2H, t, J = 7.7 Hz),


4.39 (2H, s), 4.25 (2H, q, $J = 7.2$ Hz), 3.89 (2H, t, $J = 6.5$ Hz), 3.38 (3H, s), 3.29-3.22 (2H, m), 3.22 (2H, t, $J = 6.9$ Hz), 3.08-3.00 (2H, m), 2.30-2.20 (6H, m), 2.05-1.94 (2H, m), 1.75-1.65 (2H, m), 1.40-1.30 (6H, m), 1.29 (3H, t, $J = 7.2$ Hz).
MS:ESI 678 (M+1)

5

Example 144

Methyl

2-{5-[(3-{4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl}-1-{2-(piperidin-1-yl)ethyl}ureido)methyl]-2-fluorophenoxy}acetate



10

The title compound was prepared by the method of example 26 step (ii) using the product from example 143 step (i) (0.16 g) and methanol, to give a pale yellow gum (0.17 g). Yield 100%.

15

^1H NMR δ (CDCl_3) 8.10 (1H, brs), 7.96 (1H, d, $J = 7.7$ Hz), 7.82 (1H, d, $J = 7.6$ Hz), 7.50 (1H, dd, $J = 7.2$ Hz, 7.2 Hz), 7.32-7.25 (1H, m), 7.04-6.96 (1H, m), 6.90-6.85 (1H, m), 6.85-6.80 (1H, m), 5.57 (2H, brs), 4.66 (2H, s), 4.57 (2H, t, $J = 7.8$ Hz), 4.39 (2H, s), 3.89 (2H, t, $J = 6.5$ Hz), 3.79 (3H, s), 3.38 (3H, s), 3.29-3.22 (2H, m), 3.21 (2H, t, $J = 6.5$ Hz), 3.08-3.00 (2H, m), 2.30-2.20 (6H, m), 2.05-1.94 (2H, m), 1.75-1.65 (2H, m), 1.40-1.30 (6H, m).

20


MS:ESI 664 (M+1)

Example 145

Isopropyl

2-[3-[(3-{4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propylamino}methyl)-2-methylphenoxy]acetate

25



(i) Isopropyl 2-[3-(hydroxymethyl)-2-methylphenoxy]acetate

To a solution of 3-hydroxy-2-methylbenzyl alcohol (0.77 g, 5.59 mmol) in DMF (25 mL), K_2CO_3 (1.2 g, 3.39 mmol) and Isopropyl bromoacetate (0.80 mL, 6.15 mmol) were added. After being stirred at rt overnight, the reaction mixture was diluted with EtOAc and H_2O was added to the mixture. The resulting mixture was extracted with EtOAc (x3). The combined extracts were washed with brine, dried over Na_2SO_4 and concentrated in vacuo. The residue was purified by flash column chromatography to afford the title compound (1.3 g, 95%) as colorless oil.

^1H NMR δ ($CDCl_3$) 7.14 (1H, t, $J = 7.9$ Hz), 7.03 (1H, d, $J = 7.9$ Hz), 6.69 (1H, d, $J = 7.9$ Hz), 5.13 (1H, quint, $J = 6.3$ Hz), 4.70 (2H, s), 4.60 (2H, s), 2.29 (3H, s), 1.27 (6H, d, $J = 6.3$ Hz)

ESI-MS $[M-H_2O+H]^+$: 221.12

(ii)

N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-nitrobenzenesulfonamide

The title compound was prepared by the same method of example 21 step (i) using the material from example 15 step (iv) (1.07 g, 3.57 mmol) to afford titled compound as a pale yellow solid. 1.32 g, 2.74 mmol, 77%.

^1H NMR δ ($CDCl_3$) ^1H NMR δ ($CDCl_3$) 8.07 (1H, d, $J = 7.5$ Hz), 7.93 (1H, d, $J = 7.5$ Hz), 7.85-7.79 (2H, m), 7.70-7.64 (2H, m), 7.55-7.49 (1H, m), 7.38-7.30 (1H, m), 5.62 (2H, brs), 4.67 (2H, t, $J = 7.3$ Hz), 3.95 (2H, t, $J = 5.9$ Hz), 3.38 (3H, s), 3.21 (2H, t, $J = 5.9$ Hz), 2.28-2.18 (2H, m), 1.72-1.65 (2H, m).

(iii) Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-nitrophenylsulfonamido)methyl]-2-methylphenoxy}acetate

By the method of example 21 step (ii) using the product from step (i) (0.44 g, 1.86 mmol) and the product from step (ii) (0.60 g, 1.24 mmol), to give the title

compound as pale yellow amorphousness (0.69 g, 79%)

^1H NMR δ (CDCl_3) 7.85-7.81 (2H, m), 7.73-7.71 (1H, m), 7.61-7.56 (4H, m), 7.32-7.29 (1H, m), 6.87 (1H, t, $J = 8.0$ Hz), 6.71 (1H, d, $J = 7.5$ Hz), 6.51 (1H, d, $J = 8.0$ Hz), 5.62 (2H, brs), 5.08 (1H, quint, $J = 6.3$ Hz), 4.50 (2H, s), 4.49 (2H, s), 4.36 (2H, t, $J = 7.4$ Hz), 3.84 (2H, t, $J = 6.3$ Hz), 3.39-3.34 (5H, m), 3.04 (2H, t, $J = 6.3$ Hz), 2.17 (3H, s), 1.96 (2H, q, $J = 7.4$ Hz), 1.28-1.25 (6H, m)

ESI-MS $[\text{M}+\text{H}]^+$: 705

(iv) Isopropyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)-2-methylphenoxy]acetate


By the method of example 22 step (iii) using the product from step (iv) (0.69 g, 0.972 mmol), to give the title compound as a yellow gum (0.40 g, 80%).

ESI-MS $[\text{M}+\text{H}]^+$: 520

Example 146

Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-2-methylphenoxy}acetate hydrochloride



By the method of example 2 using the product of example 145 (0.40 g, 0.770 mmol), there was obtained the title compound (0.23 g, 48%) as a pale yellow gum.


^1H NMR δ (CDCl_3) 7.95 (1H, d, $J = 7.9$ Hz), 7.87 (1H, d, $J = 8.2$ Hz), 7.57-7.53 (1H, m), 7.40-7.37 (1H, m), 7.10 (1H, t, $J = 8.1$ Hz), 6.66-6.61 (2H, m), 5.13 (1H, quint, $J = 6.3$ Hz), 5.17-5.10 (5.7H, m), 4.48-4.44 (0.3H, m), 4.08 (0.5H, s), 4.05 (1.5H, s), 3.89-3.84 (2H, m), 3.62 (2H, t, $J = 6.7$ Hz), 3.40 (3H, s), 3.17 (1.7H, t, $J = 6.3$ Hz), 3.08 (0.3H, t, $J = 6.3$ Hz), 2.20-2.14 (5H, m), 1.29-1.28 (6H, m)

ESI-MS $[\text{M}+\text{H}]^+$: 596

Example 147

Isopropyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-methylphenoxy}acetate



- 5 By the method of example 5 using the product of example 146 (0.23 g, 0.367 mmol) and diethylamine (0.38 mL, 3.67 mmol), to give the title compound as a pale yellow gum (0.17 g, 75%).


¹H NMR δ (CDCl₃) 7.94 (0.8H, d, *J* = 7.6 Hz), 7.87-7.81 (1.2H, m), 7.55-7.52 (1H, m), 7.39-7.36 (1H, m), 7.08 (0.8H, t, *J* = 8.0 Hz), 6.99 (0.2H, t, *J* = 8.0 Hz),
 10 6.67-6.62 (2H, m), 5.81-5.65 (2H, m), 5.14 (1H, quint, *J* = 6.3 Hz), 4.78 (1.6H, s), 4.64 (0.4H, s), 4.59-4.57 (2H, m), 4.54-4.50 (1.6H, m), 4.46-4.42 (0.4H, m), 3.89-3.83 (2H, m), 3.58 (2H, t, *J* = 6.9 Hz), 3.36 (2.4H, s), 3.34 (0.6H, s), 3.28 (0.4H, s), 3.16 (1.6H, t, *J* = 6.3 Hz), 3.09 (0.4H, t, *J* = 6.3 Hz), 2.61-2.53 (4H, m), 2.18-2.09 (5H, m), 1.03-0.95 (6H, m)

15 ESI-MS [M+2H]²⁺: 317

Example 148

Ethyl

20 2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate



The title compound was prepared by the method of example 5 using the product from example 54 (0.39 g) and dimethylamine, to give a colorless gum (0.31 g). Yield 84%.

25 ¹H NMR δ (CDCl₃) 7.91 (0.75H, d, *J* = 7.7 Hz), 7.83 (0.25H, d, *J* = 8.0 Hz), 7.81 (1H, d, *J* = 7.5 Hz), 7.54-7.49 (1H, m), 7.36-7.31 (1H, m), 7.21-7.16 (1H, m), 6.80-6.69 (3H, m), 5.53 (2H, brs), 4.70 (1.5H, s), 4.56 (0.5H, s), 4.53-4.46 (2H, m), 4.21 (2H,


q, $J = 7.1$ Hz), 3.86 (2H, t, $J = 6.4$ Hz), 3.55 (1.5H, t, $J = 6.8$ Hz), 3.50-3.46 (0.5H, m), 3.35 (2.25H, s), 3.34 (0.75 H, s), 3.20-3.13 (3H, m), 3.09 (0.5 H, t, $J = 6.3$ Hz), 3.05 (0.5 H, s), 2.50-2.35 (2H, m), 2.31 (4.5 H, s), 2.30-2.22 (0.5 H, m), 2.13-2.05 (3H, m), 1.57 (6H, s), 1.25-1.21 (3H, m)

5 MS:ESI 605 (M+1)

Example 149

Methyl

10 2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate



(i)

2-{3-[(*N*-{3-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]phenoxy}-2-methylpropanoic acid

15 The title compound was prepared by the method of example 26 step (i) using the product from example 148 (0.18g), to give a white solid (0.17 g). Yield 98%.

^1H NMR δ (DMSO- d_6) 7.95-7.86 (1H, m), 7.62-7.59 (1H, m), 7.44 (1H, dd, $J = 8.0$ Hz, 7.2 Hz), 7.24 (2H, brs), 7.24-7.21 (1H, m), 7.20-7.15 (1H, m), 6.79-6.66 (3H, m), 4.62 (1H, s), 4.47 (1H, t, $J = 7.4$ Hz), 4.44 (1H, s), 4.37 (1H, t, $J = 7.5$ Hz),
20 3.81-3.75 (2H, m), 3.47-3.41 (2H, m), 3.27 (3H, s), 3.17-3.09 (4H, m), 2.23 (3H, s), 2.08 (3H, s), 2.10-2.02 (1H, m), 1.95-1.86 (1H, m), 1.49 (3H, s), 1.47 (3H, s).

MS:ESI 577 (M+1)

(ii) Methyl

25 2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.14 g) and MeOH, to give a colorless gum (0.12 g). Yield 85%.

30 ^1H NMR δ (CDCl $_3$) 7.92 (0.75H, d, $J = 7.8$ Hz), 7.88 (0.25H, d, $J = 8.3$ Hz), 7.83 (1H, d, $J = 8.3$ Hz), 7.55-7.49 (1H, m), 7.38-7.32 (1H, m), 7.22-7.16 (1H, m), 6.83-6.67 (3H, m), 5.56 (1.5H, brs), 5.50 (0.5H, brs), 4.71 (1.5H, s), 4.57 (0.5H, s), 4.54-4.48


(2H, m), 3.87 (2H, t, J = 6.3 Hz), 3.75 (3H, s), 3.56 (1.5H, t, J = 6.8 Hz), 3.50-3.46 (0.5H, m), 3.36 (2.25H, s), 3.35 (0.75 H, s), 3.18-3.15 (3H, m), 3.08 (0.5 H, t, J = 7.4 Hz), 3.06 (0.5 H, s), 2.31 (4.5 H, s), 2.30-2.22 (0.5H, m), 2.13-2.03 (3H, m), 1.57 (6H, s).

5 MS:ESI 591 (M+1)

Example 150

Ethyl

10 2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-{ethyl(methyl)amino}acetamido)methyl]phenoxy}-2-methylpropanoate



The title compound was prepared by the method of example 5 using the product from example 54 (0.40 g) and ethylmethylamine, to give a colorless gum (0.34 g). Yield 88%.


15 ¹H NMR δ (CDCl₃) 7.92 (0.75H, d, J = 7.8 Hz), 7.86 (0.25H, d, J = 8.0 Hz), 7.83 (1H, d, J = 8.4 Hz), 7.55-7.50 (1H, m), 7.38-7.33 (1H, m), 7.21-7.16 (1H, m), 6.80-6.69 (3H, m), 5.54 (1.5H, brs), 5.50 (0.5H, brs), 4.74 (1.5H, s), 4.57 (0.5H, s), 4.53-4.47 (2H, m), 4.21 (2H, q, J = 7.1 Hz), 3.87 (2H, t, J = 6.4 Hz), 3.58-3.50 (2H, m), 3.36 (2.25H, s), 3.34 (0.75H, s), 3.20 (1.5H, s), 3.18-3.07 (2.5H, m), 2.47 (1.5H, q, J = 7.1 Hz), 2.40-2.32 (0.5H, m), 2.29 (2.25 H, s), 2.28-2.06 (2.75 H, m), 1.58 (6H, s), 1.26-1.22 (3H, m), 1.06-0.96 (3H, m).

20 MS:ESI 619 (M+1)

Example 151

Methyl

25 2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-{ethyl(methyl)amino}acetamido)methyl]phenoxy}-2-methylpropanoate



(i)

2-{3-[(*N*-{3-[4-Amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]phenoxy}-2-methylpropanoic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 150 (0.24 g), to give a white solid (0.21 g). Yield 97%.

¹H NMR δ (DMSO-*d*₆) 7.96-7.88 (1H, m), 7.62-7.58 (1H, m), 7.43 (1H, dd, *J* = 7.5 Hz, 7.4 Hz), 7.26-7.11 (2H, m), 6.98 (2H, brs), 6.77-6.67 (3H, m), 4.67 (1H, s), 4.47 (1H, t, *J* = 7.0 Hz), 4.43 (1H, s), 4.38 (1H, t, *J* = 8.0 Hz), 3.82-3.75 (2H, m), 3.47-3.40 (2H, m), 3.27 (3H, s), 3.15-3.08 (4H, m), 2.40 (1H, q, *J* = 7.1 Hz), 2.27 (1H, q, *J* = 7.1 Hz), 2.17 (1.5H, s), 2.10-2.05 (1H, m), 2.07 (1.5H, s), 1.98-1.90 (1H, m), 1.46 (3H, s), 1.45 (3H, s), 0.91 (1.5H, t, *J* = 7.1 Hz), 0.83 (1.5H, t, *J* = 7.2 Hz). MS:ESI 577 (M+1)

(ii) Methyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{ethyl(methyl)amino}acetamido)methyl]phenoxy}-2-methylpropanoate


The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.16 g) and MeOH, to give a colorless gum (0.15 g). Yield 74%.

¹H NMR δ (CDCl₃) 7.92 (0.75H, d, *J* = 8.1Hz), 7.86 (0.25H, d, *J* = 8.0 Hz), 7.83 (1H, d, *J* = 8.3 Hz), 7.55-7.50 (1H, m), 7.38-7.33 (1H, m), 7.22-7.16 (1H, m), 6.82-6.66 (3H, m), 5.55 (1.5H, brs), 5.49 (0.5H, brs), 4.74 (1.5H, s), 4.57 (0.5H, s), 4.53-4.47 (2H, m), 3.87 (2H, t, *J* = 6.4 Hz), 3.75 (3H, s), 3.58-3.54 (2H, m), 3.36 (2.25H, s), 3.34 (0.75H, s), 3.20 (1.5H, s), 3.18-3.08 (2.5H, m), 2.47 (1.5H, q, *J* = 7.1 Hz), 2.37 (0.5H, q, *J* = 7.1 Hz), 2.29 (2.25 H, s), 2.26-2.03 (2.75 H, m), 1.58 (6H, s), 1.03 (2.25H, t, *J* = 7.1 Hz), 0.97 (0.75H, t, *J* = 7.1 Hz).

Example 152

Isopropyl

2-(3-[[1-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy)acetate



(i) 2-[2-(3-Nitroquinolin-4-ylamino)ethoxy]ethanol

The title compound was prepared by the method of example 1 step (ii) using the product from example 1 step (i) (11.5 g) and 2-(2-aminoethoxy)ethanol, to give the title compound (6.14 g). Yield 84%. MS:ESI 278 (M+1)

(ii) 2-{2-[2-(3-Nitroquinolin-4-ylamino)ethoxy]ethyl}isoindoline-1,3-dione

To a solution of the product of step (i) (5.0 g, 18.1 mmol), triphenylphosphine (6.63 g, 25.3 mmol), and phthalimide (3.74 g, 25.4 mmol) in THF (100 ml) was added DIAD (13.3 ml, 1.9 M in THF, 25.3 mmol) at room temperature. After stirring for 45 min at the same temperature, the reaction mixture was concentrated. The residue was suspended in MeOH (150 ml) and filtered. The obtained solids were washed with MeOH to give the subtitle compound (6.30 g, 86%) as white solids. MS: ESI 407 (M+1)

(iii) 2-{2-[2-(3-Aminoquinolin-4-ylamino)ethoxy]ethyl}isoindoline-1,3-dione

The title compound was prepared by the method of example 1 step (iii) using the product from step (ii) (6.30 g), to give the title compound (4.91 g). Yield 84%. MS:ESI 377 (M+1)

(iv)

2-(2-{2-[2-(2-Methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy}ethyl)isoindoline-1,3-dione

The title compound was prepared by the method of example 15 step (i) using the product from step (iii) (4.78 g), to give the title compound (3.89 g). Yield 69%. MS:ESI 445 (M+1)

(v)

2-(2-{2-[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethoxy}ethyl)isoindoline-1,3-dione

The title compound was prepared by the method of example 1 step (v) and (vi)

using the product from step (iv) (3.89 g), to give the title compound (3.19 g). Yield 79%. MS:ESI 460 (M+1)

(vi) 1-[2-(2-aminoethoxy)ethyl]-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine

To a solution of the product from step (v) (3.03 g, 6.59 mmol) in EtOH (70 ml) was added hydrazine monohydrate (5 ml, 10.3 mmol) at room temperature. After stirring for 6 h at reflux temperature, the reaction mixture was concentrated. The residue was diluted with 20% K₂CO₃ aq. (200 ml) and extracted with CHCl₃-EtOH (3:1) (200 ml x 3). The combined organic layer was dried over Na₂SO₄ and concentrated to afford the crude of the title compound.

MS:ESI 330 (M+1)

(vii) Isopropyl

2-{3-[(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethylamino)methyl]phenoxy}acetate

The title compound was prepared by the method of example 1 step (viii) using the product from step (vi) (0.615 g), to give the title compound (0.212 g). Yield 32%. (by 2 steps) MS:ESI 536 (M+1)

(viii) Isopropyl

2-(3-{[1-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)-3-(2-{piperidin-1-yl}ethyl)ureido]methyl}phenoxy) acetate

The title compound was prepared by the method of example 125 step (iii) using the product from step (vii) (0.211 g), to give the title compound (0.159 g). Yield 59%.


¹H NMR δ (DMSO-*d*₆) 8.03 (1H, d, *J* = 8.1), 7.61 (1H, dd, *J* = 0.9, 8.3), 7.43-7.39 (1H, m), 7.25-7.19 (1H, m), 7.25-7.19 (1H, m), 7.16 (1H, t, *J* = 7.9), 6.74 (1H, dd, *J* = 2.2, 8.3), 6.68-6.61 (2H, m), 6.48 (2H, brs), 6.12-6.08 (1H, m), 5.20-4.90 (1H, m), 4.77-4.70 (2H, m), 4.67 (2H, s), 4.25 (2H, s), 3.85-3.79 (4H, m), 3.41-3.37 (2H, m), 3.27 (3H, s), 3.24-3.16 (4H, m), 3.11-3.02 (2H, m), 2.28-2.20 (6H, m), 1.43-1.35 (4H, m), 1.35-1.25 (2H, m), 1.19 (6H, d, *J* = 6.2).

MS: ESI 690 (M+1)

Example 153

Ethyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl}phenoxy)-2-methylpropanoate



5 (i) Ethyl

2-(3-{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylamino}methyl}phenoxy)-2-methylpropanoate

By the method of example 1 step (viii) using the product from example 1 step (vii) (0.30 g) and ethyl 2-(3-formylphenoxy)-2-methylpropanoate (0.24 g) there was obtained the title compound, 0.43 g (83%) as a white solid

¹H NMR δ (CDCl₃) 8.07 (1H, d, J = 8.2 Hz), 7.82 (1H, dd, J = 8.3 Hz, 0.9 Hz), 7.58-7.46 (1H, m), 7.32-7.26 (1H, m), 7.21 (1H, dd, J = 7.9 Hz, 7.8 Hz), 6.97 (1H, d, J = 7.5 Hz), 6.91-6.87 (1H, m), 6.72 (1H, dd, J = 8.1 Hz, 1.9 Hz), 5.55 (2H, brs), 4.61 (2H, t, J = 7.5 Hz), 4.23 (2H, q, J = 7.1 Hz), 3.77 (2H, s), 2.96 (2H, t, J = 7.9 Hz), 2.75 (2H, t, J = 6.2 Hz), 2.11-2.05 (2H, m), 1.90-1.82 (2H, m), 1.61 (6H, s), 1.55-1.45 (2H, m), 1.24 (3H, t, J = 7.1 Hz), 1.01 (3H, t, J = 7.4 Hz). MS:ESI 518 (M+1)

20 (ii) Ethyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-chloroacetamido)methyl}phenoxy)-2-methylpropanoate hydrochloride

By the method of example 2 using the product of step (i) (0.43 g), there was obtained the title compound, 0.50 g (96%) as colorless gum.

¹H NMR δ (CDCl₃) 7.92 (1H, d, J = 8.5 Hz), 7.60-7.55 (1H, m), 7.44 (1H, dd, J = 7.3 Hz, 7.1 Hz), 7.21 (1H, dd, J = 7.9 Hz, 7.8 Hz), 6.77-6.68 (4H, m), 4.61 (1.5H, s), 4.55 (0.5H, s), 4.52-4.47 (2H, m), 4.22 (2H, q, J = 7.1 Hz), 4.11 (1.5H, s), 4.09 (0.5H, s), 3.61 (1.5H, t, J = 6.6 Hz), 3.60-3.50 (0.5H, m), 2.88 (2H, t, J = 7.8 Hz), 2.30-2.20 (0.5H, m), 2.15-2.07 (1.5H, m), 1.89-1.80 (2H, m), 1.59 (4.5H, s), 1.54 (1.5H, s), 1.53-1.47 (2H, m), 1.24 (3H, t, J = 7.1 Hz), 1.01 (3H, t, J = 7.4 Hz). MS:ESI 595 (M+1)

(iii) Ethyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl}phenoxy)-2-methylpropanoate


5 The title compound was prepared by the method of example 5 using the product from step (ii) (0.26 g) to give a colorless gum (0.22 g). Yield 87%.

¹H NMR δ (CDCl₃) 7.89 (0.75H, d, J = 7.7 Hz), 7.82 (1.25H, d, J = 7.9 Hz), 7.54-7.49 (1H, m), 7.36-7.31 (1H, m), 7.20-7.13 (1H, m), 6.80-6.69 (3H, m), 5.51 (2H, brs), 4.75 (1.5H, s), 4.56 (0.5H, s), 4.46-4.42 (2H, m), 4.21 (2H, q, J = 7.1 Hz),
10 3.55 (2H, t, J = 6.8 Hz), 3.29 (1.5H, s), 3.24 (0.5 H, s), 2.89-2.80 (2H, m), 2.60 (3H, q, J = 7.1 Hz), 2.57-2.50 (1H, m), 2.30-2.22 (0.5 H, m), 2.19-2.00 (1.5H, m), 1.95-1.80 (2H, m), 1.57 (6H, s), 1.56-1.45 (2H, m), 1.26-1.21 (3H, m), 1.02-0.98 (9H, m). MS:ESI 631 (M+1)

15 Example 154

Methyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl}phenoxy)-2-methylpropanoate



20 (i) 2-[3-({N-[3-(4-Amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl}phenoxy)-2-methylpropanoic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 153 (0.20 g), to give a white solid (0.17 g). Yield 91%.

¹H NMR δ (DMSO-*d*₆) 7.92-7.87 (1H, m), 7.59 (1H, d, J = 8.4 Hz), 7.42 (1H, dd, J =
25 7.9 Hz, 7.4 Hz), 7.24-7.18 (2H, m), 7.18-7.00 (2H, m), 6.75-6.68 (3H, m), 4.68 (1H, s), 4.42-4.38 (2H, m), 4.35-4.30 (1H, m), 3.50 (1H, t, J = 7.3 Hz), 3.42 (1H, t, J = 7.1 Hz), 3.20 (2H, s), 2.85-2.79 (2H, m), 2.55-2.45 (1.5H, m), 2.41 (2.5H, q, J = 7.1 Hz), 2.15-2.03 (1H, m), 1.95-1.80 (1H, m), 1.79-1.70 (2H, m), 1.45-1.38 (8H, m), 0.94 (3H, t, J = 7.4 Hz), 0.89-0.82 (6H, m). MS:ESI 603 (M+1)

30

(ii) Methyl

2-[3-({*N*-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl]phenoxy]-2-methylpropanoate


The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.13 g) and methanol, to give a colorless gum (0.11 g). Yield 80%.

¹H NMR δ (CDCl₃) 7.89 (0.75H, d, *J* = 7.7 Hz), 7.83 (1.25H, d, *J* = 7.9 Hz), 7.54-7.49 (1H, m), 7.37-7.31 (1H, m), 7.20-7.14 (1H, m), 6.76-6.65 (3H, m), 5.50 (2H, brs), 4.76 (1.5H, s), 4.55 (0.5H, s), 4.47-4.40 (2H, m), 3.75 (3H, s), 3.55 (2H, t, *J* = 7.0 Hz), 3.29 (1.5H, s), 3.25 (0.5 H, s), 2.89-2.80 (2H, m), 2.60 (3H, q, *J* = 7.1 Hz), 2.57-2.50 (1H, m), 2.30-2.22 (0.5 H, m), 2.19-2.00 (1.5H, m), 1.95-1.80 (2H, m), 1.57 (6H, s), 1.56-1.45 (2H, m), 1.02-0.96 (9H, m). MS:ESI 617 (M+1)

Example 155

Ethyl

2-[3-({*N*-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(dimethylamino)acetamido)methyl]phenoxy]-2-methylpropanoate




The title compound was prepared by the method of example 5 using the product from example 153 step (ii) (0.25 g) to give a colorless gum (0.20 g). Yield 85%.

¹H NMR δ (CDCl₃) 7.92-7.82 (2H, m), 7.52 (1H, dd, *J* = 8.0 Hz, 7.3 Hz), 7.37-7.30 (1H, m), 7.20-7.14 (1H, m), 6.80-6.68 (3H, m), 5.51 (2H, brs), 4.70 (1.5H, s), 4.56 (0.5H, s), 4.48-4.42 (2H, m), 4.21 (2H, q, *J* = 7.1 Hz), 3.56 (1.5H, t, *J* = 6.7 Hz), 3.50-3.40 (0.5 H, m), 3.16 (1.5H, s), 3.03 (0.5 H, s), 2.90-2.84 (2H, m), 2.32 (4.5H, s), 2.28-2.20 (0.5 H, m), 2.10-2.00 (3H, m), 1.95-1.80 (2H, m), 1.58 (6H, s), 1.56-1.45 (2H, m), 1.26-1.20 (3H, m), 1.00 (3H, t, *J* = 7.3 Hz). MS:ESI 603 (M+1)

Example 156

Methyl

2-[3-({*N*-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(dimethylamino)acetamido)methyl]phenoxy]-2-methylpropanoate



(i)

2-[3-({N-[3-(4-Amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(dimethylamino)acetamido)methyl}phenoxy]-2-methylpropanoic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 155 (0.18 g), to give a white solid (0.15 g). Yield 89%.

¹H NMR δ (DMSO-*d*₆) 7.90-7.82 (1H, m), 7.59 (1H, d, *J* = 8.4 Hz), 7.43 (1H, dd, *J* = 7.8 Hz, 7.4 Hz), 7.24-7.12 (4H, m), 6.76-6.68 (3H, m), 4.61 (1H, s), 4.43-4.38 (2H, m), 4.30-4.26 (1H, m), 3.46-3.36 (2H, m), 3.09 (1H, s), 3.05 (1H, s), 2.83-2.77 (2H, m), 2.20 (3H, s), 2.04 (3H, s), 2.04-2.00 (1H, m), 1.90-1.80 (1H, m), 1.75-1.68 (2H, m), 1.49 (3H, s), 1.47 (3H, s), 1.45-1.37 (2H, m), 0.94 (3H, t, *J* = 7.3 Hz). MS:ESI 575 (M+1)

(ii) Methyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(dimethylamino)acetamido)methyl}phenoxy]-2-methylpropanoate


The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.12 g) and methanol, to give a colorless gum (0.11 g). Yield 92%.

¹H NMR δ (CDCl₃) 7.92-7.82 (2H, m), 7.52 (1H, dd, *J* = 8.0 Hz, 7.2 Hz), 7.37-7.30 (1H, m), 7.20-7.14 (1H, m), 6.77-6.66 (3H, m), 5.57 (2H, brs), 4.71 (1.5H, s), 4.56 (0.5H, s), 4.48-4.42 (2H, m), 3.75 (3H, s), 3.56 (1.5H, t, *J* = 6.8 Hz), 3.50-3.40 (0.5 H, m), 3.16 (1.5H, s), 3.04 (0.5 H, s), 2.90-2.82 (2H, m), 2.32 (4.5H, s), 2.28-2.20 (0.5 H, m), 2.10-2.00 (3H, m), 1.90-1.80 (2H, m), 1.58 (6H, s), 1.56-1.45 (2H, m), 1.00 (3H, t, *J* = 7.3 Hz). MS:ESI 589 (M+1)

Example 157

Isopropyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl}phenoxy]acetate



(i) Isopropyl

2-(3-[[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylamino]methyl]phenoxy)acetate

5 By the method of example 1 step (viii) using the product from example 1 step (vii) (0.50 g) and isopropyl 2-(3-formylphenoxy)acetate (0.37 g) there was obtained the title compound, 0.70 g (83%) as a white solid

¹H NMR δ (CDCl₃) 8.06 (1H, d, *J* = 7.7 Hz), 7.82 (1H, dd, *J* = 8.3 Hz, 0.8 Hz), 7.52-7.46 (1H, m), 7.32-7.24 (2H, m), 6.97 (1H, d, *J* = 7.6 Hz), 6.94 (1H, s), 6.80 (1H, dd, *J* = 8.2 Hz, 2.2 Hz), 5.48 (2H, brs), 5.17-5.08 (1H, m), 4.60 (2H, t, *J* = 7.5 Hz), 4.60 (2H, s), 3.80 (2H, s), 2.95 (2H, t, *J* = 7.9 Hz), 2.75 (2H, t, *J* = 6.3 Hz), 2.12-2.03 (2H, m), 1.90-1.82 (2H, m), 1.55-1.45 (2H, m), 1.26 (6H, d, *J* = 6.3 Hz), 1.00 (3H, t, *J* = 7.4 Hz). MS:ESI 504 (M+1)

15 (ii) Isopropyl

2-[3-({*N*-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-chloroacetamido)methyl]phenoxy]acetate

By the method of example 2 using the product of step (i) (0.61 g), there was obtained the title compound, 0.75 g (quant.) as colorless gum.

20 ¹H NMR δ (CDCl₃) 8.00 (1H, d, *J* = 8.3 Hz), 7.94 (1H, d, *J* = 8.1 Hz), 7.67-7.61 (1H, m), 7.54-7.49 (1H, m), 7.26-7.23 (1H, m), 6.80-6.77 (3H, m), 5.18-5.10 (1H, m), 4.64 (1.5H, s), 4.61 (2H, s), 4.58 (0.5H, s), 4.53-4.47 (2H, m), 4.14 (1.5H, s), 4.12 (0.5H, s), 3.61 (2H, t, *J* = 6.7 Hz), 2.88 (2H, t, *J* = 7.7 Hz), 2.30-2.20 (0.5H, m), 2.15-2.07 (2H, m), 1.93-1.83 (2.5H, m), 1.57-1.46 (2H, m), 1.29 (6H, d, *J* = 6.3 Hz), 1.03 (3H, t, *J* = 7.4 Hz). MS:ESI 581 (M+1)

(iii) Isopropyl

2-[3-({*N*-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl]phenoxy]acetate


30 The title compound was prepared by the method of example 5 using the product from step (ii) (0.25 g) to give a colorless gum (0.18 g). Yield 71%.

¹H NMR δ (CDCl₃) 7.87 (0.75H, d, J = 7.6 Hz), 7.83 (1.25H, d, J = 8.4 Hz), 7.54-7.49 (1H, m), 7.36-7.30 (1H, m), 7.21-7.15 (1H, m), 6.79-6.70 (3H, m), 5.55 (2H, brs), 5.17-5.08 (1H, m), 4.75 (1.5H, s), 4.56 (0.5H, s), 4.54 (2H, s), 4.46-4.40 (2H, m), 3.52 (2H, t, J = 7.0 Hz), 3.31 (1.5H, s), 3.25 (0.5 H, s), 2.88-2.80 (2H, m), 2.60 (3H, q, J = 7.1 Hz), 2.52 (1H, q, J = 7.2 Hz), 2.30-2.22 (0.5 H, m), 2.13-2.00 (1.5H, m), 1.90-1.80 (2H, m), 1.53-1.44 (2H, m), 1.27 (6H, d, J = 6.3 Hz), 1.02-0.96 (9H, m). MS:ESI 617 (M+1)

Example 158

Isopropyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-[ethyl(methyl)amino]acetamido)methyl}phenoxy]acetate




The title compound was prepared by the method of example 5 using the product from example 157 step (ii) (0.29 g) to give a colorless gum (0.21 g). Yield 74%.

¹H NMR δ (CDCl₃) 7.88 (0.75H, d, J = 7.9 Hz), 7.85 (1.25H, d, J = 8.4 Hz), 7.56-7.50 (1H, m), 7.37-7.30 (1H, m), 7.22-7.16 (1H, m), 6.80-6.70 (3H, m), 5.69 (2H, brs), 5.17-5.08 (1H, m), 4.73 (1.5H, s), 4.57 (0.5H, s), 4.54 (2H, s), 4.47-4.40 (2H, m), 3.54 (2H, t, J = 6.9 Hz), 3.22 (1.5H, s), 3.12 (0.5 H, s), 2.89-2.80 (2H, m), 2.50 (1.5H, q, J = 7.1 Hz), 2.42-2.32 (0.5H, m), 2.31 (2.25H, s), 2.30-2.22 (0.5 H, m), 2.15 (0.75H, s), 2.13-2.00 (1.5H, m), 1.90-1.80 (2H, m), 1.53-1.44 (2H, m), 1.27 (6H, d, J = 6.3 Hz), 1.05 (3H, t, J = 7.1 Hz), 1.00 (3H, t, J = 7.3 Hz). MS:ESI 603 (M+1)

Example 159

Isopropyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(dimethylamino)acetamido)methyl}phenoxy]acetate



(i)

2-[3-({*N*-[3-(4-Amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-[ethyl(methyl)amino]acetamido)methyl]phenoxy]acetic acid

5 The title compound was prepared by the method of example 26 step (i) using the product from example 158 (0.12 g), to give a white solid (0.11 g). Yield 98%.

¹H NMR δ (DMSO-*d*₆) 7.96-7.88 (1H, m), 7.57 (1H, d, *J* = 8.1 Hz), 7.43 (1H, dd, *J* = 7.5 Hz, 6.6 Hz), 7.40-7.15 (4H, m), 6.78-6.70 (3H, m), 4.67 (1H, s), 4.57-4.40 (4H, m), 4.38-4.30 (1H, m), 3.50-3.45 (1H, m), 3.43-3.37 (1H, m), 3.19 (1H, s), 3.11 (1H, s), 2.83 (2H, t, *J* = 7.4 Hz), 2.50-2.40 (1H, m), 2.32-2.25 (1H, m), 2.19 (1.5H, s), 2.10-2.00 (2.5H, m), 1.95-1.90 (1H, m), 1.79-1.70 (2H, m), 1.45-1.38 (2H, m), 0.96-0.83(6H, m). MS:ESI 561 (*M*+1)

(ii) Isopropyl

15 2-[3-({*N*-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(dimethylamino)acetamido)methyl]phenoxy]acetate


The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.26 g) to give a colorless gum (0.18 g). Yield 72%.

¹H NMR δ (CDCl₃) 7.87 (0.75H, d, *J* = 8.9 Hz), 7.84 (1.25H, d, *J* = 8.3 Hz), 7.55-7.49 (1H, m), 7.37-7.33 (1H, m), 7.22-7.15 (1H, m), 6.80-6.70 (3H, m), 5.61 (2H, brs), 5.17-5.08 (1H, m), 4.70 (1.5H, s), 4.57 (0.5H, s), 4.54 (2H, s), 4.47-4.40 (2H, m), 3.54 (1.5H, t, *J* = 6.8 Hz), 3.50-3.40 (0.5 H, m), 3.17 (1.5H, s), 3.03 (0.5 H, s), 2.89-2.80 (2H, m), 2.32 (4.5H, s), 2.30-2.04 (3.5 H, m), 1.90-1.80 (2H, m), 1.53-1.44 (2H, m), 1.27 (6H, d, *J* = 6.3 Hz), 1.00 (3H, t, *J* = 7.3 Hz). MS:ESI 589 (*M*+1)

Example 160

Isopropyl

30 2-[3-({*N*-[3-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl]phenoxy]acetate



(i) *tert*-Butyl 3-(2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylcarbamate

The title compound was prepared by the method of example 1 step (iv) using the product from example 1 step (iii) (5.0 g), to give the title compound (5.0 g). Yield 85%.

¹H NMR δ (DMSO-*d*₆) 9.13 (1H, s), 8.37-8.34 (1H, m), 8.15-8.12 (1H, m), 7.70-7.67 (2H, m), 7.14 (1H, t, *J* = 5.2 Hz), 4.61-4.56 (2H, m), 3.12-3.08 (2H, m), 2.95-2.91 (2H, m), 1.96-1.84 (4H, m), 1.35 (9H, s), 1.03 (3H, t, *J* = 7.6 Hz).

MS: ESI 369 (M+1)

(ii) *tert*-Butyl

3-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylcarbamate

The title compound was prepared by the method of example 1 step (v-vi) using the product from previous step (5.0 g), to give the title compound (3.8 g). Yield 73%.

¹H NMR δ (DMSO-*d*₆) 8.03 (1H, d, *J* = 8.0 Hz), 7.59 (1H, dd, *J* = 1.2, 8.0 Hz), 7.42-7.38 (1H, m), 7.23-7.19 (1H, m), 7.13 (1H, t, *J* = 5.2 Hz), 6.45 (2H, s), 4.50-4.46 (2H, m), 3.10-3.06 (2H, m), 2.89-2.84 (2H, m), 1.93-1.81 (4H, m), 1.39 (9H, s), 1.05-0.99 (3H, m).

MS: ESI 384 (M+1)

(iii) 1-(3-Aminopropyl)-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine

The title compound was prepared by the method of example 1 step (vii) using the product from step (ii) (3.52 g) to give a pale yellow solid (2.40 g). Yield 92%.

¹H NMR δ (DMSO-*d*₆) 8.13 (1H, d, *J* = 7.6 Hz), 7.60 (1H, dd, *J* = 8.3 Hz, 1.0 Hz), 7.43-7.38 (1H, m), 7.25-7.21 (1H, m), 6.44 (2H, brs), 4.57 (2H, t, *J* = 7.6 Hz), 2.92 (2H, t, *J* = 7.6 Hz), 2.67 (2H, t, *J* = 6.4 Hz), 1.90-1.78 (4H, m), 1.60 (2H, brs), 1.03 (3H, t, *J* = 7.4 Hz). MS: ESI 284 (M+1)

(iv) Isopropyl

2-(3-([3-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylamino]methyl}phenoxy)acetate

By the method of example 1 step (viii) using the product from example 1 step (vii) (0.25 g) and isopropyl 2-(3-formylphenoxy)acetate (0.20 g) there was obtained the title compound, 0.32 g (75%) as a white solid

¹H NMR δ (CDCl₃) 8.10 (1H, d, J = 8.2 Hz), 7.84 (1H, dd, J = 8.4 Hz, 1.0 Hz), 7.55-7.46 (1H, m), 7.34-7.24 (2H, m), 7.00-6.93 (2H, m), 6.85-6.80 (1H, m), 5.78 (2H, brs), 5.17-5.08 (1H, m), 4.66-4.56 (4H, m), 3.80 (2H, s), 2.96-2.90 (2H, m), 2.76 (2H, t, J = 6.2 Hz), 2.12-2.03 (2H, m), 1.96-1.86 (2H, m), 1.26 (6H, d, J = 6.3 Hz), 1.08 (3H, t, J = 7.4 Hz). MS:ESI 490 (M+1)

(v) Isopropyl

2-[3-({N-[3-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-chloroacetamido)methyl}phenoxy)acetate

By the method of example 2 using the product of step (iv) (0.32 g), there was obtained the title compound, 0.38 g (96%) as colorless gum.

¹H NMR δ (CDCl₃) 7.96 (1H, d, J = 8.1 Hz), 7.92 (1H, d, J = 7.7 Hz), 7.64-7.58 (1H, m), 7.53-7.46 (1H, m), 7.26-7.17 (1H, m), 6.78-6.75 (3H, m), 5.18-5.07 (1H, m), 4.62 (2H, s), 4.56 (2H, s), 4.50-4.42 (2H, m), 4.10 (2H, s), 3.59 (2H, t, J = 6.7 Hz), 2.84 (2H, t, J = 7.6 Hz), 2.15-2.05 (2H, m), 1.97-1.86 (2H, m), 1.28 (6H, d, J = 6.3 Hz), 1.08 (3H, t, J = 7.4 Hz). MS:ESI 567 (M+1)

(vi) Isopropyl

2-[3-({N-[3-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl}phenoxy)acetate


The title compound was prepared by the method of example 5 using the product from step (v) (0.37 g) to give a colorless gum (0.32 g). Yield 85%.

¹H NMR δ (CDCl₃) 7.87 (0.75H, d, J = 8.1 Hz), 7.83 (1.25H, d, J = 8.4 Hz), 7.54-7.49 (1H, m), 7.36-7.30 (1H, m), 7.22-7.16 (1H, m), 6.80-6.70 (3H, m), 5.57 (2H, brs), 5.17-5.08 (1H, m), 4.75 (1.5H, s), 4.56 (0.5H, s), 4.54 (2H, s), 4.46-4.40 (2H, m), 3.53 (2H, t, J = 6.9 Hz), 3.31 (1.5H, s), 3.25 (0.5H, s), 2.87-2.77 (2H, m), 2.60 (3H, q, J = 7.1 Hz), 2.52 (1H, q, J = 7.1 Hz), 2.10-2.03 (2H, m), 1.93-1.83 (2H, m), 1.27 (6H, d, J = 6.3 Hz), 1.08 (3H, t, J = 7.4 Hz), 1.01-0.97 (6H, m). MS:ESI 603 (M+1)

Example 161

Isopropyl

2-{3-[(*N*-(3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-{diethylamino}acetamido)methyl]phenoxy}acetate



(i) *tert*-Butyl 3-[2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylcarbamate

To the product of example 1 step (iii) (5.0g) in NMP (25mL), 2-ethoxyacetic acid (1.9mL, 20mmol) was added followed by WSC HCl (3.8g) and HOBt (2.7mL) under nitrogen. The resulting solution was stirred at 120°C for 4h. The reaction mixture was diluted with EtOAc (100mL), and washed with sat. NaHCO₃ (100mL x2), and saturated brine (100mL). The organic layer was dried, filtered and evaporated. The organic residue was purified by silica gel chromatography to afford the subtitle product (4.2 g). Yield 70%.

¹H NMR δ (DMSO-*d*₆) 9.17 (1H, s), 8.38-8.30 (1H, m), 8.18-8.15 (1H, m), 7.70-7.67 (2H, m), 7.13 (1H, t, *J* = 5.6 Hz), 4.81 (2H, s), 4.68-4.63 (2H, m), 3.56 (2H, q, *J* = 7.2 Hz), 3.16-3.11 (2H, m), 2.03-1.99 (2H, m), 1.39 (9H, s), 1.16 (3H, t, *J* = 7.2 Hz).

MS: ESI 385 (M+1)

(ii) *tert*-Butyl

3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylcarbamate

The product from step (i) (4.2g) was dissolved in DCM (100 mL) and cooled to 5°C. 3-Chloroperoxybenzoic acid (3.4g) was added and the reaction was allowed to warm to room temperature. The reaction mixture was stirred for 12h. The reaction mixture was washed with saturated sodium thiosulfate solution and sodium bicarbonate solution, dried, filtered and evaporated to give a product.

p-Toluenesulphonyl chloride (2.5 g) was added portionwise to a vigorously stirred mixture of the product in DCM (40 mL) and ammonium hydroxide solution (35%, 12 mL) at 0°C. The mixture was allowed to warm to rt over night then partitioned between water/DCM, washed with saturated sodium bicarbonate solution, dried, filtered and the solvent evaporated. The organic residue was purified by silica gel chromatography to give the subtitle compound (3.6 g). Yield 83%.

¹H NMR δ (DMSO-*d*₆) 8.04 (1H, d, *J* = 7.6 Hz), 7.60 (1H, dd, *J* = 1.2, 8.0 Hz),

7.47-7.42 (1H, m), 7.26-7.22 (1H, m), 7.11 (1H, t, J = 5.4 Hz), 6.60 (2H, s), 4.75 (2H, s), 4.57-4.53 (2H, m), 3.54 (2H, q, J = 6.8 Hz), 3.16-3.08 (2H, m), 2.00-1.95 (2H, m), 1.39 (9H, s), 1.18-1.14 (3H, m).

MS: ESI 400 (M+1)

5

(iii) 1-(3-Aminopropyl)-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine

The product from step (ii) (3.49g) was suspended in MeOH (14 mL) and 6N HCl (14 mL) was added. The reaction mixture was stirred at 50°C for 1h. After the removal of the solvent, water was added to the residue, washed with chloroform twice and then poured into 28% NH₃ solution, extracted with EtOH/CHCl₃ (1/3), dried and evaporated to give the subtitle compound as a pale yellow solid (2.11 g). Yield 81%.

10

¹H NMR δ (DMSO-*d*₆) 8.16 (1H, d, J = 7.6 Hz), 7.60 (1H, dd, J = 8.3 Hz, 1.0 Hz), 7.46-7.42 (1H, m), 7.29-7.24 (1H, m), 6.60 (2H, brs), 4.75 (2H, s), 4.63 (2H, t, J = 7.7 Hz), 3.54 (2H, q, J = 7.0 Hz), 2.69 (2H, t, J = 6.4 Hz), 1.96-1.87 (2H, m), 1.64 (2H, brs), 1.16 (3H, t, J = 7.0 Hz). MS: ESI 300 (M+1)

15

(iv) Isopropyl

2-[3-({3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino} methyl)phenoxy]acetate

20

To a solution of the product from step (iii) (0.25 g, 0.84 mmol) in MeOH (5 ml) were added isopropyl 2-(3-formylphenoxy)acetate (0.19 g, 0.84 mmol), AcOH (0.096 ml, 1.67 mmol) and NaBH₃CN (0.11 g, 1.67 mmol) at room temperature. After stirring for 4 h at the same temperature, 4% NH₃ aq. was added to the reaction mixture, and extracted with CHCl₃ (30 ml x 2). The combined extracts were dried over MgSO₄ and concentrated. The residue was purified by flash column chromatography to afford the subtitle compound 0.34 g (80%) as a white solid

25

¹H NMR δ (CDCl₃) 8.12 (1H, d, J = 7.4 Hz), 7.85 (1H, dd, J = 8.3 Hz, 0.8 Hz), 7.55-7.52 (1H, m), 7.34-7.26 (2H, m), 7.00-6.94 (2H, m), 6.83-6.78 (1H, m), 5.76 (2H, brs), 5.17-5.08 (1H, m), 4.84 (2H, s), 4.74 (2H, t, J = 7.7 Hz), 4.61 (2H, s), 3.81 (2H, s), 3.61 (2H, q, J = 7.0 Hz), 2.79 (2H, t, J = 6.3 Hz), 2.18-2.10 (2H, m), 1.30-1.20 (9H, m). MS:ESI 506 (M+1)

30

(v) Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-*c*

35

hloroacetamido)methyl]phenoxy}acetate

To a solution of the product of step (iv) (0.33 g, 0.66 mmol) in CHCl_3 (5 ml) was added chloroacetyl chloride (0.052 ml, 0.66 mmol) at 0°C . After stirring for 1.5 h at the same temperature, the reaction mixture was concentrated. The residue was purified by flash column chromatography to give the title compound, 0.41 g (quant.) as colorless gum.

^1H NMR δ (CDCl_3) 7.95 (1H, d, $J = 8.1$ Hz), 7.90 (1H, d, $J = 8.1$ Hz), 7.63-7.57 (1H, m), 7.48-7.42 (1H, m), 7.26-7.20 (1H, m), 6.79-6.72 (3H, m), 6.65 (2H, brs), 5.17-5.07 (1H, m), 4.77 (2H, s), 4.63 (2H, s), 4.62-4.53 (4H, m), 4.10 (2H, s), 3.66-3.58 (4H, m), 2.26-2.16 (2H, m), 1.29-1.18 (9H, m). MS:ESI 583 ($\text{M}+1$)

(vi) Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}acetate


The product from step (v) (0.40 g, 0.65 mmol) was dissolved in MeCN (5 ml) and Et_2NH (0.68 ml, 6.5 mmol) was added. After stirring for 17 h, 4% NH_3 aq. was added to the reaction mixture, and extracted with CHCl_3 (30 ml x 2). The combined extracts were dried over MgSO_4 and concentrated. The residue was purified by silica gel chromatography which afforded 0.34 g mg of the desired product as a colorless gum. The colorless gum was triturated with ether to give the desired compound as a white solid. Yield 84%.

^1H NMR δ (CDCl_3) 7.92 (0.75H, d, $J = 7.8$ Hz), 7.89-7.82 (1.25H, m), 7.57-7.52 (1H, m), 7.38-7.33 (1H, m), 7.23-7.17 (1H, m), 6.80-6.72 (3H, m), 5.55 (2H, brs), 5.17-5.08 (1H, m), 4.78-4.74 (3.5H, m), 4.59-4.52 (4.5H, m), 3.64-3.52 (4H, m), 3.30 (1.5H, s), 3.26 (0.5 H, s), 2.60 (3H, q, $J = 7.1$ Hz), 2.52 (1H, q, $J = 7.1$ Hz), 2.35-2.20 (1H, m), 2.20-2.12 (1H, m), 1.27 (6H, d, $J = 6.3$ Hz), 1.26-1.21 (3H, m), 0.99 (6H, t, $J = 7.1$ Hz). MS:ESI 619 ($\text{M}+1$)

Example 162

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate



(i) Ethyl

2-[3-({3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]phenoxy]-2-methylpropanoate

5 To a solution of the product from example 161 step (iii) (0.25 g, 0.83 mmol) in MeOH (5 ml) were added ethyl 2-(3-formylphenoxy)-2-methylpropanoate (0.20 g, 0.83 mmol), AcOH (0.095 ml, 1.67 mmol) and NaBH₃CN (0.11 g, 1.67 mmol) at room temperature. After stirring for 26 h at the same temperature, 4% NH₃ aq. was added to the reaction mixture, and extracted with CHCl₃ (30 ml x 2). The combined extracts were dried over MgSO₄ and concentrated. The residue was purified by flash column chromatography to afford the subtitle compound, 0.36 g (82%) as a white solid.

15 ¹H NMR δ (CDCl₃) 8.12 (1H, d, *J* = 7.4 Hz), 7.83 (1H, dd, *J* = 8.3 Hz, 0.8 Hz), 7.56-7.50 (1H, m), 7.33-7.26 (1H, m), 7.21 (1H, dd, *J* = 7.9 Hz, 7.8 Hz), 6.97 (1H, d, *J* = 7.6 Hz), 6.91-6.88 (1H, m), 6.72 (1H, dd, *J* = 8.0 Hz, 2.1 Hz), 5.62 (2H, brs), 4.84 (2H, s), 4.73 (2H, t, *J* = 7.7 Hz), 4.22 (2H, q, *J* = 7.1 Hz), 3.78 (2H, s), 3.60 (2H, q, *J* = 7.0 Hz), 2.78 (2H, t, *J* = 6.3 Hz), 2.18-2.09 (2H, m), 1.61 (6H, s), 1.24 (6H, t, *J* = 7.1 Hz). MS:ESI 520 (M+1)

20 (ii) Ethyl

2-{3-[(*N*-(3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl)-2-chloroacetamido)methyl]phenoxy}-2-methylpropanoate

To a solution of the product of step (i) (0.35 g, 0.68 mmol) in CHCl₃ (5 ml) was added chloroacetyl chloride (0.054 ml, 0.68 mmol) at 0°C. After stirring for 20 min at the same temperature, the reaction mixture was concentrated. The residue was purified by flash column chromatography to give the title compound, 0.43 g (quant.) as colorless gum.

30 ¹H NMR δ (CDCl₃) 7.94 (1H, d, *J* = 8.2 Hz), 7.88-7.79 (1H, m), 7.57 (1H, dd, *J* = 7.8 Hz, 7.5 Hz), 7.44-7.37 (1H, m), 7.27-7.10 (1H, m), 6.78-6.68 (3H, m), 6.42 (2H, brs), 4.77 (2H, s), 4.62 (2H, s), 4.62-4.51 (2H, m), 4.21 (2H, q, *J* = 7.1 Hz), 4.15 (2H, s), 3.61 (4H, t, *J* = 7.0 Hz), 2.32-2.16 (2H, m), 1.58 (4.5H, s), 1.56 (1.5H, s),

1.30-1.18 (6H, m). MS:ESI 597 (M+1)

(iii) Ethyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate


The product from step (ii) (0.43 g, 0.68 mmol) was dissolved in MeCN (5 ml) and Et₂NH (0.71 ml, 6.8 mmol) was added. After stirring for 20 h, 4% NH₃ aq. was added to the reaction mixture, and extracted with CHCl₃ (30 ml x 2). The combined extracts were dried over MgSO₄ and concentrated. The residue was purified by silica gel chromatography which afforded 0.36 g of the desired product as a colorless gum. Yield 83%.

¹H NMR δ (CDCl₃) 7.95 (0.75H, d, J = 7.6 Hz), 7.85-7.82 (1.25H, m), 7.58-7.52 (1H, m), 7.40-7.31 (1H, m), 7.21-7.13 (1H, m), 6.78-6.67 (3H, m), 5.57 (2H, brs), 4.77 (1.5H, s), 4.77-4.75 (2H, m), 4.59-4.56 (2H, m), 4.55 (0.5H, s), 4.21 (2H, q, J = 7.1 Hz), 3.64-3.55 (4H, m), 3.29 (1.5H, s), 3.26 (0.5 H, s), 2.60 (3H, q, J = 7.1 Hz), 2.52 (1H, q, J = 7.1 Hz), 2.30-2.22 (0.5 H, m), 2.19-2.10 (1.5H, m), 1.57 (6H, s), 1.28-1.19 (6H, m), 0.99 (6H, t, J = 7.1 Hz). MS:ESI 633 (M+1)

Example 163

Methyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate



(i)

2-{3-[(N-{3-[4-Amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoic acid

To a solution of example 162 (0.27 g, 0.42 mmol) in EtOH (5 ml), 1N NaOH (5 mL) was added at rt. After stirring for 30 min at 50°C, the reaction mixture was neutralized with 1N HCl at 0°C. The aq. layer was extracted with CHCl₃/EtOH (3/1, twice), dried over MgSO₄, and concentrated to give the title compound (0.25g, 96%) as a white solid.

¹H NMR δ (DMSO-d₆) 8.01-7.93 (1H, m), 7.61 (1H, d, J = 8.4 Hz), 7.46 (1H, dd, J = 7.3 Hz, 7.2 Hz), 7.30-7.17 (2H, m), 6.87 (2H, brs), 6.74-6.67 (3H, m), 4.75-4.73 (2H, m), 4.70 (1H, s), 4.60-4.55 (1H, m), 4.50-4.45 (1H, m), 4.44 (2H, s), 3.55-3.48 (4H, m), 3.45 (1H, t, J = 6.8 Hz), 3.20 (1H, s), 3.19 (1H, s), 2.42 (2H, q, J = 7.2 Hz), 2.20-2.10 (1H, m), 2.08-1.99 (1H, m), 1.42 (6H, s), 1.15-1.09 (3H, m), 0.89-0.82 (6H, m). MS:ESI 605 (M+1)

(ii) Methyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate


To a solution of the product from step (i) (0.18 g, 0.29 mmol) in methanol (5 mL), 4*N* HCl/dioxane solution (1 mL) was added. The reaction mixture was stirred at room temperature for 6h, and then 4% NH₃ aq. was added to the reaction mixture, and extracted with CHCl₃ (30 ml x 3). The combined extracts were dried over MgSO₄ and concentrated to afford the title compound (0.17g, 80%) as a white solid.

¹H NMR δ (CDCl₃) 7.95 (0.75H, d, J = 7.7 Hz), 7.90-7.82 (1.25H, m), 7.58-7.53 (1H, m), 7.40-7.32 (1H, m), 7.22-7.14 (1H, m), 6.80-6.66 (3H, m), 5.66 (2H, brs), 4.77 (1.5H, s), 4.76-4.74 (2H, m), 4.60-4.54 (2.5H, m), 3.76 (3H, s), 3.65-3.55 (4H, m), 3.29 (1.5H, s), 3.27 (0.5 H, s), 2.60 (3H, q, J = 7.1 Hz), 2.51 (1H, q, J = 7.1 Hz), 2.32-2.22 (0.5 H, m), 2.19-2.00 (1.5H, m), 1.58 (6H, s), 1.22 (3H, t, J = 7.0 Hz), 0.99 (6H, t, J = 7.1 Hz). MS:ESI 619 (M+1)

Example 164

Isopropyl

2-[3-[(N-{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl]-2-fluorophenoxy]acetate



(i) Isopropyl

2-(3-[(N-{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylamino)methyl]-2-fluorophenoxy)acetate

By the method of example 1 step (viii) using the product from example 1 step (vii) (0.30 g) and isopropyl 2-(2-fluoro-3-formylphenoxy)acetate (0.24 g) there was obtained the title compound, 0.53 g (quant.) as a white solid.

¹H NMR δ (CDCl₃) 8.06 (1H, d, J = 8.3 Hz), 7.83 (1H, dd, J = 8.4 Hz, 0.9 Hz), 7.53-7.47 (1H, m), 7.33-7.24 (2H, m), 7.03-7.00 (1H, m), 7.00-6.95 (1H, m), 6.85-6.80 (1H, m), 5.59 (2H, brs), 5.18-5.10 (1H, m), 4.68 (2H, s), 4.60 (2H, t, J = 7.4 Hz), 3.88 (2H, s), 2.95 (2H, t, J = 7.9 Hz), 2.73 (2H, t, J = 6.3 Hz), 2.12-2.03 (2H, m), 1.90-1.82 (2H, m), 1.55-1.45 (2H, m), 1.27 (6H, d, J = 6.3 Hz), 1.00 (3H, t, J = 7.4 Hz). MS:ESI 522 (M+1)

(ii) Isopropyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-chloroacetamido)methyl}-2-fluorophenoxy]acetate

By the method of example 2 using the product of step (i) (0.53 g), there was obtained the title compound, 0.60 g (94%) as colorless gum.

¹H NMR δ (CDCl₃) 8.00 (1H, d, J = 8.1 Hz), 7.93 (1H, d, J = 8.0 Hz), 7.65-7.62 (1H, m), 7.58-7.52 (1H, m), 7.00-6.95 (1H, m), 6.83-6.77 (1H, m), 6.73-6.55 (3H, m), 5.15-5.08 (1H, m), 4.68 (1.5H, s), 4.66 (0.5H, s), 4.64 (2H, s), 4.51-4.47 (2H, m), 4.22 (1.5H, s), 4.12 (0.5H, s), 3.56 (2H, t, J = 6.8 Hz), 2.86 (2H, t, J = 7.7 Hz), 2.40-2.30 (0.5H, m), 2.15-2.07 (1.5H, m), 1.93-1.83 (2H, m), 1.57-1.46 (2H, m), 1.27 (6H, d, J = 6.3 Hz), 1.01 (3H, t, J = 7.3 Hz). MS:ESI 599 (M+1)

(iii) Isopropyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl}-2-fluorophenoxy]acetate


The title compound was prepared by the method of example 5 using the product from step (ii) (0.30 g) to give a colorless gum (0.25 g). Yield 85%.

¹H NMR δ (CDCl₃) 7.95-7.85 (1H, m), 7.82 (1H, d, J = 8.3 Hz), 7.54-7.49 (1H, m), 7.36-7.30 (1H, m), 7.05-6.80 (1.5H, m), 6.73-6.64 (1.5H, m), 5.44 (2H, brs), 5.17-5.08 (1H, m), 4.84 (1.5H, s), 4.69 (0.5H, s), 4.65 (0.5H, s), 4.59 (1.5H, s), 4.46-4.40 (2H, m), 3.62-3.57 (0.5H, m), 3.48 (1.5H, t, J = 7.1 Hz), 3.35 (1.5H, s), 3.19 (0.5H, s), 2.89-2.83 (2H, m), 2.60 (3H, q, J = 7.1 Hz), 2.46 (1H, q, J = 7.2 Hz), 2.35-2.28 (0.5H, m), 2.13-2.00 (1.5H, m), 1.90-1.80 (2H, m), 1.53-1.44 (2H, m), 1.27 (6H, d, J = 6.2 Hz), 1.02-0.90 (9H, m). MS:ESI 635 (M+1)

Example 165

Isopropyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(dimethylamino)acetamido)methyl]-2-fluorophenoxy]acetate




The title compound was prepared by the method of example 5 using the product from example 164 step (ii) (0.30 g) to give a colorless gum (0.25 g). Yield 86%.

¹H NMR δ (CDCl₃) 7.91-7.87 (1H, m), 7.82 (1H, d, J = 8.3 Hz), 7.54-7.49 (1H, m), 7.36-7.30 (1H, m), 6.98-6.80 (1.5H, m), 6.74-6.60 (1.5H, m), 5.41 (2H, brs), 5.16-5.08 (1H, m), 4.78 (1.5H, s), 4.69 (0.5H, s), 4.65 (0.5H, s), 4.60 (1.5H, s), 4.47-4.40 (2H, m), 3.54-3.47 (2H, m), 3.21 (1.5H, s), 2.97 (0.5 H, s), 2.87 (2H, t, J = 7.8 Hz), 2.32 (4.5H, s), 2.32-2.28 (0.5 H, m), 2.12-2.05 (1.5H, m), 2.05 (1.5H, s), 1.92-1.80 (2H, m), 1.53-1.44 (2H, m), 1.26 (6H, d, J = 6.2 Hz), 1.00 (3H, t, J = 7.3 Hz). MS:ESI 607 (M+1)

Example 166

Isopropyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-fluorophenoxy}acetate



(i) Isopropyl

2-[3-({3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]-2-fluorophenoxy]acetate

By the method of example 1 step (viii) using the product from example 164 step (i) (0.30 g) and isopropyl 2-(2-fluoro-3-formylphenoxy)acetate (0.24 g) there was obtained the title compound, 0.51 g (97%) as a white solid.

¹H NMR δ (CDCl₃) 8.09 (1H, d, J = 7.5 Hz), 7.81 (1H, dd, J = 8.3 Hz, 0.8 Hz),

7.54-7.49 (1H, m), 7.33-7.26 (1H, m), 7.03-6.97 (2H, m), 6.90-6.78 (1H, m), 5.50 (2H, brs), 5.18-5.10 (1H, m), 4.84 (2H, s), 4.72 (2H, t, J = 7.6 Hz), 4.66 (2H, s), 3.89 (2H, s), 3.60 (2H, q, J = 7.0 Hz), 2.76 (2H, t, J = 6.3 Hz), 2.18-2.10 (2H, m), 1.27 (6H, d, J = 6.3 Hz), 1.26-1.21 (3H, m). MS:ESI 524 (M+1)

5

(ii) Isopropyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-2-fluorophenoxy}acetate

10 By the method of example 2 using the product of step (i) (0.50 g), there was obtained the title compound, 0.54 g (90%) as colorless gum.

¹H NMR δ (CDCl₃) 8.01-7.97 (2H, m), 7.69-7.63 (1H, m), 7.58-7.53 (1H, m), 7.03-6.96 (1H, m), 6.85-6.79 (1H, m), 6.75-6.71 (1H, m), 5.15-5.09 (1H, m), 4.80 (0.5H, s), 4.77 (1.5H, s), 4.70 (2H, s), 4.66-4.57 (4H, m), 4.21 (1.5H, s), 4.11 (0.5H, s), 3.67-3.57 (4H, m), 2.45-2.35 (0.5H, m), 2.25-2.16 (1.5H, m), , 1.29-1.19 (9H, m). MS:ESI 601 (M+1)

15

(iii) Isopropyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-diethylamino)acetamido)methyl]-2-fluorophenoxy}acetate

20 The title compound was prepared by the method of example 5 using the product from step (ii) (0.27 g) to give a colorless gum (0.21 g). Yield 79%.


¹H NMR δ (CDCl₃) 7.93 (1H, d, J = 8.1 Hz), 7.84-7.80 (1H, m), 7.56-7.52 (1H, m), 7.38-7.34 (1H, m), 7.00-6.88 (1.5H, m), 6.80-6.67 (1.5H, m), 5.43 (2H, brs), 5.17-5.08 (1H, m), 4.87 (1.5H, s), 4.78 (0.5H, s), 4.77 (1.5H, s), 4.71 (0.5H, s), 4.64 (0.5H, s), 4.61 (1.5H, s), 4.59-4.54 (2H, m), 3.65-3.52 (4H, m), 3.33 (1.5H, s), 3.21 (0.5 H, s), 2.59 (3H, q, J = 7.1 Hz), 2.48 (1H, q, J = 7.1 Hz), 2.35-2.28 (0.5 H, m), 2.20-2.15 (1.5H, m), 1.28-1.19 (9H, m), 1.02-0.90 (6H, m). MS:ESI 637 (M+1)

25

Example 167

30 Isopropyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-dimethylamino)acetamido)methyl]-2-fluorophenoxy}acetate




The title compound was prepared by the method of example 5 using the product from example 164 step (ii) (0.27 g) to give a colorless gum (0.23 g). Yield 89%.

¹H NMR δ (CDCl₃) 7.93 (1H, d, J = 8.1 Hz), 7.82 (1H, d, J = 8.3 Hz), 7.56-7.52 (1H, m), 7.38-7.34 (1H, m), 6.98-6.90 (1.5H, m), 6.80-6.64 (1.5H, m), 5.47 (2H, brs), 5.17-5.08 (1H, m), 4.81 (1.5H, s), 4.78 (0.5H, s), 4.77 (1.5H, s), 4.70 (0.5H, s), 4.65 (0.5H, s), 4.60 (1.5H, s), 4.59-4.54 (2H, m), 3.65-3.52 (4H, m), 3.19 (1.5H, s), 3.00 (0.5 H, s), 2.38-2.30 (0.5 H, m), 2.31 (4.5H, s), 2.20-2.15 (1.5H, m), 2.07 (1.5H, s), 1.28-1.19 (9H, m). MS:ESI 609 (M+1)

Example 168

Ethyl

2-[3-({N-[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]-2-(pyrrolidin-1-yl)acetamido}methyl)phenoxy]-2-methylpropanoate




The title compound was prepared by the method of example 5 using the product from example 153 step (ii) (0.32 g) to give a colorless gum (0.28 g). Yield 87%.

¹H NMR δ (CDCl₃) 7.89 (0.75H, d, J = 8.0 Hz), 7.85-7.81 (1.25H, m), 7.53-7.48 (1H, m), 7.35-7.31 (1H, m), 7.20-7.14 (1H, m), 6.80-6.68 (3H, m), 5.49 (2H, brs), 4.69 (1.5H, s), 4.55 (0.5H, s), 4.48-4.38 (2H, m), 4.21 (2H, q, J = 7.1 Hz), 3.56 (1.5H, t, J = 6.6 Hz), 3.52-3.46 (0.5H, m), 3.36 (1.5H, s), 3.19 (0.5 H, s), 2.89-2.75 (2H, m), 2.63-2.57 (3H, m), 2.48-2.40 (1H, m), 2.25-2.18 (0.5 H, m), 2.15-2.03 (1.5H, m), 1.90-1.80 (2H, m), 1.80-1.75 (3H, m), 1.68-1.62 (1H, m), 1.57 (6H, s), 1.55-1.43 (2H, m), 1.23 (3H, t, J = 7.0 Hz), 0.98 (3H, t, J = 7.4 Hz). MS:ESI 629 (M+1)

Example 169

Methyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(pyrrolidin-1-yl)acetamido)methyl)phenoxy]-2-methylpropanoate



(i)

2-[3-({N-[3-(4-Amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(pyrrolidin-1-yl)acetamido)methyl)phenoxy]-2-methylpropanoic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 168 (0.25 g), to give a white solid (0.23 g). Yield 97%.

¹H NMR δ (DMSO-*d*₆) 7.93-7.85 (1H, m), 7.62-7.59 (1H, m), 7.47-7.42 (1H, m), 7.38-7.12 (4H, m), 6.78-6.66 (3H, m), 4.56 (1H, s), 4.46-4.42 (2H, m), 4.36-4.32 (1H, m), 3.68-3.58 (2H, m), 3.45-3.40 (2H, m), 2.90-2.79 (4H, m), 2.73-2.70 (2H, m), 2.12-2.05 (1H, m), 1.90-1.85 (1H, m), 1.79-1.64 (6H, m), 1.45-1.35 (8H, m), 0.97-0.91 (3H, m). MS:ESI 601 (M+1)

(ii) Methyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(pyrrolidin-1-yl)acetamido)methyl)phenoxy]-2-methylpropanoate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.16 g) and methanol, to give a colorless gum (0.15 g). Yield 90%.


¹H NMR δ (CDCl₃) 7.89 (0.75H, d, *J* = 8.1 Hz), 7.83 (1.25H, d, *J* = 8.4 Hz), 7.54-7.49 (1H, m), 7.36-7.31 (1H, m), 7.21-7.15 (1H, m), 6.80-6.65 (3H, m), 5.40 (2H, brs), 4.70 (1.5H, s), 4.56 (0.5H, s), 4.49-4.40 (2H, m), 3.76 (3H, s), 3.57 (1.5H, t, *J* = 6.6 Hz), 3.51-3.46 (0.5H, m), 3.36 (1.5H, s), 3.20 (0.5 H, s), 2.90-2.79 (2H, m), 2.63-2.57 (3H, m), 2.47-2.40 (1H, m), 2.20-2.12 (0.5 H, m), 2.12-2.03 (1.5H, m), 1.92-1.75 (5H, m), 1.68-1.64 (1H, m), 1.58 (6H, s), 1.56-1.47 (2H, m), 1.00 (3H, t, *J* = 7.3 Hz). MS:ESI 615 (M+1)

Example 170

Ethyl

2-{3-[(N-[3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl]-2-}

pyrrolidin-1-yl}acetamido)methyl]phenoxy}-2-methylpropanoate




The title compound was prepared by the method of example 5 using the product from example 162 step (ii) (0.32 g) to give a colorless gum (0.28 g). Yield 89%.

5 ¹H NMR δ (CDCl₃) 7.94 (0.75H, d, J = 8.2 Hz), 7.87 (0.25H, d, J = 8.2 Hz), 7.82 (1H, d, J = 8.3 Hz), 7.56-7.50 (1H, m), 7.39-7.33 (1H, m), 7.21-7.12 (1H, m), 6.81-6.68 (3H, m), 5.44 (2H, brs), 4.77 (1.5H, s), 4.76 (0.5H, s), 4.71 (1.5H, s), 4.60-4.54 (2.5H, m), 4.21 (2H, q, J = 7.1 Hz), 3.64-3.57 (3.5H, m), 3.50 (0.5H, t, J = 7.5 Hz), 3.36 (1.5H, s), 3.23 (0.5 H, s), 2.62-2.58 (3H, m), 2.49-2.43 (1H, m), 2.29-2.22 (0.5H, m), 2.19-2.12 (1.5 H, m), 1.78-1.74 (3H, m), 1.69-1.65 (1H, m), 1.58 (6H, s),
10 1.24 (6H, t, J = 7.1 Hz). MS:ESI 631 (M+1)

Example 171

Methyl

15 2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-{pyrrolidin-1-yl}acetamido)methyl]phenoxy}-2-methylpropanoate



(i)

20 2-{3-[(N-{3-[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-{pyrrolidin-1-yl}acetamido)methyl]phenoxy}-2-methylpropanoic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 170 (0.24 g), to give a white solid (0.22 g). Yield 95%.

¹H NMR δ (DMSO-d₆) 8.01-7.93 (1H, m), 7.61 (1H, d, J = 8.3 Hz), 7.48-7.44 (1H, m), 7.31-7.12 (2H, m), 6.94 (2H, brs), 6.74-6.67 (3H, m), 4.74 (0.5H, s), 4.73 (0.5H, s), 4.63 (1H, s), 4.60-4.55 (1H, m), 4.52-4.48 (2H, m), 3.57-3.44 (6H, m),
25 3.30-3.26 (1H, m), 2.72-2.64 (2H, m), 2.52-2.47 (2H, m), 2.14-2.10 (1H, m), 2.04-2.00 (1H, m), 1.69-1.64 (2H, m), 1.57-1.53 (2H, m), 1.43 (6H, s), 1.15-1.09

(3H, m). MS:ESI 603 (M+1)

(ii) Methyl

2-{3-[(*N*-(3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-{pyrrolidin-1-yl}acetamido)methyl]phenoxy}-2-methylpropanoate


The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.16 g) and methanol, to give a colorless gum (0.15 g). Yield 92%.

¹H NMR δ (CDCl₃) 7.94 (0.75H, d, *J* = 7.9 Hz), 7.86-7.81 (1.25H, m), 7.56-7.51 (1H, m), 7.38-7.32 (1H, m), 7.21-7.14 (1H, m), 6.81-6.65 (3H, m), 5.49 (2H, brs), 4.77 (1.5H, s), 4.75 (0.5H, s), 4.71 (1.5H, s), 4.60-4.54 (2.5H, m), 3.75 (3H, s), 3.64-3.56 (3.5H, m), 3.51-3.46 (0.5H, m), 3.36 (1.5H, s), 3.23 (0.5 H, s), 2.62-2.56 (3H, m), 2.48-2.44 (1H, m), 2.30-2.10 (2H, m), 1.78-1.72 (3H, m), 1.69-1.64 (1H, m), 1.58 (4.5H, s), 1.55 (1.5H, s), 1.21 (3H, t, *J* = 7.1 Hz). MS:ESI 615 (M+1)

Exmple172

Isopropyl

2-{3-[(*N*-(3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-{pyrrolidin-1-yl}acetamido)methyl]phenoxy}acetate




The title compound was prepared by the method of example 5 using the product from example 161 step (v) (0.32 g) to give a colorless gum (0.25 g). Yield 81%.

¹H NMR δ (CDCl₃) 7.93 (0.75H, d, *J* = 8.0 Hz), 7.87 (0.25H, d, *J* = 8.4 Hz), 7.82 (1H, d, *J* = 8.3 Hz), 7.57-7.50 (1H, m), 7.38-7.32 (1H, m), 7.24-7.18 (1H, m), 6.80-6.73 (3H, m), 5.43 (2H, brs), 5.18-5.08 (1H, m), 4.77 (1.5H, s), 4.76 (0.5H, s), 4.72 (1.5H, s), 4.60-4.53 (4.5H, m), 3.64-3.55 (3.5H, m), 3.51 (0.5H, t, *J* = 7.4 Hz), 3.37 (1.5H, s), 3.23 (0.5 H, s), 2.62-2.58 (3H, m), 2.49-2.43 (1H, m), 2.29-2.22 (0.5H, m), 2.21-2.12 (1.5 H, m), 1.78-1.74 (3H, m), 1.70-1.65 (1H, m), 1.27 (6H, d, *J* = 6.3 Hz), 1.25-1.19 (3H, m). MS:ESI 617 (M+1)

Example173

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(propoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}-2-methylpropanoate



5 (i) *tert*-Butyl

3-[2-(propoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylcarbamate

The title compound was prepared by the method of example 15 step (i) using the product from example 1 step (iii) (3.00 g), to give the title compound (3.44 g). Yield 91%.

10 ¹H NMR δ (CDCl₃) 9.30 (1H, s), 8.31-8.27 (1H, m), 8.24-8.21 (1H, m), 7.74-7.63 (2H, m), 4.99-4.95 (1H, m), 4.89 (2H, s), 4.75-4.71 (2H, m), 3.54-3.36 (2H, m), 3.34-3.29 (2H, m), 2.25-2.18 (2H, m), 1.69-1.62 (2H, m), 1.46 (9H, s), 0.94 (3H, t, *J* = 7.4 Hz).

MS: ESI 399 (M+1)

15

(ii) 1-(3-Aminopropyl)-2-(propoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine

The title compound was prepared by the method of example 15 step (ii-iv) using the product from previous step (3.44 g), to give the title compound (1.10 g). Yield 37%.

20 ¹H NMR δ (CDCl₃) 8.10 (1H, d, *J* = 8.2 Hz), 7.83 (1H, d, *J* = 8.3 Hz), 7.54 (1H, dd, *J* = 8.2 Hz, 7.2 Hz), 7.35 (1H, dd, *J* = 8.1 Hz, 7.2 Hz), 5.42 (2H, brs), 4.85 (2H, s), 4.73 (2H, t, *J* = 7.7 Hz), 3.52 (2H, t, *J* = 6.7 Hz), 2.90 (2H, t, *J* = 6.6 Hz), 2.16-2.07 (2H, m), 1.70-1.40 (4H, m), 0.94 (3H, t, *J* = 7.4 Hz).

MS: ESI 314 (M+1)

25

(iii) Ethyl

2-[3-({3-[4-amino-2-(propoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]phenoxy]-2-methylpropanoate

By the method of example 1 step (viii) using the product from step (ii) (0.23 g) and ethyl 2-(3-formylphenoxy)-2-methylpropanoate (0.17 g) there was obtained the title compound, 0.28 g (74%) as a white solid

30

¹H NMR δ (CDCl₃) 8.12 (1H, d, J = 7.4 Hz), 7.83 (1H, d, J = 8.4 Hz), 7.55-7.49 (1H, m), 7.32-7.26 (1H, m), 7.21 (1H, dd, J = 7.9 Hz, 7.8 Hz), 7.01-6.97 (1H, m), 6.91-6.88 (1H, m), 6.72 (1H, dd, J = 7.9 Hz, 2.2 Hz), 5.48 (2H, brs), 4.84 (2H, s), 4.74 (2H, t, J = 7.6 Hz), 4.22 (2H, q, J = 7.1 Hz), 3.78 (2H, s), 3.50 (2H, t, J = 6.7 Hz), 2.77 (2H, t, J = 6.3 Hz), 2.18-2.09 (2H, m), 1.68-1.60 (2H, m), 1.62 (6H, s), 1.24 (3H, t, J = 7.1 Hz), 0.92 (3H, t, J = 7.4 Hz). MS:ESI 534 (M+1)

(iv) Ethyl

2-[3-[(N-{3-[4-amino-2-(propoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]phenoxy]-2-methylpropanoate hydrochloride

By the method of example 2 using the product of step(iii) (0.28 g), there was obtained the title compound, 0.33 g (98%) as colorless gum.

¹H NMR δ (CDCl₃) 7.97 (1H, d, J = 8.1 Hz), 7.90-7.81 (1H, m), 7.59 (1H, dd, J = 7.4 Hz, 7.4 Hz), 7.46-7.38 (1H, m), 7.27-7.10 (1H, m), 6.78-6.68 (3H, m), 6.30 (2H, brs), 4.78 (2H, s), 4.62 (2H, s), 4.62-4.51 (2H, m), 4.20 (2H, q, J = 7.1 Hz), 4.09 (2H, s), 3.63 (1.5H, t, J = 6.6 Hz), 3.54-3.40 (2.5H, m), 2.30-2.16 (2H, m), 1.67-1.58 (2H, m), 1.59 (4.5H, s), 1.54 (1.5H, s), 1.26-1.22 (3H, m), 0.93 (3H, t, J = 7.4 Hz). MS:ESI 611 (M+1)

(v) Ethyl

2-{3-[(N-{3-[4-amino-2-(propoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}-2-methylpropanoate

The title compound was prepared by the method of example 5 using the product from step (iv) (0.33 g) to give a colorless gum (0.31 g). Yield 93%.


¹H NMR δ (CDCl₃) 7.95 (0.75H, d, J = 7.7 Hz), 7.88-7.82 (1.25H, m), 7.57-7.52 (1H, m), 7.29-7.31 (1H, m), 7.21-7.14 (1H, m), 6.79-6.67 (3H, m), 5.40 (2H, brs), 4.78 (1.5H, s), 4.77-4.75 (2H, m), 4.60-4.55 (2.5H, m), 4.21 (2H, q, J = 7.1 Hz), 3.59 (2H, t, J = 6.9 Hz), 3.52-3.47 (2H, m), 3.29 (1.5H, s), 3.25 (0.5 H, s), 2.60 (3H, q, J = 7.1 Hz), 2.52 (1H, q, J = 7.2 Hz), 2.30-2.22 (0.5H, m), 2.19-2.10 (1.5H, m), 1.64-1.57 (2H, m), 1.57 (6H, s), 1.28-1.20 (3H, m), 0.99 (6H, t, J = 7.1 Hz), 0.92 (3H, t, J = 7.4 Hz). MS:ESI 647 (M+1)

Example 174

Methyl

2-[3-[(N-{3-[4-amino-2-(propoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-

{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate



(i)

2-{3-[(N-{3-[4-Amino-2-(propoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoic acid

The title compound was prepared by the method of example 26 step (i) using the product from example 173 (0.30 g), to give a white solid (0.26 g). Yield 92%.

¹H NMR δ (DMSO-d₆) 8.01-7.93 (1H, m), 7.61 (1H, d, J = 8.3 Hz), 7.46 (1H, dd, J = 7.8 Hz, 7.4 Hz), 7.30-7.20 (1H, m), 7.18-7.07 (1H, m), 6.92 (2H, brs), 6.75-6.67 (3H, m), 4.74-4.73 (2H, m), 4.70 (1H, s), 4.60-4.55 (1H, m), 4.50-4.45 (1H, m), 4.43 (1H, s), 3.55-3.48 (1H, m), 3.45-3.42 (1H, m), 3.42 (2H, t, J = 6.6 Hz), 3.20 (1H, s), 3.18 (1H, s), 2.55-2.46 (2H, m), 2.40 (2H, q, J = 6.9 Hz), 2.20-2.10 (1H, m), 2.08-1.99 (1H, m), 1.60-1.48 (2H, m), 1.42 (6H, s), 0.89-0.80 (9H, m). MS:ESI 619 (M+1)

(ii) Methyl

2-{3-[(N-{3-[4-amino-2-(propoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate

The title compound was prepared by the method of example 26 step (ii) using the product from step (i) (0.20 g) and methanol, to give a white solid (0.19 g). Yield 92%.

¹H NMR δ (CDCl₃) 7.95 (0.75H, d, J = 7.7 Hz), 7.90-7.80 (1.25H, m), 7.57-7.52 (1H, m), 7.39-7.33 (1H, m), 7.22-7.14 (1H, m), 6.79-6.66 (3H, m), 5.43 (2H, brs), 4.78-4.75 (3.5H, 3), 4.60-4.55 (2.5H, m), 3.76 (3H, s), 3.58 (2H, t, J = 6.8 Hz), 3.52-3.44 (2H, m), 3.29 (1.5H, s), 3.26 (0.5 H, s), 2.60 (3H, q, J = 7.1 Hz), 2.52 (1H, q, J = 7.2 Hz), 2.32-2.22 (0.5 H, m), 2.20-2.10 (1.5H, m), 1.68-1.58 (2H, m), 1.58 (6H, s), 0.99 (6H, t, J = 7.1 Hz), 0.92-0.85 (3H, m). MS:ESI 633 (M+1)

Biological Assay

Human TLR7 assay

The most common variant sequence of human TLR7 (represented by the EMBL

sequence AF240467) was cloned into the mammalian cell expression vector pUNO and transfected into a HEK293 cell line already stably expressing the pNiFty2-SEAP reporter plasmid; integration of the reporter gene was maintained by selection with the antibiotic zeocin. Transfectants with stable TLR7
5 expression were selected using the antibiotic blasticidin. In this reporter cell-line, expression of secreted alkaline phosphatase (SEAP) is controlled by an NFkB/ELAM-1 composite promoter comprising five NFkB sites combined with the proximal ELAM-1 promoter. TLR signaling leads to the translocation of NFkB and activation of the promoter results in expression of the SEAP gene.
10 TLR7-specific activation was assessed by determining the level of SEAP produced following overnight incubation of the cells at 37°C with the standard compound in the presence of 0.1%(v/v) dimethylsulfoxide (DMSO). Concentration dependent induction of SEAP production by compounds was expressed as the concentration of compound which produced half of the maximal level of SEAP induction for that
15 compound (EC₅₀).

Compound	hTLR7 EC50 (nM)	Compound	hTLR7 EC50 (nM)
Example 1	Not tested.	Example 34	Not tested.
Example 2	Not tested.	Example 35	Not tested.
Example 3	Not tested.	Example 36	84.5
Example 4	Not tested.	Example 37	38.3
Example 5	247.1	Example 38	Not tested.
Example 6	168.9	Example 39	Not tested.
Example 7	633.1	Example 40	243.4
Example 8	904.0	Example 41	136.6
Example 9	191.6	Example 42	Not tested.
Example 10	135.1	Example 43	Not tested.
Example 11	323.1	Example 44	22.7
Example 12	432.5	Example 45	20.4
Example 13	136.2	Example 46	Not tested.
Example 14	73.6	Example 47	Not tested.
Example 15	181.3	Example 48	24.7
Example 16	Not tested.	Example 49	Not tested.
Example 17	348.7	Example 50	Not tested.
Example 18	1274.2	Example 51	42.6
Example 19	178.4	Example 52	24.2
Example 20	31.7	Example 53	Not tested.
Example 21	786.6	Example 54	Not tested.
Example 22	188.3	Example 55	46.4
Example 23	Not tested.	Example 56	33.1
Example 24	Not tested.	Example 57	Not tested.
Example 25	58.7	Example 58	Not tested.
Example 26	54.6	Example 59	69
Example 27	66.1	Example 60	Not tested.
Example 28	49.9	Example 61	Not tested.
Example 29	174.3	Example 62	84.2
Example 30	1461.7	Example 63	211.9
Example 31	149.6	Example 64	Not tested.
Example 32	177.3	Example 65	Not tested.
Example 33	177.2	Example 66	27.3

Compound	hTLR7 EC50 (nM)	Compound	hTLR7 EC50 (nM)
Example 67	45.8	Example 99	Not tested.
Example 68	Not tested.	Example 100	Not tested.
Example 69	Not tested.	Example 101	>10000
Example 70	25.9	Example 102	>10000
Example 71	23	Example 103	>10000
Example 72	55.8	Example 104	Not tested.
Example 73	Not tested.	Example 105	Not tested.
Example 74	Not tested.	Example 106	>10000
Example 75	404.7	Example 107	>10000
Example 76	210.7	Example 108	Not tested.
Example 77	Not tested.	Example 109	Not tested.
Example 78	Not tested.	Example 110	128
Example 79	51.8	Example 111	122.9
Example 80	56.6	Example 112	756.3
Example 81	56.1	Example 113	83.4
Example 82	114.7	Example 114	67.8
Example 83	61.3	Example 115	172.9
Example 84	Not tested.	Example 116	Not tested.
Example 85	Not tested.	Example 117	Not tested.
Example 86	52.5	Example 118	77.4
Example 87	Not tested.	Example 119	93.2
Example 88	Not tested.	Example 120	278.2
Example 89	95.7	Example 121	Not tested.
Example 90	81	Example 122	Not tested.
Example 91	Not tested.	Example 123	50.2
Example 92	Not tested.	Example 124	40.3
Example 93	73.9	Example 125	11.2
Example 94	27.9	Example 126	47
Example 95	447.4	Example 127	42.9
Example 96	303.8	Example 128	130.1
Example 97	256.5	Example 129	203.7
Example 98	227.5	Example 130	24.4

Compound	hTLR7 EC50 (nM)	Compound	hTLR7 EC50 (nM)
Example 131	37.5	Example 153	86.1
Example 132	56.4	Example 154	67.7
Example 133	114.5	Example 155	235.2
Example 134	20.9	Example 156	168.1
Example 135	16.6	Example 157	100.3
Example 136	111.5	Example 158	105.0
Example 137	87.7	Example 159	139.2
Example 138	Not tested.	Example 160	259.9
Example 139	57	Example 161	262.1
Example 140	79.1	Example 162	96.4
Example 141	201.3	Example 163	173.7
Example 142	57.5	Example 164	158.0
Example 143	49.4	Example 165	296.6
Example 144	79.2	Example 166	474.9
Example 145	Not tested.	Example 167	715.7
Example 146	Not tested.	Example 168	165.9
Example 147	183	Example 169	155.5
Example 148	114.9	Example 170	521.0
Example 149	181.3	Example 171	559.8
Example 150	84.6	Example 172	433.8
Example 151	82	Example 173	Not tested
Example 152	266	Example 174	117.5

Certain of the compounds exemplified exhibited low activity on the Human TLR7 assay described above. Accordingly, in one embodiment according to the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt as described herein other than the compounds:

Ethyl

2-(3-((N-(2-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethyl)-2-(diethylamino)acetamido)methyl)phenoxy)acetate;

Methyl

2-(3-((N-(2-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethyl)-2-

(diethylamino)acetamido)methyl)phenoxy)acetate;

Isopropyl

2-(3-((N-(2-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethyl)-2-(diethylamino)acetamido)methyl)phenoxy)acetate;

5 Ethyl

2-(3-((N-(2-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethyl)-2-(diethylamino)acetamido)methyl)phenoxy)-2-methylpropanoate; and Methyl
2-(3-((N-(2-(4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethyl)-2-(diethylamino)acetamido)methyl)phenoxy)-2-methylpropanoate.

10

Effect of the compounds on antigen-induced pulmonary inflammation in a rat asthma model

15

Rats were sensitized and challenged to produce allergic airway inflammation in a similar manner to that described by Underwood et al (British Journal of Pharmacology 2002; 137: 263-275, 2002). Male Brown Norway rats were sensitized subcutaneously with ovalbumin (OVA) and aluminum hydroxide on day 0, and challenged with aerosolized OVA solution on day14. The test compound was administered twice intratracheally 24 hours before and 24 hours after the OVA-challenge and bronchoalveolar lavage fluid (BALF) was collected 48
20 hours after the OVA-challenge. Then eosinophils and Th2 cytokines (IL-5 and IL-13) in the BALF were measured to evaluate efficacy of the test compounds of this invention. The results obtained are shown in the following table.

Eosinophils and Th2 cytokines in BALF


Compounds	Dose(mg/kg)	Eosinophiles	IL-5	IL-13
Example 9	0.1 (n=6)	53%	66%	89%
	1.0 (n=6)	77%	72%	85%
Example 20	0.01(n=6)	14%	No effect	No effect
	0.1 (n=5)	56%	No effect	22%
Example 27	0.1(n=5)	64%	41%	72%
	1(n=5)	89%	90%	88%
Example 56	0.1(n=4)	78%	86%	89%
	1.0 (n=6)	94%	99%	98%
Example 80	0.1(n=5)	15%	No effect	No effect
	1(n=5)	89%	91%	83%
Example 94	0.1(n=6)	68%	34%	50%
	1(n=6)	91%	90%	82%
Example 161	0.03(n=8)	54%	NT	No effect
	0.3(n=8)	66%	NT	64%
Example 163	0.03(n=8)	45%	NT	50%
	0.3(n=8)	65%	NT	80%

* Eosinophil(Cells/BALF), IL-5(pg/mL BALF) and IL-13(pg/mL BALF): data shows inhibition(%) to OVA-Challenge control.

“No effect” in the Table means that the test compound showed the almost same level of IL-5/IL-13 induction as the OVA-challenge control.

CLAIMS

1. A compound of formula (I):



(I)

, wherein

R¹ represents C₁-C₈ alkyl, C₃-C₈ cycloalkyl, or a 3- to 8-membered saturated heterocyclic ring group comprising a O atom, wherein R¹ is optionally substituted by one or more substituents independently selected from halogen, cyano, hydroxyl and C₁-C₃ alkoxy;

Z¹ represents a C₂-C₆ alkylene group, wherein a carbon atom in Z¹ which is not adjacent to a nitrogen atom may be replaced with an oxygen atom;

X¹ represents NR⁵, >N-COR⁵, >N-CONR⁵R^{5a}, CONR⁵, NR⁵CO, NR⁵CONR⁶ or NR⁶CONR⁵;

Y¹ represents a single bond or C₁-C₆ alkylene;

each R² is independently selected from halogen, cyano, hydroxy, thiol, C₁-C₃ alkyl, C₁-C₃ hydroxyalkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy, C₁-C₃ haloalkoxy, C₁₋₃ alkylthio, C₁₋₃ alkylsulfonyl and C₁₋₃ alkylsulfinyl ;

R³ represents C₁₋₆ alkyl optionally substituted by C₁₋₆ alkoxy;

each R^a is independently selected from halogen, cyano, hydroxy, thiol, C₁-C₃ alkyl, C₁-C₃ hydroxyalkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy, C₁-C₃ haloalkoxy, C₁₋₃alkylthio, C₁₋₃alkylsulfonyl and C₁₋₃alkylsulfinyl;

R⁵ and R^{5a} each independently represents hydrogen, a 3- to 8-membered saturated heterocyclic ring comprising a ring group O, S(O)_p or NR¹⁰, a C₁-C₆ alkyl group or C₃-C₆ cycloalkyl group, the latter two groups being optionally substituted by one or more substituents independently selected from NR⁷R⁸ or R⁹,

R⁷ and R⁸ each independently represent hydrogen, a 3- to 8-membered saturated heterocyclic ring comprising a ring group O, S(O)_p or NR^{10a}, C₁-C₆ alkyl or C₃-C₆ cycloalkyl, the latter two groups being optionally substituted by one or more groups independently selected from halogen, cyano, S(O)_qR¹¹, OR¹², CO₂R¹²,

OC(O)R¹², SO₂NR¹²R¹³, CONR¹²R¹³, NR¹²R¹³, NR¹²SO₂R¹⁴, NR¹²COR¹³, or a 3- to 8-membered saturated heterocyclic ring comprising a ring group O, S(O)_p or NR^{10b},

or R⁷ and R⁸ together with the nitrogen atom to which they are attached form a 3- to 8-membered saturated heterocyclic ring comprising a ring nitrogen atom and optionally one or more further heteroatoms independently selected from nitrogen, oxygen, sulphur and sulphonyl, the heterocyclic ring being optionally substituted by one or more substituents independently selected from halogen, cyano, S(O)_qR¹⁵, OR¹⁵, CO₂R¹⁵, COR¹⁵, OC(O)R¹⁵, SO₂NR¹⁵R¹⁶, CONR¹⁵R¹⁶, NR¹⁵R¹⁶, NR¹⁵SO₂R¹⁷, NR¹⁵COR¹⁶, NR¹⁵CO₂R¹⁶, heteroaryl, C₁-C₆ haloalkyl, C₃-C₈ cycloalkyl and C₁-C₆ alkyl, the latter two groups being optionally substituted by one or more groups independently selected from cyano, S(O)_qR¹⁸, OR¹⁸, CO₂R¹⁸, SO₂NR¹⁸R¹⁹, CONR¹⁸R¹⁹ or NR¹⁸R¹⁹;

R⁹ represents halogen, cyano, CO₂R²⁰, S(O)_qR²⁰, OR²⁰, SO₂NR²⁰R²², CONR²⁰R²², NR²⁰SO₂R²¹, NR²⁰CO₂R²¹, NR²⁰COR²² or a 3- to 8-membered saturated heterocyclic ring comprising a ring group NR^{10c};

R¹⁰, R^{10a}, R^{10b} and R^{10c} independently represent hydrogen, CO₂R²³, S(O)_qR²³, COR²⁴, or a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₃-C₈ cycloalkyl group, each of which may be optionally substituted by one or more substituents independently selected from halogen, cyano, OR²⁵ or NR²⁵R²⁶;

R⁶, R¹¹, R¹², R¹³, R¹⁵, R¹⁶, R¹⁸, R¹⁹, R²⁰, R²², R²⁴, R²⁵ and R²⁶ each independently represent hydrogen, C₁-C₆ alkyl or C₃-C₆ cycloalkyl;

R¹⁴, R¹⁷, R²¹ and R²³ each independently represent C₁-C₆ alkyl or C₃-C₆ cycloalkyl;

m, n, p and q each independently represent an integer 0, 1 or 2; and

A represents a monocyclic or bicyclic C₆-C₁₀ aryl or a monocyclic or bicyclic C₅-C₁₂ heteroaryl group containing 1-3 heteroatoms; and

R^b and R^c independently represent hydrogen or C₁-C₆ alkyl, or R^b and R^c combine together to form C₃-C₈ cycloalkyl.

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein R¹ is straight chain C₁₋₄ alkyl.

3. A compound according to claim 2, wherein R¹ is methyl or ethyl.

4. A compound according to claim 2 or 3, wherein at least one of R^b and R^c is C₁₋₃ alkyl, or R^b and R^c combine together to form C₃-C₆ cycloalkyl.

5. A compound according to claim 4, wherein R¹, R^b and R^c are methyl.

6. A compound according to claim 4, wherein R¹ is ethyl, R^b is methyl and R^c is hydrogen.

7. A compound according to claim 1 wherein R¹ is a branched chain C₃₋₆ alkyl, a C₃₋₆ cycloalkyl or a tetrahydropyranyl.

5 8. A compound according to claim 7, wherein R¹ is isopropyl.

9. A compound according to claim 7 or 8, wherein R^b and R^c are hydrogen.

10. A compound according to any one of the preceding claims wherein Z¹ is n-propylene.

10 11. A compound according to any one of the preceding claims wherein X¹ is a group NR⁵, >NCOR⁵, or >NCONR⁵ R^{5a}.

12. A compound according to any one of the preceding claims wherein X¹ is a group >NCOR⁵.

15 13. A compound according to any one of the preceding claims wherein R⁵ is hydrogen or a C₁-C₆ alkyl optionally substituted by one or more groups NR⁷R⁸ or R⁹ where R⁷, R⁸ and R⁹ are as defined in claim 1.

14. A compound according to any one of the preceding claims wherein Y¹ represents C₁-C₆ alkylene.

15. A compound according to any one of the preceding claims wherein A is phenyl.

20 16. A compound according to any one of the preceding claims where n is 0.

17. A compound according to any one of the preceding claims where R³ is n-propyl, n-butyl, methoxyethyl or ethoxymethyl.

18. A compound according to any one of the preceding claims where m is 0.

25 19. A compound according to claim 1 selected from the group consisting of following compounds or a pharmaceutically acceptable salt thereof:

Methyl

2-(3-{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylamino}methyl}phenoxy)acetate,

Methyl

30 (3-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(chloroacetyl)amino}methyl}phenoxy)acetate,

Methyl (4-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}amino}methyl}phenoxy)acetate,

Methyl

35 (4-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(chloroacetyl)ami

no]methyl}phenoxy)acetate,

Methyl

(4-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(*N,N*-dimethylglycyl)amino]methyl}phenoxy)acetate,

5 Methyl

(4-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(piperidin-1-ylacetyl)amino]methyl}phenoxy)acetate,

Methyl

10 [4-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}}{(4-methylpiperazin-1-yl)acetyl}amino]methyl}phenoxy]acetate,

Methyl

{4-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}}{4-(2-methoxyethyl)piperazin-1-yl]acetyl}amino)methyl}phenoxy)acetate,

Methyl

15 (3-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(*N,N*-dimethylglycyl)amino]methyl}phenoxy)acetate,

Methyl

(3-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(piperidin-1-ylacetyl)amino]methyl}phenoxy)acetate,

20 Methyl

[3-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}}{(4-methylpiperazin-1-yl)acetyl}amino]methyl}phenoxy]acetate,

Methyl

25 {3-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}}{4-(2-methoxyethyl)piperazin-1-yl]acetyl}amino)methyl}phenoxy)acetate,

Methyl

(3-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}}{(pyrrolidin-1-ylacetyl)amino]methyl}phenoxy)acetate,

Methyl

30 (3-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}(*N,N*-diethylglycyl)amino]methyl}phenoxy)acetate,

Methyl

(3-{{{3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}}amino]methyl}phenoxy)acetate,

Methyl

35 (3-{{{3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}}(chlor

oacetyl)amino)methyl}phenoxy)acetate,

Methyl

(3-{{{3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}}(*N,N*-dimethylglycyl)amino)methyl}phenoxy)acetate,

5 Methyl

(3-{{{3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}}[(4-methylpiperazin-1-yl)acetyl]amino)methyl}phenoxy)acetate,

Methyl

(3-{{{3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}}(piperidin-1-ylacetyl)amino)methyl}phenoxy)acetate,

10

Methyl

(3-{{{3-(4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}}(*N,N*-diethylglycyl)amino)methyl}phenoxy)acetate,

Methyl

15 (3-{{{3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl}}(3-morpholinopropyl)amino)methyl}phenoxy)acetate,

Methyl

[4-{{{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}amino)carbonyl}[3-(dimethylamino)propyl]amino)methyl}phenoxy]acetate,

20

Ethyl

2-[3-{{{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}amino)methyl}phenoxy]acetate,

Ethyl

2-[3-{{{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl}phenoxy]acetate,

25

Ethyl

2-[3-{{{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl}phenoxy]acetate,

Propyl

30 2-[3-{{{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl}phenoxy]acetate,

Isopropyl

2-[3-{{{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl}phenoxy]acetate,

35

Isobutyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]phenoxy}acetate,

2-Methoxyethyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]phenoxy}acetate,

2-Hydroxyethyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]phenoxy}acetate,

Ethyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(pyrrolidin-1-yl)acetamido)methyl]phenoxy}acetate,

Ethyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(piperidin-1-yl)acetamido)methyl]phenoxy}acetate,

Ethyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(dimethylamino)acetamido)methyl]phenoxy}acetate,

Methyl

2-[4-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]phenoxy}acetate,

Methyl

2-{4-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-chloroacetamido)methyl]phenoxy}acetate,

Methyl

2-{4-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]phenoxy}acetate,

Ethyl

2-{4-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]phenoxy}acetate,

Methyl

2-[2-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]phenoxy}acetate,

Methyl

2-{2-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-chloroacetamido)methyl]phenoxy}acetate,

Methyl

2-{2-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate,

Ethyl

5 2-{2-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate,

Ethyl

2-{3-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butylamino)methyl]phenoxy}acetate,

10 Ethyl

2-{3-[(N-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-2-chloroacetamido)methyl]phenoxy}acetate,

Ethyl

15 2-{3-[(N-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate,

Isopropyl

2-{3-[(N-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate,

tert-Butyl

20 2-{3-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butylamino)methyl]phenoxy}acetate,

tert-Butyl

2-{3-[(N-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-2-chloroacetamido)methyl]phenoxy}acetate,

25 *tert*-Butyl

2-{3-[(N-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-2-(diethylamino)acetamido)methyl]phenoxy}acetate,

Methyl

30 2-{3-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]phenoxy}propanoate,

Methyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]phenoxy}propanoate,

Methyl

35 2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-

-(diethylamino)acetamido)methyl]phenoxy}propanoate,

Ethyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl}propyl)-2

-(diethylamino)acetamido)methyl]phenoxy}propanoate,

5 Ethyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl}propylamin
o)methyl]phenoxy]-2-methylpropanoate,

Ethyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl}propyl)-2

10 -chloroacetamido)methyl]phenoxy}-2-methylpropanoate,

Ethyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl}propyl)-2

-(diethylamino)acetamido)methyl]phenoxy}-2-methylpropanoate,

Methyl

15 2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl}propyl)-2

-(diethylamino)acetamido)methyl]phenoxy}-2-methylpropanoate,

Ethyl

1-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl}propylamin
o)methyl]phenoxy]cyclobutanecarboxylate,

20 Ethyl

1-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl}propyl)-2

-chloroacetamido)methyl]phenoxy}cyclobutanecarboxylate,

Ethyl

1-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl}propyl)-2

25 -(diethylamino)acetamido)methyl]phenoxy}cyclobutanecarboxylate,

Ethyl

2-[5-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl}propylamin
o)methyl)-2-methoxyphenoxy]acetate,

Ethyl

30 2-{5-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl}propyl)-2

-chloroacetamido)methyl]-2-methoxyphenoxy}acetate,

Ethyl

2-{5-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl}propyl)-2

-(diethylamino)acetamido)methyl]-2-methoxyphenoxy}acetate,

35 Methyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]-2-methoxyphenoxy}acetate,

Ethyl

2-[5-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylamino)methyl]-2-methylphenoxy]acetate,

Ethyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-chloroacetamido)methyl]-2-methylphenoxy}acetate,

Ethyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]-2-methylphenoxy}acetate,

Isopropyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]-2-methylphenoxy}acetate,

Methyl

2-[3-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylamino)methyl]phenoxy]butanoate,

Methyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-chloroacetamido)methyl]phenoxy}butanoate,

Methyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]phenoxy}butanoate,

Ethyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]phenoxy}butanoate,

Isopropyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-(diethylamino)acetamido)methyl]-2-methoxyphenoxy}acetate,

Isopropyl

2-[5-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propylamino)methyl]-2-methoxyphenoxy]acetate,

Isopropyl

2-{5-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-chloroacetamido)methyl]-2-methoxyphenoxy}acetate,

Isopropyl

2-{5-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]-2-methoxyphenoxy}acetate,

Isopropyl

5 2-{5-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{ethyl(methyl)amino}acetamido)methyl]-2-methoxyphenoxy}acetate,

Methyl

1-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)phenoxy]cyclopropanecarboxylate,

10 Methyl

1-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]phenoxy}cyclopropanecarboxylate,

Methyl

15 1-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}cyclopropanecarboxylate ,

Cyclopentyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}acetate,

Cyclobutyl

20 2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}acetate,

Tetrahydro-2*H*-pyran-4-yl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}acetate,

25 Butyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}acetate,

tert-Butyl

30 2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)phenoxy]acetate,

tert-Butyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]phenoxy}acetate,

tert-Butyl

35 2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2

-(diethylamino)acetamido)methyl]phenoxy}acetate,

Ethyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl}-2-methoxyphenoxy]acetate,

5 Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-2-methoxyphenoxy}acetate,

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]-2-methoxyphenoxy}acetate,

10

Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]-2-methoxyphenoxy}acetate,

Ethyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl}-2-fluorophenoxy]acetate,

15

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-2-fluorophenoxy}acetate,

20

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]-2-fluorophenoxy}acetate,

Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(diethylamino)acetamido)methyl]-2-fluorophenoxy}acetate,

25

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(dimethylamino)acetamido)methyl]-2-fluorophenoxy}acetate,

Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(dimethylamino)acetamido)methyl]-2-fluorophenoxy}acetate,

30

Ethyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-(ethyl(methyl)amino)acetamido)methyl]-2-fluorophenoxy}acetate,

35

Isopropyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-ethyl(methyl)amino}acetamido)methyl]-2-fluorophenoxy}acetate,

Ethyl

2-[3-[(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethylamino)methyl]phenoxy]acetate,

Ethyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-chloroacetamido)methyl]phenoxy}acetate,

Ethyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-diethylamino}acetamido)methyl]phenoxy}acetate,

Methyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-diethylamino}acetamido)methyl]phenoxy}acetate,

Isopropyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-diethylamino}acetamido)methyl]phenoxy}acetate,

Ethyl

2-[3-[(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethylamino)methyl]phenoxy]-2-methylpropanoate,

Ethyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-chloroacetamido)methyl]phenoxy}-2-methylpropanoate,

Ethyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate,

Methyl

2-{3-[(*N*-(2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)ethyl)-2-diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate,

Cyclopentyl

2-[3-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]phenoxy]acetate,

Cyclopentyl

2-{3-[(*N*-(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl)-2-chloroacetamido)methyl]phenoxy}acetate,

Cyclopentyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]phenoxy}acetate,

Cyclopentyl

5 2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{ethyl(methyl)amino}acetamido)methyl]phenoxy}acetate,

Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-morpholinoacetamido)methyl]phenoxy}acetate,

10 Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]phenoxy}acetate,

Isopropyl

15 2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{ethyl(methyl)amino}acetamido)methyl]phenoxy}acetate,

Isopropyl

2-{3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{(2-methoxyethyl)(methyl)amino}acetamido)methyl]phenoxy}acetate,

Isopropyl

20 2-[5-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]-2-fluorophenoxy]acetate,

Isopropyl

2-{5-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-2-fluorophenoxy}acetate,

25 Isopropyl

2-{5-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-fluorophenoxy}acetate,

Ethyl

30 2-{5-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-fluorophenoxy}acetate,

Methyl

2-{5-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-fluorophenoxy}acetate,

Isopropyl

35 2-[3-[(3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino)methyl]-2-fluorophenoxy]acetate,

o)methyl]-5-fluorophenoxy}acetate,

Isopropyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-5-fluorophenoxy}acetate,

5 Isopropyl

2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-5-fluorophenoxy}acetate,

Ethyl

10 2-{3-[(N-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-5-fluorophenoxy}acetate,

Ethyl

2-{4-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy}acetate,

Ethyl

15 2-{3-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy}acetate,

Ethyl

2-{3-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{2-(dimethylamino)ethyl}ureido)methyl]phenoxy}acetate,

20 Ethyl

2-{3-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{3-(piperidin-1-yl)propyl}ureido)methyl]phenoxy}acetate,

Ethyl

25 2-{3-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-{3-(dimethylamino)propyl}ureido)methyl]phenoxy}acetate,

Ethyl

2-{3-[(3-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-{2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy}acetate,

Ethyl

30 2-{4-[(3-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-{2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy}acetate,

Isopropyl

2-{3-[(4-{4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}{2-[dimethylamino]ethyl}amino)methyl]phenoxy}acetate,

35 Isopropyl

2-{3-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl){3-morpholinopropyl}amino)methyl]phenoxy}acetate,

Ethyl

2-{3-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl){2-(dimethylamino)ethyl}amino)methyl]phenoxy}-2-methylpropanoate,

Methyl

2-{3-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl){2-(dimethylamino)ethyl}amino)methyl]phenoxy}-2-methylpropanoate,

Ethyl

2-{3-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl){3-morpholinopropyl}amino)methyl]phenoxy}-2-methylpropanoate,

Methyl

2-{3-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl){3-morpholinopropyl}amino)methyl]phenoxy}-2-methylpropanoate,

Isopropyl

2-[5-[(4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butylamino)methyl]-2-fluorophenoxy]acetate,

Isopropyl

2-{5-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-(2-(piperidin-1-yl)ethyl)ureido)methyl]-2-fluorophenoxy}acetate,

Ethyl

2-{5-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-(2-(piperidin-1-yl)ethyl)ureido)methyl]-2-fluorophenoxy}acetate,

Methyl

2-{5-[(1-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-3-(2-(piperidin-1-yl)ethyl)ureido)methyl]-2-fluorophenoxy}acetate,

Isopropyl

2-{5-[(3-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-(2-(piperidin-1-yl)ethyl)ureido)methyl]-2-fluorophenoxy}acetate,

Ethyl

2-{5-[(3-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-(2-(piperidin-1-yl)ethyl)ureido)methyl]-2-fluorophenoxy}acetate,

Methyl

2-{5-[(3-{4-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]butyl}-1-(2-(piperidin-1-yl)ethyl)ureido)methyl]-2-fluorophenoxy}acetate,

Isopropyl

2-[3-({3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propylamino}methyl)-2-methylphenoxy]acetate,

Isopropyl

5 2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-chloroacetamido)methyl]-2-methylphenoxy]acetate,

Isopropyl

2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-methylphenoxy]acetate,

10 Ethyl

2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]phenoxy]-2-methylpropanoate,

Methyl

15 2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]phenoxy]-2-methylpropanoate,

Ethyl

2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{ethyl(methyl)amino}acetamido)methyl]phenoxy]-2-methylpropanoate,

Methyl

20 2-[3-[(*N*-{3-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{ethyl(methyl)amino}acetamido)methyl]phenoxy]-2-methylpropanoate,

Isopropyl

2-[3-({1-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)-3-{2-(piperidin-1-yl)ethyl}ureido)methyl]phenoxy]acetate,

25 Ethyl

2-[3-({*N*-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl]phenoxy]-2-methylpropanoate,

Methyl

30 2-[3-({*N*-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl]phenoxy]-2-methylpropanoate,

Ethyl

2-[3-({*N*-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(dimethylamino)acetamido)methyl]phenoxy]-2-methylpropanoate,

Methyl

35 2-[3-({*N*-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(dimethyla

mino)acetamido)methyl]phenoxy]-2-methylpropanoate,

Isopropyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl]phenoxy]acetate,

5 Isopropyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-[ethyl(methyl)amino]acetamido)methyl]phenoxy]acetate,

Isopropyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(dimethylamino)acetamido)methyl]phenoxy]acetate,

10

Isopropyl

2-[3-({N-[3-(4-amino-2-propyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl]phenoxy]acetate,

Isopropyl

15 2-[3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy]acetate,

Ethyl

2-[3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy]-2-methylpropanoate,

20

Methyl

2-[3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy]-2-methylpropanoate,

Isopropyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(diethylamino)acetamido)methyl]-2-fluorophenoxy]acetate,

25

Isopropyl

2-[3-({N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(dimethylamino)acetamido)methyl]-2-fluorophenoxy]acetate,

Isopropyl

2-[3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]-2-fluorophenoxy]acetate,

30

Isopropyl

2-[3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{dimethylamino}acetamido)methyl]-2-fluorophenoxy]acetate,

35

Ethyl

2-[3-((N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(pyrrolidin-1-yl)acetamido)methyl)phenoxy]-2-methylpropanoate,

Methyl

2-[3-((N-[3-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)propyl]-2-(pyrrolidin-1-yl)acetamido)methyl)phenoxy]-2-methylpropanoate,

Ethyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{pyrrolidin-1-yl}acetamido)methyl]phenoxy}-2-methylpropanoate,

Methyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{pyrrolidin-1-yl}acetamido)methyl]phenoxy}-2-methylpropanoate,

Isopropyl

2-{3-[(N-{3-[4-amino-2-(ethoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{pyrrolidin-1-yl}acetamido)methyl]phenoxy}acetate,

Ethyl


2-{3-[(N-{3-[4-amino-2-(propoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate and Methyl 2-{3-[(N-{3-[4-amino-2-(propoxymethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]propyl}-2-{diethylamino}acetamido)methyl]phenoxy}-2-methylpropanoate.

20. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 19 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

21. A compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 19 for use in the treatment of allergic or viral diseases or cancers or for use in treating asthma, COPD, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis B, hepatitis C, HIV, HPV, bacterial infections and dermatosis.

22. A method of treating, or reducing the risk of, a disease or condition in which modulation of TLR7 activity is beneficial which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 19.

23. A compound of formula (I'):



wherein Z^1 , Y^1 , R^a , R^b , R^c , R^2 , R^3 , m and n are as defined in Claim 1; and R^1 represents hydrogen, C_1 - C_8 alkyl, C_3 - C_8 cycloalkyl, or a 3- to 8-membered saturated heterocyclic ring group comprising a O atom, wherein R^1 is optionally substituted by one or more substituents independently selected from halogen, cyano, hydroxyl and C_1 - C_3 alkoxy; or a salt thereof.

INTERNATIONAL SEARCH REPORT

International application No

PCT/JP2010/071773

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D471/04 A61K31/4745 A61P37/02
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2008/135791 A1 (ASTRAZENECA AB [SE]; DAINIPPON SUMITOMO PHARMA CO [JP]; ASTRAZENECA UK) 13 November 2008 (2008-11-13) claims 1, 7 -----	1-23



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 March 2011

Date of mailing of the international search report

22/03/2011

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040,
 Fax: (+31-70) 340-3016

Authorized officer

Bakboord, Joan

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/JP2010/071773

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2008135791 A1	13-11-2008	AR 066492 A1	26-08-2009
		AU 2008247165 A1	13-11-2008
		CA 2686163 A1	13-11-2008
		CN 101687867 A	31-03-2010
		EC SP099750 A	26-02-2010
		EP 2155743 A1	24-02-2010
		JP 2010526129 T	29-07-2010
		KR 20100016289 A	12-02-2010
		PE 02762009 A1	21-04-2009
		US 2010280001 A1	04-11-2010
		UY 31069 A1	05-01-2009
